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Foreword
Currently, there is a global debate taking place on “the right way in drug policy”. The International 
Narcotics Control Board (INCB) will participate in this debate, given its mandate to monitor imple-
mentation of and compliance with the three international drug control conventions. 
The General Assembly has decided to convene a special session on the world drug problem in April 
2016 to review progress in the implementation of the 2009 Political Declaration and Plan of Action 
on International Cooperation towards an Integrated and Balanced Strategy to Counter the World 
Drug Problem and to assess the achievements and challenges in countering the world drug prob-
lem, within the framework of the three international drug control conventions and other relevant 
United Nations instruments. The special session, which will examine world drug policy, should lead 
to a rethinking and refocusing of the world’s drug control priorities and promote global coopera-
tion in countering drug abuse and drug-related crime, while affirming that the global capacity to 
resolve these issues requires commensurate global political and legal commitment. 
The International Narcotics Control Board is uniquely placed to contribute to current discussions 
on international trends and emerging threats in drug control. It will contribute the insight and 
experience it has accumulated over decades of monitoring the implementation of the drug control 
conventions and identifying achievements, challenges and weaknesses in drug control. INCB will 
engage in the special session and its preparation by highlighting and clarifying the approaches and 
principles underlying the international system of drug control and making recommendations based 
upon the conventions. In its annual reports, published pursuant to the treaties, INCB has been 
addressing, particularly in the thematic chapters, most of the relevant aspects of the global drug 
problem and most of the critical points in the ongoing debate on the “right way in drug policy”. 
Equally, the release of the present annual report of the Board for 2015, the annual report on pre-
cursors1 and the supplementary report on the availability of internationally controlled drugs2 is part 
of our contribution to the special session and the forthcoming policy discussions.
The present report of the Board for 2015 contains a thematic chapter on the health and welfare of 
mankind and the international drug control system. It shows that concern for health and welfare 
is at the core of the international drug control system. INCB emphasizes that the system in place, 
when fully implemented, contributes to protecting the health and welfare of people worldwide and 
ensures balanced national approaches that take into account local socioeconomic and sociocultural 
conditions. 
Even with the reality of the constantly shifting contours of the drug problem, the 1961, 1971 and 
1988 conventions have proved their value as the cornerstone of international cooperation in drug 
policy. The fact that the conventions have been almost universally ratified by States underscores 
that the desire to counter the world’s drug problem is shared globally. States have regularly reaf-
firmed their commitment to working within the framework of the three international drug control 
conventions and the political declarations. 
Assessing the achievements and challenges of the current drug control system, INCB believes that 
the control of the international licit trade in narcotic drugs, psychotropic substances and precur-
sors has been an undeniable success, as today no noteworthy diversion of those substances from 
licit to illicit channels is taking place. On the other hand, the availability and accessibility of nar-
cotic drugs and psychotropic substances for medical purposes is not at all satisfactory at the global 
level. Equally, the goal of a noticeable reduction in the illicit demand for and supply of drugs has 
not been reached. Finally, there are numerous new challenges emerging, such as new psychoactive 
substances.
 1 E/INCB/2015/4.
 2 E/INCB/2015/1/Supp.1.
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However, INCB is convinced that these challenges can be met by fully implementing the conven-
tions and the principles of the political declarations. The drug control system is a balanced system, 
driving towards improving public health and welfare, based on the underlying principles of pro-
portionality, collective responsibility and compliance with international human rights standards. 
Implementing this system means putting the health and welfare of mankind at the core of drug 
policies, applying comprehensive, integrated and balanced approaches to elaborating drug control 
policy, promoting human rights standards, giving higher priority to prevention, treatment, rehabil-
itation and the reduction of the negative consequences of drug abuse, and strengthening interna-
tional cooperation based on shared responsibility.
States parties to the treaties have a certain flexibility in their interpretation and implementation of 
the treaties, within the boundaries that they themselves set out and agreed upon during treaty nego-
tiations. The treaties provide for alternatives to punishment: they do not require the incarceration 
of drug users for drug use or minor offences. Instead of or in addition to conviction or punish-
ment, States can take measures for the prevention of abuse of drugs and for education, early iden-
tification, treatment, aftercare, rehabilitation and social reintegration of affected persons. In addition, 
States have a certain latitude regarding the sanctions they apply against unlawful behaviour, sub-
ject to their constitutional principles and the basic concepts of their legal systems.
Thus, it remains imperative that Governments give due regard to the letter and spirit of the drug 
control conventions in the elaboration of future policies. States will continue to have their own 
practical and operational approaches to addressing local drug problems, but compliance with the 
conventions means fully implementing the underlying principles and obligations.
The special session should reaffirm these principles. Governments should demonstrate that drug 
control is a shared responsibility among all States and that together Governments can focus on 
identifying measures to ensure full implementation of the conventions.
Recognizing that the framework of the conventions has sometimes been misinterpreted, INCB 
believes that the special session will provide an opportunity to emphasize that the spirit of the con-
ventions and political declarations—namely, promoting the health and welfare of mankind—rests 
upon the ability of States to enact policies and practices that are grounded in evidence. The first 
chapter of this publication, the Board’s annual report for 2015, shows that the current framework 
is both comprehensive and cohesive, promoting the application of scientific knowledge, proportion-
ally and in moderation. 
The present report, together with the supplementary report on the availability of internationally 
controlled drugs and the report on precursors, provides an update on the functioning of the inter-
national drug control system and delivers an analysis of developments in the world drug situation. 
These reports promote greater understanding of the role and work of the Board as the treaty- 
monitoring body and the importance of compliance by Member States with the conventions. Any 
proposals to work outside the framework of the treaties undermine the broad-based consensus 
upon which the drug-control system is founded. 
INCB looks forward in the coming year to the continuing global dialogue and elaboration, through 
the special session of the General Assembly on the world drug problem, of a set of practical actions 
to address emerging challenges.
 Werner Sipp
 President
 International Narcotics Control Board
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Explanatory notes
Data reported later than 1 November 2015 could not be taken into consideration in preparing this 
report.
The designations employed and the presentation of the material in this publication do not imply 
the expression of any opinion whatsoever on the part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city or area or of its authorities, or concerning the 
delimitation of its frontiers or boundaries.
Countries and areas are referred to by the names that were in official use at the time the relevant 
data were collected.
References to dollars ($) are to United States dollars, unless otherwise stated.
The following abbreviations have been used in this report:
APAAN alpha-phenylacetoacetonitrile
ASEAN Association of Southeast Asian Nations
ATS amphetamine-type stimulants
BZP N-benzylpiperazine
CSTO Collective Security Treaty Organization 
CICAD Inter-American Drug Abuse Control Commission
ECOWAS Economic Community of West African States
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
Europol European Police Office
GHB gamma-hydroxybutyric acid
ha hectare
I2ES International Import and Export Authorization System
INCB International Narcotics Control Board
INTERPOL International Criminal Police Organization
IONICS Project Ion Incident Communication System 
LSD lysergic acid diethylamide
MDMA methylenedioxymethamphetamine 
MDPV methylenedioxypyrovalerone
OAS Organization of American States
PEN Online Pre-Export Notification Online 
PICS Precursors Incident Communication System
THC tetrahydrocannabinol
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
WHO World Health Organization
1Chapter I.
The health and welfare of mankind: challenges 
and opportunities for the international control of 
drugs
A. Health and welfare as the main 
objectives of the international drug 
control treaties 
1. The ultimate goal of the three international drug con-
trol conventions is to protect public and individual health 
and welfare. All three treaties—the Single Convention on 
Narcotic Drugs of 1961,3 the Convention on Psychotropic 
Substances of 19714 and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 19885—make reference to that concern. 
Along with the limitation of the use of narcotic drugs and 
psychotropic substances exclusively for medical and sci-
entific purposes, the conventions require Governments to 
take all practicable measures for the prevention of drug 
abuse and for the early identification, treatment, educa-
tion, aftercare, rehabilitation and social reintegration of 
the persons involved (article 38 of the 1961 Convention 
and article 20 of the 1971 Convention).
2. With the special session of the General Assembly on 
the world drug problem to be held in 2016, the time has 
come to make a critical assessment of the global drug sit-
uation and drug control policies and to review how the 
main principles of the drug control treaties and the inher-
ent balanced approach have been implemented in prac-
tice. The world has changed, as have drug policies, and 
it is therefore necessary to consider how policy changes 
 3 Single Convention on Narcotic Drugs of 1961 as amended by the 
1972 Protocol (United Nations, Treaty Series, vol. 976, No. 14152).
 4 United Nations, Treaty Series, vol. 1019, No. 14956.
 5 Ibid., vol. 1582, No. 27627.
to address emerging challenges can be achieved within 
the existing international legal drug control framework, 
which continues to enjoy almost universal support, 
although its objectives have sometimes been misunder-
stood or misinterpreted. Building on its findings with 
respect to the implementation of a comprehensive, inte-
grated and balanced approach, as examined in the annual 
report of the Board for 2014 and previous years, the 
Board presents in this thematic chapter a number of addi-
tional considerations on the subject of drugs and health. 
B. Drugs and the health and 
welfare of mankind 
3. The use of substances to influence mood, sensation, 
perception and cognition is a near-universal human phe-
nomenon. The substances so used, whether consumed in 
the form of naturally occurring plant material, extracts, 
derivatives or pure synthetics, are generically referred to 
as “drugs” (this term will be used in the present chapter 
for the sake of brevity). Many of those substances pose 
the risk of addiction or, more largely, problematic pat-
terns of use and abuse among people who take them.
4. The use of a substance liable to abuse—regardless of 
whether the substance is controlled—has characteristic 
risks, with the level and combination of risks varying 
widely depending on the substance, the individual, the 
social setting and the mode of administration. The abuse 
of any substance poses a risk to the health and welfare of 
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the users and those around them. Drugs are placed under 
international and national control precisely because they 
can seriously endanger the health and welfare of individ-
uals. Similarly, all Governments have chosen to distrib-
ute most medications in pharmacies and by prescription 
because many of those substances may have seriously 
toxic and noxious effects when administered without 
expert supervision.
5. Psychoactive substances—whether or not they are 
under international control—are no ordinary commodi-
ties in the sense that a large fraction of the revenue to 
the sellers comes from users whose habits and addiction 
are not under voluntary rational control. Even in a hypo-
thetical political, social and legal system that assumed 
that the consumption choices of adults should be left 
unconstrained and that producers should be free to sup-
ply and foster consumer demand with the use of market-
ing, an exception might reasonably be made for 
psychoactive substances. This would be done to protect 
consumers against gaps in their knowledge and defects 
in their own decision-making (which can be impaired by 
the consumption of the substance itself), to minimize 
avoidable disease and death and to protect others from 
the consequences of drug-influenced behaviour. 
6. In recent years, there have been additional challenges 
such as the appearance of new psychoactive substances. 
Governments acknowledge the complexity of dealing 
with an ever-changing spectrum of substances made 
especially to circumvent controls. In most cases, such 
substances have unknown short- and long-term effects 
and may have highly addictive and toxic profiles. A grow-
ing number of those substances are now being manipu-
lated and peddled to people, especially youth, at the 
expense of their health. It is therefore a matter of health 
and welfare to ensure that those substances are kept away 
from potential users and that the targeted population 
groups are provided with information on the risks asso-
ciated with such substances and primary prevention 
services.
7. The international drug control conventions recognize 
and promote the medical use of narcotic drugs and psy-
chotropic substances, which serve as an indispensable 
source of relief from pain and suffering and other medi-
cal conditions. However, although these drugs can be a 
source of great benefit, they also have the potential to be 
a source of harm. The conventions therefore oblige States 
parties to properly regulate, control and limit exclusively 
to medical and scientific purposes the production, man-
ufacture, export, import and distribution of, trade in, and 
use and possession of drugs, which, if inappropriately 
administered, can also be subject to abuse. 
8. Globally, access to medicines containing controlled 
substances is still very uneven, with consumption con-
centrated primarily in some developed countries. Three 
quarters of the world’s population live in countries with 
low levels of access, or no access, to medicines contain-
ing scheduled substances. The International Narcotics 
Control Board (INCB) has long pointed out such major 
discrepancies and has repeatedly stressed that the situa-
tion could be improved through corrective action by 
States to address the regulatory, attitudinal, knowledge-
related, economic and procurement-related problems 
identified as the main causes of inadequate availability. 
The present annual report of the Board is accompanied 
by a supplement devoted exclusively to the analysis of this 
issue.6
9. The imbalance in the availability of opioid analgesics 
is particularly worrying, as the latest data show that many 
of the conditions that require pain management, particu-
larly cancer, are prevalent and increasing in low-income 
and middle-income countries.7 At the same time, in 
recent years there has been an increase in the abuse of 
prescription drugs and related overdose deaths in 
 countries with high per capita levels of consumption of 
opioid analgesics.
10. The conventions do not require any specific modal-
ity for the treatment of drug addiction; INCB urges States 
parties to base any such practice on scientific evidence. 
The provision of appropriate treatment services for drug 
abuse is as much an obligation for States parties as is the 
suppression of drug trafficking. Failure to provide appro-
priate treatment can exacerbate the health and social 
damage resulting from drug abuse and contribute to illicit 
demand for substances of abuse. It is therefore generally 
recognized that medically accepted standards of care for 
opioid dependence, including for opioid-dependent per-
sons under criminal justice supervision, advance the goals 
of the international drug control treaties. The use of sub-
stitution therapy for the treatment of opioid dependence 
has a substantial evidence base, but its application varies 
among Member States. 
11. The Board considers that programmes for the treat-
ment of drug abuse should be held to the same standards 
of safety and efficacy as programmes for the treatment of 
other ailments. Inhumane or degrading forms of treat-
ment of drug users should be eliminated. 
 6 Availability of Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes (E/INCB/2015/1/Supp.1).
 7 World Health Organization and Worldwide Palliative Care Alli-
ance, Global Atlas of Palliative Care at the End of Life (Worldwide Pallia-
tive Care Alliance, 2014).
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C. The conventions and their results
12. The achievements of the conventions are difficult to 
measure because of the difficulty of predicting what 
would have happened in the absence of international 
agreement on drug control measures. In 1906/7, prior to 
the adoption of any international drug control agreement, 
global opium production was estimated at 41,600 tons, 
with a world population of less than 2 billion. The most 
recent estimate of global illicit opium production, pub-
lished in the 2015 edition of the UNODC World Drug 
Report,8 was 7,554 tons, a fraction of what was produced 
100 years ago, whereas the world’s population today is 
over 7 billion. In addition, the difficulty of diverting from 
licit international trade narcotic drugs, psychotropic sub-
stances and precursor chemicals can be attributed, at least 
partly, to the effective implementation of the treaties by 
Governments. 
13. Moreover, the abuse of drugs has been contained in 
comparison with the consumption of other substances 
that are more easily available, such as alcohol and tobacco. 
The prevalence of abuse of drugs is much lower than that 
of alcohol and tobacco. Alcohol causes more violence, and 
tobacco more harm to health, than all the controlled 
drugs combined, mainly due to the greater availability of 
and exposure to those two substances and the prevalence 
of their use and abuse. Indeed, alcohol and tobacco kill 
many times more the number of people than controlled 
substances do. These examples from commercially regu-
lated markets underline the dangers of the use of con-
trolled substances for non-medical purposes. The 
conventions are designed to protect the health and well-
being of populations by avoiding these dangers.
14. The challenge for States when implementing their 
treaty obligations is to determine the appropriate balance 
of their drug control efforts. States ought to ensure that 
their control efforts do not result in unwanted side effects. 
Problem users, who constitute only a minority of all drug 
users, consume the overwhelming majority of drugs, typ-
ically more than 80 per cent by volume. Furthermore, 
drug users who are continuously or regularly intoxicated 
account for a larger proportion of the total health and 
social damage. One of the most efficient ways to deter 
traffickers would be to reduce their user base. Removing 
a significant portion of the source of demand by imple-
menting effective prevention and treatment measures 
would have a significant impact upon any illicit drug mar-
ket. Such action should include efforts to prevent drug 
use in an effective and systematic manner. 
 8 United Nations publication, Sales No. E.15.XI.6.
15. Although integrated and balanced approaches have 
existed since the inception of the treaties, they have come 
to the forefront of international drug control only in 
recent decades. There are some historical and legal factors 
for this. International conventions, by definition, deal with 
cross-border issues of mutual interest to sovereign States, 
such as international trade. Hence, the conventions, as 
adopted, focused largely on international trade and traf-
ficking, whereas the development and implementation at 
the national level of the measures that we now call 
“demand reduction”—while mandated by the conven-
tions—were left to the discretion of each sovereign State.
D. Socioeconomic and 
sociopolitical context of drug control 
16. Addressing social, economic and political issues that 
can create opportunities for violence and drug use may 
be as valuable as the efforts directly targeting the drugs 
themselves. As the Board has noted in the past, both the 
supply and demand sides of the drug problem are affected 
by socioeconomic factors such as poverty, hunger, eco-
nomic inequality, social exclusion, deprivation, migration 
and displacement, limited access to education and 
employment prospects, and exposure to violence and 
abuse. Those factors are important drivers of the drug 
problem and need to be taken into consideration as part 
of a comprehensive approach. When designing and imple-
menting policies to assist people living with substance 
abuse disorders, States must look deeper at socioeco-
nomic factors such as poverty, marginalization, gender 
and child development. The role and responsibility of 
families and society in protecting children by creating 
environments that are conducive to prevention of drug 
abuse cannot be overemphasized.
17. The drug problem has many contributing factors 
and can be influenced by policies in other areas not aimed 
specifically at illicit drug supply and use. For example, 
policies that strengthen resiliency at the individual, fam-
ily and community levels can reduce vulnerability to drug 
abuse and enhance the prospects for the speedy and last-
ing recovery of those who have developed drug abuse 
problems. Robust public institutions that are transparent 
and accountable can help minimize corrupting efforts of 
drug trafficking organizations. Likewise, strong commu-
nities with rich economic potential are more likely to 
withstand the deleterious impact of illicit drug crop cul-
tivation and the corrupting influence of drug dealing and 
drug trafficking. 
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E. Social health and challenges 
18. Promoting the welfare of mankind requires the pre-
vention and reduction of social harm. Some drug users 
suffer health damage due to the drugs themselves, impu-
rities in the drugs or the means by which the drugs are 
administered. Other drug users cause harm to themselves 
or to others by acting carelessly, negligently or criminally 
while under the influence of drugs, and some users find 
that their drug use has escaped voluntary control and has 
become an unwanted and in some cases persistent and 
recurrent addiction that can result in significant health 
and personal costs, not to mention the costs to family 
and society. Even people with no diagnosable drug abuse 
disorder may contribute to a social problem both by sup-
porting illicit drug markets and by engaging in risky 
behaviour while under the influence of the drug. An 
important social harm is the impact of the incarceration 
of drug users, for whom incarceration can have signifi-
cant financial, familial and occupational repercussions. 
19. In addition to the damage drugs cause to the users 
and the people around them, activities and circumstances 
related to the illicit production and supply of drugs also 
threaten the health and welfare of the individual, the 
community and the State. In the case of substances sold 
on illicit markets, product quality is unknown, as illicit 
drugs can be of unknown or deleterious quality. Illicitly 
supplied drugs may be adulterated or may contain dan-
gerous impurities, and drug users typically have little 
capacity to ascertain what they are actually consuming. 
These factors all increase the risk of accidental overdose 
and other forms of toxicity.
20. Some drug-taking behaviour particularly com-
pounds the problem of drug abuse. An example is the 
spread of HIV and the hepatitis C virus through the use 
of non-sterile injecting equipment. Since those viruses 
can also be transmitted in other ways, persons who never 
use controlled substances may also become infected as an 
indirect consequence of the drug-taking activities of 
others.
21. The cost of drugs can impoverish, or further impov-
erish, persons dependent on the drug in question. This 
leads some drug users to become involved in criminal 
activity to support their drug addiction, leading to fur-
ther harm not only for the drug user but also for others 
and society as a whole.
22. The behaviour of illicit drug markets generates harm 
for society, most notably violence by, among and against 
drug traffickers. Criminal elements meet the illicit 
demand for drugs, and illicit drug markets are controlled 
by organized criminal groups. Violence, social disorder 
and corruption associated with the illicit production and 
supply of drugs threatens the security of citizens and 
undermines the rule of law. Weak governance provides, 
in turn, ground for the development of the illegal drug 
industry and markets.
23. Law enforcement efforts targeting illicit markets 
may either reduce or exacerbate such violence and also 
generate harm: violence against and by law enforcement 
agents; incarceration and other forms of punishment; and 
corruption among, and human rights violations by, law 
enforcement agencies. 
24. Violence is perhaps the most visible and pernicious 
outcome of drug trafficking. The lucrative economic 
opportunities generated by the illicit demand for drugs 
attract criminals and enhance their willingness and capa-
bility to use violence to protect their illicit drug opera-
tions. Territorial disputes among rival drug trafficking 
organizations, score-settling and intimidation lead to the 
use of violence to dominate the illicit trade in drugs; this 
is especially true for communities situated in or near 
illicit drug production areas, along drug trafficking routes 
and in neighbourhoods where drug dealing openly 
occurs. Also, there are many transit countries in which 
violence associated with drug trafficking takes place. High 
levels of violence may result when one group of drug traf-
fickers challenges another, or the State, for control of an 
area. When drug dealing becomes intertwined with polit-
ical conflicts, horrific levels of violence may ensue.
25. Drug-related corruption undermines national and 
global efforts to combat lawlessness. At the national level, 
corruption threatens the legitimacy of political institu-
tions and industries. The corruption of political parties, 
state agencies, officials, professionals and leaders of the 
community obstructs political and economic develop-
ment in many countries. Drug trafficking organizations 
understand this well and seek to undermine state capa-
city by means of corruption and violence. Corruption and 
drug-related problems are mutually reinforcing, and cor-
ruption and other social problems greatly contribute to 
the development of the illicit drug industry. 
26. Corruption of state officials continues to be a  constant 
challenge in drug control efforts, undermining public wel-
fare. States must seek ways to ensure that public and law 
enforcement officials, as well as politicians, can fulfil their 
duties honestly. Citizens need to demand more from their 
elected representatives and state officials. Nothing has a 
more debilitating effect on efforts to curtail the illicit drug 
trade than the successful attempts of criminal organiza-
tions to intimidate and corrupt public officials. 
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27. One of the most serious challenges includes the loss 
of state control to organized criminal groups. Impunity 
and ungovernability pose a challenge to the collective 
security and well-being of any State, as well as the regional 
and global community. When state structures become 
involved with and affected by violence and systemic cor-
ruption, drug trafficking can further weaken the efficacy 
of Governments to the point of creating “failed State” con-
ditions at the national or subregional level. Given the 
enormous amounts of money available to drug traffick-
ers, law enforcement agencies are especially vulnerable to 
the threat of corruption, and that threat is greatly exa-
cerbated when law enforcement agents are inadequately 
paid.
28. One of the most recent challenges to the interna-
tional drug control system is that posed by the use of the 
Internet for drug trafficking. States must do more to ena-
ble the investigation of such illegal operations in order to 
ensure that such operations are identified, restricted and 
eliminated and that the international postal system is not 
used for illicit drug shipments. Internet pharmacies and 
other dispensing methods that physically separate the 
prescriber or provider from the patient pose a particular 
risk and require the development of more effective regu-
latory approaches. In such systems of supply, it is more 
difficult for prescribers and dispensers to evaluate the 
needs of patients to ensure that the prescriptions will be 
used for legitimate medical purposes so as to protect the 
health and well-being of the individual. States should be 
mindful of the challenges that such methods for the sup-
ply of medications may pose.
F. Supply reduction efforts and 
their limitations 
29. In any drug control system, supply reduction and 
the enforcement of regulations will always be an impor-
tant element of an integrated and balanced approach. 
Efforts to suppress the illicit production and supply of 
drugs, when properly designed and implemented, are 
essential tools for reducing the social and health damage 
resulting from illicit drug markets. 
30. In recent years, some criticisms have singled out 
efforts to suppress the illicit supply and use of drugs, 
claiming that they are failed policies on the grounds that 
drug abuse remains prevalent. The logic behind that argu-
ment is questionable. Nobody has advocated abandoning 
the global response to AIDS or hunger because those 
problems have not been eliminated. Rather, those efforts 
are held to be the more reasonable standards for improv-
ing the situation, compared with the alternative of 
inaction. 
31. All other things being equal, higher prices—which 
may result from a more restricted illicit supply due to law 
enforcement efforts—will lead to reduced demand. But 
higher drug prices can affect not only the problems asso-
ciated with drug-taking but also the problems associated 
with drug trafficking and with law enforcement efforts. 
Where the extent of the trafficking falls less than propor-
tionally to the increase in prices, more vigorous law 
enforcement activity may increase the total revenue avail-
able to traffickers and thus increase the incentive to 
engage in that illicit trade and to struggle for dominance 
within that trade. 
32. Law enforcement policy therefore needs to be care-
fully designed, keeping in mind both the objective of drug 
control and the possible unintended results. It is not the 
case that the world must choose between “militarized” 
drug law enforcement and the legalization of non- medical 
use of internationally controlled drugs. The conventions 
do not mandate a “war on drugs”.
G. The principle of proportionality 
33. Incorporating the provisions of the international 
drug control conventions into national law is subject to 
the internationally recognized principle of proportional-
ity. That principle guides a State’s response to acts pro-
hibited by law or custom. When applied to the criminal 
justice system, the principle permits punishment as an 
acceptable response to crime, provided that it is not dis-
proportionate to the seriousness of the crime.
34. Whether or not a response to drug-related offences 
is proportionate depends in turn on how the legislative, 
judicial and executive arms of government respond in 
both law and practice. Given their limited resources, 
Governments should ensure that law enforcement and 
justice systems accord high priority to investigating, pros-
ecuting and convicting the most violent of actors and 
those involved in the illicit supply chain, such as those 
who control, organize, manage or provide inputs, 
 production and other services for drug trafficking 
organizations. 
35. The deterrent effect of criminalizing drug posses-
sion depends on the specific circumstances of countries. 
The conventions oblige States to ensure that possession 
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of drugs—even in small quantities—shall be a punisha-
ble offence. At the same time, the conventions offer alter-
natives to conviction or punishment including treatment, 
education, aftercare, rehabilitation and social reintegra-
tion. The 1988 Convention allows a certain flexibility 
regarding sanctions for possession for personal consump-
tion, making that obligation subject to the constitutional 
principles and the basic concepts of the legal system of 
States. As the Board has stated on numerous occasions, 
the international drug control conventions do not require 
the incarceration of drug users. Rather, they oblige States 
parties to criminalize supply-related behaviour while 
encouraging them to consider prevention, treatment and 
rehabilitation as alternatives to punishment.
H. Respect for human rights 
36. Drug control action must be consistent with inter-
national human rights standards. States parties need to 
make full use of international legal instruments to pro-
tect children from drug abuse and ensure that national 
and international drug control strategies are in the best 
interests of the child. The Board has also advised all coun-
tries that continue to retain the death penalty for drug-
related offences to consider abolishing capital punishment 
for this category of offences. 
37. In addition to indirect and unintentional conse-
quences for human rights via lawless, corrupt and arbi-
trary governance, violence can threaten efforts to 
safeguard human rights. This is especially true when drug 
trafficking and corruption weaken legitimate institutions 
of governance and contribute to the failure of national 
authorities or prevent weak States from developing robust 
structures. 
I. Unintended consequences 
38. There are a number of unintended consequences 
that can flow from a variety of factors, including the 
unbalanced implementation of national and international 
drug control measures. However, the argument that the 
unintended consequences of implementation of the drug 
control system are evidence that currently scheduled sub-
stances should be authorized for non-medical purposes 
is based on the incorrect assumption that those undesired 
consequences cannot be addressed within the framework 
of the international drug control system. While these 
consequences are unintended, they are not unexpected, 
and they may be prevented or managed. The challenge 
that States parties face is to implement their treaty obli-
gations in a balanced way that minimizes the negative 
impact of drug abuse and measures to control drug traf-
ficking, and to educate and treat victims of such 
trafficking.
39. Most of the discussion surrounding the non- medical 
use of scheduled substances ignores the nature of drug 
abuse and addiction and the particularities of drug law 
implementation. This ignores the realities of many coun-
tries, in which the Governments are already overwhelmed 
by the negative effects, particularly the negative social 
effects, of loosely controlled or poorly regulated alcohol 
and tobacco products and in which narcotic drugs for 
medical use are either too scarce or overconsumed and 
abused.
J. Conclusions and 
recommendations: how drug control 
can promote human health and 
welfare
40. Drugs can be used as medicines but can also cause 
serious harm to health. Drug control policies can prevent 
harm but can also result in unintended damage. The 
international drug control system should therefore pro-
mote the application of scientific knowledge, humane 
thinking, proportionality and moderation to the set of 
problems related to drugs. Use of scheduled substances 
for non-medical purposes is not an adequate solution to 
the existing challenges. 
41. States parties have made important strides towards 
a more cohesive and coherent drug control strategy as 
envisioned in the conventions. However, the evolving 
nature of this complex social problem requires that States 
be cognizant of the challenges and opportunities they 
face. The special session of the General Assembly on the 
world drug problem to be held in 2016 is a timely oppor-
tunity to reaffirm drug control policies and practices 
grounded in evidence and science. Some of the existing 
policies in some countries, such as militarized law 
enforcement, policies that disregard human rights, over-
incarceration, the denial of medically appropriate treat-
ment and inhumane or disproportionate approaches, are 
not in accordance with the principles of the conventions. 
It is recommended that States approach this review with 
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the goal of reinforcing what works while modifying what 
does not and expanding the range of interventions to 
cope with new psychoactive substances, marketing tech-
nologies used to promote and facilitate drug abuse such 
as the use of the Internet and social media. Simplistic 
calls for permitting and regulating the non-medical use 
of scheduled substances should be seen as inadequate to 
remedy the drug-related problems to be faced in a glo-
balized and unequal world.
42. The continued threat of transnational organized 
crime needs to be managed in a more focused, cohesive 
and international manner. States need to improve the 
quality and transparency of government institutions and 
agencies so as to confront corruption. Destination coun-
tries need to assume their share of responsibility and take 
more effective action to suppress domestic drug traffick-
ing and demand. 
43. States are reminded of their obligations to employ 
effective drug abuse prevention, treatment and rehabili-
tation programmes. Such programmes can involve more 
than drug-specific policies; interventions that strengthen 
social ties and individuals’ capacity for self-determination 
and resilience tend to reduce the prevalence of drug 
abuse.
44. States should provide effective and humane help to 
people affected by drug abuse, including both medically 
appropriate and evidence-based treatment. Drug users 
should be offered alternatives to punishment. Harsh treat-
ment programmes, including any that involve the use of 
physical punishment, should be discontinued. Evidence-
based treatment modalities that have been found to 
reduce drug abuse behaviour deserve consideration. 
Reducing drug abuse is a major step towards protecting 
and improving the health and well-being of individuals 
and societies. Reducing the adverse health and social con-
sequences of drug abuse is a complementary element of 
a comprehensive demand reduction strategy. However, 
prevention of substance abuse in society in general, and 
in particular among young people, should remain the pri-
mordial objective of government action. 
45. The international drug control system, as established 
by the conventions and built upon by the relevant polit-
ical declarations, provides a comprehensive and cohesive 
framework which can be effective only if States fulfil their 
treaty obligations, taking into account their domestic sit-
uation, including realities of drug supply and demand, 
the capacity of state institutions, social considerations and 
the scientific evidence of the effectiveness of existing and 
future policy options.

9Chapter II.
Functioning of the international drug control 
system
A. Promoting the consistent 
application of the international drug 
control treaties
46. In its capacity as custodian of the three inter-
national drug control conventions, the International 
Narcotics Control Board (INCB) works closely with 
Governments to ensure that the conventions receive the 
widest possible ratification. Reflecting this fact, INCB has 
continued to engage the Governments of States parties 
and non-parties alike in an effort to promote the 
 universal ratification and comprehensive implementation 
of the conventions.
47. As in the past, this has been accomplished through 
regular consultations in the form of sustained dialogue 
with Governments, including high-level meetings, coun-
try missions, extensive correspondence on technical and 
policy matters and the delivery of training activities.
48. INCB has urged Governments, in their implemen-
tation of the treaty obligations incumbent upon them, to 
take a balanced approach to the formulation of drug 
 policy. Such an approach should have the welfare of 
humankind at its centre and should reflect the following 
imperatives: the need to control licit trade in controlled 
substances to prevent their diversion for trafficking pur-
poses while not hindering their availability for legitimate 
medical and scientific purposes; the need to have struc-
tures in place for the prevention of drug abuse, the early 
identification and treatment of drug abuse and the edu-
cation, aftercare, rehabilitation and social reintegration of 
persons affected by drug abuse; and the need to have drug 
policies that respect human rights and penal policies that 
are proportionate and measured, in keeping with the 2009 
Political Declaration and Plan of Action on International 
Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem.
Status of adherence to the international drug 
control treaties
49. Reflecting the widespread consensus they enjoy 
among States, the international drug control treaties are 
among the most widely ratified international legal 
instruments. 
50. Following the accession of Afghanistan, as at 
1  November 2015, the number of States parties to the 
1961 Convention as amended by the 1972 Protocol was 
185. Prior to that accession, Afghanistan had been a party 
to the Single Convention on Narcotic Drugs of 1961 in 
its unamended form. Chad is now the only State party to 
the 1961 Convention that has not yet acceded to the 1972 
Protocol. Only 11 States have yet to accede to the 1961 
Convention as amended: 2 States in Africa (Equatorial 
Guinea and South Sudan), 2 in Asia (State of Palestine 
and Timor-Leste) and 7 in Oceania (Cook Islands, 
Kiribati, Nauru, Niue, Samoa, Tuvalu and Vanuatu).
51. In 2015, the number of States parties to the 1971 
Convention remained 183, with 14 States not yet parties 
to that Convention: 3 States in Africa (Equatorial Guinea, 
Liberia and South Sudan), 1 State in the Americas (Haiti), 
2 States in Asia (State of Palestine and Timor-Leste) and 
8 in Oceania (Cook Islands, Kiribati, Nauru, Niue, Samoa, 
Solomon Islands, Tuvalu and Vanuatu).
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52. The 1988 Convention has been ratified or acceded to 
by a total of 189 States. As at 1 November 2015, nine States 
were not party to the 1988 Convention: three States in 
Africa (Equatorial Guinea, Somalia and South Sudan), one 
in Asia (State of Palestine) and five in Oceania (Kiribati, 
Palau, Papua New Guinea, Solomon Islands and Tuvalu).
53. INCB welcomes the near universal ratification of the 
drug control conventions by States and reminds those 
States that have not yet acceded to one or more of the 
conventions of the importance of doing so without fur-
ther delay and of ensuring their comprehensive imple-
mentation within the national legal order.
B. Ensuring the implementation of 
the provisions of the international 
drug control treaties
54. The fundamental goal of the international drug con-
trol systems is assuring the health and welfare of human-
kind. This goal is to be achieved through two, twin 
actions: ensuring the availability of internationally con-
trolled substances for medical and scientific purposes; 
and preventing the diversion of controlled substances into 
illicit channels or, in the case of precursor chemicals, for 
use in the illicit manufacture of narcotic drugs and psy-
chotropic substances.
55. To monitor compliance with the international drug 
control treaties, the Board examines action taken by 
Governments to implement the treaty provisions aimed 
at achieving the overall goals of the conventions. Over 
the years, the treaty provisions have been supplemented 
with additional control measures adopted by the Economic 
and Social Council and the Commission on Narcotic 
Drugs to enhance their effectiveness. In the present sec-
tion, the Board highlights action that needs to be taken 
to implement the international drug control system, 
describes problems encountered in that regard and pro-
vides specific recommendations on how to deal with 
those problems.
1. Preventing the diversion of 
controlled substances
(a) Legislative and administrative basis
56. Governments have to ensure that national legisla-
tion complies with the provisions of the international 
drug control treaties. They also have the obligation to 
amend lists of substances controlled at the national level 
when a substance is included in a schedule of an inter-
national drug control treaty or transferred from one 
schedule to another. Inadequate legislation or implemen-
tation mechanisms at the national level or delays in bring-
ing lists of substances controlled at the national level into 
line with the schedules of the international drug control 
treaties will result in inadequate national controls being 
applied to substances under international control and 
may lead to the diversion of substances into illicit chan-
nels. The Board is therefore pleased to note that, as in 
previous years, Governments have continued to furnish 
information to the Board on legislative or administrative 
measures taken to ensure compliance with the provisions 
of the international drug control treaties.
57. In its decision 58/3 of 13 March 2015, the Com-
mission on Narcotic Drugs decided to include AH-7921 
in Schedule I of the 1961 Convention as amended. In 
accordance with article 3, paragraph 7, of the 1961 
Convention as amended, that decision was communi-
cated by the Secretary-General to all Governments, to the 
World Health Organization (WHO) and to the Board on 
8 May 2015, and became effective with respect to each 
party on the receipt of that notification. INCB therefore 
requests all Governments to amend the lists of sub­
stances controlled at the national level  accordingly and 
to apply to those substances all control measures 
required under the 1961 Convention as amended.
58. The Board also wishes to draw the attention of 
Governments to the fact that nine substances were put 
under international control under the 1971 Convention 
by the Commission on Narcotic Drugs in March 2015. 
The substances concerned are 25B-NBOMe (2C-B-
NBOMe), 25C-NBOMe (2C-C-NBOMe) and 25I-NBOMe 
(2C-I-NBOMe), which were added to Schedule I of the 
1971 Convention, and AM-2201, JWH-018, 3-4-methyl-
enedioxypyrovalerone (MDPV), mephedrone (4-methyl-
methcathinone), methylone (beta-keto-MDMA) and 
N-benzylpiperazine (BZP), which were added to 
Schedule  II of that Convention in accordance with 
Commission decisions 58/1, 58/6, 58/7, 58/8, 58/9, 58/10, 
58/11, 58/12 and 58/13 of 13 March 2015. In accordance 
with article 2, paragraph 7, of the 1971 Convention, those 
decisions of the Commission were communicated by the 
Secretary-General to all Governments, to WHO and to 
the Board on 8 May 2015, and became fully effective with 
respect to each party on 4 November 2015. INCB there­
fore requests all Governments to amend the lists of sub­
stances controlled at the national level accordingly and 
to apply to those substances all control measures 
required under the 1971 Convention. 
ChaPTER II. fuNCTIONINg Of ThE INTERNaTIONal dRug CONTROl sysTEm  11
59. The Board wishes to remind Governments that 
gamma-hydroxybutyric acid (GHB) was transferred from 
Schedule IV to Schedule II of the 1971 Convention, in 
accordance with Commission on Narcotic Drugs decision 
56/1 of 13 March 2013. The decision of the Commission 
became fully effective with respect to each party on 
4 December 2013. The Board notes that some States par-
ties have not yet reflected this change in their national 
regulatory systems. INCB therefore reminds all 
Governments of their obligations to amend the list of 
substances controlled at the national level accordingly, 
and to apply to GHB all control measures foreseen for 
the substances in Schedule II of the 1971 Convention, 
including the introduction of an import and export 
authorization requirement.
60. In accordance with Economic and Social Council 
resolutions 1985/15, 1987/30 and 1993/38, Governments 
are required to introduce an import authorization require-
ment for zolpidem, a substance that was included in 
Schedule IV of the 1971 Convention in 2001. In response 
to the Board’s request made in its annual reports for 2012 
and 2013, a number of additional Governments have pro-
vided the requisite information. Thus, as at 1 November 
2015, relevant information is now available for 128 coun-
tries and territories. Of those, 118 countries and territo-
ries have introduced an import authorization requirement, 
and 2 countries (Indonesia and the United States of 
America) require a pre-import declaration. Six countries 
and territories do not require an import authorization for 
zolpidem (Cabo Verde, Ireland, New Zealand, Singapore, 
Vanuatu and Gibraltar). Imports of zolpidem into 
Azerbaijan are prohibited, and Ethiopia does not import 
the substance. At the same time, information on the con-
trol of zolpidem remains unknown for 86 countries and 
territories. INCB therefore again invites the Governments 
of those countries and territories to supply it with infor­
mation on the control status of zolpidem as soon as 
possible.
61. With regard to precursor chemicals, the Board 
notes that in a number of countries, the necessary legis-
lation and control measures are still not in place or fully 
implemented. As a Government’s domestic regulatory 
system is also a prerequisite for being able to notify 
importing countries of exports of chemicals prior to their 
departure, Governments are requested to adopt and 
implement national control measures to effectively 
 monitor the movement of precursor chemicals. 
Governments are also requested to further strengthen 
existing precursor control measures, should any weak-
nesses be identified. By implementing those measures, 
countries will limit their exposure to the risk of being 
targeted by drug traffickers. 
(b) Prevention of diversion from 
international trade
Estimates and assessments of annual 
requirements for controlled substances
62. The system of estimates and assessments of annual 
licit requirements for narcotic drugs and psychotropic 
substances is the cornerstone of the international drug 
control system. It enables exporting and importing coun-
tries alike to ensure that trade in those substances stays 
within the limits determined by the Governments of 
importing countries and that diversions of controlled sub-
stances from international trade are effectively prevented. 
For narcotic drugs, such a system is mandatory under the 
1961 Convention, and the estimates furnished by 
Governments need to be confirmed by the Board before 
becoming the basis for calculating the limits on manu-
facture or import. The system of assessments of annual 
requirements for psychotropic substances was adopted by 
the Economic and Social Council and the system of esti-
mates of annual requirements for selected precursors was 
adopted by the Commission on Narcotic Drugs, in its res-
olution 49/3, to help Governments to prevent attempts by 
traffickers to divert controlled substances into illicit chan-
nels. The assessments of annual requirements for psycho-
tropic substances and estimates of annual requirements 
for selected precursors help Governments to identify 
un usual transactions. In many cases, the diversion of a 
controlled substance has been prevented when the 
 exporting country refused to authorize the export of the 
substance because the quantities of the substance to be 
exported would have exceeded the quantities required in 
the importing country.
63. The Board regularly investigates cases involving pos-
sible non-compliance by Governments with the system of 
estimates or assessments, as such non-compliance could 
facilitate the diversion of controlled substances from licit 
international trade into illicit channels. In that connec-
tion, the Board provides advice to Governments on the 
details of the system for estimates or assessments, as 
necessary.
64. Governments have the obligation to comply with 
the limits on imports and exports of narcotic drugs pro-
vided for under articles 21 and 31 of the 1961 Convention. 
Article 21 stipulates, inter alia, that the total of the quan-
tities of each drug manufactured and imported by any 
country or territory in a given year shall not exceed the 
sum of the quantity consumed for medical and scientific 
purposes; the quantity used, within the limits of the 
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relevant estimates, for the manufacture of other drugs, 
preparations or substances; the quantity exported; the 
quantity added to the stock for the purpose of bringing 
that stock up to the level specified in the relevant esti-
mate; and the quantity acquired within the limit of the 
relevant estimate for special purposes. Article 31 requires 
all exporting countries to limit the export of narcotic 
drugs to any country or territory so that the quantities 
imported fall within the limits of the total of the estimates 
of the importing country or territory, with the addition 
of the amounts intended for re-export.
65. As in previous years, the Board found that the sys-
tem of imports and exports generally continues to be 
respected and works well. In 2015, a total of 14 countries 
were contacted regarding possible excess imports or 
excess exports identified with regard to international 
trade in narcotic drugs that had been effected during 
2014. Most of the cases were clarified as: (a) a result of 
errors in reporting on imports or exports; (b) substances 
imported for re-export; (c) a result of errors in the report-
ing of the substance or trading partner; and (d) seized 
drugs imported as court evidence. However, four coun-
tries confirmed that excess exports or excess imports had 
actually occurred and they were reminded of the need to 
ensure full compliance with the relevant treaty provisions. 
The Board continues to pursue the matter with those 
countries that have failed to respond.
66. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of annual domestic 
medical and scientific requirements for psychotropic sub-
stances in Schedules II, III and IV of the 1971 Convention. 
The assessments received are communicated to all States 
and territories to assist the competent authorities of 
exporting countries when approving exports of psycho-
tropic substances. As at 1 November 2015, the Gov-
ernments of all countries and territories, except for South 
Sudan, for which assessments were established by the 
Board in 2011, had submitted at least one assessment of 
their annual medical requirements for psychotropic 
substances.
67. The Board recommends that Governments review 
and update the assessments of their annual medical and 
scientific requirements for psychotropic substances at 
least every three years. However, 24 Governments have 
not submitted a revision of their legitimate require-
ments for psychotropic substances for at least three 
years. The assessments valid for those countries and 
 territories may therefore no longer reflect their actual 
medical and scientific requirements for psychotropic 
substances. 
68. When assessments are lower than the actual legiti-
mate requirements, the importation of psychotropic sub-
stances needed for medical or scientific purposes may be 
delayed. When assessments are significantly higher than 
legitimate needs, the risk of psychotropic substances 
being diverted into illicit channels may be increased. In 
its interaction with State parties, the Board has repeat-
edly reminded countries that it is important that 
Governments estimate and assess correctly and accurately 
the initial needs of their country. Therefore, INCB calls 
upon all Governments to review and update their assess­
ments and estimates on a regular basis and to keep it 
informed of all modifications, with a view to prevent­
ing any unnecessary importation and, at the same time, 
facilitating the timely importation of psychotropic sub­
stances needed for medical purposes. 
69. As in previous years, the system of assessments of 
annual requirements for psychotropic substances contin-
ues to function well and is respected by most countries 
and territories. In 2014, the authorities of eight countries 
issued import authorizations for substances for which 
they had not established any such assessments or for 
quantities that significantly exceeded their assessments. 
Only two countries exported psychotropic substances in 
quantities exceeding the relevant assessment.
Requirement for import and export 
authorizations
70. One of the main pillars of the international drug con-
trol system is the universal application of the requirement 
for import and export authorizations. Such authorizations 
are required for transactions involving any of the sub-
stances controlled under the 1961 Convention or listed in 
Schedules I and II of the 1971 Convention. Competent 
national authorities are required by those conventions to 
issue import authorizations for transactions involving the 
importation of such substances into their country. The 
competent national authorities of exporting countries must 
verify the authenticity of such import authorizations before 
issuing the export authorizations required to allow ship-
ments containing the substances to leave their country.
71. The 1971 Convention does not require import and 
export authorizations for trade in the psychotropic sub-
stances listed in Schedules III and IV of the Convention. 
However, in view of the widespread diversion of those sub-
stances from licit international trade in the 1970s and 
1980s, the Economic and Social Council, in its resolutions 
1985/15, 1987/30 and 1993/38, requested Governments to 
extend the system of import and export authorizations to 
cover those psychotropic substances as well.
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72. Most countries and territories have already intro-
duced an import and export authorization requirement for 
psychotropic substances in Schedules III and IV of the 
1971 Convention, in accordance with the above-mentioned 
Economic and Social Council resolutions. By 1 November 
2015, specific information had been made available to the 
Board by 206 countries and territories, showing that all 
major importing and exporting countries now require 
import and export authorizations for all psychotropic sub-
stances in Schedules III and IV of the 1971 Convention. 
A table showing the import authorization requirements for 
substances in Schedules III and IV applied pursuant to the 
relevant Economic and Social Council resolutions by indi-
vidual countries is disseminated by the Board to all 
Governments twice a year. That table is also published in 
the secure area of the Board’s website, which is accessible 
only to specifically authorized Government officials so that 
the competent national authorities of exporting countries 
may be informed as soon as possible of changes in import 
authorization requirements in importing countries. INCB 
urges the Governments of the few States in which national 
legislation does not yet require import and export author­
izations for all psychotropic substances, regardless of 
whether they are States parties to the 1971 Convention, 
to extend such controls to all substances in Schedules III 
and IV of the 1971 Convention as soon as possible and 
to inform the Board accordingly.
Developing an international electronic import 
and export authorization system for narcotic 
drugs and psychotropic substances
73. Import and export authorizations are required for 
narcotic drugs in all Schedules of the 1961 Convention 
and for psychotropic substances listed in Schedules I and 
II of the 1971 Convention. Furthermore, pursuant to the 
relevant Economic and Social Council resolutions, 
Governments are urged to apply an import and export 
authorization requirement to substances listed in 
Schedules III and IV as well. As part of its endeavours to 
harness technological progress to the effective and effi-
cient implementation of the import and export authori-
zation regime for licit international trade in narcotic 
drugs and psychotropic substances, the Board has spear-
headed efforts to develop an electronic tool to facilitate 
and expedite the work of competent national authorities 
and to reduce the risks of diversion of those drugs and 
substances. The new tool, called the International Import 
and Export Authorization System (I2ES), is an innova-
tive, web-based application that was developed by the 
Board in cooperation with UNODC and with the sup-
port of Member States. I2ES allows Governments to elec-
tronically generate import and export authorizations for 
licit imports and exports of narcotic drugs and psycho-
tropic substances, to exchange those authorizations in real 
time and to instantly verify the legitimacy of individual 
transactions while ensuring full compliance with the 
requirements of the international drug control conven-
tions. I2ES significantly reduces the risk of drug consign-
ments being diverted into illicit channels.
74. As all participating Government officials are individ-
ually pre-screened by the INCB secretariat before being 
given “administrator” access to I2ES, Governments can 
know with certainty that any I2ES-generated authorization 
is legitimate and authentic. I2ES automatically checks the 
amount(s) to be imported against the estimates and assess-
ments of importing countries and alerts users to excess 
imports. I2ES also sends electronic alerts when the amounts 
actually received in the importing country are smaller than 
the amounts that were authorized for export. 
75. Designed to complement, but not replace, existing 
national electronic systems, I2ES is able to link with other 
national electronic systems so that Governments do not 
need to abandon their own domestic electronic monitoring 
systems. For countries without national electronic monitor-
ing systems, it is possible to generate import and export 
authorizations in I2ES and to download and print them as 
necessary. The system is expected to streamline and facili-
tate the process of verification of import and export author-
izations by the competent national authorities. In developing 
I2ES, the Board has ensured that the format of and the 
types of information to be included in those electronic 
authorizations meet all the requirements provided for in the 
international drug control conventions. 
76. I2ES was officially launched on the margins of the fifty-
eighth session of the Commission on Narcotic Drugs, held 
in Vienna in March 2015. In its resolution 58/10, the 
Commission welcomed the launch of I2ES, urged Member 
States to promote and facilitate the fullest possible use of the 
system and invited Member States to provide voluntary 
financial contributions for its administration and mainte-
nance. Since its launch, I2ES has been open for registration 
by competent national authorities. So far, competent national 
authorities from 15 countries (Algeria, Australia, Bangladesh, 
Brazil, Canada, Chile, Colombia, Germany, Malaysia, Peru, 
Singapore, Switzerland, Thailand, Turkey and Zambia) have 
registered. The Board stands ready to provide further infor-
mation on I2ES to interested Governments at any time. 
Detailed information on I2ES is also available on the Board’s 
website (www.incb.org), in the secure area for Governments. 
INCB wishes to encourage all competent national autho­
rities that have not yet done so to register and start using 
I2ES as soon as possible, as only through its widespread 
application will Governments be able to avail themselves 
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of all the advantages that the tool provides. The Board 
stands ready to assist in that regard. The Board reiterates 
the call to Member States contained in Commission on 
Narcotic Drugs resolution 58/10 to provide the fullest pos­
sible financial support to enable the secretariat of the Board 
to continue administering and monitoring the system.
Pre-export notifications for precursor chemicals
77. To help prevent the diversion of precursor chemicals 
from international trade, the 1988 Convention, and specif-
ically its article 12, paragraph 10 (a), allows the Governments 
of importing countries to make it mandatory for export-
ing countries to inform them of any planned export of pre-
cursors to their territory. The importing country has the 
opportunity to verify the shipment’s legitimacy using that 
pre-export notification. Currently, 113 States and territo-
ries have invoked the provision and have formally requested 
pre-export notifications. Although this represents an 
increase compared with the previous year, there is still a 
significant number of Governments and regions that 
remain unaware of, and vulnerable to, precursors entering 
their territory. INCB encourages the remaining 
Governments to invoke article 12, paragraph 10 (a), of 
the 1988 Convention without further delay.
78. To help Member States easily provide each other 
with information on planned exports of precursor chem-
icals, the Board established Pre-Export Notification Online 
(PEN Online) in 2006. PEN Online allows users to raise 
alerts when the legitimacy of a given shipment is suspect. 
A total of 151 countries and territories have registered to 
use PEN Online, and increasing use has led to an average 
of more than 2,600 pre-export notifications  communicated 
each month. The Board is aware that some countries con-
tinue to export scheduled chemicals without sending pre-
export notifications via the PEN Online  system, in some 
cases despite the fact that the importing country requires 
such pre-export notifications. INCB calls on Governments 
to actively and systematically use PEN Online and urges 
the remaining States that have not  registered to use the 
system to do so as soon as possible.
(c) Effectiveness of the control measures 
aimed at preventing the diversion of 
controlled substances from international 
trade 
79. The system of control measures laid down in the 1961 
Convention provides effective protection to international 
trade in narcotic drugs against attempts to divert such 
drugs into illicit channels. Similarly, as a result of the 
almost universal implementation of the control measures 
stipulated in the 1971 Convention and the related Economic 
and Social Council resolutions, in recent years there have 
been no identified cases involving the diversion of psycho-
tropic substances from international trade into illicit chan-
nels. In addition, the 1988 Convention obliges parties to 
prevent the diversion of precursor chemicals from interna-
tional trade to the manufacture of narcotic drugs and psy-
chotropic substances. The Board has developed various 
systems to monitor compliance with that aspect of the 1988 
Convention and has recorded limited cases of diversion 
from licit international trade. 
80. Discrepancies in Government reports on interna-
tional trade in narcotic drugs and psychotropic sub-
stances are regularly investigated with the competent 
authorities of the relevant countries to ensure that no 
diversion of narcotic drugs and psychotropic substances 
from licit international trade takes place. Those investi-
gations may reveal shortcomings in the implementation 
of control measures for narcotic drugs and psychotropic 
substances, including the failure of companies to comply 
with national drug control provisions.
81. Since May 2015, investigations regarding discrepan-
cies for 2014 related to the trade in narcotic drugs have 
been initiated with 32 countries. The responses indicated 
that the discrepancies were caused by clerical and tech-
nical errors in preparing the reports, reporting on exports 
or imports of preparations in Schedule III of the 1961 
Convention without indicating it on the form, and inad-
vertent reporting of transit countries as trading partners. 
In some cases, countries confirmed the quantities reported 
by them, resulting in follow-up investigations with their 
respective trading partners being initiated. Reminder let-
ters were sent to the countries that did not reply.
82. Similarly, with regard to international trade in psy-
chotropic substances, investigations into 549 discrepan-
cies related to 2013 data were initiated with 74 countries. 
As at 4 September 2015, 28 countries had provided replies 
relating to 393 cases involving discrepancies, leading to 
the resolution of 107 of those cases. In all cases in which 
the data provided were confirmed by the responding 
countries, follow-up actions with the counterpart coun-
tries were initiated. All responses received so far indicate 
that the discrepancies were caused by clerical or techni-
cal errors, in most cases either the failure to convert 
amounts into anhydrous base or “overlapping”, i.e. an 
export in a given year was received by the importing 
country only at the beginning of the following year. None 
of the cases investigated showed a possible diversion of 
psychotropic substances from international trade.
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83. INCB calls upon Governments to continue to 
monitor international trade in narcotic drugs, psycho­
tropic substances and precursors by using the tools 
mentioned above. Competent national authorities are 
encouraged to request the Board to assist in verifying 
the legitimacy of suspicious individual transactions.
(d) Prevention of diversion of precursors 
from domestic distribution channels
84. Diversion from domestic distribution channels has 
become a major source of precursors used for illicit drug 
manufacture, including methamphetamine. The control 
measures applied to domestic trade in and distribution of 
chemical substances often lag behind those used in interna-
tional trade, and the extent of control over domestic trade 
and distribution varies significantly from one country to 
another. More information on diversion from domestic dis-
tribution channels can be found in the report of the Board 
for 2015 on precursors. INCB encourages Governments to 
actively participate in the activities under Project Prism and 
Project Cohesion, the two international initiatives focusing 
on precursors used in the illicit manufacture of ampheta­
mine­type stimulants, and cocaine and heroin, respectively. 
The Board also recommends that all Governments regu­
larly review their annual legitimate requirements for the 
import of pseudoephedrine and ephedrine, as published, 
amend them as necessary utilizing the most recent market 
data and inform the Board accordingly. 
2. Ensuring the availability of 
internationally controlled substances for 
medical and scientific purposes
85. In line with its mandate to ensure the availability of 
internationally controlled substances for medical and sci-
entific purposes, the Board carries out various activities 
related to narcotic drugs and psychotropic substances. 
The Board monitors action taken by Governments, inter-
national organizations and other bodies to support the 
availability and rational use of controlled substances for 
medical and scientific purposes.
(a) Supply of and demand for opiate raw 
materials
86. INCB regularly examines issues affecting the supply 
of and demand for opiates for licit requirements, and 
endeavours to ensure a standing balance between that 
supply and demand on the basis of data provided by 
Governments. 
87. To establish the status of the supply of and demand 
for opiate raw materials, the Board analyses the data pro-
vided by Governments on opiate raw materials and on 
opiates manufactured from those raw materials. In addi-
tion, INCB also analyses information on the utilization 
of those raw materials, estimated consumption for licit 
use and stocks at the global level. A detailed analysis of 
the current situation with regard to the supply of and 
demand for opiate raw materials is contained in the 2015 
technical report of the Board on narcotic drugs.9 The fol-
lowing paragraphs provide a summary of that analysis.
88. INCB recommends that global stocks of opiate raw 
materials be maintained at a level sufficient to cover 
global demand for approximately one year, in order to 
ensure the availability of opiates for medical needs in case 
of an unexpected shortfall in production, for example, 
caused by adverse weather conditions in producing coun-
tries, and, at the same time, limit the risk of diversion 
associated with excessive stocks.
89. In 2014, the area sown with opium poppy rich in 
morphine in major producing countries decreased com-
pared with the levels of the previous year in Australia and 
France, but increased slightly in Turkey and stayed at the 
same level in India and Spain. In Hungary, the actual area 
harvested more than doubled in 2014. The advance data 
for 2015 show a 12 per cent increase in the total esti-
mated area of opium poppy rich in morphine harvested 
in major producing countries. That may be attributed to 
the expected increase in Turkey (131 per cent). In 2016, 
the cultivation of opium poppy rich in morphine will 
increase relative to 2015 in Spain, but it will decrease in 
most of the other main producing countries. It is expected 
to stay at the same level in Turkey.
90. India is the only opium-producing country that 
exports opium. It reduced its cultivation of opium poppy 
by 75 per cent in 2013, and its cultivation in 2014 
remained at that 2013 level, with 5,329 ha actually har-
vested in 2014.
91. In 2014, the cultivation of opium poppy rich in the-
baine increased in France and Spain and decreased in 
Australia. In 2015, the cultivation of opium poppy rich 
in thebaine measured in terms of area harvested is 
expected to decrease in Australia and to increase in Spain. 
France is not expected to cultivate opium poppy rich in 
thebaine in 2015.
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92. The actual area harvested for opium poppy rich in 
codeine in 2014 was 2,117 ha for Australia and 1,859 ha 
for France. Both Australia and France, being the only 
countries among the main producers that cultivate opium 
poppy rich in codeine, are expected to increase their cul-
tivation in 2015. However, Australia has forecast a dra-
matic decrease in the cultivation of opium poppy rich in 
codeine, from 5,220 ha in 2015 to 662 ha in 2016, while 
France has forecast an increase in the cultivation of that 
variety of opium poppy.
93. The total production of morphine-rich opiate raw 
materials in the main producing countries increased to 
534 tons10 in morphine equivalent in 2014 and it is 
expected to be about 626 tons in morphine equivalent in 
2015. Of that quantity, poppy straw will account for 596 
tons (95 per cent) and opium will account for 30 tons 
(5  per cent). In 2016, it is estimated that global produc-
tion will increase further, to 739 tons in morphine equi-
valent. In 2014, the global production of opiate raw 
materials rich in thebaine was 364 tons11 in thebaine 
equivalent. It is expected to increase to about 376 tons in 
thebaine equivalent in 2015 but to decrease to about 309 
tons in 2016. As in previous years, the actual production 
of opiate raw materials in 2015 and 2016 may differ con-
siderably from the estimates, depending on weather and 
other conditions.
94. INCB measures demand for opiates in two ways: 
(a)  in terms of the utilization of opiate raw materials, in 
order to reflect demand by manufacturers; and (b) in 
terms of global consumption of all opiates controlled 
under the 1961 Convention for medical and scientific 
purposes.12
95. Stocks of opiate raw materials rich in morphine in 
the form of poppy straw, concentrate of poppy straw and 
opium amounted to about 495 tons in morphine 
 10 The analysis is based predominantly on raw materials obtained 
from opium poppy rich in morphine but includes the morphine alkaloid 
contained in opium poppy rich in thebaine and in opium poppy rich in 
codeine whenever appropriate.
 11 The analysis is based predominantly on raw materials obtained 
from opium poppy rich in thebaine but includes the thebaine alkaloid 
contained in opium poppy rich in morphine whenever appropriate.
 12 Prior to 2003, INCB measured global demand only by global 
consumption of major opiates controlled under the 1961 Convention, 
expressed in morphine equivalent. However, by using that approxima-
tion, the following were excluded: (a) demand for less commonly used 
narcotic drugs; (b) demand for substances not controlled under the 
1961 Convention but manufactured from opiate raw materials and for 
the consumption of which data are not available to INCB; and 
(c)  fluctuations in the utilization of raw materials owing to  developments 
in the market anticipated by the manufacturers, such as expectations of 
sales of opiates and expected changes in the prices of raw materials or 
 opiates.
equivalent at the end of 2014. Those stocks were con-
sidered to be sufficient to cover 13 months of expected 
global demand by manufacturers at the 2015 level. 
Stocks of opiate raw materials rich in thebaine (poppy 
straw, concentrate of poppy straw and opium) increased 
to about 287 tons in thebaine equivalent by the end of 
2014. Those stocks would be sufficient to cover the 
expected global demand by manufacturers in 2015 for 
about 14 months.
96. Global stocks of opiates based on morphine-rich 
opiate raw material, mainly in the form of codeine and 
morphine, held at the end of 2014 (574 tons in morphine 
equivalent) were sufficient to cover global demand for 
medical and scientific purposes for those opiates for 
about 17 months. On the basis of data reported by 
Governments, total stocks of both opiates and opiate raw 
materials are sufficient to cover demand for medical and 
scientific purpose for morphine-based opiates. Global 
stocks of opiates based on thebaine-rich raw material 
(oxycodone, thebaine and a small quantity of oxymor-
phone) decreased to 225 tons in thebaine equivalent at 
the end of 2014 and were sufficient to cover global 
demand for medical and scientific purposes for thebaine-
based opiates for about 17 months.
97. In 2014, global demand by manufacturers for opi-
ate raw materials rich in morphine increased to 471 tons 
in morphine equivalent, but it is expected to decrease 
slightly in 2015, owing to the decrease in demand for 
opium, and then to increase again in 2016; it is antici-
pated to be about 460 tons in 2015 and about 480 tons 
in 2016. Global demand by manufacturers for opiate raw 
materials rich in thebaine has been decreasing since 2012, 
probably owing to restrictions on prescription drugs 
introduced in the main market (the United States). In 
2014, total demand decreased to 202 tons of thebaine 
equivalent, from 235 tons in 2013. Global demand for 
raw materials rich in thebaine is expected to rise to about 
240 tons of thebaine equivalent in 2015 and reach 260 
tons in 2016.
98. Codeine and hydrocodone are the most consumed 
opiates manufactured from morphine. Global demand for 
morphine-based opiates for medical and scientific pur-
poses has increased, with fluctuations since 2010, reach-
ing 416 tons in morphine equivalent in 2014. Demand 
for thebaine-based opiates is concentrated mainly in the 
United States and has increased sharply since the late 
1990s. Similar to morphine-based opiates, the global 
demand for thebaine-based opiates increased in 2014, to 
151 tons. Global demand is anticipated to reach approx-
imately 160 tons of thebaine equivalent in 2015 and 180 
tons in 2016.
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99. The global production of opiate raw materials rich 
in morphine has exceeded the global demand for those 
raw materials since 2009. As a result, stocks have been 
increasing, albeit with fluctuations. In 2014, stocks 
decreased to 495 tons in morphine equivalent and were 
sufficient to cover the expected global demand for about 
13 months. In 2015, global production of opiate raw 
materials rich in morphine is expected to exceed global 
demand again, with the result that global stocks of those 
raw materials will further increase in 2016. Stocks are 
expected to reach 661 tons by the end of 2015, which is 
equivalent to about 17 months of expected global demand 
at the 2016 level of demand (although not all data are 
available to have a complete forecast). For 2016, produc-
ing countries indicated that they plan to increase produc-
tion. Stocks are anticipated to reach about 920 tons at the 
end of 2016, sufficient to cover several months in excess 
of one year of expected global demand. The global sup-
ply of opiate raw materials rich in morphine (stocks and 
production) will remain fully sufficient to cover global 
demand.
100. In 2014, global production of opiate raw materials 
rich in thebaine was again higher than demand, leading 
to an increase in stocks (287 tons) at the end of 2014, 
equivalent to global demand for 14 months. Production 
is expected to increase in 2015 and then to decrease in 
2016. By the end of 2015, global stocks of opiate raw 
materials rich in thebaine will likely reach 423 tons, suf-
ficient to cover global demand for about 20 months, and 
at the end of 2016 may reach 472 tons, sufficient to cover 
global demand for several months in excess of one year. 
The global supply of opiate raw materials rich in thebaine 
(stocks and production) will be more than sufficient to 
cover global demand in 2015 and 2016.
(b) Consumption of narcotic drugs and 
psychotropic substances
101. For 2014, a total of 53 Governments (of 50 States 
and three territories) have submitted information on con-
sumption of some or all psychotropic substances, in 
accordance with Commission resolution 54/6. That is 
similar to the number of countries that did so for 2013. 
The Board is pleased to note that among those 
Governments are countries that are major manufacturers 
and consumers of psychotropic substances, such as 
Belgium, Brazil, China, Denmark, France, Germany, the 
Netherlands, South Africa, the United Kingdom of Great 
Britain and Northern Ireland and the United States. That 
development will enable the Board to more accurately 
analyse the consumption levels for psychotropic sub-
stances in the countries and territories concerned and to 
better monitor consumption trends in countries and 
regions, with a view to identifying unusual or undesira-
ble developments. INCB therefore encourages those 
Governments that have submitted consumption data on 
psychotropic substances to continue doing so, and those 
that have not yet done so to start without further delay. 
Such information would enable the Board to analyse 
levels of consumption of psychotropic substances in an 
accurate manner and to promote their adequate availa­
bility in different regions across the globe.
C. Governments’ cooperation with 
the Board
1. Provision of information by 
Governments to the Board
102. The Board is mandated to publish each year two 
reports: the annual report and the report of the Board on 
the implementation of article 12 of the 1988 Convention. 
It also publishes technical reports that provide Gov-
ernments with analyses of statistical information on the 
manufacture, trade, consumption, utilization and stocks 
of internationally controlled substances, as well as analy-
ses of estimates and assessments of requirements for those 
substances.
103. The Board’s reports and technical publications are 
based on information that parties to the international 
drug control treaties are obligated to submit. In addition, 
and pursuant to resolutions of the Economic and Social 
Council and the Commission on Narcotic Drugs, Gov-
ernments voluntarily provide information on drug con-
trol in order to facilitate an accurate and comprehensive 
evaluation of treaty compliance and the overall function-
ing of the international drug control system.
104. The provision of data by and other information 
received from Governments allows the Board to monitor 
licit activities involving narcotic drugs, psychotropic 
 substances and precursor chemicals. On the basis of its 
analysis, INCB makes recommendations to improve the 
system with a view to ensuring the availability of narcotic 
drugs and psychotropic substances for medical and 
 scientific needs, while at the same time preventing their 
diversion from licit into illicit channels, as well as 
 preventing the diversion of precursors into illicit drug 
manufacture.
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2. Submission of statistical 
information
105. Governments have an obligation to furnish to the 
Board statistical reports containing information required 
by the international drug control conventions on an 
annual basis and in a timely manner.
106. As at 1 November 2015, annual statistical reports 
on narcotic drugs (form C) for 2014 had been furnished 
by 135 States and territories (representing 63 per cent of 
the States and territories requested to submit such 
reports), although more Governments are expected to 
submit their reports for 2014 in due course. In total, 178 
States and territories provided quarterly statistics on their 
imports and exports of narcotic drugs for 2014, amount-
ing to 83 per cent of the States and territories required 
to provide such statistics. A large number of Governments 
in Africa, the Caribbean and Oceania do not submit their 
statistics regularly, despite repeated requests by the Board.
107. As at 1 November 2015, annual statistical reports 
for 2014 on psychotropic substances (form P), in con-
formity with the provisions of article 16 of the 1971 
Convention, had been submitted to the Board by 131 
States and territories, amounting to 60 per cent of the 
States and territories required to provide such statistics. 
INCB notes that the rate of submission for 2014 is sim-
ilar to that for 2013. In addition, 108 Governments vol-
untarily submitted all four quarterly statistical reports on 
imports and exports of substances listed in Schedule II 
of the Convention, in conformity with Economic 
and  Social Council resolution 1981/7, and a further 
53 Governments submitted some quarterly reports.
108. While the majority of Governments regularly sub-
mit the mandatory and voluntary statistical reports, the 
cooperation of some has not been satisfactory. Among 
the countries that failed to submit form P before the 
deadline of 30 June 2015 were major manufacturing, 
importing and exporting countries such as Belgium, 
Brazil, Canada, China, France, India, Ireland, Italy, Japan, 
Pakistan, Spain and the United Kingdom. At the same 
time, the Board notes with satisfaction that the Republic 
of Korea, a significant importer and exporter of psycho-
tropic substances that did not furnish form P for the years 
2011-2013, resumed reporting to INCB for 2014.
109. The Board notes with concern that the number of 
countries and territories that have not furnished form P 
to INCB is again highest in Africa, Oceania and the 
Caribbean. A total of 38 countries and territories in 
Africa (68 per cent) failed to furnish form P for 2014 to 
INCB. Likewise, 50 per cent of the countries and territo-
ries in Oceania and 41 per cent in the Caribbean did not 
furnish form P for 2014. In contrast, form P for 2014 was 
furnished by all but two countries and one territory in 
Europe (Greece and Serbia, and Gibraltar) and by all but 
three countries in North and South America (Canada, 
Mexico and Paraguay).
110. Difficulties encountered by Governments in sub-
mitting statistical reports to the Board may indicate defi-
ciencies in their national mechanisms for regulating 
controlled substances. INCB therefore wishes to invite 
Governments concerned to take steps to enhance, as 
necessary, their mechanisms for regulating licit activi­
ties involving controlled substances, including national 
systems for compiling data for the mandatory and 
 voluntary statistical reports on narcotic drugs, psycho­
tropic substances and precursors, and the provision of 
adequate training to the staff of the national competent 
authorities, in line with the requirements of the inter­
national drug control treaties. 
111. The Economic and Social Council, in its resolu-
tions 1985/15 and 1987/30, requested Governments to 
provide the Board with details on trade (data broken 
down by countries of origin and destination) in sub-
stances listed in Schedules III and IV of the 1971 
Convention in their annual statistical reports on psycho-
tropic substances. For 2014, complete details on such 
trade were submitted by 117 Governments (89 per cent 
of all submissions of form P), which is about the same as 
for 2013. For the other 14 Governments, there were only 
some missing trade data for 2014. The Board notes with 
appreciation that a number of countries have already been 
in a position to submit consumption data for psycho-
tropic substances on a voluntary basis in accordance with 
Commission on Narcotic Drugs resolution 54/6. Thus, in 
2014, a total of 54 countries and territories submitted data 
on consumption of some or all psychotropic substances. 
INCB appreciates the cooperation of the Governments 
concerned and calls upon all other Governments to fur­
nish information on the consumption of psychotropic 
substances, as such data are key to an improved evalu­
ation of the availability of psychotropic substances for 
medical and scientific purposes.
112. With regard to precursor chemicals, pursuant to 
article 12 of the 1988 Convention, parties are obliged to 
report information on substances frequently used in the 
illicit manufacture of narcotic drugs and psychotropic 
substances. By providing that information annually on 
form D, Governments help the Board identify emerging 
trends in precursor trafficking and the illicit manufacture 
of drugs.
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113. As at 1 November 2015, a total of 113 States and 
territories had submitted form D for 2014. However, 66 
countries failed to meet their obligation to submit the 
form on time by the annual deadline of 30 June 2015.
114. Of the States and territories that provided data for 
2014, 54 Governments reported seizures of scheduled 
substances, and 33 Governments reported seizures of 
non-scheduled substances, fewer than in the previous 
year. Many Governments did not provide details on the 
methods of diversion and illicit manufacture or on 
stopped shipments. The Board urges Governments to put 
the relevant mechanisms in place to ensure that all data 
submitted to INCB are comprehensive and timely.
115. On form D, Governments are urged to provide on 
a voluntary and confidential basis information about their 
licit trade in precursor chemicals. The Board requests this 
information in accordance with Economic and Social 
Council resolution 1995/20. By accessing those data, 
INCB is able to identify discrepancies in data reported 
by trading partners and help prevent the diversion of 
chemicals. As at 1 November 2015, 125 States and terri-
tories had provided relevant information on licit trade for 
the 2014 reporting period, and 98 States and territories 
had informed INCB about the licit uses of and require-
ments for some or all of those substances.
116. In 2014, the international community continued to 
use a variety of innovative tools to reinforce and bolster 
the precursor control regime. Domestic legislation or new 
regulatory measures were used by Australia, China, 
Colombia, the Lao People’s Democratic Republic, Poland, 
Turkey and the European Union to strengthen controls 
over the manufacture, import, distribution, or sale of pre-
cursor chemicals.
117. The INCB Precursors Incident Communication 
System (PICS) is a secure online tool for worldwide 
 information-sharing between national authorities on pre-
cursor incidents, including seizures, shipments stopped 
in transit, diversions and diversion attempts and illicit 
laboratories. Registration with PICS is cost-free and sim-
ple for Government authorities to access and use. It is 
now available in four languages: English, French, Russian 
and Spanish.
118. PICS has seen tremendous growth, both in the 
number of users and the number of incidents communi-
cated, demonstrating that it is now a key tool of the inter-
national precursor control regime. As at 1 November 
2015, there were more than 420 registered users of PICS 
from 94 countries, representing some 200 national agen-
cies and 10 international and regional agencies. Nearly 
1,500 incidents have been communicated since the launch 
of PICS in 2012.
3. Submission of estimates and 
assessments
119. Pursuant to the 1961 Convention, States parties are 
obliged to provide the Board each year with estimates of 
their requirements for narcotic drugs for the following 
year. As at 1 November 2015, a total of 149 States and 
territories had submitted estimates of their requirements 
for narcotic drugs for 2016, representing 70 per cent of 
the States and territories required to furnish annual esti-
mates for confirmation by the Board. As was the case in 
previous years, the Board had to establish estimates for 
those States and territories that had not submitted their 
estimates on time, in accordance with article 12 of the 
1961 Convention.
120. As at 1 November 2015, the Governments of all 
countries except South Sudan and all territories had sub-
mitted to the Board at least one assessment of their 
annual medical and scientific requirements for psycho-
tropic substances. The assessments of requirements for 
psychotropic substances for South Sudan were established 
by INCB in 2011, in accordance with Economic and 
Social Council resolution 1996/30, in order to allow that 
country to import such substances for medical purposes 
without undue delay.
121. Pursuant to Economic and Social Council resolu-
tions 1981/7 and 1991/44, Governments are requested to 
provide to the Board assessments of their annual medi-
cal and scientific requirements for psychotropic sub-
stances listed in Schedules II, III and IV of the 1971 
Convention. Assessments for psychotropic substances 
remain in force until Governments modify them to reflect 
changes in national requirements. In this regard, the 
Board created a new form, entitled “Supplement to form 
B/P”, designed to facilitate the submission to INCB by 
competent national authorities of modifications to assess-
ments for psychotropic substances. The form was trans-
lated into the six official languages of the United Nations 
and introduced to all Governments in October 2014. A 
year after the official release of the form, almost all coun-
tries providing modifications to their assessments have 
already begun using the new form.
122. INCB recommends that Governments review and 
update the assessments of their annual medical and sci­
entific requirements for psychotropic substances at least 
once every three years.
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123. Since 1 November 2014, a total of 87 countries and 
6 territories have submitted fully revised assessments of 
their requirements for psychotropic substances, and a fur-
ther 88 Governments submitted modifications to assess-
ments for one or more substances. Governments of 23 
countries and 1 territory have not submitted any revision 
of their legitimate requirements for psychotropic sub-
stances for over three years.
124. The Board wishes to emphasize the importance 
of determining accurate initial levels of estimates for 
narcotic drugs and assessments for psychotropic 
 substances that adequately reflect actual licit needs. If 
estimates and assessments are lower than the legitimate 
requirements, the importation or use of narcotic drugs or 
psychotropic substances needed for medical or scientific 
purposes may be delayed or impeded, whereas estimates 
or assessments that are significantly higher than legiti-
mate requirements might increase the risk that imported 
narcotic drugs and psychotropic substances are diverted 
into illicit channels. INCB reminds all Governments that 
they have the possibility of submitting to the Board sup­
plementary estimates for narcotic drugs or modifica­
tions to assessments for psychotropic substances at any 
time during the year, whenever they find that their 
country’s current estimates or assessments are not suf­
ficient to cover licit needs. To be able to adequately 
assess their country’s needs, Governments may wish to 
avail themselves of the Guide on Estimating Requirements 
for Substances under International Control, published in 
February 2012, which was developed by INCB and the 
World Health Organization for use by competent 
national authorities and is available on the INCB  website 
( www.incb.org) in the six official languages of the 
United Nations.
125. The Commission on Narcotic Drugs, in its resolu-
tion 49/3, requested Member States to provide annual 
estimates to the Board of their legitimate requirements 
for substances frequently used in the manufacture of 
amphetamine-type stimulants, including 3,4-methylene-
dioxyphenyl-2-propanone (3,4-MDP-2-P), pseudoephed-
rine, ephedrine and 1-phenyl-2-propanone (P-2-P) and, 
to the extent possible, for preparations containing those 
substances. Those data help give the competent authori-
ties of exporting countries indications of the needs of 
importing countries, thus alerting them to any potential 
oversupply and preventing diversion attempts. The infor-
mation is provided each year on form D and can be 
updated with INCB at any time and is available on the 
INCB website. Of note in 2015 was the reduction by 
almost 70 per cent of the annual legitimate requirement 
for the import of pseudoephedrine raw material to the 
Islamic Republic of Iran.
126. As at 1 November 2015, 157 Governments had 
provided estimates for at least one of the above- mentioned 
substances. It is noteworthy that the number of estimates 
provided by individual Governments has increased stead-
ily over the past 10 years. The number of competent 
authorities of exporting countries that have consulted 
with the Board about the legitimate requirements of their 
trading partners has also steadily increased, thus indicat-
ing the value of the estimates and the increased aware-
ness and use of this basic tool.
127. The Board wishes to remind all Governments that 
the totals of estimates of annual medical and scientific 
requirements for narcotic drugs, as well as assessments 
of requirements for psychotropic substances, are pub­
lished in yearly and quarterly publications and that 
monthly updates are available on the Board’s website. 
Updated information on annual estimates of legitimate 
requirements for precursors of amphetamine-type stimu-
lants is also available on the website.
4. Data examination and identified 
reporting deficiencies
128. Problems encountered by Governments in fur-
nishing adequate statistics and/or estimates and assess-
ments to the Board are often an indication of deficiencies 
in the national control mechanisms and/or health-care 
systems in the countries concerned. Such deficiencies 
may reflect problems in the implementation of treaty 
provisions, for instance, gaps in national legislation, 
shortcomings in administrative regulations or lack of 
training of staff of competent national authorities. INCB 
invites all Governments concerned to find the causes 
for deficiencies in reporting statistics and/or estimates 
and assessments to the Board, with a view to resolving 
those problems and ensuring adequate reporting. To 
assist Governments, INCB has developed tools and kits 
for use by competent national authorities that are avail­
able on its website free of charge. Governments are 
invited to make full use of those tools in the execution 
of their functions under the international drug control 
treaties. INCB also wishes to encourage Governments 
to avail themselves of the specific training that is pro­
vided by INCB upon request and provide support to 
the Board in this regard.
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D. Evaluation of overall treaty 
compliance
1. Evaluation of overall treaty 
compliance in selected countries
129. The Board regularly reviews the drug control situ-
ation in different countries and overall compliance by 
Governments with the provisions of the international 
drug control treaties. The Board’s analysis covers various 
aspects of drug control, including the functioning of 
national drug control administrations, the adequacy of 
national drug control legislation and policy, measures 
taken by Governments to combat drug trafficking and 
abuse and to ensure the adequate availability of narcotic 
drugs and psychotropic substances for medical purposes, 
and the fulfilment by Governments of their reporting 
obligations under the treaties.
130. The findings of the review and the Board’s recom-
mendations for remedial action are conveyed to the 
Governments concerned as part of the ongoing dialogue 
between the Board and Governments to enhance the 
implementation of the international drug control treaties.
131. In 2015, the Board reviewed the drug control sit-
uation in Ecuador, France, Jamaica, Morocco and the 
Philippines, as well as measures taken by the Governments 
of those countries to implement the international drug 
control treaties. In doing so, the Board took into account 
all available information, paying particular attention to 
new developments in drug control in those countries.
(a) Ecuador
132. The Board notes that the National Assembly of 
Ecuador adopted a comprehensive drug control law in 
October 2015, which will replace or supersede several leg-
islative provisions and significantly modify the operation 
of the drug control system in the country. The new law 
provides, among other things, for the establishment of a 
new institutional structure for the coordination of drug 
control efforts in the country through the creation of an 
inter-institutional committee mandated with formulating 
and coordinating drug-related public policy. It also pro-
vides for the creation of a technical secretariat on drugs 
mandated with regulating and monitoring the produc-
tion, manufacturing, import, export and transport of con-
trolled substances. The law will also confer upon the 
National Health Authority the responsibility to establish 
thresholds for the possession of narcotic drugs and psy-
chotropic substances for personal use.
133. The Board wishes to reiterate that the 1961 
Convention establishes, in its article 4 (“General obliga-
tions”), that the parties to the Convention shall take such 
legislative and administrative measures as may be neces-
sary to give effect to and carry out the provisions of the 
Convention and to limit exclusively to medical and sci-
entific purposes the production, manufacture, export, 
import, distribution of, trade in, use and possession of 
drugs. In addition, article 3, paragraph 2, of the 1988 
Convention sets forth the obligation for each State party, 
subject to its constitutional principles and the basic con-
cepts of its legal system, to adopt such measures as may 
be necessary to establish as a criminal offence under its 
domestic law, when committed intentionally, the posses-
sion, purchase or cultivation of narcotic drugs or psycho-
tropic substances for personal consumption.
134. The Board also notes that in July 2014 the 
Government of Ecuador adopted regulations affecting 
possession of narcotic drugs or psychotropic substances 
for personal use as published in the official gazette. 
Current drug control legislation criminalizes the posses-
sion of certain controlled narcotic drugs and psychotropic 
substances in the amounts above the thresholds set out 
in resolution No. 001 CONSEP-CD-2013, while posses-
sion of narcotic and psychotropic substances for personal 
use in quantities below those thresholds is not punisha-
ble pursuant to constitutional principles. Those principles 
include the supremacy of the Constitution, the right to 
personal development and the principle of proportional-
ity of sanctions. In addition, the Constitution defines 
addiction as a public health problem and establishes the 
State’s responsibility for the prevention of drug abuse and 
provides that the drug use shall not be criminalized. The 
Board is engaged in an active dialogue with the 
Government of Ecuador regarding the conformity of its 
legal framework on possession with its international obli-
gations under the drug control treaties.
135. The Board notes the commitment, expressed by the 
Government of Ecuador, to adopting an integrated 
approach to ensure that controlled substances are han-
dled effectively and that their diversion from licit distri-
bution channels is countered through effective control 
measures, and urges the Government to continue to 
strengthen its efforts to address illicit drug manufacture, 
trafficking and abuse in the country. 
(b) France
136. In April 2015, the French National Assembly 
adopted a draft bill on the modernization of the national 
health system at first reading. The bill was transmitted to 
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the Senate, examined by the Commission of Social Affairs 
and returned to the National Assembly for further 
consideration. 
137. One of the measures provided for in the draft bill 
is the establishment of so-called “low-risk consumption 
rooms” on a six-year trial basis which would begin as of 
the date of the opening of the first of those establish-
ments. The Government of France has mandated the 
French National Institute for Health and Medical Research 
to conduct, at the end of the six-year trial, the prepara-
tion of a comprehensive scientific review of the impact 
of drug-consumption rooms on the target population.
138. According to the French authorities, the establish-
ment of drug consumption rooms is part of the country’s 
“harm reduction” policy and has three main objectives: 
to forge links with drug users who constitute a margin-
alized group often having little or no contact with the for-
mal health-care system and to bring them back into the 
system; to reduce the transmission of blood-borne dis-
eases among individuals who abuse drugs by injection 
and reduce drug overdose cases; and to reduce the nui-
sance and disturbance to public order of drug abuse by 
injection.
139. In the past, the Board has expressed its concern 
that the establishment of drug consumption rooms may 
not be consistent with the provisions of the international 
drug control conventions. INCB reminds all States that 
the ultimate goal of drug treatment measures should be 
cessation of drug use through treatment of addiction, 
which should be accompanied by the provision of reha-
bilitation and social reintegration measures. As such, any 
form of assistance offered to persons suffering from drug 
dependence should be delivered within a framework that 
provides for the active referral of that person to treatment 
services.
140. As it does with other Governments on similar 
issues, the Board has actively engaged with the French 
authorities in an ongoing dialogue on this matter. The 
Board looks forward to continuing its dialogue with the 
Government of France to ensure that the drug control 
measures taken in that country continue to comply with 
the provisions of the international conventions.
(c) Jamaica
141. The Board takes note of the amendments to the 
Dangerous Drugs Act approved by the Jamaican 
Parliament in March 2015. The newly approved measures 
modify the country’s drug control legislation to the effect 
that possession of up to two ounces of cannabis (56.7 
grams) by an adult, including use for religious purposes, 
is reclassified as a non-criminal offence and will be sub-
ject to a fine. The Board notes that following the adop-
tion of the Act, possession of cannabis in amounts greater 
than the defined threshold remains a penal crime and 
that the Government of Jamaica has stated that it is not 
promoting or approving the use of cannabis for recrea-
tional purposes. The Board also notes the commitment 
made by the Government of Jamaica to refer individuals 
caught in possession of less than two ounces of cannabis 
but who appear to be drug-dependent to a drug treat-
ment and rehabilitation programme, as well as its planned 
national education campaign on drug abuse prevention. 
142. The Board underlines that the 1961 Convention 
establishes, in its article 4 (“General obligations”), that the 
parties to the Convention shall take such legislative and 
administrative measures as may be necessary to give effect 
to and carry out the provisions of the Convention and to 
limit exclusively to medical and scientific purposes the 
production, manufacture, export, import, distribution of, 
trade in, use and possession of drugs.
143. The Board stresses the importance of universal 
implementation of the international drug control treaties 
by all States parties and urges the Government of Jamaica 
to review implementation of its obligations under inter-
national drug control treaties and ensure that implemen-
tation of domestic legislation does not contravene the 
provisions of the international conventions to which 
Jamaica is a party. The Board will continue to monitor 
developments in Jamaica and looks forward to continu-
ing its dialogue with the Jamaican authorities on matters 
related to the implementation of the drug control 
conventions. 
(d) Morocco
144. The Board notes that since its high-level mission 
to Morocco in 2009, there has been a heightened level of 
cooperation between the Government of Morocco and 
the Board. 
145. Morocco remains one of the world’s largest pro-
ducers of cannabis resin and continues to be a major 
source country for cannabis resin trafficked to Europe. 
Over the past decade, Morocco has been one of the three 
countries most frequently cited as source or transit coun-
tries for cannabis resin seized worldwide. 
146. Morocco has made significant efforts to counter 
illicit cannabis cultivation, leading to a decrease in 
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reported cannabis cultivation in 2014 in comparison with 
2012. The Board also notes that progress has been made 
in addressing drug-related problems particularly with 
regard to the prevention and treatment and reduction of 
illicit cultivation and trafficking of cannabis in the coun-
try. While seizures of cannabis resin reported by the 
Moroccan authorities have declined significantly since 
2012, the country is witnessing the emergence of the traf-
ficking of cocaine, which is being smuggled on commer-
cial flights from Brazil and transits through West Africa 
and Morocco en route to Europe. 
147. The National Commission on Narcotic Drugs of 
Morocco has continued to adopt measures for the imple-
mentation of the international drug control treaties. Over 
the past two years, Morocco has extended its national 
action plan on drug use, creating more treatment centres 
throughout the country. Morocco has implemented its 
national action plan on harm reduction, launching new 
opiate substitution treatment programmes and initiating 
the first such programme in a prison setting. The country 
has released the first report of the National Observatory 
on Drugs and Addictions and has carried out its second 
national study on drug use among high-school students. 
148. Morocco is currently developing a sectoral coop-
eration strategy for the period 2016-2021 with WHO. At 
a meeting of the steering committee for the development 
of that strategy held in June 2015, representatives of the 
Government and WHO discussed the modalities of the 
proposed strategy. 
149. Despite the progress made by Morocco in its drug 
control efforts, several important challenges remain. The 
Board notes that illicit drug production in Morocco con-
tinues to pose a significant challenge to the Government’s 
efforts to address the drug problem. The Board encour-
ages the Government of Morocco to pursue its drug con-
trol efforts, in particular those taking aim at illicit 
cannabis cultivation and trafficking in the country and 
stands ready to assist in whatever manner it can.
(e) Philippines
150. The Board continues to engage in a constructive 
dialogue with the Government of the Philippines on 
drug-related developments in the country, with a view to 
promoting compliance by the Government and assisting 
it with meeting the requirements of the international drug 
control treaties. 
151. The Board welcomes the adoption by the 
Philippines of an integrated approach to combating drug 
abuse and trafficking through its national anti-drug plan 
of action for the period 2015-2020 and its implementa-
tion plan which covers five strategic concepts: supply 
reduction, demand reduction, alternative development, 
civic awareness and response, and regional and interna-
tional strategies. This updated framework redefines the 
mandates of all stakeholders involved and outlines the 
national priority areas related to drug abuse and 
control.
152. In accordance with the national anti-drug plan, the 
Dangerous Drugs Board, which formulates the national 
drug-control policy, plays a significant role in realizing 
the objectives set forth in the Philippine Development 
Plan, particularly in the areas of peace and security and 
social development, and in international and regional 
agreements and declarations. The Dangerous Drugs Board 
provides the applicable measures for coordination, as well 
as monitoring and evaluation. 
153. The Board acknowledges the legislative and admin-
istrative changes introduced by the Government of the 
Philippines to improve the effectiveness of law enforce-
ment and expand the scope of drug control. There were 
significant cannabis seizures in 2014 (164 kilograms of 
cannabis herb and 576 kilograms of dried cannabis); 
718.5 kilograms of methamphetamine were also seized. 
The volume of tablets of 3,4-methylenedioxymetham-
phetamine (MDMA, commonly known as “ecstasy”) 
seized in 2014 was the largest total amount recorded in 
the country since 2002.
154. The Board notes with concern that there was also 
a reported increase in the abuse of amphetamine-type 
stimulants, in particular methamphetamine, and a high 
rate of HIV prevalence among people who inject drugs 
(46.1 per cent).
155. The Board notes that there remain challenges to be 
addressed, including illicit cannabis cultivation in high-
altitude areas of the country that are of difficult access 
and are often not reached by the eradication efforts of the 
law enforcement authorities. The Board encourages the 
Government of the Philippines to take further action in 
this regard.
2. Country missions
156. In the context of its responsibility to promote com-
pliance by Governments with the international drug con-
trol conventions and to monitor the functioning of the 
international drug control system, the Board undertakes 
missions to selected countries every year in order to 
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maintain direct dialogue with Governments on matters 
relating to the implementation of the provisions of those 
conventions.
157. The purpose of the missions is to obtain detailed, 
first-hand information on the drug control policies in 
place in the countries visited and to discuss with compe-
tent national authorities their practical experience in 
implementing the conventions, including problems 
encountered, good practices identified and additional 
measures to be considered in order to optimize treaty 
compliance. 
158. The Board’s missions are aimed at appraising the 
prevailing situation in the countries visited on a wide 
variety of drug control matters within the ambit of the 
drug control conventions, including national drug con-
trol legislation; the supply reduction measures in place; 
regulatory aspects related to the provision of estimates, 
assessments, statistics and trade data to the Board; the 
availability of narcotic drugs and psychotropic substances 
for medical needs; precursor chemical control; and struc-
tures in place for the prevention of drug abuse and the 
treatment, rehabilitation and social integration of persons 
suffering from drug dependency and related health 
conditions.
159. In order to gain as comprehensive an overview as 
possible, the Board meets with senior officials from var-
ious institutional stakeholders at the political and regu-
latory levels within the country. In addition, the Board 
requests that the mission programme include visits to 
drug treatment facilities and social reintegration initia-
tives. Recognizing the important role played by non-
governmental organizations and other civil society 
groups, the Board carries out meetings with such enti-
ties, identified in consultation with the Vienna NGO 
Committee on Drugs, within the context of its country 
missions.
160. Based on the outcome of meetings held and infor-
mation collected, the Board issues a series of confidential 
recommendations on possible measures to bolster the 
implementation by the Governments concerned of their 
treaty obligations under the drug control conventions. 
The Board encourages all Governments to respond 
promptly and effectively to requests to conduct country 
missions, which constitute a pillar of treaty implementa-
tion monitoring.
161. During the period under review, the Board under-
took missions to Bahrain, Ghana, Honduras, Iran (Islamic 
Republic of), Italy, the Republic of Moldova, Timor-Leste 
and Venezuela (Bolivarian Republic of).
(a) Bahrain
162. A mission of the Board visited Bahrain in December 
2014 to discuss the implementation of the three drug con-
trol conventions including the legislative and institutional 
measures taken by the Government to control narcotic 
drugs, psychotropic substances and precursor chemicals. 
163. Bahrain is a party to the three international drug 
control treaties, and the country’s primary drug legisla-
tion is Law No. 15 of 2007 concerning narcotic drugs and 
psychotropic substances.
164. The national anti-drug strategy for the period 
2010-2015 covers two major sectors of activity: drug 
 supply reduction and demand reduction. The substantive 
areas covered in discussions with the authorities of 
Bahrain included the implementation of a coordination 
mechanism established under the chairmanship of the 
Ministry of the Interior at the policymaking/ministe-
rial  level to develop national drug-related policies and 
ensure  coordination among the relevant government 
stakeholders. 
165. The country is also facing the emergence of new 
psychoactive substances. Although it has introduced 
some changes to its consumer safety regulations to con-
trol new psychoactive substances, none of those emerg-
ing substances are currently scheduled under the national 
drug control law. 
166. Challenges persist in the implementation of the 
drug control treaties in Bahrain, including the need for 
more data on drug use prevalence to inform drug con-
trol policy, and the limited availability of narcotic drugs 
and psychotropic substances for medical treatment. 
(b) Ghana
167. A mission of the Board visited Ghana in April 
2015. Ghana is a party to all three international drug con-
trol conventions. The mission discussed with the author-
ities the Board’s concern about the high level of imports 
of diazepam into the country over the past few years, 
inquired about the availability of opioid medications for 
pain alleviation and palliative care, informed the 
Government about INCB tools to counter trafficking in 
precursors and assessed the progress made by the coun-
try since the Board’s last mission in 2005. 
168. In the past several years, Ghana has made signifi-
cant progress in drug-related enforcement measures, as 
evidenced by the sound internal coordination among 
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different government agencies and cooperation with the 
international community. 
169. Diazepam consumption in recent years has 
remained high. The substance is controlled under the 
1971 Convention and is the only anxiolytic available for 
medical use in Ghana. A number of control measures 
have been enforced by the Government to monitor the 
utilization of diazepam at the wholesale level.
170. Data on drug use prevalence in Ghana continue to 
be limited, which may impact the adoption of evidence-
based drug control policy as such information could serve 
as a basis for the development of pertinent demand 
reduction strategies and interventions. 
(c) Honduras
171. A mission of the Board visited Honduras in 
February 2015. Honduras is a party to the three interna-
tional drug control conventions. The mission examined 
recent developments in drug abuse and trafficking in 
Honduras, the Government’s cooperation with INCB, 
measures taken by the Government to control narcotic 
drugs, psychotropic substances and the chemicals used in 
their illicit manufacture, and policies to reduce demand 
for illicit drugs and treat and rehabilitate drug users. 
Drug-related violence in Honduras was also discussed. 
The number of homicides in the country, of which a sig-
nificant part are drug-related, has declined over the past 
two years. 
172. The most recent available data on drug use preva-
lence were from 2005. An up-to-date and objective assess-
ment of the current drug abuse situation is essential to 
developing policies and appropriate programmes for the 
prevention of drug abuse and treatment and rehabilita-
tion of those affected by drug abuse and for ensuring the 
efficient use of limited resources. 
173. The consumption of narcotic drugs and psycho-
tropic substances for medical purposes in Honduras con-
tinues to be very low, which may impede access to 
necessary medical treatment. 
(d) Islamic Republic of Iran
174. In May 2015, a mission of the Board visited the 
Islamic Republic of Iran in order to discuss the imple-
mentation by the Iranian Government of the three inter-
national drug control conventions, to which the country 
is a party. In particular, the mission discussed with 
authorities the country’s overall approach to addressing 
drug abuse and trafficking; the legislative and practical 
measures it has adopted to curb the supply of illicit drugs, 
reduce illicit demand and rehabilitate drug users; and its 
efforts to make available controlled substances for medi-
cal and scientific purposes. 
175. The Islamic Republic of Iran has adopted an inte-
grated approach to combating drug abuse and traffick-
ing through its national anti-drug strategy for the period 
2011-2015, which covers five pillars of work: combating 
drug trafficking, treatment and rehabilitation of drug 
addicts, “harm reduction”, development of alternative 
livelihoods, and the promotion of regional and inter-
national cooperation on issues of drug trafficking and 
abuse. 
176. The Islamic Republic of Iran has adopted drug con-
trol legislation, the most significant law being the Anti-
Narcotics Law of 1988. The reform of the law in 2011 
provided for the treatment and rehabilitation of drug 
addicts. The Government is currently working on new 
drug control legislation that would consolidate all the 
schedules of controlled substances. 
177. The Islamic Republic of Iran is among the coun-
tries with the greatest drug addiction problems, and there 
may be a need to collect up-to-date information on the 
prevalence of drug abuse in the country. Substantially 
fewer treatment and rehabilitation services are available 
to women compared to those available for men.
178. The availability of narcotic drugs, in particular opi-
oids, and psychotropic substances for medical purposes 
continues to be low. 
179. The Government of the Islamic Republic of Iran 
continues to apply corporal punishment and the death 
penalty for drug-related offences.
(e) Italy
180. A mission of the Board visited Italy in February 
2015. Italy is a party to the three international drug con-
trol conventions. The objective of the mission was to 
review the drug control situation in Italy and the 
Government’s compliance with the three international 
drug control conventions. 
181. Cannabis is cultivated in Italy within the frame-
work of a pilot project to generate a reliable source of 
supply of cannabis for persons authorized to use canna-
bis for medical reasons. The Board encourages the 
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Government to proceed with the establishment of a 
national cannabis agency, which is required pursuant to 
the provisions of the 1961 Convention, as well as all other 
obligations related to the cultivation of cannabis, includ-
ing reporting requirements. 
182. Italy has an extensive network of activities to 
reduce the demand for illicit drugs, with many drug 
prevention activities targeting selected population 
groups that are deemed to be vulnerable to drug abuse. 
Services to treat and rehabilitate drug users are avail-
able all over the country, although the level of care 
 provided varies.
183. Action against illicit trafficking in drugs is well 
coordinated, and several significant seizures of drugs have 
been made over the past years. Italy has also adopted a 
national action plan on new psychoactive substances and 
has established a national early warning system to be able 
to respond to the emergence of those substances in a 
timely manner.
(f ) Republic of Moldova
184. A mission of the Board visited the Republic of 
Moldova in May 2015. The objective of the mission was 
to review the drug control situation in the country and 
the Government’s compliance with the three international 
drug control conventions to which the Republic of 
Moldova is a party. 
185. Since the last INCB mission to the country in 1996, 
the Government has made significant progress in some 
areas of drug control. The Permanent Committee on 
Drug Control and the Republican Narcology Dispensary 
have taken measures to fully implement the provisions of 
the international drug control treaties. In particular, the 
Government has taken noticeable steps to address the 
emerging problems generated by increasing levels of drug 
abuse and the need to provide the affected population 
with adequate treatment, including opioid substitution 
therapy. In order to ensure the adoption of targeted and 
effective drug control policies, regular national surveys 
on drug abuse, particularly among youth, may be of 
benefit.
186. Despite the progress achieved, significant chal-
lenges remain. The Republic of Moldova continues to 
be used as a transit country for illicit drug shipments 
and precursor chemicals trafficked through its territory 
to markets in Europe. The Republic of Moldova is 
continuing to strengthen law enforcement, border pro-
tection, regional cooperation and information-sharing 
to  prevent drug trafficking within and through the 
country.
187. The availability of narcotic drugs and psychotropic 
substances used for medical purposes in the country is 
very low. The Government may need to assess the require-
ments for those substances, identify possible impedi-
ments to their availability and ensure that narcotic drugs 
and psychotropic substances are available to those in need 
in adequate quantities. 
(g) Timor-Leste
188. The Board’s mission to Timor-Leste in February 
2015 was the Board’s first since the country became a 
State Member of the United Nations in 2002. Timor-Leste 
acceded to the 1988 Convention in 2014 but is not yet 
party to the 1961 Convention or the 1971 Convention. 
The objective of the mission was to obtain detailed infor-
mation on the Government’s policy, national legislation 
and practical experience in the area of drug control, and 
to discuss obstacles to the accession of Timor-Leste to the 
international drug control treaties.
189. Timor-Leste does not have a national drug control 
strategy in place and the country’s main drug control leg-
islation is only at the draft stage. Timor-Leste lacks an 
institutionalized mechanism to implement the provisions 
of the international drug control conventions, notably in 
the area of precursor control. Progress needs to be made 
in several areas of drug control, including ensuring avail-
ability of opioid medications; promoting rational use of 
opioids for palliative care and pain management; drug 
demand reduction, especially drug use prevention; rais-
ing awareness on precursor control; and training and 
capacity-building for law enforcement. 
190. The Board recognizes the efforts of and the pro-
gress achieved by the Government of Timor-Leste in 
building a State with functioning institutions. The Board 
urges the Government of Timor-Leste to accede to the 
1961 Convention and the 1971 Convention and imple-
ment their provisions. Furthermore, the Board encour-
ages the Government of Timor-Leste to take steps to draw 
up a national strategy for drug control and proceed with 
setting up a dedicated national coordinating body as 
envisaged in the draft drug control law. The Board also 
encourages the Government of Timor-Leste to adopt a 
balanced approach to the drug problem, to recognize the 
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need for demand reduction efforts and to increase aware-
ness within its institutions, as well as civil society, about 
illicit drugs.
(h) Bolivarian Republic of Venezuela
191. INCB carried out a mission to the Bolivarian 
Republic of Venezuela in December 2014. The country is 
a party to all three drug control conventions. The objec-
tive of the mission was to review the progress made by 
the Bolivarian Republic of Venezuela in the implementa-
tion of the three international drug control conventions 
since its last mission in 2001.
192. The Board discussed with the relevant government 
agencies the national drug control strategy, which is well 
defined and embraces the call for a comprehensive and 
balanced approach to drug control by devoting resources 
to supply reduction and by investing considerable 
resources in drug demand reduction. 
193. The Government’s cooperation with INCB has 
been good, as has its compliance with the international 
drug control conventions. A new national drug control 
plan is in development. The Board notes that the 
Government remains committed to combating the traf-
ficking of drugs from neighbouring countries and to con-
tinuing to effectively fund the activities of the various 
governmental agencies involved in drug control and 
prevention. 
194. The Bolivarian Republic of Venezuela aims to 
strengthen its regional and cross-border cooperation in 
tackling drug trafficking by engaging with subregional 
organizations and the relevant agencies of other 
Governments in the region. The Board trusts that the 
Government will continue to implement its air control 
and interception programme in full respect of the rele-
vant international protocols and conventions.
195. Several prevention activities are being implemented 
in the country, and the Government is taking steps to 
 evaluate the quality and effectiveness of those interven-
tions. The Government may also wish to take into 
 consideration the International Standards on Drug Use 
Prevention prepared by UNODC in an effort to further 
refine the prevention strategy and approaches. The Board 
is encouraged by the fact that the overall level of consump-
tion of narcotic drugs and psychotropic substances for 
medical use in the Bolivarian Republic of Venezuela has 
improved in recent years and trusts that the Government 
will continue its effort to ensure the adequate availability 
of those substances for rational medical use. 
3. Evaluation of the implementation by 
Governments of recommendations made 
by the Board following its country 
missions 
196. As part of its ongoing dialogue with Governments, 
the Board also conducts on a yearly basis an evaluation 
of Governments’ implementation of the Board’s recom-
mendations pursuant to its country missions. In 2015, the 
Board invited the Governments of the following six coun-
tries, to which it had sent missions in 2012, to provide 
information on progress made in the implementation of 
its recommendations: Brazil, Cambodia, Cuba, Nigeria, 
Pakistan and Peru. 
197. The Board wishes to express its appreciation to the 
Governments of Brazil, Cuba, Nigeria, Pakistan and Peru 
for submitting the requested information. Their coopera-
tion facilitated the Board’s assessment of the drug control 
situation in those countries and the Governments’ com-
pliance with the international drug control treaties. 
Information from the Government of Cambodia, once 
received, will be reviewed by the Board and the outcome 
of its review will be included in the annual report for 2016.
198. In 2015, the Board also reviewed the implementa-
tion of the Board’s recommendations following its 2011 
mission to Serbia, for which the information was not 
received in time for review in 2014. The Board wishes to 
express its appreciation to the Government of Serbia for 
the information provided.
(a) Brazil
199. The Board notes that, following its mission to 
Brazil in 2012, the Government of that country has taken 
substantial measures to implement the Board’s recom-
mendations in a number of areas. In order to streamline 
and optimize the drug control efforts of stakeholders at 
the federal, state and municipal levels, Brazil has created 
both formal and ad hoc mechanisms for increased com-
munication and cooperation. In this regard, the Board 
welcomes the planned establishment of a permanent 
forum for the exchange of information and focal points 
to enhance inter-institutional dialogue between the 
Brazilian National Health Surveillance Agency (ANVISA) 
and the Federal Police. In addition, the Board commends 
Brazil for its efforts to engage State authorities in order 
to promote cooperation between them and between the 
various levels of government on drug control matters. 
Brazil has also actively initiated and participated in 
regional and interregional cooperation initiatives, in 
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particular under the framework provided by the Southern 
Common Market (MERCOSUR) and the Community of 
Portuguese-speaking Countries. In addition, Brazil has 
also taken steps to improve its reporting to the Board, in 
particular by increasing the resources of the Office of 
Controlled Substances. 
200. The Board commends the Government of Brazil 
for its efforts in the field of primary prevention, in par-
ticular for its adoption of a comprehensive drug abuse 
prevention programme prepared by the Ministry of 
Health. In order to further complement that initiative, the 
Board wishes to recommend that the prevention materi-
als be supplemented with references to the dangers of psy-
choactive substances available through Internet pharmacies 
and social networking sites and with references to the 
dangers associated with the abuse of traditional herbal 
substances and new psychoactive substances. Brazil has 
also invested significant resources in the prevention of 
“crack” cocaine abuse and the study of measures for the 
treatment of “crack” cocaine abuse and dependence. The 
Board encourages the Government of Brazil to dissemi-
nate its findings with respect to treatment of “crack” 
cocaine addiction to the international community.
201. The Board notes those positive developments and 
encourages the Government of Brazil to continue to pur-
sue the establishment of comprehensive treatment and 
rehabilitation services to be offered in Brazilian prisons 
to inmates with drug abuse problems. The Board notes 
that a research programme has been launched and is 
jointly carried out with the National Prison Department 
and the Ministry of Health, in order to provide the same 
health services to inmates as those available to the gen-
eral public. The Board welcomes that positive initiative 
and wishes to underline the importance of the establish-
ment of treatment and rehabilitation programmes, tai-
lored to the prison setting, and recalls the importance of 
ensuring that treatment and rehabilitation programmes 
are offered to inmates with drug abuse problems in all 
penitentiaries.
202. The Board also notes that the Government of 
Brazil has reported making progress regarding guidelines 
for travellers under treatment with internationally con-
trolled drugs, in particular the updating of the country’s 
guidelines for travellers to bring it in line with the new 
national legislation adopted in February 2015. However, 
the Board underlines the importance of training law 
enforcement officers on the guidelines for international 
travellers and ensuring that those guidelines are accessi-
ble to all international travellers, especially given Brazil’s 
status as a major tourist destination and as host country 
of the 2016 Olympic Games. 
203. The Board also reiterates its request to the 
Government of Brazil to take steps to ensure the adequate 
availability of controlled substances for medical and sci-
entific purposes in the light of the actual demand of the 
population. For that purpose, the Board recommends that 
the Government of Brazil take measures to ensure the 
rational use of narcotic drugs and psychotropic sub-
stances for medical purposes, including the use of opi-
oids for the treatment of pain, in accordance with the 
Guide on Estimating Requirements for Substances under 
International Control prepared by INCB and WHO. 
(b) Cuba
204. The Government of Cuba has acted on the Board’s 
recommendations following its mission to the country in 
2012, and progress has been made in a number of areas 
of drug control. 
205. The Board notes the measures taken to consolidate 
the organizational structure of the Directorate of 
Medicines and Medical Technology and its Section for 
the Control of Narcotic Drugs, Psychotropic Substances 
and Substances with Similar Effects under the Ministry 
of Health, with the aim of improving availability of nar-
cotic drugs and psychotropic substances for medical pur-
poses. The Board notes that, based on the legislative 
framework established in 2014, the Analysis and Planning 
Department of the Ministry of Health has adopted a new 
system to identify the requirements of health-care estab-
lishments and pharmacies of narcotic drugs and psycho-
tropic substances at various levels of the national health 
system. The Board encourages the Government to take 
further measures, in conjunction with the National 
Anaesthesia and Pain Management Group to update the 
range of treatment options available for acute and chronic 
pain and ensure the necessary availability of narcotic 
drugs and psychotropic substances for pain management 
and other medical purposes.
206. The Board notes the measures taken to ensure 
security at locations where narcotic drugs, psychotropic 
substances and substances with similar effects are stored, 
produced or handled. The Board welcomes the measures 
taken by the Government to systematically monitor com-
pliance with established requirements for the storage of 
controlled substances and redress eventual shortcomings 
to ensure full compliance with the established security 
standards.
207. While acknowledging the country’s technological 
limitations affecting the systematic collection, processing 
and analysis of drug control data, the Board invites the 
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Government to examine the process of reporting to the 
Board and ensure that information reported continues to 
be of good quality. Furthermore, the Board encourages 
the Government of Cuba to strengthen its cooperation 
with the Board for the control of precursors, in particu-
lar by using PEN Online for pre-export notification for 
shipments of precursor chemicals, pursuant to article 12, 
paragraph 10 (a), of the 1988 Convention. The Board 
encourages the Government to continue its efforts in the 
area of drug control and to keep the Board informed of 
the drug control situation in Cuba and further measures 
taken against drug trafficking and abuse in the country. 
(c) Nigeria
208. The Government of Nigeria has acted on the 
Board’s recommendations following its mission to the 
country in 2012, and progress has been made in a num-
ber of areas of drug control. The Board notes with appre-
ciation that the Government has initiated the development 
of a new National Drug Control Master Plan for the 
period 2015-2019, under the leadership of the Inter-
ministerial Committee on Drug Control, as recom-
mended by the Board. 
209. The Board welcomes the measures taken against 
illegal cultivation of cannabis plant and against drug traf-
ficking. The drug control division of the federal police 
has stepped up its eradication efforts in collaboration with 
authorities at the state level and local communities in the 
areas most affected. Drug interdiction capacities at the 
Lagos international airport have been significantly 
strengthened, and operations to detect and destroy “can-
nabis farms” have been conducted jointly by the National 
Drug Law Enforcement Agency and other law enforce-
ment agencies. Measures taken include the establishment 
of an inter-agency coordination team to improve opera-
tional cooperation at the airport among the relevant drug 
law enforcement entities, as well as capacity-building 
training sessions for law enforcement personnel such as 
police staff, airport administration personnel, regional 
police supervisors and customs officials. 
210. While welcoming those measures, the Board notes 
that continued efforts need to be made in the area of drug 
abuse prevention and availability of treatment, under the 
leadership of the National Agency for Food and Drug 
Administration and Control. The Board notes the plans 
supported by the Government to conduct a national sur-
vey on drug abuse in Nigeria, which will assist the 
Government in developing a drug prevention and treat-
ment policy that reflects the needs of the Nigerian pop-
ulation. The Board encourages the Government to 
increase its efforts in the prevention of drug use, particu-
larly among young people and to ensure that activities in 
this area address all commonly abused controlled sub-
stances, including pharmaceutical preparations contain-
ing such substances. 
211. The Board notes that little progress has been made 
in ensuring the availability of narcotic drugs and psycho-
tropic substances for medical purposes in Nigeria. The 
availability of opioids for the treatment of pain in medi-
cal institutions continues to be inadequate. The Board 
notes that efforts are under way for the decentralization 
of the distribution of opioid-based medicines, in order to 
increase access to those substances in each of the six geo-
political zones of Nigeria, a key activity stipulated in the 
National Drug Control Master Plan for the period 2015-
2019. The Board further notes that the Government is 
currently working on developing estimation guidelines to 
improve accessibility and rational use of controlled sub-
stances for medical purposes and at the same time pre-
vent their diversion into illicit channels. The Board 
requests that the Government examine the current situ-
ation and take the steps necessary to ensure that narcotic 
drugs and psychotropic substances, particularly opioids, 
are made available for medical purposes to the entire pop-
ulation in need, and, in this pursuit, the Board encour-
ages the Government to make use of the Guide on 
Estimating Requirements for Substances under International 
Control. 
(d) Pakistan
212. The Board notes that some progress has been made 
by the Government of Pakistan in drug control since the 
mission of the Board to that country in 2012. The 
Government has introduced a number of measures to 
strengthen coordination among the relevant government 
agencies under the Drug Regulatory Authority of Pakistan, 
established in 2012. The Government has also strength-
ened its cooperation in the exchange of information on 
precursor chemicals with the neighbouring countries par-
ticipating in several international initiatives. Pakistan has 
invoked article 12, paragraph 10 (a), of the 1988 
Convention and is actively using PEN Online to clear 
import and export shipments of precursors from and into 
the country. The Board remains concerned that informa-
tion on trafficking and seizures of precursor chemicals in 
Pakistan continues to be limited.
213. While drugs are widely abused in Pakistan, the 
extent of drug abuse in the country is not known to the 
authorities, as there has never been a systematic assess-
ment of the nature, extent and patterns of drug abuse. 
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The Board calls on the Government to carry out an 
assessment of drug abuse, including the collection and 
analysis of data on the incidence, prevalence and other 
characteristics of drug abuse. Such an objective assess-
ment is indispensable for the design of programmes for 
the prevention of drug abuse and the treatment and reha-
bilitation of drug abusers. 
214. In addition, the Board notes that little progress has 
been made in ensuring the availability of narcotic drugs 
for medical purposes in Pakistan. Allocation of opioids 
(morphine, pethidine and fentanyl) is made by the 
Narcotics Control Division of the Ministry of Interior and 
Narcotics Control of Pakistan based on recommendations 
received from provincial governments. The availability of 
narcotic drugs and psychotropic substances, particularly 
opioids for the treatment of pain in medical institutions, 
continues to be inadequate. The Board requests the 
Government to examine the current situation and take 
the steps necessary to ensure that narcotic drugs and psy-
chotropic substances, particularly opioids, are made avail-
able for medical purposes and encourages the Government 
of Pakistan to make use of the Guide on Estimating 
Requirements for Substances under International Control 
in its efforts to do so.
(e) Peru
215. The Board notes that efforts have been made by 
the Government of Peru in the implementation of the 
Board’s recommendations following the INCB mission to 
that country in 2012. The Board notes that the National 
Coca Company has adopted its institutional strategic plan 
for the period 2013-2017, which seeks to improve the 
management of the collection, processing and sale of coca 
leaf for legal purposes.
216. The Board notes that increased efforts have been 
made in Peru to limit the cultivation of coca bush. In 2013, 
the area of coca bush cultivation decreased for the second 
consecutive year, to 49,800 hectares—a decrease of 17.5 per 
cent compared with the 60,400 hectares of  cultivation in 
2012. That decline is the most successful outcome in the 
past 14 years and is due to the sustained eradication and 
post-eradication measures carried out within the frame-
work of the Peruvian Government’s  integral and sustaina-
ble alternative development programme. 
217. The Board calls on the Government of Peru to 
establish a system for controlling precursors and other 
chemicals used in the illicit manufacture of drugs. That 
is particularly important as Peru has already been used 
by traffickers for the diversion of those substances. The 
Board invites the Government to further strengthen 
cooperation with it in the control of precursors and to 
provide prompt responses to the Board’s inquiries on the 
legitimacy of orders for export of precursors to Peru, in 
particular by using the PEN Online system. 
218. The Board notes that further efforts need to be 
made to ensure the availability of narcotic drugs and psy-
chotropic substances for medical purposes in Peru. The 
availability of opioids for the treatment of pain in medi-
cal institutions continues to be particularly inadequate. 
The Board requests the Government to examine the cur-
rent situation and take the steps necessary to ensure that 
narcotic drugs and psychotropic substances, particularly 
opioids, are made available for medical purposes. 
219. Although Peru has improved its system for the 
treatment and rehabilitation of drug abuse, further devel-
opment of the system is required to fully respond to 
actual demand for those services. The Board encourages 
the Government to increase its efforts to ensure that suf-
ficient treatment facilities are available to cover the needs 
of the population. The Board also encourages the 
Government to take measures to increase programmes 
addressing prevention of drug abuse, particularly among 
youth, and to ensure that activities in this area address 
all commonly abused controlled substances.
(f ) Serbia
220. The Board notes that since its mission to Serbia in 
2011, the Government has taken steps to implement the 
Board’s recommendations in a number of areas. 
221. The Board welcomes the adoption by the Gov-
ernment of Serbia of a new national drug strategy and 
action plan for the period 2014-2021. Moreover, the 
Board notes the efforts that have been undertaken to 
strengthen Serbia’s drug addiction prevention and treat-
ment frameworks, by including the development of reha-
bilitation programmes in the national drug strategy. 
222. The Board also commends the Government of 
Serbia for its adoption in July 2014 of the decree for the 
establishment of the Office for Combating Drugs to 
improve the coordination of governmental drug control 
measures and improve inter-agency cooperation. During 
its mission, the Board underscored the importance of the 
Government ensuring the adequate availability and 
rational use of opioids for the treatment of pain. The 
Board encourages the Government of Serbia to take 
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further action on this matter and recommends that the 
Government review its framework for the elaboration of 
estimates and assessments of controlled substances for 
medical and scientific purposes, taking into account the 
Guide on Estimating Requirements for Substances under 
International Control. 
223. The Board also continues to emphasize the impor-
tance of greater regional and international cooperation 
in the area of drug control and invites the Government 
of Serbia to continue to strengthen its efforts in this 
area. 
E. Action taken by the Board to 
ensure the implementation of the 
international drug control treaties
224. The period under review in Afghanistan was char-
acterized by the formation of a National Unity Government 
and the introduction of several interim measures to 
ensure continuity in governance, increased regional 
engagement and improved bilateral relations with neigh-
bouring countries.
225. Challenges for the implementation of the drug 
control treaties remain, including an increase in security-
related incidents, weak border control enforcement, 
stunted economic development and limited human and 
material resources. 
226. During the period under review, drug crop eradi-
cation efforts in various Afghan provinces contributed to 
a 19 per cent decrease in the area under opium poppy 
cultivation in the country, with the total area of eradica-
tion of opium poppy cultivation increasing by 40 per cent. 
However, a significant amount of illicit cultivation of can-
nabis continued, posing a further challenge to Afghan 
drug control efforts.13
227. Afghan law enforcement authorities continue to 
conduct counter-narcotics operations, resulting in the 
 seizure of large amounts of heroin, opium and cannabis 
resin.
 13 See also the section on West Asia in chapter III, below.
1. Action taken by the Board pursuant 
to article 14 of the 1961 Convention as 
amended by the 1972 Protocol and 
article 19 of the 1971 Convention 
228. Article 14 of the 1961 Convention as amended by 
the 1972 Protocol, and article 19 of the 1971 Convention 
set out measures that the Board may take to ensure the 
execution of the provisions of those Conventions. Such 
measures, which consist of increasingly severe steps, are 
considered by the Board when it has objective reason to 
believe that the aims of the Conventions are being seri-
ously endangered by the failure of a party, country or ter-
ritory to comply with the treaty obligations contained 
therein.
229. Since its establishment, INCB has invoked those 
provisions with respect to a limited number of States. The 
Board’s objective in doing so has been to encourage com-
pliance with the Conventions when other means have 
failed. The names of the States concerned are not publicly 
disclosed until the Board has decided to bring the situa-
tion to the attention of the parties, the Economic and 
Social Council and the Commission on Narcotic Drugs. 
Following extensive dialogue with INCB, according to the 
process set out in the above-mentioned articles, most of 
the States concerned have taken remedial measures, result-
ing in a decision by INCB to discontinue action taken 
under the relevant articles with respect to those States.
230. As at 1 November 2015, Afghanistan was the only 
State regarding which action was being taken pursuant to 
article 14 of the 1961 Convention as amended by the 1972 
Protocol. 
2. Consultation with the Government 
of Afghanistan pursuant to article 14 of 
the 1961 Convention as amended by the 
1972 Protocol
231. Consultations between the Board and the 
Government of Afghanistan pursuant to article 14 of the 
1961 Convention as amended by the 1972 Protocol have 
continued in 2015.
232. On the margins of the fifty-eighth session of the 
Commission on Narcotic Drugs, held in Vienna from 9 
to 17 March 2015, the President of the Board met with 
the delegation of Afghanistan, which was headed by the 
Minister of Counter Narcotics. The Minister provided the 
Board with information on measures taken by the 
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Government of Afghanistan to address the drug control 
situation in the country, including the planned establish-
ment of a new faculty of drug education; the develop-
ment of alternative livelihood programmes; the continued 
action aimed at countering opium poppy cultivation and 
trafficking; the strengthening of regional cooperation and 
enforcement measures to address the trafficking of pre-
cursors; and the establishment of good governance prin-
ciples. The Government representatives acknowledged the 
need for greater investment in drug treatment and reha-
bilitation and the importance of breaking the cycle of 
poverty and political instability affecting Afghanistan. 
Furthermore, they highlighted the need for greater 
resources to reduce cannabis cultivation, the need to 
enhance regional cooperation to address drug abuse in 
the country and the need for technical assistance to 
enhance capacity-building. 
233. In June 2015, an Afghan delegation headed by the 
Minister of Counter Narcotics briefed the Board on 
recent developments with respect to drug control in 
Afghanistan. Among the issues discussed were the devel-
opment and implementation of a new counter-narcotics 
strategy, progress made in the Government’s opium poppy 
eradication efforts, legislative amendments to the coun-
try’s drug control legal framework and the further imple-
mentation of demand reduction activities. The Minister 
also briefed the Board on the Government’s continued 
efforts to stem the cultivation of opium poppy through 
assistance to farmers in the form of alternative develop-
ment and through improving security, good governance 
and community mobilization. 
234. INCB has continued to engage the Government of 
Afghanistan in the planning of its high-level mission to 
the country, scheduled to take place in 2016, during 
which consultations under article 14 of the 1961 
Convention as amended by the 1972 Protocol will be con-
tinued. The Board has also continued its dialogue with 
the Government of Afghanistan through regular contact 
between its secretariat and representatives of the 
Permanent Mission of Afghanistan to the United Nations 
(Vienna) to follow up on the Government’s implementa-
tion of the international drug control treaties and the 
upcoming high-level mission to the country. 
Cooperation with the Board 
235. In recent years, there has been continued cooper-
ation on the implementation of the international drug 
control treaties between the Government of Afghanistan 
and the Board. 
236. The Government has substantially improved its 
reporting performance since 2010, submitting data to 
INCB regularly, as required under the international drug 
control treaties. 
237. In February 2015, Afghanistan acceded to the 1972 
Protocol amending the 1961 Convention, a development 
welcomed by the Board. 
238. In June 2015, the Government submitted its 2014 
report to the Board, reflecting the Government’s efforts 
to comply with their reporting requirements with regard 
to the implementation of the international drug control 
treaties and relating to its efforts to facilitate the delivery 
of the required technical assistance. 
239. INCB notes an increase in the counter-narcotics 
operations led by Afghan law enforcement authorities. 
However, the lack of budgetary allocation for addressing 
the cultivation of cannabis plant in the country remains 
a challenge. 
Cooperation with the international community 
240. The Government of Afghanistan has continued to 
take steps to enhance regional and international cooper-
ation to address the drug-related threats affecting the 
country. Afghanistan pursued its engagement with Afghan 
national ethnic groups and regional interlocutors to pro-
mote national reconciliation.
241. In terms of interregional cooperation, successful 
global and interregional activities undertaken in the past 
few years continued, including the Paris Pact Initiative, a 
well-established key international partnership to counter 
the trafficking in and consumption of opiates originating in 
Afghanistan. In addition, the United Nations Office on 
Drugs and Crime (UNODC) Global Programme against 
Money-Laundering, Proceeds of Crime and the Financing 
of Terrorism continued to assist the national authorities of 
Afghanistan and neighbouring countries in collecting infor-
mation on illicit financial flows linked to Afghan opiates. 
242. Contact was made several times at a high level 
between Afghanistan and Pakistan, in particular between 
officials from both countries responsible for implement-
ing the relevant provisions of international treaties, in 
order to strengthen their bilateral relationship and dem-
onstrate the will of both countries to enhance coopera-
tion. This cooperation is particularly important, as 
large-scale cross-border population movements continue 
as a result of military operations in the North Waziristan 
Region of Pakistan.
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243. At the fifty-eighth session of the Commission on 
Narcotic Drugs, the Executive Director of UNODC pre-
sented a report entitled “Strengthening international 
cooperation in combating illicit opiates originating in 
Afghanistan through continuous and reinforced support 
to the Paris Pact initiative” (E/CN.7/2015/12). The report 
describes steps taken by UNODC, as a technical assis-
tance provider, towards the implementation of resolution 
56/3 throughout the first year of the fourth phase of the 
initiative, entitled “Reducing drug abuse and dependence 
through a comprehensive approach”.
244. In March 2015, the President of Afghanistan and 
the President of the United States released a joint state-
ment announcing a new development partnership, 
through which up to $800 million in bilateral economic 
assistance would be earmarked for Afghan development 
and reform priorities. The parties also announced that the 
United States would maintain a military presence of 9,800 
troops in Afghanistan until the end of 2017.
245. Ministers for foreign affairs discussed the situation 
in Afghanistan during meetings of the Collective Security 
Treaty Organization and of the Commonwealth of 
Independent States, both held in April 2015. Also in April 
2015, experts from Afghanistan, Pakistan and Tajikistan 
met in Dushanbe, where they finalized the draft Trilateral 
Transit Trade Agreement. In the same month, the 
President of Afghanistan visited the Islamic Republic of 
Iran. The two countries pledged to increase cooperation 
in the area of counter-narcotics. 
246. During the first quarter of the year, several initia-
tives were implemented involving the participation of 
international bodies such as the Organization for Security 
and Cooperation in Europe, the United Nations Regional 
Centre for Preventive Diplomacy in Central Asia and the 
United Nations Counter-Terrorism Implementation Task 
Force. Other examples of initiatives to combat money-
laundering are the Criminal Assets Southern Hub 
(CASH), which is aimed at countering illicit money flows 
and confiscating the assets of drug trafficking networks 
in Afghanistan and neighbouring countries, and the 
Southern Trafficking Operational Plan (STOP), which is 
focused on interdiction efforts within the Triangular 
Initiative, involving Afghanistan, Iran (Islamic Republic 
of) and Pakistan.
247. In September 2015, the Minister of Counter-
Narcotics of Afghanistan gave a briefing at UNODC 
headquarters in Vienna on the current drug control sit-
uation in Afghanistan and on the measures taken and 
progress made under article 14 of the 1961 Convention 
as amended, as well as the main challenges and trends 
that the country faces. The Minister also presented an 
overview of the Afghan counter-narcotics strategy, a cor-
nerstone of the national development agenda. The strat-
egy acknowledges the links between counter-narcotics 
and the need to address the financing of terrorism and 
the challenges related to border management. The 
Minister announced that her country’s action plan would 
be released shortly and reiterated Afghanistan’s commit-
ment to implementing drug control measures through a 
multidimensional approach incorporating development 
considerations and international cooperation.
248. Improved coordination of regional bodies was fos-
tered through the initiatives of the Afghanistan National 
Disaster Management Authority, supported by Japan 
under the Heart of Asia-Istanbul Process confidence-
building measures. The National Intelligence Working 
Group on Precursors continued to support inter-agency 
cooperation in strengthening precursor control and infor-
mation-sharing in the country. 
249. Cooperation by the international community 
involves all relevant stakeholders in the country, includ-
ing non-governmental organizations and civil society 
groups. The civil society-led Afghan People’s Dialogue on 
Peace commenced its third phase of activities, focusing 
on convening policymakers and civil society organiza-
tions to assist in the implementation of national and pro-
vincial road maps for peace. Facilitation continues to be 
provided by the United Nations Mission in Afghanistan. 
250. New regional criminal intelligence centres, mod-
elled upon good practices from the International Criminal 
Police Organization (INTERPOL), the European Police 
Office (Europol) and the World Customs Organization 
(WCO), have been established in the Central Asian 
Regional Information and Coordination Centre and the 
Criminal Information Centre to Combat Drugs of the 
Cooperation Council for the Arab States of the Gulf, 
together with a joint planning cell covering Afghanistan, 
Iran (Islamic Republic of) and Pakistan.
251. Regional cooperation remains a crucial element in 
reinforcing the likelihood of success of Afghan-led recon-
ciliation efforts, political stability and sustainable eco-
nomic development.
Conclusions
252. Afghanistan continued to face major challenges in 
the period under review despite the decrease in illicit 
opium poppy cultivation reported in 2015.
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253. Other challenges remain, such as the transition 
of security functions from international military forces 
to the national army and police, the ongoing national 
reconciliation process, the impact of conflict and the 
limited capacity of the Government to give priority 
attention to the increasing levels of drug trafficking and 
abuse in the country. 
254. Despite those challenges, the Government has 
invested in an increase in licit crop cultivation, primar-
ily in areas which are relatively poppy-free, and has 
expressed its commitment to addressing the illicit cul-
tivation of opium poppy and cannabis plant in the coun-
try. It has also expressed its commitment to addressing 
drug trafficking and drug abuse through eradication 
campaigns, law enforcement measures, alternative live-
lihood initiatives and international cooperation at the 
regional and global levels. The Government has been 
fully cooperative with the Board, including through its 
readiness to facilitate a high-level mission of INCB to 
Afghanistan and its submission of a progress report on 
the drug-related situation in the country. INCB notes 
the increased engagement of the Government of 
Afghanistan with neighbouring countries during the 
reporting period. 
255. While noting the progress made in Afghanistan 
over the last year, the Board remains concerned about the 
significant challenges surrounding the drug control situ-
ation. INCB asks the Government of Afghanistan to con-
tinue to keep it informed of developments with regard to 
the adoption and implementation of new national 
counter- narcotics policies. The Board recommends that 
the Government of Afghanistan continue strengthening 
its counter-narcotics capacity by drawing on specialized 
international technical assistance to address the drug 
problem and to strengthen its cooperation at the regional 
and international levels. 
256. The Board encourages the Government of 
Afghanistan to strengthen its efforts to address wide-
spread drug abuse in the country through the adoption 
of measures aimed at prevention, treatment, rehabilita-
tion and aftercare for affected individuals. INCB notes the 
fundamental role played by alternative development ini-
tiatives in curbing opium poppy cultivation and provid-
ing farmers with legitimate means for supporting 
themselves and their families. INCB calls upon members 
of the international community to continue to support 
the Government of Afghanistan in its drug control and 
development efforts. INCB will continue to closely mon-
itor the drug control situation in Afghanistan in cooper-
ation with the authorities, as well as measures taken and 
progress made by the Government of Afghanistan in all 
areas of drug control. To that end, the Board looks 
 forward to its mission to Afghanistan in 2016.
F. Special topics
1. Precursor control: new 
developments, challenges and the way 
forward
257. Measures to monitor trade in precursor chemicals 
and prevent their diversion into illicit channels are key 
components of all strategies to prevent or curb illicit 
manu facture of and trafficking in narcotic drugs and 
 psychotropic substances.
258. The mechanism for the monitoring of licit trade 
and the prevention of diversion is laid down in article 12 
of the 1988 Convention, which has been complemented 
over the years by a series of resolutions at various levels 
of the international drug control system. The fundamen-
tal assumption underlying the system of international 
precursor control is that chemicals that can be used as 
drug precursors are licit commodities and that any trans-
action involving them is therefore presumed to be legit-
imate unless there is suspicion or evidence that the 
chemical concerned is to be used for illicit purposes. As 
such, “the procurement of chemicals necessary to manu-
facture drugs is one of the few points … where drug traf-
ficking intersects with legitimate commerce. Regulation 
of legitimate commerce to deny traffickers the chemicals 
they need is one of our most valuable tools in the battle 
against drug criminals.”14
259. INCB has reviewed the achievements, progress and 
challenges of international precursor control in its annual 
reports on precursors.15 Over the past 25 years, since the 
entry into force of the 1988 Convention on 11 November 
1990, States have succeeded, through the Convention and 
the oversight work undertaken by INCB, in substantially 
reducing the diversion of substances listed in Tables I and 
II of the 1988 Convention from international trade into 
illicit drug manufacture. After a quarter of a century, the 
1988 Convention enjoys near universal adherence by 
States worldwide. Through its provisions and require-
ments, the Convention has served to establish, in 
 14 Chemical Action Task Force, Status Report for the 1992 Economic 
Summit (Washington, D.C., June 1992), p. 11.
 15 See E/INCB/2011/4, E/INCB/2012/4, E/INCB/2013/4 and E/
INCB/2014/4.
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partnership with industry, the infrastructure for the con-
trol of precursor chemicals. To support the monitoring 
of the licit trade in precursor chemicals and to prevent 
their diversion into illicit channels, INCB has developed 
electronic tools such as PEN Online and PICS, which are 
available to all States upon request at no cost. These tools 
have served the international community well in prevent-
ing illicit drug manufacture and the diversion of con-
trolled chemicals.
New developments and challenges
260. In reviewing the effectiveness of international pre-
cursor control, INCB has also identified remaining gaps 
and has concluded that the key challenges facing precur-
sor control today are a result of the following:
 (a) The lack of comprehensive and systematic 
implementation of the provisions of the 1988 Convention 
and related resolutions of the General Assembly, the 
Economic and Social Council and the Commission on 
Narcotic Drugs;
 (b) The emergence of new challenges not compre-
hensively addressed in the existing legal framework.
261. That the implementation of existing treaty provi-
sions could be further improved is reflected in the fact 
that 150 Governments have registered for use of PEN 
Online, the automated global online system for the 
exchange of pre-export notifications, but only 109 Gov-
ernments have requested to be pre-notified of some or all 
planned shipments to their territories.16 Considering that 
the international precursor control system focuses on the 
monitoring of international trade, it is now evident that 
in the past, insufficient attention had been placed on 
national controls and on the monitoring of domestic 
movements and the end use of precursor chemicals. 
INCB estimates that, depending on the specific precursor 
or group of precursors, between 30 and 95 per cent of all 
seizures reported are of substances originating within the 
country of seizure; in other words, those diversions are 
occurring outside the international precursor trade mon-
itoring system. While serving as a reminder of the need 
for further action at the national level, those statistics are 
at the same time a reflection of the successes in prevent-
ing diversion at the international level.
 16 Importing countries can make it mandatory for exporting coun-
tries to inform them prior to a planned export by invoking article 12, 
paragraph 10 (a), of the 1988 Convention.
262. One of the largest new challenges today is the 
emergence of non-scheduled substitute chemicals, includ-
ing “designer precursors”, to circumvent controls. In 
recent years, an increasing variety of such “designer” 
chemicals has emerged, typically manufactured on a 
made-to-order (demand) basis. The manufacture of those 
non-scheduled chemicals is, in itself, legal according to 
the existing international legal framework, although those 
chemicals are sourced with no other purpose than for use 
in illicit drug manufacture. Many of the chemicals are 
derivatives or common intermediates in regular drug 
 synthesis that can be easily converted into a controlled 
precursor; many have no regular legitimate commerce or 
use, thus creating a challenge for the existing control 
 system due to the sheer number of possible chemical 
starting materials and because the sourcing of those 
chemicals further blurs the area where drug trafficking 
intersects with legitimate commerce.
263. A second, related challenge identified by INCB is 
that posed by the great increase in the sophistication, 
diversification and scale of illicit synthetic drug manufac-
turing operations. As a result, there are virtually no lim-
itations to the range of chemicals and manufacturing 
methods that can potentially be employed in illicit manu-
facture, including chemicals and methods that had pre-
viously been considered to be impracticable in illicit 
settings. Sophisticated, industrial-scale illicit manufactur-
ing operations have been dismantled in all regions with 
the exception of Africa and most parts of Oceania. Such 
laboratories are the source of a significant portion of the 
illicit worldwide supply of synthetic drugs, while small-
scale manufacture continues to supply markets of a more 
local nature.
264. The emergence of what are known as synthetic new 
psychoactive substances17 adds a potentially unlimited 
number of chemicals to those already being monitored 
in connection with the illicit manufacture of drugs under 
international control. However, the concepts and 
approaches developed in connection with monitoring 
non-scheduled chemicals could also be directly applied 
to address precursors of new psychoactive substances.18
 17 Although there is no universally accepted definition of new psy-
choactive substances, broadly they are referred to as substances of abuse, 
in either a pure form or a preparation, that are not controlled under the 
1961 Convention or the 1971 Convention but which may pose a public 
health threat. New psychoactive substances can be man-made, synthetic 
substances or natural materials.
 18 They could also possibly apply to new psychoactive substances end 
products which are—from a chemical and control point of view—another 
set of non-scheduled substances, often with no known legitimate use 
other than in small amounts for research and laboratory analysis 
 purposes.
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265. Challenges are also evident in relation to heroin 
and cocaine manufacture. Especially in the case of cocaine 
manufacture, the chemicals and processes now being used 
increase manufacturing efficiency and reduce the amount 
of chemicals required. With regard to the sources of the 
chemicals used, there are still significant information 
gaps. What seems to be clear, however, is that the major-
ity of those chemicals are either sourced from within the 
country of drug manufacture or are sourced from another 
country within the same region and then smuggled to the 
country of manufacture. For example, more than 80 per 
cent of potassium permanganate, the key oxidizer used 
in illicit cocaine manufacture, and more than 90 per cent 
of solvents originate within the country of seizure.19 For 
acetic anhydride, the key chemical for heroin manufac-
ture, available data suggest that more than 80 per cent of 
the substance can be traced to other countries within the 
same region.20 Further, there have been no reports of the 
diversion of potassium permanganate or acetic anhydride 
from international trade in more than five years.
266. Other developments posing a challenge for precur-
sor control efforts at the national, regional and interna-
tional levels are a consequence of the improvements in 
global communication, transportation and trade facilita-
tion. An area of increasing concern is the growth of free 
trade zones and free ports, which often lack sufficient 
transparency. Another fact of modern life is the increase 
in the number and geographic extent of trade and cus-
toms unions.
The way forward: areas for action
267. In view of these developments, INCB has identi-
fied a set of priority actions for Governments,21 includ-
ing the following:
 (a) Public-private partnerships. All national author-
ities should adopt the concept of making industry a crit-
ical partner in the prevention of chemical diversion and 
formalize their commitment to such partnerships; indus-
tries and industry associations should incorporate the 
principles of chemical diversion prevention as integral 
components of corporate industry responsibility, account-
ability and credibility;
 19 E/INCB/2014/4, figure V.
 20 E/INCB/2014/4, figure XVI.
 21 Technical details are contained in the 2015 report on precursors 
(E/INCB/2015/4) and the reports of previous years.
 (b) National regulatory controls. Governments 
should review the effectiveness of their national chemical 
control systems and work to close any gaps in those 
domestic systems and make them fit their purpose;
 (c) Law enforcement. Governments should provide 
their law enforcement authorities with the legal frame-
work enabling them to take appropriate law enforcement 
action, where required. (The 1988 Convention provides 
guidance to develop national legislation to that effect for 
substances in Tables I and II and, in combination with 
article 13, for non-scheduled chemicals.) Law enforce-
ment authorities should pay more attention to precursor 
chemicals used in illicit manufacture by investigating sei-
zures, stopped shipments and attempted diversions in 
order to identify the sources of diversion and the crimi-
nal organizations behind those activities, and share their 
findings globally to prevent future diversions using sim-
ilar modi operandi.
268. The special session of the General Assembly on 
the world drug problem to be held in 2016 provides an 
opportunity to recall the fundamental basis of precur-
sor control, namely, international cooperation to prevent 
chemicals from being used in the manufacture of sub-
stances of abuse. The special session also provides an 
opportunity to acknowledge that the existing control 
system, which is based on the monitoring of licit trade, 
has a limited ability to deal and keep pace with large 
numbers of emerging chemicals, including series of 
related chemicals and “designer” chemicals, largely as 
most of these chemicals are without legitimate use and/
or trade.
269. On the basis of those insights, INCB hopes that 
Governments will make use of the special session of the 
General Assembly in 2016 to reconfirm the importance 
of precursor control as a preventive component in a bal-
anced drug control strategy. The Board also hopes that 
Governments will demonstrate the political will to accept 
a shared responsibility for precursor control, as there is 
virtually no country in which chemicals are not either 
manufactured, domestically distributed, used, imported, 
exported or re-exported or through which they transit. 
Finally, the special session in 2016 will provide the 
 opportunity to lay the bases for a forward-looking stra-
tegy that addresses the limitations of the existing system, 
mainly in relation to non-scheduled chemicals, including 
“designer precursors” and precursors of new psychoactive 
substances. Concepts are available, such as those known 
as “immediate precursors” and the reversal of the burden 
of proof, which bring to life the spirit of article 12 of the 
1988 Convention without overburdening authorities and 
industry. 
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2. The use of benzodiazepines among 
older adults
270. According to the WHO Global Health Observatory, 
global life expectancy at birth has increased by six years 
since 1990. In 2013, the global population aged 60 years 
could expect to live another 20 years on average, 2 years 
longer than in the 1990s. Life expectancy at age 60 in 
high-income countries was six years longer than that in 
low-income and lower-middle-income countries. Fur-
thermore, according to the Population Division of the 
Department of Economic and Social Affairs of the 
Secretariat, the percentage of the global population aged 
60 and over increased from 8.5 per cent in 1980 to 
12.3  per cent in 2015. This upward trend is expected to 
continue (see figure 1).
Figure 1. Percentage of the population aged 
60 and over, estimated for 1980-2015 and 
projected to 2050 
Ageing is not a disease 
271. Ageing is by no means an illness. However, old age 
is often accompanied by illness. Illness affects older 
 people more because it comes on top of changes in their 
health resulting from normal ageing. In older people, the 
distinction between healthy and sick is much more 
 difficult to make, which increases the likelihood that 
they  are overmedicated, undermedicated or medicated 
unnecessarily.
272. Older people often face isolation and loneliness. 
They often suffer from chronic illness and certain condi-
tions associated with ageing such as Alzheimer’s disease, 
anxiety, insomnia, depression and dementia, and co- 
morbidity is common. Their sleeping patterns are differ-
ent from those of younger people, and insomnia seems 
common among otherwise healthy individuals aged 65 
and older, making them an attractive target group for 
manufacturers of sleeping pills. There are concerns that 
insomnia is being treated excessively as a result. This 
could be dangerous, as the elderly generally have more 
medical problems, and many of them take medications 
for more than one condition.
273. In most cases, the treatment of insomnia in older 
patients involves psychosomatic therapy and requires pre-
scription drugs, in particular anxiolytics and hypnotics. 
Furthermore, given the demographic changes and the 
ageing of the population worldwide, the proportion of 
older patients undergoing surgery and therefore anaes-
thesia is increasing.
274. Pharmaceutical preparations containing benzodi-
azepines have been proved effective. Hypnotics, sedatives 
and anxiolytics are an essential part of health care, and 
they are prescribed worldwide to patients of all ages. 
Benzodiazepines have a wide range of indications; they 
are prescribed as hypnotics, sedatives, muscle relaxants 
and anxiolytics, as well as for pre-medication (prior to 
surgical procedures) and the induction of general anaes-
thesia. There are currently 35 benzodiazepines under 
international control, almost all of which are listed in 
Schedule IV of the 1971 Convention.
275. When they are well prescribed, benzodiazepines 
are considered relatively safe, as they are effective, fast-
acting, have low toxicity and can be prescribed to patients 
of all ages. However, as with any medicine, their use also 
carries the risk of side effects and toxic reactions, par-
ticularly among the elderly. The elderly are more prone 
to adverse reactions because they tend to eliminate med-
ication more slowly and for that reason often need lower 
doses.
Overuse and unwarranted use
276. In the United States of America, people aged 65 
and over make up about 10 per cent of the total popula-
tion, yet they account for 30 per cent of medical prescrip-
tions. The discrepancy is wider than the figures suggest, 
because the elderly are more sensitive to medication and 
therefore need less of it.
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277. According to the information available to the 
Board, the overall manufacture of benzodiazepine-type 
sedative hypnotics and anxiolytics and their global calcu-
lated consumption in absolute terms have been stable in 
recent years. Since 2000, manufacture of these substances 
has stood at around 30 billion defined daily doses for sta-
tistical purposes (S-DDD) with consumption rates at sim-
ilar levels, despite an increasing number of older patients 
(see figure 2).
278. Europe has traditionally been the region with the 
highest calculated average national consumption rates for 
benzodiazepine-type anxiolytics. In 2014, the United 
States, Brazil, Spain, Japan, France, Italy, Argentina, 
Germany and the United Kingdom (in descending order) 
were the largest consumers of benzodiazepine-type anxi-
olytics in absolute terms. Recently there have been reports 
from the United States about widespread overuse, under 
medical supervision, of psychoactive drugs among elderly 
people suffering from dementia.
Figure 2. Global manufacture and calculated 
consumption of benzodiazepines (anxiolytics 
and sedative-hypnotics)
Hazardous use
279. The debate about the use of benzodiazepines 
among older people is not new. Numerous studies on the 
consequences of unwarranted and chronic use among 
older adults have highlighted the risk of drug 
dependence.
280. A recent Japanese study showed that the prevalence 
of prescriptions for hypnotics and anxiolytics is dispro-
portionately high among elderly patients. The study also 
showed that the simultaneous prescription of anxiolytics 
and hypnotics in high doses is common among patients 
suffering from sleep and/or anxiety disorders, that more 
than half of the prescriptions in question are issued by 
physicians, and that the long-term prescription of benzo-
diazepines is still widespread in spite of international clin-
ical guidelines recommending benzodiazepine treatment 
to be limited to only a few weeks (two to four weeks).
281. The unwarranted prescribing and use of benzodi-
azepines by older patients is not harmless. A French study 
suggests that benzodiazepines are associated with an 
increased risk of dementia. The study found that patients 
over the age of 65 who start taking benzodiazepines had 
a 50 per cent higher chance of developing dementia 
within 15 years, compared to people who had never used 
them.
282. With an increased sensitivity to benzodiazepines 
and a slower metabolism, older patients are at high risk 
of developing delirium and cognitive impairment, and are 
more susceptible to falls and fractures. Moreover, long-
term use of benzodiazepines is commonly associated with 
withdrawal syndrome.
Sensible use for better care
283. In its 2012 update of the Beers criteria for poten-
tially inappropriate medication use in older adults, the 
American Geriatrics Association recommended avoiding 
all benzodiazepines in the treatment of insomnia, agita-
tion or delirium. Furthermore, successful treatment dis-
continuation may result in improvement of cognitive and 
psychomotor function, particularly in older people.
284. As already noted, the Board fully recognizes that 
hypnotics, sedatives and anxiolytics containing controlled 
benzodiazepines have been proved to be effective and are 
essential in medical practice and health care. However, 
the Board calls on all Governments to be alert to adverse 
reactions and problems resulting from the misuse and 
overuse of benzodiazepines, particularly among older 
adults. INCB calls on the Governments concerned to 
adopt, where necessary, measures to prevent the over­
prescription and misuse of sedative­hypnotics and anxi­
olytics containing benzodiazepines among older patient 
groups. 
285. To avoid the harmful side effects of benzodiaz-
epines, Governments must ensure that health-care 
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providers carefully consider the risk-benefit ratio, safety, 
adverse drug reactions and the simultaneous use of other 
drugs before prescribing any medications containing ben-
zodiazepines to older patients. Guidelines for clinical care 
and training should be made available to health-care pro-
viders, in particular in nursing homes and geriatric care 
facilitates. Other measures may involve raising awareness 
of the risks associated with inappropriate use of benzo-
diazepines, targeting, in particular, family members of 
elderly patients, their caregivers, nursing staff and employ-
ees at residential facilities for the elderly.
3. New psychoactive substances
286. New psychoactive substances are a very heteroge-
neous group of substances that, in different forms, con-
tinues to grow in every region of the world. As at October 
2015, the UNODC early warning advisory on new psy-
choactive substances, which monitors the emergence of 
new psychoactive substances as reported by Member 
States, had identified 602 unique substances, a 55 per cent 
increase from the 388 substances reported in October 
2014. 
287. As in the past, the most reported substances con-
tinued to be synthetic cannabinoids, which accounted for 
nearly 40 per cent of all the substances reported, and 
phenethylamines and synthetic cathinones, which together 
accounted for about one third of all substances. While 
the number of new psychoactive substances continues to 
grow, not all those substances become established sub-
stances of abuse. In fact, many may be encountered only 
once.
288. The definition of “new psychoactive substances” 
used for the purposes of the early warning advisory 
encompasses both synthetic and plant-based substances 
(such as khat (Catha edulis), kratom (Mitragyna speciosa) 
and Salvia divinorum), as well as substances with estab-
lished medical uses (e.g., ketamine). What all new psy-
choactive substances have in common is not necessarily 
that they have recently been invented but that they have 
recently emerged on the market and have not been sched-
uled under the international drug control conventions.
289. INCB uses the same definition, except that it 
focuses on synthetic substances of abuse with little or no 
known medical or industrial use. The Board believes that 
these substances pose particular challenges, given the var-
ious possible modifications that can be made to them to 
circumvent existing legislation and the lack of knowledge 
about their health effects. 
290. In the light of the number and transient nature of 
many of the new psychoactive substances, as has been 
previously noted,22 INCB is providing Member States with 
the infrastructure, known as Project Ion (international 
operations on new psychoactive substances) for real-time 
information-sharing on incidents involving new psycho-
active substances (e.g., suspicious shipments, trafficking, 
or manufacture or production, for any new psychoactive 
substance), as well as follow-up between authorities of the 
countries concerned with a view to assisting investiga-
tions and devising practical solutions aimed at prevent-
ing those substances from reaching consumer markets. 
The task force on new psychoactive substances, which 
steers Project Ion activities, held two meetings in 2015.
291. Since the Board’s annual report for 2014, the global 
focal point network on new psychoactive substances for 
Project Ion expanded to 120 countries, in every region of 
the world. A special operation, Operation Postman, con-
ducted in March and April 2015, focused on postal and 
express courier shipments containing non-scheduled syn-
thetic new psychoactive substances. Forty-one countries 
worldwide participated, resulting in the communication 
of nearly 200 individual incidents involving some 70 dif-
ferent new psychoactive substances. 
292. In December 2014, the Project Ion Incident 
Communication System (IONICS) was launched, a secure 
platform dedicated to the real-time communication of 
incidents involving suspicious shipments, trafficking, 
manufacture or production of new psychoactive sub-
stances. After just under one year of operation, in 
November 2015, the system had more than 170 users 
from 60 countries in all regions of the world (see map 
below). There have been more than 500 incidents com-
municated in as little as two days after the incident 
occurred. The majority of incidents involved synthetic 
cathinones (e.g., methylone, mephedrone, MDPV, 
3-methyl methcathinone (3-MMC)), synthetic cannabi-
noids (e.g., APINACA), and phenethylamines (e.g., 2C-I-
NBOMe).23 Information communicated through IONICS 
has triggered follow-up investigations in countries of 
 destination that led to significant additional seizures of 
new psychoactive substances, seizures of money and 
arrests of distributors.
 22 E/INCB/2014/1, paras. 248-256.
 23 The difference in order of classes of new psychoactive substances 
compared with the early warning advisory on new psychoactive sub-
stances is due to differences in the user bases and the purposes of the two 
systems, focusing on, respectively, unique substances (reported to early 
warning advisory) and individual new psychoactive substance incidents 
(communicated through IONICS).
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Map of Project Ion focal point network, as at 1 November 2015
293. Other important developments since the last annual 
report of the Board were the decisions of the Commission 
on Narcotic Drugs, at its fifty-eighth session, upon the rec-
ommendations of the WHO Expert Committee on Drug 
Dependence, placing 10 new psychoactive substances 
under international control, as follows: AH-7921, a syn-
thetic opioid, was added to Schedule I of the 1961 
Convention; 25B-NBOMe (2C-B-NBOMe), 25C-NBOMe 
(2C-C-NBOMe) and 25I-NBOMe (2C-I-NBOMe) were 
added to Schedule I of the 1971 Convention; and BZP, 
JWH-018, AM-2201, MDPV, mephedrone (4-methylmeth-
cathinone) and methylone (beta-keto-MDMA) were added 
to Schedule II of the 1971 Convention. Decision 58/3, 
scheduling AH-7921 under the 1961 Convention, became 
effective on 8 May 2015, and the other nine decisions, all 
for substances scheduled under the 1971 Convention, 
became effective on 4 November 2015.
294. At its thirty-seventh meeting in November 2015, 
the WHO Expert Committee on Drug Dependence 
reviewed, among other substances, MT-45, acetylfentanyl, 
alpha-pyrrolidinovalerophenone (α-PVP), 4-fluoroam-
phetamine (4-FA), para-methyl-4-methylaminorex (4,4’-
DMAR), para-methoxymethylamphetamine (PMMA) 
and methoxetamine (MXE). The Expert Committee’s rec-
ommendations will be transmitted to the Commission on 
Narcotic Drugs, which will decide at its next session on 
the international scheduling of all or some of those sub-
stances. In that connection, the Board acknowledges the 
cooperation between WHO and UNODC to establish cri-
teria for the prioritization of substances for the Expert 
Committee’s review.
295. In addition to scheduling at the international level, 
countries also continue to bring new psychoactive sub-
stances under national controls. India, often cited as a 
source of new psychoactive substances, took the impor-
tant step of controlling mephedrone and its salts and 
preparations under the Narcotic Drugs and Psychotropic 
Substances Act, 1985, effective 5 February 2015. China 
had already taken steps to control several new psychoac-
tive substances in January 2014; effective 1 October 2015, 
116 substances were placed in a new list of “non- medical 
narcotic drugs and psychotropic substances”. Additionally, 
since the Board’s last report, Project Ion has received 
information on national controls of various new psycho-
active substances in several countries, including Argentina, 
Armenia, Chile, Egypt, Mexico, Sweden, Turkey and 
Ukraine. The information was communicated to the 
Project Ion focal point network with a view to enabling 
operational cooperation in cases of shipments of a 
 controlled new psychoactive substance known to have 
The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United 
Nations. The final boundary between the Sudan and South Sudan has not yet been determined. The dotted line represents approximately 
the Line of Control in Jammu and Kashmir agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been 
agreed upon by the parties. A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern 
Ireland concerning sovereignty over the Falkland Islands (Malvinas).
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originated in, or be destined for, one of the countries with 
newly enacted national legislation. 
296. New psychoactive substances have also been the 
subject of an increasing number of meetings, conferences 
and symposiums in almost all regions of the world; how-
ever, effective strategies are still forthcoming. At the same 
time, the challenges posed by new psychoactive sub-
stances and the diversification of the market continue to 
grow, with a rising number of reports about the role of 
such substances in hospital emergencies and deaths, and 
other worrying developments such as the use of new psy-
choactive substances by injection. 
297. At its fifty-eighth session, the Commission on 
Narcotic Drugs adopted a resolution on promoting the 
protection of children and young people, with particular 
reference to the illicit sale and purchase of, among other 
substances, new psychoactive substances via the Internet 
(Commission resolution 58/3) and a resolution on 
promoting international cooperation in responding to 
new psychoactive substances (Commission resolution 
58/11). At a joint INCB/UNODC international confer-
ence on precursor chemicals and new psychoactive sub-
stances held in Bangkok on 21-24 April 2015, some 200 
experts from 37 countries and 9 international organiza-
tions adopted an outcome document entitled “Proposed 
measures against the misuse of scheduled and non- 
scheduled precursors and new psychoactive substances”. 
298. INCB encourages all Governments to build on 
those and previous resolutions and recommendations, 
regional experiences and the experiences of individual 
Member States, and use the upcoming sessions of the 
Commission on Narcotic Drugs and the special session 
of the General Assembly on the world drug problem to 
devise practical and realistic solutions to protect individ-
uals and the public at large from the adverse conse-
quences of using harmful new psychoactive substances 
belonging to a wide range of substance classes.
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Chapter III.
Analysis of the world situation
HIGHLIGHTS
• The increasing prominence of East africa as a transit area for afghan heroin has led to the increased abuse of 
opiates in the subregion. west africa has been identified as a source of the amphetamine-type stimulants reach-
ing asia.
• The region of Central america and the Caribbean remains a significant supplier of cannabis and a transit route 
for cocaine to North america and Europe. The region continues to be affected by drug trafficking and drug-related 
violence and has homicide rates that are among the highest in the world.
• North america had the highest rates of drug-related mortality in the world, including a growing number of acci-
dental overdose deaths, and was affected by the growing public security and health consequences of widespread 
cannabis abuse in the united states and Canada.
• Coca bush cultivation in Colombia increased by 44 per cent in 2014, reversing the decreases of recent years, while 
Bolivia (Plurinational state of) and Peru once again registered decreases.
• amphetamine-type stimulants, in particular methamphetamine, continue to be the largest drug threat for East 
and south-East asia. The rapid emergence of new psychoactive substances remains an additional major 
concern.
• In south asia, the rise in the illicit manufacturing, trafficking and abuse of methamphetamine and the diversion 
and abuse of pharmaceutical preparations containing narcotic drugs and psychotropic substances remain major 
drug-related challenges.
• The security and conflict situation in some countries in west asia and the resultant mass movement of people 
within the region and beyond provide significant opportunities for organized criminal groups to traffic drugs and 
increased drug abuse.
• The number of new psychoactive substances identified and distributed in western and Central Europe continued 
to grow in 2014. 
• In Eastern and south-Eastern Europe, rates of drug abuse by injection are nearly five times the world average.
• Oceania is actively engaged in enhancing joint operations and improving border control, particularly given the 
region’s vulnerability to the abuse and trafficking of drugs, including amphetamine-type stimulants.
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A. Africa 
1. Major developments
299. Africa continues to be one of the main transit areas 
for drug trafficking. West Africa is regularly used by traf-
fickers to smuggle cocaine and other drugs into Europe. 
Furthermore, North Africa remains a primary source of 
drugs entering Europe, while East Africa is increasingly 
being used as a trafficking hub for Afghan heroin des-
tined for Europe. The latter development is evidenced by 
the fact that East African countries and certain European 
countries have reported annual growth in seizures of her-
oin of African origin. This may be a reason for the 
increased abuse of heroin in East Africa. 
300. Traffickers in search of new illicit markets for 
cocaine and heroin have targeted the nascent middle class 
in certain African countries, such as Benin, which has 
been used as a transit country for many decades, and 
Namibia, a transit country that is becoming a consumer 
country. Drug trafficking in West Africa may have an 
impact on the abuse of certain types of drugs, such as 
cannabis, cocaine, heroin and amphetamine-type stimu-
lants, in the subregion.
301. The increase in drug trafficking has been accom-
panied not only by growing illicit drug use, especially 
among younger people, but also by increasing activities 
of organized criminal groups. In West and Central Africa, 
organized crime continues to contribute to social and 
economic costs by increasing drug trafficking and addic-
tion and by concentrating wealth and power in the hands 
of comparatively few well-armed criminals.
302. Although the Economic Community of West 
African States (ECOWAS) has made efforts to counter the 
impact of drug trafficking and abuse in West Africa, there 
has been an overall increase in drug trafficking between 
Latin America and Europe using Africa as a transit area. 
The increase in illicit drug use in West Africa has resulted 
in challenges related to security, treatment and negative 
health and social consequences of that drug use.
303. According to South African law enforcement 
authorities, drug trafficking organizations from China 
and the Balkans have established a significant presence in 
Southern Africa. In addition to importing drugs directly 
into Southern Africa, drug trafficking organizations ship 
drugs to Maputo, and from there the drugs are trans-
ported by truck to South Africa.
2. Regional cooperation
304. A five-year strategic framework on drug control, 
focusing on drug abuse prevention and treatment stand-
ards, as well as the establishment of national and regional 
drug observatories, was discussed at the first meeting of 
the African Union Specialized Technical Committee on 
Health, Population and Drug Control, held in Addis 
Ababa in April 2015. During that meeting, African min-
isters of health, population and drug control held a meet-
ing to discuss linkages between health and drug control. 
The recommendations contained in the final report of the 
ministers’ meeting include: (a) the establishment of a 
regional drug control focal point by the regional economic 
community secretariats to develop and implement regional 
drug control strategies and to support individual States; 
and (b) the development of regional and national centres 
of excellence for the treatment and care of drug depend-
ence. The ministers also recommended that the member 
States of the African Union, in partnership with WHO 
and UNODC, should develop model laws to provide a 
basis for legislative review at the member State level to 
address new and emerging drug control challenges.
305. An ECOWAS action plan for the period 2016-2020 
establishes the following priorities for combating drug 
trafficking and transnational organized crime in West 
Africa: (a) improvement in the effectiveness of national 
and subregional cooperation in the detection and 
 suppression of drug trafficking and organized crime; 
(b)  the establishment of appropriate, adequate and effec-
tive criminal justice systems; (c) effective and sustainable 
demand reduction through the prevention of drug abuse, 
the treatment of drug addiction and the rehabilitation of 
drug-dependent persons; and (d) the establishment of a 
viable system for the collection of valid and reliable data 
for monitoring drug trafficking, organized crime and 
drug abuse.
306. Officials from 13 African countries attended the 
fourth International Annual Meeting of the Airport 
Communication Project (AIRCOP), held in Panama City 
from 21 to 23 April 2015. The meeting was organized 
jointly by UNODC, INTERPOL and WCO, with the sup-
port of the National Security Council of Panama, with 
the aim of creating a link between countries participat-
ing in AIRCOP, the interregional initiative aimed at facil-
itating the exchange of experiences and good practices in 
countering drug trafficking by air, to strengthen the coor-
dination of their activities and share information between 
the joint airport interdiction task forces. In May 2015, 
joint airport interdiction task forces were operational in 
Benin, Cabo Verde, Côte d’Ivoire, the Gambia, Ghana, 
Mali, the Niger, Nigeria, Senegal and Togo. 
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307. A technical level meeting on heroin trafficking in 
the maritime domain was held on Mahé, in Seychelles, 
from 30 March to 1 April 2015. The meeting was aimed 
at enhancing drug control cooperation among littoral and 
island States of the Indian Ocean. The interregional ini-
tiative, supported by the UNODC Maritime Crime 
Programme, was attended by high-ranking officers from 
drug law enforcement agencies and state prosecutors, 
who proposed recommendations to counter drug traffick-
ing in the area of the Indian Ocean.
3. National legislation, policy and 
action
308. In 2014, Egypt, Ghana and Nigeria took steps 
towards strengthening their national legislation and 
capacities to counter trafficking in drugs, including new 
psychoactive substances.
309. In November 2014, the Egyptian authorities sched-
uled five synthetic cannabinoids. The Ministry of Health 
added the following substances to the list of controlled 
substances included in the law of 1960: JWH-018, JWH-
073, JWH-200, CP 47,497 and the C8 homologue of CP 
47,497. According to the new law, the import, export, 
production, possession, handling, buying and selling of 
these substances are banned.
310. In Ghana, the authorities broadened the scope of 
their surveillance operations to include the monitoring of 
websites through which psychoactive substances are sold. 
The Parliament of Ghana is considering amendments to 
the Provisional National Defence Council law to 
strengthen sanctions related to synthetic psychotropic 
substances such as methamphetamine and its derivatives; 
and in order to introduce legislation to transform the 
Narcotics Control Board, under the Ministry of the 
Interior, into a drug control commission, under the 
President, with prosecutorial powers.
311. The Government of Nigeria approved its third 
national drug control master plan, covering the period 
2015-2019. The new master plan, which was launched on 
26 June 2015, provides a framework for reducing harm 
caused by drugs and for suppressing illicit drug produc-
tion, supply and trafficking, as well as a platform for 
strengthening drug control responses. The master plan, 
developed by the interministerial committee on drug 
 control, has four pillars: (a) law enforcement; (b) drug 
demand reduction; (c) access and control of narcotic 
drugs and psychotropic substances used for medical 
and  scientific purposes; and (d) coordination of 
implementation.
312. In April 2015, the authorities of South Africa con-
vened a conference to examine, among other issues, the 
potential use of cannabis for medical purposes. The 
round-table discussions focused on how to address the 
problems of cannabis use, abuse and dependence in the 
country.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
313. Illicit cannabis cultivation, production, trafficking 
and use continue to represent major challenges to coun-
tries in Africa. While the illicit production of cannabis 
resin is concentrated in a few countries in North Africa, 
cannabis herb is produced throughout the continent.
314. Production of cannabis herb continues to be an 
issue of concern in Nigeria, where 158 tons of packaged 
cannabis herb were seized in 2014. Nigeria reported that 
over 53 million kg of cannabis illicitly cultivated on a total 
of 4,529 hectares (ha) of farmland were seized and 
destroyed in 2014, the highest level reported in 10 years. 
That also represents a dramatic increase over the level 
reported in 2013 (the eradication of cannabis covering a 
total area of 847 ha).
315. Nigeria was confirmed as a source country for 
cannabis destined for China, through the analysis of sei-
zures made at the international airport near Lagos, 
where a total of 94.3 kg of cannabis were seized in 2014. 
At the same airport, 90.9 kg of cannabis destined for 
China also, as well as 64.5 kg destined for the United 
Arab Emirates, were seized between January and July 
2015. In Ghana, 98  kg of cannabis destined for the 
United Kingdom were seized at Kotoka International 
Airport in Accra in 2014.
316. Morocco remains one of the world’s largest pro-
ducers of cannabis resin and continues to supply canna-
bis resin to Europe. Seizures of cannabis resin reported 
by the Moroccan authorities have declined significantly 
since 2012 (from 137 tons in 2012 to 107 tons in 2013 
and to about 70 tons in 2014), whereas there was an 
increase in seizures of cannabis resin in other countries 
in North Africa. The Moroccan authorities made signifi-
cant efforts to counter illicit cannabis cultivation. In 2013, 
the Moroccan authorities reported 47,196 ha of cannabis 
cultivation, 9.2 per cent less than in 2012. The authori-
ties expect the total area under cannabis cultivation to 
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decline further, to 34,000 ha, in the next few years. It has 
been reported that the concentration of tetrahydrocan-
nabinol (THC) in cannabis cultivated in Morocco has 
increased.
317. Other countries in North Africa continue to report 
large amounts of seized cannabis resin. Seizures of can-
nabis resin increased in North Africa by 31 per cent in 
2013. The increase was mainly attributed to large quan-
tities of cannabis resin reported seized in Algeria and 
Egypt. In 2014, however, the seizures of cannabis resin 
reported by Algeria declined by nearly 14 per cent (from 
211 tons in 2013 to 182 tons in 2014), and seizures 
reported by Egypt declined by 35 per cent (from 84 tons 
in 2013 to 55 tons in 2014). Most of the cannabis resin 
seized in Algeria was reportedly seized in a province in 
the north-western part of the country, on its border with 
Morocco. Other African countries also reported substan-
tial seizures of the substance in 2014. For example, 
Tunisian authorities intercepted consignments of canna-
bis resin totalling 11 tons.
318. In 2014, Egyptian authorities resumed eradication 
campaigns targeting cannabis and opium poppy cultiva-
tion sites, eradicating cannabis plants covering a total area 
of 344.7 ha and opium poppy covering a total area of 
306.5 ha. In 2014, Egyptian authorities seized over 395 
tons of cannabis herb, compared with 212 tons seized 
during the previous year.
319. For West Africa, cocaine trafficking remains a 
major concern. Cocaine arriving from South America 
transits in particular countries in West Africa on its way 
to Europe. One of the main modes of transport used for 
such trafficking is commercial aircraft; it is likely that that 
development is related to the increased number of com-
mercial flights between Brazil and West Africa. Data pro-
vided by the National Drug Law Enforcement Agency of 
Nigeria on drug interceptions at the international airport 
near Lagos indicate that a total of about 120 kg of cocaine 
were seized at the airport in 2014.
320. Togolese authorities seized about 268 kg of cocaine 
in 2014. Since December 2013, when direct flights to 
Brazil from the international airport at Lomé first began, 
the volume of cocaine seized at the airport has increased, 
reaching 221 kg in 2014. In 2014, 32 cocaine consign-
ments were seized at the international airport at Lomé 
from flights originating in Brazil; of those consignments, 
25 per cent had been destined for Nigeria, 22 per cent 
for Benin, 16 per cent for Togo and 13 per cent for 
Guinea-Bissau. Morocco also witnessed the emergence of 
cocaine trafficking using commercial flights from Brazil. 
In 2014, 570 kg of cocaine were seized in Morocco.
321. Cabo Verde continues to be used as a hub for 
organized criminal groups trafficking in cocaine. Cabo 
Verdean authorities reported in November 2014 the sei-
zure of 521 kg of cocaine, and the interception by the 
Spanish navy of a consignment of 1,500 kg of cocaine in 
the Atlantic, 129 km west of Cabo Verde, was reported 
in January 2015.
322. Seizures of cocaine continue to be reported by 
countries in East Africa, but to a lesser extent than in 
previous years. Countries in the subregion had reported 
the seizure of large quantities of cocaine between 2010 
and 2012; the quantities reported in 2014 were smaller. 
That may indicate a shift in the concealment methods 
used, from sending large amounts of cocaine in fewer 
consignments to sending smaller amounts packed in 
small consignments to avoid detection by law enforce-
ment authorities. In 2014, the Kenyan authorities seized 
11 kg of cocaine, 30 per cent of which had arrived by air. 
Because of the high price of cocaine, estimated at $35,000-
$36,000 per kilogram, most of the cocaine is reportedly 
intended for illicit markets in European and other coun-
tries and only a small portion of it is kept for local 
consumption.
323. Africa’s importance as a transit area for Afghan 
heroin destined for Europe and other regions has grown, 
as suggested by increasing seizures of heroin reported in 
recent years by some African countries, particularly in 
East Africa. In 2014, Kenyan authorities reported the sei-
zure of 387 kg of heroin, 3,200 litres of water mixed with 
heroin and 2,400 litres of diesel mixed with heroin; 
377 kg of the 387 kg of heroin had been seized on a  single 
ship in the port of Mombasa.
324. Kenyan authorities reported that heroin is trans-
ported to the country in large ships that anchor in the 
high seas and are then offloaded onto small vessels, 
including dhows, fishing boats and speedboats. The main 
countries of destination were Italy, the Netherlands, the 
United Kingdom and the United States. As a result of 
the heroin being trafficked through Kenya, heroin has 
become one of the most commonly abused drugs in the 
country, second only to cannabis. Most of the cases 
involving heroin abuse in Kenya have been reported in 
Mombasa.
325. Seizure data indicate that the smuggling of heroin 
to and through the United Republic of Tanzania has also 
increased. Of all the substances seized by Tanzanian 
authorities, cannabis, khat (Catha edulis) and heroin (in 
that order) accounted for the highest amounts seized. 
During the first eight months of 2014, Tanzanian author-
ities intercepted consignments containing over 321 kg of 
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heroin, more than in any previous year. The seized her-
oin originated in Afghanistan, India, Iran (Islamic 
Republic of) and Pakistan and had been destined for 
China, Japan, South Africa, Turkey and the United States, 
as well as countries in Europe.
326. Egyptian authorities reported that seizures of her-
oin increased significantly from 260 kg in 2013 to 613 kg 
in 2014. Algerian and Moroccan authorities also reported 
seizures of heroin; however, the quantities seized were 
smaller, totalling less than 10 kg in 2014.
(b) Psychotropic substances
327. The South African Police Service reported an 
increase in the number of clandestine drug manufactur-
ing laboratories producing synthetic drugs such as meth-
amphetamine (known locally as “tick”), largely intended 
for the illicit market in South Africa.
328. West Africa appears to have become an established 
source of the methamphetamine that is smuggled into 
East and South-East Asia via South Africa or Europe. 
According to information provided by UNODC, the sig-
nificant volume of amphetamine-type stimulants seized 
in West Africa over the past year may indicate an increase 
in the illicit manufacturing of and trafficking in amphet-
amine-type stimulants, in particular methamphetamine. 
A total of 10 clandestine methamphetamine laboratories 
were dismantled in Nigeria between 2011 and July 2015.
329. In May 2015, Nigerian authorities dismantled two 
facilities used for the illicit manufacture of methamphet-
amine in Anambra State. Between January and July 2015, 
Nigerian authorities effected four seizures of metham-
phetamine, totalling approximately 92 kg, at the interna-
tional airport near Lagos. Three of the seizures were of 
minimal amounts; however, the fourth seizure is note-
worthy for its size—about 91 kg. In addition, Nigerian 
authorities also reported the detection of 2.6 kg of liquid 
methamphetamine and 250 g of crystalline methamphet-
amine and some laboratory equipment used for the illicit 
manufacture of methamphetamine.
330. Senegalese authorities have reported major sei-
zures of amphetamine-type stimulants, including the sei-
zure of 30 kg of methamphetamine at Kidira, near the 
Malian border, in January 2015, followed by the seizure 
of an additional 82 kg of methamphetamine in 
Koumpetoum in February 2015. In both cases, the drugs 
had originated in Mali and had been smuggled out of 
Bamako.
331. In 2014, the smuggling of amphetamine-type stim-
ulants through East Africa to illicit markets in Asian 
countries continued. Kenya reported the illicit manufac-
ture of crystalline methamphetamine using ephedrine 
and pseudoephedrine, precursors that are legally imported 
into the country and then diverted. The methampheta-
mine is then smuggled predominantly to Asian countries 
and South Africa, the biggest illicit markets for the sub-
stance being Japan, Malaysia, the Republic of Korea and 
Thailand. The abuse of methamphetamine is also increas-
ing in Kenya.
332. West Africa did not play a key role in the synthetic 
drug market until recent years. The reasons behind the 
change, part of an overall increase in global illicit demand 
for amphetamine-type stimulants, may be explained by 
weak controls on legal imports of their precursors and 
the socioeconomic situation in the subregion.
(c) Precursors
333. Countries in Africa continue to be vulnerable to 
trafficking in precursor chemicals, in particular as coun-
tries of destination and/or transit countries. The main 
precursor chemicals involved are ephedrine and pseudo-
ephedrine, which are used in the illicit manufacture of 
amphetamine-type stimulants. According to information 
provided through PICS, the following African countries 
have been identified as having been involved in incidents 
reported between November 2014 and November 2015: 
Democratic Republic of the Congo, Ethiopia, Malawi, 
Mozambique, Nigeria, Seychelles, South Africa and 
Zimbabwe. The seizures communicated through PICS, 
however, involved relatively small amounts of ephedrine 
(totalling over 500 kg) and pseudoephedrine (totalling 
about 70 kg).
334. The data on seizures of substances listed in Tables 
I and II of the 1988 Convention and seizures of inter-
nationally non-scheduled substances remain limited. 
Information on methods of diversion and illicit 
 manufacture, stopped shipments and thefts involving 
those substances, which is provided annually by 
Governments to the Board, has also been insufficient. As 
at 1 November 2015, the Governments of 16 African 
countries24 provided form D for 2014 to the Board. Only 
4 of the 16 countries (Namibia, Senegal, Zambia and 
Zimbabwe) reported the seizure of moderate amounts of 
ephedrine (in bulk form and in the form of 
 24 Algeria, Benin, Côte d’Ivoire, Democratic Republic of the Congo, 
Egypt, Ghana, Morocco, Mozambique, Namibia, Senegal, Sudan, Tunisia, 
Uganda, United Republic of Tanzania, Zambia and Zimbabwe.
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pharmaceutical preparations), ergometrine, isosafrole and 
potassium permanganate. Most of the ephedrine seized 
(82 kg) was reported by Senegal.
335. As noted by the Board in its report for 2014,25 by 
1 November 2014, the Governments of only a few African 
countries had invoked article 12, paragraph 10 (a), of the 
1988 Convention, requiring them to be informed of 
 shipments of substances in Table I of the Convention 
prior to their departure from the exporting country. 
Effective May 2015, the Government of the Sudan requires 
pre-export notification for imports of all substances in 
Tables  I and II.
336. In May 2015, Nigerian authorities dismantled at 
least three clandestine laboratories in south-east Nigeria, 
where toluene, a substance in Table II of the 1988 
Convention that is commonly used as a solvent, had been 
found. There are indications that the precursors were 
obtained locally, from domestic distribution channels, 
after they had been legally imported. 
337. In February 2015, 133 kg of ephedrine were seized 
at the international airport near Lagos. The consignment 
had been sent as cargo and had been destined for 
Mozambique and South Africa.
338. An additional challenge has emerged in Africa: 
online sales of controlled drugs (web-based marketplace 
sales via the Internet). The increase in online trafficking 
has made it difficult for law enforcement authorities to 
identify website owners and users involved in trafficking 
in precursor chemicals.
339. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the 2015 report of the Board on the implementation 
of article 12 of the 1988 Convention.
(d) Substances not under international 
control
340. Some African countries continue to raise their con-
cerns over the abuse of substances not under interna-
tional control, namely ketamine and tramadol. Nigeria, 
where ketamine is widely used in human and veterinary 
practice as an anaesthetic, brought tramadol and keta-
mine under national control in 2010.
 25 E/INCB/2014/1, para. 295.
341. The abuse of and trafficking in tramadol, a syn-
thetic opioid not under international control, continues 
to represent challenges to a number of countries in Africa, 
notably in North Africa and West Africa. In 2014, more 
than 43,578 kg of tramadol were seized by the joint port 
control units of Cotonou, Benin, and Tema, Ghana. In 
February 2015, the joint port control unit of Cotonou 
seized 13,612 kg of tramadol, which had arrived from 
India and had been destined for the Niger. Seizures of 
tramadol in Egypt declined significantly, from 435 mil-
lion tablets in 2012 to 157 million tablets in 2014. 
According to the Egyptian authorities, the decrease could 
be attributed to the fact that tramadol had been brought 
under national control in 2013.
342. There continues to be only limited information 
about the African continent regarding the emergence of 
new psychoactive substances, the extent of their abuse 
and their seizures. However, according to information 
provided to the Board, incidents with new psychoactive 
substances in 2015 involved the following African coun-
tries, particularly as countries of origin or as transit coun-
tries: Ethiopia, Kenya, South Africa and United Republic 
of Tanzania. The majority of the incidents concerned 
khat; the amounts of khat involved were in the range of 
6-166 kg. Other seizures communicated during the 
reporting period included 27 kg of methylone, a synthetic 
cathinone included in Schedule II of the 1971 Convention 
by the Commission on Narcotic Drugs at its fifty-eighth 
session, in 2015.
5. Abuse and treatment
343. Although the prevention and treatment of drug 
abuse are part of the main provisions of the international 
drug control treaties, it is estimated that in Africa only 1 
out of 18 people suffering from drug use disorders or 
drug dependence receive treatment each year and that a 
large proportion of drug users may not be dependent but 
may still require intervention.
344. The fact that almost half of the problem drug users 
who inject drugs follow unsafe injecting practices con-
tributes to the rise in the incidence of HIV. In Southern 
Africa, for example, evidence indicates that high-risk 
injecting practices, such as the reuse and sharing of nee-
dles and syringes and the ineffective cleaning of injecting 
equipment, contribute to HIV transmission among peo-
ple who inject drugs. This is also the case in sub- Saharan 
countries such as Kenya, Senegal, Uganda and the United 
Republic of Tanzania, where people who inject drugs 
often use non-sterile injecting equipment.
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345. Despite the paucity of data on drug abuse in Africa, 
it is estimated that the annual prevalence of cannabis use 
in the region remains high (7.5 per cent of the popula-
tion aged 15-64), almost double the global annual aver-
age (3.9 per cent), and it is particularly high in West and 
Central Africa (12.4 per cent). Cannabis is reported to be 
the primary substance for which people in Africa receive 
treatment for substance abuse.
346. According to information on demand for treatment, 
heroin remains the second most abused drug (after canna-
bis), in Africa. The annual prevalence of opiate abuse in 
the region is estimated at 0.3 per cent of the population 
aged 15-64 (or about 1.88 million individuals).
347. The annual prevalence of cocaine use in Africa, 
estimated at 0.4 per cent, remains comparable with the 
global estimate.
348. In West Africa, the growing availability of cocaine, 
heroin and amphetamine-type stimulants may have led 
to increased drug abuse and dependence. This increase is 
attributable to the emergence of illicit production and dis-
tribution centres for synthetic drugs in Côte d’Ivoire, 
Guinea and Nigeria.
349. The Government of Senegal has increased the 
availability and accessibility of services for the evidence-
based treatment and care of drug dependence by setting 
up in December 2014 the Dakar integrated treatment cen-
tre for persons with addictions. The centre, located at the 
University Hospital of Dakar, also provides a methadone 
maintenance programme, drug dependence treatment 
services, outreach programmes and programmes for the 
treatment of HIV infection and hepatitis infection for 
drug users.
350. Cabo Verde is piloting a “one-stop shop” for drug 
abusers, a centre offering multiple drug abuse treatment 
services in a vulnerable neighbourhood in the capital city 
of Praia, promoting the implementation of a community-
based treatment approach.
351. In Kenya, after an opioid substitution treatment 
facility (known locally as a medically assisted therapy 
clinic) was opened in Nairobi in December 2014, a second 
facility was opened in Malindi in February 2015 and two 
others were opened in Mombasa in September 2015. The 
national medically assisted therapy programme, launched 
on 18 August 2015, has been made available to people who 
inject drugs. In 2014, there were approximately 18,327 
injecting drug users in Kenya, about 18 per cent of whom 
were HIV-positive, which is significantly higher than the 
HIV prevalence in the general population (5.6 per cent).
352. Several countries in Africa, namely Burundi, 
Comoros, Eritrea, Madagascar and the United Republic 
of Tanzania, have improved national systems for the treat-
ment of drug dependence, mainly as a result of skill 
development and capacity-building initiatives. According 
to UNODC, Kenya and the United Republic of Tanzania 
have enhanced their capacity to prevent HIV infection 
and hepatitis infection among people who inject drugs. 
Mauritius and Seychelles have received technical support 
in this area.
353. In South Africa, the government of Gauteng prov-
ince opened a centre for the treatment of substance abuse 
in Soweto in May 2015. The centre offers free assistance 
to alcohol- and drug-dependent persons.
B. Americas
Central America and the Caribbean
1. Major developments
354. The region of Central America and the Caribbean 
continues to be used as a major trans-shipment area for 
consignments of drugs originating in South America and 
destined for North America and Europe. In the Caribbean, 
countries have begun playing an increasing role as sec-
ondary distribution points for cocaine shipments to 
Europe.26 Impunity, corruption and weak institutions 
undermine drug control efforts and the rule of law in the 
region, despite attempts to reform law enforcement and 
judicial systems. Drug trafficking activities are often car-
ried out under the protection of local gangs (maras) oper-
ating in border areas, especially in El Salvador, Guatemala 
and Honduras.
355. There are indications that links have been estab-
lished between drug cartels and criminal organizations 
operating in the region. Law enforcement authorities have 
reported a significant change in trafficking patterns, with 
drug traffickers cancelling confirmed flights at the last 
minute, only to make bookings immediately thereafter on 
the same flight, in an attempt to avoid detection during 
the process of screening the passenger list.27 
356. Drug trafficking has become a major security threat 
and is contributing to an increase in drug abuse in the sub-
region. The number of homicides linked to organized 
 26 World Drug Report 2015.
 27 Ibid.
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crime has risen in areas where criminal groups fight to 
gain control of local drug distribution. The increase in 
criminal acts may be linked to the struggle to control local 
markets and the increasing availability of drugs, which in 
turn may be attributable to the fact that drug traffickers 
are frequently paid in drugs rather than cash. 
357. The drug problem has also led to drug-related cor-
ruption, which has increasingly weakened the criminal 
justice systems in Central America and the Caribbean. 
Corruption, including among police and other law 
enforcement officials, has interfered with the ability of 
Governments in the region to promote development, 
blocking the delivery of services and distorting public 
spending. Drug money and corruption have become 
entrenched in the security services in Central America, 
paving the way for other forms of organized crime, 
including trafficking in firearms. Limited law enforcement 
capacity, corruption and weak governability in Central 
America and the Caribbean have facilitated the use of 
smuggling channels and drug trafficking activities. INCB 
encourages the Governments of countries in Central 
America and the Caribbean to consider regional strate-
gies for countering the drug problem that involve con-
certed action in the area of crime prevention and criminal 
justice reform, together with regional approaches to 
reducing drug trafficking and controlling firearms.
358. In February 2015, Jamaican legislators passed an 
amendment to the Dangerous Drugs Act to the effect that 
possession of two ounces or less of cannabis (56.6 g) is no 
longer a criminal offence and will no longer result in a 
criminal record. The use of cannabis for personal con-
sumption has also been authorized for members of the 
Rastafari community, in the context of their religious activ-
ities. The amendment entered into force on 1 April 2015.
359. The Board continues to closely follow drug policy 
developments in the region, including the adoption of 
amendments to the legal frameworks regulating substances 
under international control in Costa Rica, Guatemala and 
Jamaica. INCB underscores that Governments, whenever 
considering potential changes to their national drug legis-
lation and policies, should take steps to ensure that those 
changes are consistent with their obligations under the 
three international drug control conventions.
2. Regional cooperation
360. A regional seminar on the role of research in the 
development of effective policy in the field of drug abuse 
prevention was held in Port of Spain from 29 to 31 
October 2014. The seminar was organized by the 
Inter-American Drug Abuse Control Commission, 
through its Inter-American Observatory on Drugs, and 
the Government of Trinidad and Tobago, with the par-
ticipation of representatives of 30 Caribbean States mem-
bers of the Organization of American States (OAS). 
Participants emphasized the need to strengthen State 
institutions and their capacity to gather, analyse and 
report drug-related information to guide the drug-related 
policy of the participating countries.
361. On 12 February 2015, the Montevideo Declaration 
was adopted by the seventeenth high-level meeting of the 
Coordination and Cooperation Mechanism on Drugs 
between the European Union and the Community of 
Latin American and Caribbean States (CELAC). In the 
declaration, States committed to continuing to provide 
support to projects in the region, in both demand and 
supply reduction areas, and emphasized the need to 
address the world drug problem using a comprehensive, 
multidisciplinary, intersectoral and balanced approach.
362. The Seventh Summit of the Americas was held in 
Panama City on 10 and 11 April 2015. Participants 
emphasized the need for a comprehensive and effective 
strategy against the world drug problem in the Americas. 
In its final “Mandates for action” document, the Summit 
decided to continue with the dialogue in preparation for 
the special session of the General Assembly on the world 
drug problem to be held in 2016. 
363. A workshop on drug trafficking over the Internet 
was held in San José on 19 May 2015. It was organized 
by the Inter-American Drug Abuse Control Commission 
(CICAD) of OAS and the Costa Rican Drug Institute. The 
objective of the seminar was to develop mechanisms to 
control and prevent the diversion and abuse of pharma-
ceutical products over the Internet.
364. The Twenty-fifth Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and the 
Caribbean, was held in San Pedro Sula, Honduras, from 
5 to 9 October 2015. Among the major issues discussed 
were: (a) prevention, investigation and prosecution of 
microtrafficking and its links to transnational criminal 
networks; (b) border management; (c) ways to address 
current trends in trafficking in cocaine; and (d) curbing 
access to the supply of precursor chemicals.
3. National legislation, policy and 
action
365. In February 2015, Jamaican legislators passed an 
amendment to the Dangerous Drugs Act to the effect that 
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possession of two ounces or less of cannabis (56.6 g) is 
no longer a criminal offence and will no longer result in 
a criminal record. Possession for personal use will be 
treated as an administrative offence, similar to a traffic 
violation, with a 30-day period to pay the administrative 
fine. The amendment also allows each household to cul-
tivate up to five cannabis plants. The amendment pro-
vides for a cannabis licensing authority to be established 
to monitor the distribution of cannabis for scientific and 
medical purposes. The use of cannabis for personal con-
sumption has also been authorized for members of the 
Rastafari community in the context of their religious 
activities. The amendment entered into force on 1 April 
2015. 
366. In June 2015, the Ministry of Health of Costa Rica 
released an expert opinion that included details of imple-
mentation of a pending bill to promote cannabis for med-
ical and industrial purposes. Among the conditions 
specified by the Ministry are that medical cannabis may 
be prescribed only as the last-resort medical alternative, 
while recreational use of cannabis remains illegal. Medical 
cannabis may be distributed through conventional phar-
macies, exclusively on prescription. The bill, pending 
since late 2014, contains a proposal on the legalization of 
the growing, processing and sale of cannabis for medical 
and industrial use. The pending bill is expected to be 
debated by the Parliament by the end of 2015. 
367. In Guatemala, the National Commission for the 
Reform of Drug Policy was established in 2014. The 
Commission aims to conduct a comprehensive review of 
the current policy on drugs and to propose reforms. It 
also aims to guide Government drug policy reform in the 
context of a broad and informed dialogue worldwide.
4. Cultivation, production, 
manufacture and trafficking
368. In Central America and the Caribbean, circum-
stances such as poverty, social inequality and a lack of 
economic opportunities for young people have contrib-
uted to an increase in drug trafficking. The migration sit-
uation in Central American countries is one of the most 
complex in the world, with many thousands of migrants 
arriving, transiting and departing every year. The easily 
accessible coasts of Jamaica have been used increasingly 
by various criminal networks to use the country as a tran-
sit and destination country for smuggling drugs, firearms, 
ammunition and migrants.
369. Cocaine continues to be trafficked from the bor-
der area between Colombia and Venezuela (Bolivarian 
Republic of) to airstrips in Central America and the 
Caribbean, in addition to the use of the more established 
sea routes via Haiti and the Dominican Republic. In terms 
of maritime trafficking, remote coastal areas of Honduras 
and parts of northern Nicaragua are also used. Once 
offloaded, shipments are moved further north by air.28 In 
Nicaragua, most cocaine is seized in remote, underpop-
ulated and isolated areas along the Atlantic coast.
370. Drug trafficking by sea remains a major problem 
in Central America and the Caribbean. In addition, light 
aircraft operating from clandestine airstrips in remote 
areas of South America are increasingly being used to 
transport cocaine. More and more often, drug traffickers 
use stolen or falsified aircraft registration numbers when 
transporting illicit consignments by air. INCB encourages 
Governments to monitor the sale and movement of light 
aircraft more closely, step up airspace security and 
strengthen control over privately owned landing fields.
(a) Narcotic drugs
371. Significant levels of cannabis herb are produced in 
most countries in Central America and the Caribbean. 
Jamaica remains the largest producer of cannabis in the 
Caribbean, with total cultivation of cannabis plant esti-
mated by local authorities at about 15,000 ha. Jamaican 
law permits only manual eradication. Eradication of can-
nabis increased in 2014, with the destruction of 588 ha, 
compared with 247 ha in 2013. In the Dominican 
Republic, the cannabis cultivated is mainly for local con-
sumption, and seizures are concentrated in the north-
western and south-western provinces that border Haiti. 
In 2014, seizures of more than 1 ton of cannabis were 
reported by the Dominican Republic.
372. In the eastern Caribbean countries (Antigua and 
Barbuda, Barbados, Dominica, Saint Kitts and Nevis, Saint 
Lucia, and Saint Vincent and the Grenadines), South 
American drug cartels use the many uninhabited islands 
for trafficking and temporarily storing cocaine shipments 
for onward trafficking to North America and Europe. 
Cannabis plant cultivation is present in the mountainous 
regions of Dominica, Grenada and Saint Vincent and the 
Grenadines. Law enforcement authorities in Barbados 
have reported an increased number of shipments of can-
nabis and cocaine originating in Trinidad and Tobago. 
Antigua and Barbuda reported an increased flow of can-
nabis and cocaine from Jamaica via Sint Maarten.
 28 United Nations Office on Drugs and Crime, Transnational Organ-
ized Crime in Central America and the Caribbean: A Threat Assessment 
(Vienna, September 2012).
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373. In 2014, according to official statistics, drug sei-
zures in the Caribbean totalled about 1.7 tons of cocaine 
and more than 376 tons of cannabis. Those seizures led 
to a total of 277 drug-related arrests, 234 drug-related 
prosecutions and 218 convictions during that year.
374. Saint Vincent and the Grenadines continues to be 
an important source of cannabis in the Caribbean. 
Another important source of cannabis in the region is 
Costa Rica, a regional leader in the eradication of canna-
bis plants and the seizure of cannabis. In Costa Rica, 
locally grown cannabis is primarily for domestic use; only 
a small fraction is exported. Seizures of cannabis from 
Colombia and Jamaica are also fairly common in Costa 
Rica; most of it is intended for the domestic market.
375. Cocaine and synthetic drugs are not produced in 
Jamaica. Drugs are trafficked from and through Jamaica 
by maritime vessels, air freight, human couriers and, to 
a limited degree, private aircraft. Factors contributing to 
drug trafficking include the country’s strategic geographic 
position, its lengthy and largely unprotected coastline and 
the large numbers of tourists visiting the country and the 
corresponding airline traffic. Cannabis and cocaine are 
trafficked from and through Jamaica mainly to markets 
in Belgium, Canada, Germany, the Netherlands, the 
United Kingdom and the United States, as well as other 
Caribbean countries. Reports indicate that Jamaica is 
emerging as a transit point for cocaine, in addition to 
cannabis leaving Central America and destined for the 
United States.
376. According to UNODC, cocaine trafficking patterns 
in Central America in 2013 remained the same as those 
in previous years. Costa Rica reported significant changes: 
from being primarily a transit country, it has become a 
secondary distribution point and a country of temporary 
storage of cocaine for onward trafficking.
377. Central America and the Caribbean was the only 
region worldwide where cocaine seizures increased in 
2013, to 162 tons, compared with 78 tons in 2012. The 
largest quantities of cocaine seized in 2013 were in 
Panama (41 tons) and Costa Rica (20 tons). That, how-
ever, was significantly lower than the 26 tons of cocaine 
seized in Costa Rica in 2014. In 2013, Trinidad and 
Tobago reported seizures of cocaine totalling 2.3 tons.29 
In 2014, authorities in the Dominican Republic seized 
more than 5 tons of cocaine, down from the approxi-
mately 8 tons seized in 2013, a decline owing partially to 
disruptions to trafficking organizations. The drug squad 
of Saint Vincent and the Grenadines reported a surge in 
 29 World Drug Report 2015.
the trans-shipment of cocaine, and authorities indicated 
that trafficking in drugs to and from nearby Guadeloupe 
had increased manifold over the previous few years.
378. Panama reported seizing more than 35 tons of 
cocaine in 2014. Several local drug trafficking organiza-
tions in Panama continued to provide logistical support 
to international trafficking organizations smuggling 
cocaine into Panama for further distribution northward 
into Central America. These organizations, based along 
the Caribbean coast of Panama, coordinate the receipt of 
“go-fast” vessels from several organizations in Colombia. 
Once in Panama, these vessels are refuelled and the illicit 
drugs stored in remote locations along the coastline, from 
where they are trafficked further north.
(b) Psychotropic substances
379. There are reports indicating that methampheta-
mine laboratories are being increasingly established in 
Central America. Over the past few years, clandestine lab-
oratories used for manufacturing amphetamine-type 
stimulants have been dismantled in Belize, Jamaica, 
Guatemala, Honduras and Nicaragua.
380. The Board has noted the scarcity of data reported 
on manufacture and trafficking of psychotropic sub-
stances and on the nature and extent of drug abuse of 
such substances in most countries in the region. INCB 
once again urges Governments to take additional meas-
ures to increase national capacity to collect data and con-
duct national assessments to determine the true extent 
and nature of problems caused by availability of psycho-
tropic substances in the region.
(c) Precursors
381. The Central American subregion has also report-
edly witnessed an increase in imports of chemicals that 
are not subject to international control but are suspected 
of being illicitly used in the manufacture of drugs. 
Following the adoption of legislation regulating the use 
of such chemicals in many countries in the subregion, the 
number of reported attempts to divert chemicals has 
declined. 
382. In Central American and Caribbean countries, 
additional measures are being taken to address the 
increasing diversion of precursors used in illicit drug 
manufacture; some countries, such as Antigua and 
Barbuda, Barbados, Costa Rica and Grenada, have estab-
lished mechanisms for regulating the use and distribution 
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of controlled chemicals. In the region as a whole, how-
ever, the movement of precursors is poorly monitored 
and regulated owing to weak infrastructure and the inad-
equate level of resources allocated by Governments. INCB 
encourages the Governments of countries in Central 
America and the Caribbean to adopt and strengthen leg-
islation and to establish a regional cooperation mecha-
nism for preventing trafficking in and diversion of 
precursors.
383. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
384. New psychoactive substances also continue to be 
reported by countries of Central America and the 
Caribbean, in particular Costa Rica. According to the 
UNODC early warning advisory, Costa Rica continued 
to report substances in the groups of phenethylamines, 
piperazines and other substances in 2015. Use of those 
substances may have serious health consequences, as the 
effects of such substances on the human body are not 
fully understood or known. In addition, the trafficking of 
those substances creates additional challenges for the 
 regulatory and enforcement authorities.
5. Abuse and treatment
385. Cannabis abuse patterns and trends in the region 
have remained fairly stable. The prevalence of cocaine 
abuse in Central America and the Caribbean remains 
higher than the global average,30 with an estimated aver-
age annual prevalence of 0.6 per cent for both subregions. 
As regards the use of opioids in Central America, 
UNODC has estimated annual prevalence at 0.2 per cent, 
which is below the global average.
386. According to the Report on Drug Use in the 
Americas, 2015,31 annual cannabis prevalence among sec-
ondary school students in Central America was reported 
to be highest in Belize, at 15.8 per cent, and lowest in 
Honduras, with a little more than 1 per cent. In the 
 30 World Drug Report 2015.
 31 Inter-American Drug Abuse Control Commission of the Organi-
zation of American States, Report on Drug Use in the Americas, 2015.
Caribbean, Saint Lucia reported the highest annual prev-
alence rates, of more than 15 per cent. Prevalence rates 
of less than 5 per cent were reported in Antigua and 
Barbuda, Barbados, Dominica, the Dominican Republic, 
El Salvador, Guyana, Haiti, Honduras, Panama, Saint Kitts 
and Nevis, and Saint Vincent and the Grenadines.
387. According to the Report on Drug Use in the 
Americas, 2015, the annual prevalence of cocaine abuse 
among high-school students in the Caribbean ranges 
from 0.5 per cent to slightly more than 2 per cent. In six 
countries (Antigua and Barbuda, Grenada, Haiti, Saint 
Kitts and Nevis, Saint Lucia and Trinidad and Tobago) 
reported prevalence is about 1.5 per cent and three coun-
tries in Central America have prevalence rates of about 
1 per cent (Belize, El Salvador and Panama). Approximately 
50 per cent of all demand for treatment for drug abuse 
in the region is reportedly related to cocaine abuse. 
Cocaine is also ranked as the main substance causing 
drug-induced or drug-related deaths.
388. Cocaine abuse among secondary school students 
is higher among male students in all countries, regardless 
of the prevalence rate reported. The exception is Saint 
Vincent and the Grenadines, where the estimated preva-
lence among males is 0.58 per cent, while for women it 
is 0.69 per cent. In Grenada, the country with the  highest 
level of cocaine use in the Caribbean, the ratio of male 
to female use is 32 to 1, followed by Saint Lucia with 7 to 
1, and Haiti and Jamaica, with about 3 to 1. In Honduras 
and Costa Rica, cocaine abuse by male students is three 
and four times higher than females, respectively.32 
389. The highest prevalence rates of “crack” cocaine in 
the Caribbean, ranging between 1.5 per cent and 2.2 per 
cent, are found in Antigua and Barbuda, Barbados, 
Grenada, Haiti, Saint Kitts and Nevis, and Saint Lucia. 
Guyana, Jamaica, Panama, and Trinidad and Tobago 
reported prevalence rates of around 1 per cent. The low-
est prevalence rates (under 0.5 per cent) in Central 
America are found in Costa Rica and Honduras. The low-
est prevalence rates in the Caribbean are found in the 
Dominican Republic.
390. The Board notes with concern the increase in the 
abuse of MDMA (“ecstasy”) in countries in Central 
America and the Caribbean, particularly in Antigua and 
Barbuda, and Belize. Abuse of “ecstasy”-type substances 
is also increasing in Jamaica, especially in the tourist areas 
of Negril and Montego Bay. The “ecstasy” found in the 
 32 World Drug Report 2015.
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region continues to be smuggled from European coun-
tries or, more recently, from Canada.33 
391. “Ecstasy” use among high-school students in the 
Caribbean remains high, with the highest annual preva-
lence rate (3.7 per cent) reported in Antigua and Barbuda. 
In Central America, the highest rate was found in Belize, 
with 2.4 per cent. In terms of lifetime prevalence of 
“ecstasy” among the general population, Belize reported 
the highest rate in Central America (0.5 per cent).34 
392. Inhalant abuse is particularly high in the Caribbean. 
Of the 12 Caribbean countries that have provided infor-
mation on abuse of those substances, 8 have prevalence 
rates of over 5.9 per cent, which are higher than the rates 
in all other countries of the western hemisphere, with the 
exception of the Dominican Republic. In Central America, 
there are considerable differences between the country 
with the highest rate of inhalant use (Belize, at 
5.5  per  cent), and that with the lowest (Honduras, with 
0.6 per cent).35 
393. The development and successful implementation of 
programmes for the prevention and treatment of drug 
abuse in Central America and the Caribbean are largely 
restricted by the limited resources and institutional  capacity 
of countries in the region. INCB recognizes that a central 
problem in the design of effective prevention and treat-
ment programmes is that, throughout Central America and 
the Caribbean, there is a lack of capacity for the collection 
of drug-related data and a lack of centralized agencies 
mandated to assess that information. In addition, Gov-
ernments have to strike a balance between competing 
developmental priorities and the need to adopt drug abuse 
prevention and treatment measures. INCB reiterates the 
importance of Governments in the region taking tangible 
steps to improve frameworks for the collection and analy-
sis of drug-related data to be used to implement adequate 
programmes for prevention and treatment that are availa-
ble to the entire population of the region.
North America
1. Major developments
394. Opioid abuse has remained one of the major chal-
lenges facing North America (Canada, Mexico and the 
 33 World Drug Report 2014 .
 34 Report on Drug Use in the Americas, 2015, chap. 6.
 35 Ibid., chap. 4.
United States), with a regional annual prevalence rate of 
3.8 per cent in 2013, significantly higher than the global 
average of 0.7 per cent. However, patterns of abuse and 
trafficking have continued to shift, requiring Govern-
ments in the region to adapt their drug control policies 
accordingly. 
395. Abuse of prescription drugs continues to be the 
single biggest challenge to drug control efforts in the 
region. In the United States, federal authorities have 
reported that deaths involving controlled prescription 
drugs outnumber those involving heroin and cocaine 
combined. The lucrative nature of illicit trade in prescrip-
tion drugs in North America has led to the growing 
involvement of organized transnational criminal groups 
in trafficking, which had previously been controlled by 
small-scale dealers and street gangs.
396. Prescription drug abuse continues to exact a heavy 
human and economic toll on the region; it is one of the 
leading causes of accidental death and costs Governments 
in the region billions of dollars annually. In the United 
States, drug overdose deaths, primarily related to pre-
scription drug abuse, continue to outnumber those caused 
by motor vehicle accidents, thus constituting the single 
leading cause of “injury deaths” in the country. The Drug 
Enforcement Administration of the United States esti-
mates that the costs of the non-medical use of prescrip-
tion drugs alone total more than $53 billion annually.
397. The growth of the illegal market in prescription 
drugs has been spurred in part by the imposition of 
stricter controls on the prescription and dispensing of 
those drugs in various jurisdictions in the region, includ-
ing through the establishment of programmes for pre-
scription drug monitoring, increased controls on 
pharmacies and greater cooperation between law enforce-
ment agencies, although there remain significant gaps in 
that system, in part because they are state-level rather 
than national-level control systems.
398. Stricter controls on the availability of prescription 
opioids have also contributed to the continued resurgence 
of heroin as a major substance of abuse in North America, 
reversing years of decline in prevalence. The increase in 
heroin abuse has been particularly pronounced in the 
United States, where it has affected urban centres and—
increasingly—rural regions where historically large-scale 
abuse of the drug had not been an issue. United States law 
enforcement officials have reported that Mexican drug car-
tels have been increasing their share of the United States 
illicit heroin market using established distribution channels 
for other drugs. There has also been an increased incidence 
of drug overdose deaths caused by fentanyl-laced heroin.
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399. Cannabis remains the most commonly abused 
drug in the region, in part due to its high level of avail-
ability. The drug is illicitly cultivated in all three coun-
tries for domestic abuse and, to a lesser extent, trafficked 
between countries. In the United States, the high supply 
of cannabis is due to extensive illegal production within 
the country, large-scale smuggling from Mexico and 
large-scale production and diversion from states within 
the United States that allow cannabis production for non-
medical purposes and for medical cannabis programmes. 
Authorities of some states have complained of a spillover 
effect created in their territory by the diversion for traf-
ficking purposes of cannabis from neighbouring states 
that have legalized the drug for non-medical purposes. 
United States authorities have also reported a 62 per cent 
increase in the number of cannabis-related emergency 
department visits between 2004 and 2011. In 2011, the 
number of medical emergency visits for illicit drug use-
related causes that were cannabis-related were second 
only to those for cocaine.
400. In Mexico, drug syndicates continue to constitute 
a major source of criminal activity, including murders, 
abductions and corruption, posing a sustained threat to 
public order and security in many parts of the country. 
In addition, there are signs that the illicit manufacture of 
methamphetamine destined for the United States illicit 
market has been on the increase. The number of meth-
amphetamine laboratories detected in Mexico has 
increased significantly since 2008, and seizures of the 
drug at the United States border have increased by a fac-
tor of three since 2009.
2. Regional cooperation
401. Regional cooperation between the three countries 
in the region is extensive and generally considered to be 
effective. It includes high-level political summits, joint 
action plans, intelligence-sharing, joint law enforcement 
activities and border control initiatives.
3. National legislation, policy and 
action
402. In late 2014, the United States Justice Department 
sent a “policy statement regarding marijuana issues in 
Indian country” to all United States attorneys. The doc-
ument was intended to provide additional guidance on 
the enforcement by United States attorneys of the 
Controlled Substances Act on tribal lands on cannabis-
related matters. It reiterated the eight enforcement prior-
ities set by the Department of Justice in its 2013 
memorandum36 to United States attorneys and established 
their applicability to reservations and tribal lands, many 
of which traverse state borders and federal districts.
403. In December 2014, Oklahoma and Nebraska, two 
states bordering Colorado, filed a lawsuit against the State 
of Colorado before the United States Supreme Court urg-
ing the Court to prohibit the establishment of a regula-
tory regime for the cannabis industry. Oklahoma and 
Nebraska argue that because of the federal Government’s 
prohibition of cannabis under the Controlled Substances 
Act, states cannot act in contradiction of that ban by cre-
ating a regulatory framework for legalization. The suit 
argues that Colorado’s official efforts to regulate the legal 
cannabis industry bring the state into conflict with fed-
eral and international drug laws. In addition, both states 
argue that Colorado’s official regulation of recreational 
cannabis imposes a nuisance burden on surrounding 
states due to an increase in drug trafficking. The Supreme 
Court has not yet decided whether it will accept the case.
404. The Board reiterates its view that measures taken 
in various states of the United States to legalize the pro-
duction, sale and distribution of cannabis for non- 
medical and non-scientific purposes are inconsistent 
with the provisions of the international drug control 
treaties. INCB wishes once again to draw attention to the 
fact that the 1961 Convention as amended establishes 
that the parties to the Convention should take such leg-
islative and administrative measures as may be necessary 
“to limit exclusively to medical and scientific purposes 
the production, manufacture, export, import, distribu-
tion of, trade in, use and possession of drugs”. The lim-
itation of the use of controlled substances to medical and 
scientific purposes is a fundamental principle which lies 
at the heart of the international drug control legal frame-
work which cannot be derogated from. Regardless of 
whether they are federal or unitary States, all parties to 
the conventions have a legal obligation to give effect to 
and carry out the  provisions of the convention within 
their own territories.
405. In February 2015, the United States Government 
announced that the President’s 2016 budget submission 
to Congress would request historic levels of public fund-
ing for “health responses to illicit drug use” totalling more 
than $25 billion. Of that amount, $12 billion in federal 
funds are to be earmarked to fund initiatives for demand 
reduction, representing an increase of more than $760 
million over the President’s 2015 budget submission. Of 
that funding for 2016, $133 million has been earmarked 
to intensify efforts to reduce opioid abuse. The initiatives 
 36 See E/INCB/2014/1, para. 141.
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to be funded include prevention measures such as the 
strengthening and increased interoperability of State pre-
scription drug monitoring programmes and the expan-
sion of mechanisms for the disposal of prescription drugs. 
Additional funding will be provided to the Centers for 
Disease Control and Prevention to study measures to 
curb heroin overdose deaths and provide naloxone, which 
is used to rapidly counteract the effects of opioid over-
dose, to first responders and train them in its use. Part 
of the earmarked funds will also be used to offer sub-
stance abuse treatment to all eligible federal prison 
inmates through the Department of Justice’s Federal 
Bureau of Prisons.
406. In July 2015, Health Canada announced that it was 
reviewing the prescription requirement for naloxone. 
That initiative comes at a time when opioid overdoses 
continue to increase across the country. As a first step 
towards facilitating access to the medicine, the federal 
Government was undertaking consultations with provin-
cial and territorial health authorities to collect informa-
tion about the use of naloxone, in particular with respect 
to the possibility of allowing a wider range of profession-
als, including first responders, to inject patients with 
naloxone. 
407. In August 2015, the United States Administration 
announced $13.4 million in funding for the high- intensity 
drug trafficking areas (HIDTA) programme, which is 
intended to ensure coordination among federal, state, 
local and tribal law enforcement agencies operating in 
areas identified as critical drug trafficking areas of the 
country. Of the total investment, $5 million will be ear-
marked to fund efforts to reduce heroin trafficking and 
abuse, including $2.5 million to fund the Heroin Response 
Strategy, a partnership among five regional HIDTA pro-
grammes to address the severe heroin threat facing those 
communities through public health-public safety partner-
ships across 15 states. In addition, $1.3 million in HIDTA 
funds will be directed to the five regional HIDTA pro-
grammes along the United States-Mexico border to 
enhance investigations of large-scale transnational crim-
inal organizations, reduce the flow of dangerous drugs, 
including heroin and methamphetamine, across the bor-
der, and prevent illicit drug use in border communities. 
Finally, nearly $500,000 will be used to address challenges 
posed by illicit drug use on tribal lands in six states 
through the investigation and dismantling of organiza-
tions that exploit tribal communities to traffic and dis-
tribute dangerous drugs.
408. In Mexico, health authorities continue to take 
measures to increase access to controlled substances for 
medical purposes. In June 2015, the head of the Federal 
Commission for Protection against Health Risks 
(COFEPRIS), announced the establishment of an elec-
tronic prescription system to facilitate access to morphine 
for patients suffering from severe pain. Under the previ-
ous system, doctors wishing to prescribe morphine 
needed to go to COFEPRIS offices in order to secure a 
bar code that validated morphine prescriptions, with the 
result that very few prescriptions were ever actually 
issued. The Mexican Secretariat of Health expressed its 
confidence that the new system in place would help to 
reduce barriers to availability of morphine for the treat-
ment of severe pain.
409. In August 2015, the Minister of Health of Canada 
announced regulatory changes to make Salvia divinorum 
and its preparations and derivatives controlled substances 
under schedule IV of the Controlled Drugs and Substances 
Act. All activities beyond simple possession will be ille-
gal unless authorized by regulation or by an exemption. 
The scheduling of Salvia divinorum will also enable law 
enforcement agencies to take action against suspected 
illegal activities involving those substances.
410. In June 2015, the Respect for Communities Act 
came into effect in Canada. The legislation, which amends 
the Controlled Drugs and Substances Act, establishes spe-
cific criteria that must be met by applicants seeking an 
exemption for activities involving illicit substances at a 
“supervised consumption site” in order for the exemption 
request to be considered by the Ministry of Health. 
Canada currently has one supervised consumption site, 
but additional applications for the establishment of drug 
consumption rooms have been received by Health Canada 
and are currently under consideration. 
411. In June 2015, the Supreme Court of Canada issued 
its judgement in the R. v. Smith case relating to the def-
inition of “marihuana” in the country’s medical cannabis 
programme which, until then, limited the lawful use of 
cannabis to “dried herb”. Pursuant to the judgement, indi-
viduals licensed to possess and consume cannabis under 
the Marihuana for Medical Purposes Regulations may 
now possess cannabis derivatives for their own personal 
use, in addition to or instead of dried cannabis herb. 
412. Also in June 2015, Health Canada announced 
amendments to the Narcotic Control Regulations and the 
Marihuana for Medical Purposes Regulations to further 
strengthen public health and safety. The new measures 
respond to requests from medical licensing bodies for 
increased information on how doctors are authorizing 
cannabis use. The regulations require licensed producers 
of cannabis for medical purposes to provide quarterly 
reports to health-care licensing bodies on how health-care 
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practitioners are authorizing the use of cannabis, which 
will be provided to provincial and territorial medical and 
nurse licensing bodies upon request, allowing them to 
more effectively monitor the professional practice of their 
members.
413. In May 2015, the Government of Canada announced 
that it was providing the Canadian Institute for Health 
Information with over 4 million Canadian dollars over 
five years to develop a coordinated national approach for 
the monitoring and surveillance of prescription drug 
abuse in cooperation with provinces, territories and other 
stakeholders in order to develop and enhance data col-
lection and dissemination and contribute to a national 
report on surveillance.
414. In response to the persistent public health threat 
posed by prescription drug abuse, authorities in Canada 
and the United States have continued to stage “prescrip-
tion drug take-back days”. In November 2014, the United 
States Drug Enforcement Administration reported that it 
had collected over 2,400 tons of unwanted prescription 
drugs in the previous four years of take-back initiatives.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
415. There continue to be various source countries of 
the heroin trafficked and abused in North America. 
Afghan heroin, mostly smuggled through India, Iran 
(Islamic Republic of) and Pakistan, accounts for approx-
imately 90 per cent of the heroin abused in Canada, while 
most of the heroin abused in the United States is sourced 
from Mexico and South America and smuggled across 
the United States-Mexico border. However, according to 
UNODC, the market share of Afghan-manufactured her-
oin abused in the United States may be increasing.
416. According to the Drug Enforcement Admin-
istration, the threat posed by heroin is increasing in all 
parts of the United States, particularly in the north-east 
and north-central regions. Based on reports from law 
enforcement agencies, the availability of heroin appears 
to be increasing. Heroin seizures in the United States have 
increased by 81 per cent over five years, from just over 
2,763 kilograms (kg) in 2010 to over 5,000 kg in 2014. 
Over the same period, the average size of heroin seizures 
grew from 0.86 kg to 1.74 kg. Heroin-related arrests dou-
bled between 2007 and 2014, and, in 2014, surpassed 
 cannabis-related arrests for the first time.
417. Heroin seizures reported by authorities in Mexico 
amounted to over 386 kg in 2014. Mexican drug cartels 
have also increased their market share of the illicit her-
oin market in the United States and are now the most 
prominent wholesale-level heroin traffickers in several 
large cities in the country. The number of heroin seizures 
and the quantities seized at the border with Mexico have 
also risen sharply, from 846 kg seized in 295 incidents in 
2009 to 2,196 kg seized in 580 incidents in 2013. The 
increased smuggling of Mexican and Colombian heroin 
into the United States through the Mexican border has 
led to a change in heroin trafficking patterns, as western 
states in the United States are becoming major transit 
areas for the drug.
418. In Mexico, opium poppy eradication efforts have 
continued. According to UNODC, Mexico eradicated 
14,662 hectares of opium poppy cultivation in 2013, a 
decrease of 7 per cent since 2012.
419. Most of the cocaine available in the United States 
continues to be produced in Colombia and smuggled 
across the Mexican border and, to a lesser extent, through 
the Caribbean. Despite the fact that cocaine continues to 
be widely available throughout the country, its availabil-
ity has decreased continually since 2007, with the biggest 
markets for the drug concentrated along the east coast of 
the United States. Mexico, for instance, reportedly seized 
2.8 tons of cocaine in 2014, a decrease of 11 per cent 
compared with 2013.
420. Law enforcement officials in the region attribute the 
decrease in availability of cocaine to less coca bush culti-
vation in producing countries in South America, success-
ful law enforcement efforts, changing patterns of abuse 
and conflicts between transnational criminal groups.
421. Despite declining seizures of cannabis herb in 
Mexico and the United States, cannabis has maintained 
its status as the most widely available and most widely 
abused illicit drug in North America. 
422. In all three countries, domestic production of can-
nabis has continued, particularly in indoor growth oper-
ations and on private land. In addition, large quantities 
of the drug are also smuggled into the United States from 
Mexico, with seizures remaining at 1.3 million kg to 1.4 
million kg per year. Smuggling methods include subter-
ranean tunnels, shipment containers and hidden com-
partments in private vehicles. Mexican authorities 
estimate that of the 868 tons of cannabis seized in the 
country in 2014, just over 84 per cent was intended for 
domestic consumption, while over 15 per cent was 
intended to be trafficked to the United States.
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423. According to the Drug Enforcement Admin-
istration, states neighbouring those in which cannabis has 
been legalized for non-medical purposes have reported a 
spillover effect as the drug is trafficked into their juris-
dictions. The Drug Enforcement Administration has also 
found that the legalization of cannabis in some states has 
not eliminated the illicit market for the drug in those 
states due to high taxes and other state-imposed restric-
tions on the legal cannabis.
424. The THC content of cannabis seized in the region 
has also reportedly continued to increase. In its “2014 
National drug threat assessment summary”, the Drug 
Enforcement Administration reported an increase in 
potency, with THC levels rising from 3.96 per cent in 
1995 to an average potency of 12.55 per cent in 2013. 
Another growing trend has been the production and 
abuse of cannabis concentrates through THC extraction 
from cannabis plant materials, which can yield THC 
 levels of up to 80 per cent. 
425. Trafficking of fentanyl-laced drugs has continued 
to emerge as a major threat to public health in the region, 
particularly in Canada and the United States. In Canada, 
the Royal Canadian Mounted Police has identified two 
primary ways the drug is infiltrating the illicit drug mar-
ket. The first is the diversion of pharmaceutical fentanyl 
products (primarily transdermal patches) from domestic 
supply and distribution channels into illicit trade. The 
second is the smuggling into Canada of pharmaceutical-
grade fentanyl and fentanyl analogues. Law enforcement 
authorities in western Canada, which is particularly 
affected by fentanyl trafficking, have indicated that the 
main source region is Asia (in particular China), with 
fentanyl being smuggled into British Columbia by organ-
ized criminal groups and, from there, further eastward to 
other provinces, particularly the province of Alberta. 
426. Fentanyl is typically smuggled in powder form and 
is often combined with illicit drugs (primarily heroin) and 
illicit synthetic drug tablets manufactured in domestic 
clandestine laboratories which is often sold as counterfeit 
oxycodone tablets. According to data from Health 
Canada’s Drug Analysis Service, the number of seizures 
of fentanyl in Canada increased by a factor of more than 
30 in five years, from 29 seizures in 2009 to 894 seizures 
in 2014. In the United States, a nationwide alert on fen-
tanyl was issued, identifying trafficking of the substance 
as a threat to health and public safety. The Drug 
Enforcement Administration has reported that most fen-
tanyl-induced deaths in the United States are caused by 
clandestinely manufactured fentanyl and not by diverted 
pharmaceutical fentanyl. Seizures of the drug continue to 
increase, and law enforcement authorities have identified 
some trends such as the smuggling of the drug in hid-
den compartments in sport utility vehicles.
(b) Psychotropic substances
427. On the basis of a wide variety of indicators includ-
ing seizure data, law enforcement reporting and local-
level treatment information, the Drug Enforcement 
Administration has indicated that large-scale metham-
phetamine trafficking and abuse are continuing to increase 
in the United States. The Drug Enforcement Admin-
istration’s “2014 National drug threat assessment sum-
mary”, notes that almost 32 per cent of responding 
agencies indicated that methamphetamine was the 
 greatest drug threat in their areas.
428. United States authorities have stated that most of 
the methamphetamine available in the United States is 
manufactured in Mexico. While most of the methamphet-
amine is smuggled into the United States in powder or 
crystal form, the drug is increasingly being trafficked 
across the border in liquid form after its dilution in a 
 liquid solvent, making its detection more difficult. 
Reflecting that trend, methamphetamine seizures reported 
by Mexico in 2014 amounted to 19.7 tons, an increase of 
more than 34 per cent over the amount in 2013. The 
country also reported an increase in the number of meth-
amphetamine laboratories dismantled, with 131 clandes-
tine laboratories dismantled in 2014, primarily in the 
States of Guerrero, Michoacán and Sinaloa. Mexico has 
also been identified as a source country for crystalline 
methamphetamine seized in East and South-East Asia 
and Oceania.
(c) Precursors
429. Methamphetamine manufacture in the United 
States continues to be dominated by small-scale labora-
tories using ephedrine and pseudoephedrine prepara-
tions. In 2014, the United States reported a decrease in 
domestic methamphetamine manufacture, likely attribut-
able to an increase in the supply of methamphetamine 
manufactured in Mexico.
430. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention.
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(d) Substances not under international 
control
431. Despite a slight decline in availability, new psycho-
active substances, particularly cathinones and synthetic 
cannabinoids, continue to pose a significant challenge to 
drug control efforts in the region, which is one of the 
largest and most diversified markets in the world for new 
psychoactive substances. Most manufacture, trafficking 
and abuse of new psychoactive substances in the region 
takes place in Canada and the United States, with reports 
of new psychoactive substances having tripled in those 
two countries between 2010 and 2013. A major challenge 
is that those substances continue to be widely available 
through retail outlets in both countries, as well as through 
the Internet. 
432. In response to the threat posed by new psychoac-
tive substances, Governments in the region have contin-
ued to make use of legislative, administrative and law 
enforcement mechanisms to remove those substances 
from the market and to investigate and prosecute 
 individuals responsible for their manufacture and 
trafficking.
5. Abuse and treatment
433. With annual prevalence rates of 11.6 per cent, can-
nabis continues to be the drug most commonly abused 
in North America among the population aged 15-64 
years. According to UNODC, cannabis abuse in the 
United States is on the increase, including among high 
school students, for which annual prevalence rates rose 
from 24.7 per cent in 2012 to 25.8 per cent in 2013.
434. North America continues to have the highest rate 
of drug-related mortality in the world, with 43,300 drug-
related deaths in 2013, a rate of 136.8 deaths per million 
inhabitants compared with an estimated global average 
range of 40.8-50.5 deaths per million inhabitants. In 2013, 
there were 40,239 drug-related deaths in the United States 
alone, accounting for one of every five drug-related deaths 
worldwide. According to data released by the White 
House Office of National Drug Control Policy in January 
2015, deaths due to drug overdose in the United States 
have increased overall by 6 per cent since 2012. While 
deaths related to prescription opioids have remained rel-
atively stable, increasing by 1 per cent from 2012 to 2013, 
the mortality rate for other drugs has significantly 
increased. The number of overdose deaths related to 
cocaine in 2013 saw a 12 per cent increase over 2012. The 
biggest increase in the number of overdose deaths iden-
tified was related to heroin. Drug overdose deaths related 
to heroin increased by 39 per cent from 2012 to 2013, 
the third consecutive annual increase. The United States 
administration attributes the stability of the number of 
deaths related to prescription opioids to prevention cam-
paigns and stricter control measures on prescribing and 
dispensing practices.
435. According to information provided by the United 
States Government based on the 2013 National Survey on 
Drug Use and Health, there were an estimated 7.6 mil-
lion people in need of drug treatment in the country in 
2014. 
436. The public health effects of heroin abuse in the 
United States have continued to increase, with abuse 
spreading from its traditional urban base to suburban and 
rural areas. From 2010 to 2013, the number of recorded 
heroin-related drug overdose deaths almost tripled, reach-
ing 8,620 deaths in 2013, although public health officials 
assume the real number of deaths is much higher because 
heroin rapidly metabolizes into morphine and is difficult 
to detect. According to United States officials, possible 
reasons for that increase include an overall increase in 
the number of heroin users; batches of the drug with 
greater purity being sold in certain markets; an increase 
in new and inexperienced heroin users, including those 
using heroin to supplement or replace prescription opi-
oids; and the presence of toxic substances such as fenta-
nyl in the heroin consumed.
437. In Canada and the United States, deaths related to 
fentanyl abuse have continued to increase, with many rec-
reational drug users succumbing to overdoses after ingest-
ing opioids (primarily counterfeit oxycodone) which they 
were unaware were fentanyl-laced. According to the Drug 
Enforcement Administration, individuals who have over-
dosed on fentanyl represent a diverse population from all 
regions of the United States, all age groups and both sexes 
and include both new and more experienced users.
438. While the Canadian Pharmacists Association have 
identified fentanyl-related overdoses as a public health 
threat affecting people from all parts of the country, the 
problem has been particularly acute in the provinces of 
British Columbia, Alberta and Ontario. According to the 
British Columbia Coroners Service, of the 300 deaths 
related to opioid overdose in 2014, approximately 25 per 
cent involved fentanyl, compared with 5 per cent in 2011. 
In Alberta, public health authorities have indicated that 
120 people died as a result of fentanyl-related overdoses 
in 2014, compared with 6 overdoses in 2011. In order to 
address the growing public health risk, British Columbia 
launched the “Know your source” initiative in March 
2015 to make the public aware of the dangers of 
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consuming fentanyl-laced drugs, suggest ways of mini-
mizing overdose risks and direct the public to public 
health resources. The province has also increased its dis-
tribution of “take-home naloxone kits”, which began in 
2012. In August 2015, provincial health authorities 
announced that 250 overdoses in the province had been 
reversed since the kits first became available in 2012. 
Similarly, the Government of Alberta began implement-
ing a “take-home naloxone” programme across the prov-
ince in the summer of 2015 in response to the growing 
number of fentanyl-related deaths in the province. The 
take-home project provides naloxone kits to people who 
are at high risk of overdose so that the drug can be 
administered immediately should an overdose occur.
439. In North America, as in many parts of the world, 
the problem of drug injection is compounded in the cor-
rectional setting. According to UNODC, it is estimated 
that between 24 and 36 per cent of all people using her-
oin in the United States—more than 200,000 people—
pass through the correctional system each year. Drug use 
in prison settings, including intravenous injection, is 
commonplace. INCB reminds Governments in the region 
of the importance of ensuring adequate measures for the 
prevention and treatment of drug abuse in the prison sys-
tem in accordance with article 38 of the 1961 Convention 
as amended.
440. Drug abuse by injection in North America has led 
to the increasing transmission of blood-borne diseases in 
the region. According to estimates submitted to UNODC 
by the Government of Mexico, drug use by injection in 
the country has led to hepatitis C prevalence rates of up 
to 96 per cent among people who abuse drugs by injec-
tion. Hepatitis C prevalence rates in Canada and the 
United States for people who inject drugs also continue 
to be high: 68 per cent and 73 per cent respectively. In 
March 2015, the Governor of the State of Indiana declared 
a public health emergency in a rural southern county of 
the state that had been heavily affected by an HIV out-
break linked to intravenous drug use. In an executive 
order, the Governor authorized the county to institute a 
“targeted short-term needle exchange programme” to 
contain the outbreak. According to public health author-
ities, most of the cases of HIV infection were due to abuse 
of oxymorphone tablets, which were dissolved and then 
injected.
441. In states of the United States that have medical 
cannabis programmes, the diversion of cannabis from the 
programmes has been reported as a major source for the 
drug’s illicit use, particularly among young people. 
Prevalence surveys cited by the Drug Enforcement 
Administration indicate that 34 per cent of the twelfth 
grade students (aged 17-18 years) who had used  cannabis 
in the past 12 months and who lived in states that have 
medical cannabis schemes, identified medical cannabis 
prescribed to another person as one of their sources for 
the drug. 
442. Authorities in the United States have indicated that 
the medical consequences of cannabis abuse continue to 
grow: the percentage of emergency room visits and 
admissions to treatment reported as cannabis-related 
increased from 6.9 per cent in 1993 to 17.5 per cent of 
all drug-related admissions in 2012. At the same time, 
surveys conducted in the North American region indi-
cate that among young people there is a low perception 
of risk associated with regular cannabis use. In the United 
States, the Monitoring the Future Survey showed that 
60  per cent of twelfth grade students (aged 17-18 years) 
do not consider regular cannabis use to be harmful.
443. In the State of Colorado, which has legalized the 
sale and distribution of cannabis for non-medical pur-
poses, cannabis prevalence rates are higher and increas-
ing faster than the national average, according to the 
results of the United States National Survey on Drug Use 
and Health. According to the United States Government, 
based on data for the period 2001-2012, the number of 
primary treatment admissions for cannabis in Colorado 
is significantly higher than the national average and is ris-
ing (160 admissions to treatment per 100,000 people aged 
12 or older in Colorado in 2012, compared with less than 
120 nationally).
444. An increasing number of cases of ingestion of 
 cannabis edibles by young children has also been reported 
in the United States, particularly in states that have 
 legalized the drug for non-medical purposes. The Rocky 
Mountain Poison Control Center has reported that, since 
2009, the Children’s Hospital Colorado has seen an increase 
in the number of children under 5 years of age being 
treated in emergency rooms due to the ingestion of edible 
cannabis products such as brownies, cookies and peanut 
butter, increasing from no cases in the five years prior to 
 medical liberalization to 14 cases between 2009 and 2011.
445. Public health authorities in the United States have 
reported a sharp rise in calls to poison centres related to 
synthetic cannabis. In 2013, poison centres in the coun-
try received 2,668 calls about exposure to synthetic can-
nabis. In 2014, that number increased to 3,680. In 2015, 
the numbers of reports of exposure to synthetic cannabis 
had already surpassed 5,300 by mid-August. While calls 
to poison centres are but one indicator of increased use 
in the country, that trend is corroborated by other sources 
such as law enforcement agency records. 
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446. While annual prevalence rates for methampheta-
mine use have remained relatively stable in the United 
States, at 0.5-0.6 per cent of the general population aged 
15-64 years, there have been indications that abuse has 
increased in some pockets of the country. In the 
Minneapolis-Saint Paul metropolitan area, the number 
of people treated for methamphetamine use increased by 
19 per cent from 2011 to 2012. In Ohio, treatment admis-
sions for the drug increased by 34 per cent from 2009 
to 2012. In the county of San Diego, deaths related to 
methamphetamine increased by 70 per cent from 2008 
to 2012. 
South America
1. Major developments
447. South America has a relatively strong institutional 
capacity in the wider context of Latin America and the 
Caribbean, and countries in the region have been  making 
considerable efforts at the national and international 
 levels to curb the illicit supply of drugs and address the 
increasing rates of drug abuse.
448. While the region continues to account for virtually 
all the world’s coca bush cultivation and supply of coca 
paste and cocaine, the efforts made by the Governments 
of Bolivia (Plurinational State of), Colombia and Peru in 
2013 resulted in the lowest total amount of coca bush cul-
tivation since 1990. According to UNODC, that trend 
may have contributed to a reduction in the global avail-
ability of cocaine, which has affected some of the main 
markets. The trend of a decreasing total area of coca bush 
cultivation continued in Bolivia (Plurinational State of) 
and Peru in 2014. Colombia, in contrast, reported an 
increase of 44 per cent in the area of cultivation com-
pared with 2013, making it once again the country with 
the largest area of coca bush cultivation in the world. 
Nonetheless, the area under coca bush cultivation in 
Colombia is still 30 per cent lower than it was in 2007, 
and 58 per cent lower than in 2000.
449. Several countries in the region, including Brazil, 
Chile, Colombia, Ecuador and Uruguay, are debating 
and enacting new legislation, decisions and resolutions 
on the use of cannabis. Those range from regulations 
for the cultivation of cannabis plants and the importa-
tion of medicines containing cannabidiol for medical 
use in some countries, to the further regulation of a 
market for cannabis for non-medical use, as is the case 
of Uruguay.
2. Regional cooperation
450. South America continues to be a particularly active 
region for regional cooperation at the political and tech-
nical levels. Several bilateral, intraregional and inter-
regional initiatives took place in the period 2014-2015, 
including consultations and the exchange of information, 
joint investigations, extraditions, military and law enforce-
ment operations, capacity-building and the development 
of standards and guidelines. Cooperation has taken place 
in diverse and mutually-reinforcing regional initiatives 
and forums such as the Hemispheric Information 
Exchange Network for Mutual Assistance in Criminal 
Matters and Extradition of OAS, the Hemispheric Drug 
Strategy of CICAD, the Police Community of the 
Americas, the Ibero-American Network for International 
Legal Cooperation (IberRed), the South American 
Council on the World Drug Problem of the Union of 
South American Nations, the supply control component 
of the Community of Latin American and Caribbean 
States, the meetings of Heads of National Drug Law 
Enforcement Agencies, Latin America and the Caribbean, 
and the Cooperation Programme on Drug Policies 
between Latin America and the European Union.
451. Expert cooperation in the region to counter drug 
trafficking has been particularly active in the area of pre-
cursor control, in which States in the region successfully 
collaborated in the UNODC project “Prevention of the 
diversion of drug precursors in Latin America and the 
Caribbean”, as well as in the area of countering money-
laundering in the context of the Asset Recovery Network 
of the Financial Action Task Force of Latin America 
against Money-Laundering. The 15 countries that com-
prise the Network37 developed guidelines for international 
judicial cooperation on asset recovery and approved the 
Network’s action plan for the strengthening of informa-
tion exchange and the development of guidelines on joint 
and combined investigations.
452. The growing concern at the increasing levels of 
drug abuse in the region has led mostly to responses at 
the national level, but many countries have also engaged 
in regional cooperation to address drug demand, such as 
the international network of drug dependence treatment 
and rehabilitation resource centres (Treatnet) and the 
“Support project on reduction of demand of illegal drugs 
in the Andean Community (PREDEM)”, both supported 
by UNODC.
 37 Argentina, Brazil, Bolivia (Plurinational State of), Colombia, 
 Costa Rica, Chile, Cuba, Ecuador, Guatemala, Honduras, Mexico, 
 Panama, Paraguay, Peru and Uruguay.
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453. The countries of the region are taking action to 
ensure the availability of narcotic drugs and psychotropic 
substances for medical purposes. The Inter-American 
Convention on Protecting the Human Rights of Older 
Persons, adopted in June 2015 by the General Assembly 
of OAS, which in its article 19, entitled “Right to health”, 
urges Member States to ensure the availability of con-
trolled medicines for the rehabilitation and palliative care 
of older persons. Palliative care is required in the treat-
ment of cancer and many other diseases and for end-of-
life patients of all ages. Some countries in the region have 
reported a low level of consumption of narcotic drugs 
and psychotropic substances for medical use.
454. At its meeting held in Lima in August 2014, the 
Group of Experts on Chemical Substances and Pharma-
ceutical Products of CICAD submitted a model adminis-
trative system for the control of chemical substances and 
guidelines on the disposal of used fentanyl transdermal 
patches and suggestions for establishing designated ports 
of entry/exit for controlled chemical substances. Those 
proposals were approved by CICAD at its regular session 
held in Guatemala City on 19-24 November 2014.
455. Bilateral and trilateral counter-narcotics operations 
continue to abound in the region. Examples include the 
implementation by Bolivia (Plurinational State of) and 
Peru of a joint strategy to eliminate the cocaine traffick-
ing “air bridge” between their territories. A total of 5,170 
individual operations resulted in the elimination of 50 
clandestine airstrips and the seizure of aircraft and drugs 
(34.8 tons of cannabis, 7.3 tons of cocaine and 6 tons of 
coca paste). At a joint ministerial-level meeting held in 
June 2015, the two countries agreed to further strengthen 
border control (including control of chemical precursors) 
and the fight against drug trafficking, money-laundering 
and smuggling. Operation Trapézio, conducted by Brazil 
and Peru, led to the dismantling of 28 cocaine-manufac-
turing laboratories. The joint Operation Bracolper, involv-
ing the navies of Brazil, Colombia and Peru, which has 
taken place for 41 consecutive years, was conducted once 
again in 2015.
3. National legislation, policy and 
action
456. The Brazilian National Health Surveillance Agency 
rescheduled cannabidiol from a “prohibited” to a “con-
trolled” substance, as established in resolution RDC No. 
17 of 6 May 2015, effective as of 7 July 2015. The resched-
uling follows the receipt by the Agency of several requests 
for imports of products containing cannabidiol and other 
cannabinoids for medical treatment. 
457. In 2014, Brazil continued joint operations with 
Paraguay as part of Operation Aliança, the goal of which 
is to eradicate cannabis plant cultivation. The operations 
resulted in the destruction of 2,571 tons of cannabis cul-
tivation. The country is also targeting cultivation fields in 
north-eastern Brazil, where the Brazilian Federal Police 
conducts eradication operations.
458. Following the enactment of the legislation on can-
nabis in December 2013, the Government of Uruguay 
issued a presidential decree in May 2014 further regulat-
ing the import, production, storage, sale and distribution 
of cannabis for non-medical use. The decree establishes 
procedures for the registration of producers of cannabis 
for distribution in pharmacies and of domestic produc-
ers, cannabis clubs, consumers and pharmacies, and regu-
lates the production and commercialization of cannabis 
seeds and cuttings. In addition, the Government enacted 
decrees regulating aspects of non-psychoactive cannabis 
for industrial use, and the sale and use of cannabis for 
medical purposes. Once again, INCB wishes to draw 
attention to its view that the legislation permitting the 
non-medical use of cannabis is contrary to the provisions 
of the international drug control conventions, specifically 
article 4, paragraph (c), and article 36 of the 1961 
Convention as amended by the 1972 Protocol, and 
 article 3, paragraph 1 (a), of the 1988 Convention.
459. In the first half of 2015, the Colombian Congress 
approved the National Development Plan 2014-2018. The 
document contains the Government’s action plan for the 
four-year period. In relation to the issue of drug control, 
the Plan aims to address the drug problem by means of 
a comprehensive and balanced approach. That objective 
is to be attained through the following six actions: (a) for-
mulating a comprehensive policy to counter illicit drugs 
that adopts a human rights-based approach; (b)  creating 
a national intervention plan for the reduction of illicit 
crops in Colombia; (c) designing and implementing 
 alternatives to imprisonment for the most vulnerable 
population groups; (d) controlling the microtrafficking 
phen omenon by adopting a social intervention and ter-
ritorial control approach; (e) preventing and addressing 
problematic drug consumption from a health perspective; 
and (f) containing the entry of illicit drugs into the coun-
try, their production within the country, and the illegal 
diversion of controlled substances.
460. In September 2015, the Ministry of Defence of 
Colombia announced its new strategy to combat drug 
trafficking, which focuses on improving the justice 
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framework and procedures and targets illicit cultivation, 
including by strengthening manual eradication.
461. In May 2015, Colombia’s National Narcotics 
Council approved the suspension of aerial spraying of 
coca bush cultivation with glyphosate. The decision fol-
lowed a recommendation made by the Colombian 
Ministry of Health and Social Protection in April 2015 
based on the classification of the herbicide glyphosate as 
“probably carcinogenic to humans’’ by the International 
Agency for Research on Cancer of WHO. The National 
Narcotics Council established a technical commission to 
explore alternative means of eradication, and the country 
is now exploring the use of other herbicides that may be 
used in aerial spraying.
462. Colombia’s Ministry of Justice and Law and the 
Bogotá Chamber of Commerce are supporting the har-
monization of the national legislation in line with the 
standards for the prevention of money-laundering of the 
Financial Action Task Force. Additionally, the country 
has developed risk assessment tools on money- laundering 
and the financing of terrorism for the non-profit and real 
estate sectors, aimed at raising awareness and promoting 
self-regulating business environments to prevent the 
laundering of the proceeds of drug trafficking and con-
nected crimes. Other countries in South America, includ-
ing Argentina, Chile and Peru, are also adopting initiatives 
that are in line with the standards of the Financial Action 
Task Force and focused on risk assessments for the 
 prevention of money-laundering and the financing of 
terrorism.
463. In August 2015, the Government of Peru approved 
Law No. 30339, on the control, vigilance and defence of 
the national air space. The law regulates national airspace, 
including the definition of “hostile acts” and “hostile air-
craft”. It specifies a number of actions that may lead to 
declare that an aircraft is “hostile”, including acts where 
there is evidence or reasonable suspicion that the aircraft 
may be engaged in drug trafficking. In such circum-
stances, an aircraft may be declared “hostile” and may be 
subject to interception and other measures. Law No. 
30339 provides guidelines for the measures that could be 
undertaken against a hostile aircraft, including the use of 
force. Notably, articles 11 and 12 stipulate general guide-
lines for the interception of a hostile aircraft in the air or 
on the ground or water. The law further specifies that an 
aircraft cannot be declared “hostile” if it is carrying pas-
sengers who are not participating in the “hostile act”. 
Drug traffickers have increasingly resorted to transport-
ing cocaine shipments by air. UNODC has detected an 
increasing number of clandestine landing strips since 
2011, from 49 clandestine landing strips in 2011 to 77 in 
2012 and 80 as of October 2014. Similar to the terrestrial 
routes, the re-established aerial routes lead to the 
Plurinational State of Bolivia as an intermediary destina-
tion and then to Brazil. INCB urges Peru and other 
Governments implementing such measures to ensure that 
these measures are carried out in full respect of relevant 
international protocols and conventions. 
464. Following a risk assessment, in 2014 Brazil placed 
various new psychoactive substances under national con-
trol, including synthetic cathinones such as methylone, as 
well as NBOMe derivatives (including 25P-NBOMe, 
25T2-NBOMe and 25H-NBOMe) and synthetic cannab-
inoids (including JWH-122, JWH-073 and AM-2201).
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
465. South America is greatly affected by the illicit cul-
tivation and trafficking of cannabis herb. The proportion 
of global cannabis herb seizures that are recorded in Latin 
America and the Caribbean rose from 20 per cent in 2012 
to 30 per cent in 2013. There was a sharp increase of 
almost 60 per cent in cannabis seizures in South America 
between 2012 and 2013, from 821 tons to 1,308 tons. 
That increase was largely driven by seizures in, in descend-
ing order of seizure amounts, Paraguay, Colombia and 
Brazil.
466. While the cannabis seized in Colombia in 2014 was 
cultivated domestically, the seizures reported by Brazil 
were of cannabis entering the country from Paraguay. 
Cannabis is widely consumed in the region, but it is also 
sometimes trafficked together with cocaine and used as 
payment for transporting, storage and distribution ser-
vices along the routes towards North America and Europe.
467. South America continues to be the main source of 
all cocaine manufactured worldwide, with the cultivation 
of coca bush and the manufacturing of cocaine and coca 
paste taking place mainly in Bolivia (Plurinational State 
of), Colombia and Peru. However, the seizure of coca leaf 
and coca paste, as well as the discovery of clandestine 
laboratories, in neighbouring countries such as Argentina 
and Chile suggests that refining also takes place elsewhere 
in the region. Argentina reported the discovery of 15 
clandestine laboratories for refining, tableting, cutting or 
packaging in 2014, 12 of which were for cocaine. In the 
same year, Chile reported the discovery of 22 clandestine 
kitchen laboratories, all of them dedicated to cocaine 
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manufacture. The cocaine manufactured in South America 
is destined for its largest consumer markets—North 
America and Western and Central Europe—as well as 
local markets. To reach North America, cocaine is traf-
ficked by land, air and sea, transiting Central America, 
Mexico and the Caribbean. The cocaine-trafficking route 
to Europe involves transit by land, rivers and air, affect-
ing all countries but most notably Argentina, Brazil and 
Venezuela (Bolivarian Republic of), before crossing the 
Atlantic Ocean as maritime and air cargo, either directly 
or by way of the Caribbean or West Africa. Maritime traf-
ficking appears to be the preferred means for large ship-
ments, while trafficking by air is more frequent.
468. For cases of individual drug seizures in the period 
2005-2014, Argentina and Brazil were the countries most 
frequently mentioned as transit hubs on the routes to 
North America and Western and Central Europe. In 2014, 
Colombia, the Bolivarian Republic of Venezuela, Brazil, 
the Dominican Republic, Panama, Peru and Ecuador, in 
that order, were most frequently mentioned as the coun-
tries of origin, departure or transit for cocaine shipments 
from South America and Central America and the 
Caribbean to Europe. For cocaine seizures, the most sig-
nificant countries of departure for shipments to Europe 
in 2014 were, in descending order of volume seized, Costa 
Rica, Ecuador, Colombia, Brazil, the Bolivarian Republic 
of Venezuela and Argentina. For individual cocaine sei-
zure cases reported in Europe in 2014, the list of coun-
tries of departure in the greatest number of cases was 
headed by Brazil, followed by Colombia and Argentina. 
Trafficked drugs enter Argentina through the country’s 
northern provinces, which are vulnerable due to their 
remote areas and geographical proximity to the 
Plurinational State of Bolivia and, to a lesser extent, Peru. 
The illicit narcotics are mainly transported by land using 
roads that cross the border but also, to a lesser extent, by 
air. Argentina is making efforts to counter such threats 
through Operation North Shield, aimed at combating 
drug trafficking, trafficking in persons and smuggling in 
the area. After a sharp increase in the quantities seized 
in 2012 (when the amount of cocaine seized totalled 
about 10.5 tons, an increase of 151.4 per cent from the 
previous year), cocaine seizures have remained fairly 
 stable, amounting to 10.4 tons in 2014. In 2014, seizures 
of coca leaf amounted to about 118 tons, an increase of 
34.8 per cent from 2013.
469. For the fourth consecutive year, the Plurinational 
State of Bolivia reported a decrease in the area of coca 
bush cultivation. In 2014, the area of coca bush cultiva-
tion fell to 20,400 hectares (ha), which was 11 per cent 
less than in 2013 and the lowest level since 2001. The 
main areas of cultivation were Yungas de La Paz, 
responsible for about 70 per cent of the cultivated area, 
followed by Trópico de Cochabamba with about 30 per 
cent of the cultivated area, and the northern provinces of 
the department of La Paz with less than 1 per cent. The 
reported decreases in the cultivated areas in Yungas de 
La Paz and Trópico de Cochabamba in 2014 were 10 per 
cent and 14 per cent respectively. Among the factors con-
tributing to that decrease are the efforts of the Government 
in the area of coca bush eradication through the Strategic 
Operational Command “Tte. Gironda”, under the coordi-
nation of the Vice-Ministry of Social Defence and 
Controlled Substances.
470. Brazil is vulnerable to the transit of cocaine by air, 
land and rivers (especially in the Amazon area) and is 
considered to have a strategic role in the trafficking of 
cocaine. It is a transit country from which cocaine is 
shipped overseas and is the largest cocaine market in 
South America. Seizures in the country doubled from 
2012 to 2013, before decreasing to around 33.8 tons in 
2014, which is still above the 2012 level. According to 
estimates for 2014, only 30 per cent of the cocaine seized 
in Brazil was destined for external markets. Brazil is 
intensifying cooperation with several partners to target 
transnational criminal organizations operating in the 
country, as exemplified by Operation Monte, a joint 
undertaking with the governments of the United 
Kingdom, Italy and Spain, resulting in the seizure of 
1.3  tons of cocaine intended for distribution in Europe.
471. Colombia saw an increase of 44 per cent in the 
area of estimated coca bush cultivation in 2014, and thus 
became once again the country with the largest area of 
coca cultivation in the world. The area of cultivation grew 
from 48,000 ha in 2013 to 69,000 ha in 2014, and poten-
tial cocaine production has seen an even greater increase 
of 52.7 per cent, rising from 290 tons in 2013 to 442 tons 
in 2014. Most of the cultivation is located in the south-
ern departments of Nariño, Cauca, Putumayo and 
Caquetá, as well as in the northern region of Catatumbo, 
located in the department of Norte de Santander, which, 
altogether, account for 73 per cent of the area of coca 
bush cultivation.
472. Among the factors that may be contributing to the 
increase in coca bush cultivation in Colombia, UNODC 
has pointed to the expected benefits for coca-growing 
farmers in the context of the negotiations for a peace 
agreement with the Revolutionary Armed Forces of 
Colombia (FARC), as there is a perceived leverage asso-
ciated with growing coca bushes in the negotiations with 
the Government. Another factor that may also be con-
tributing to the increase in coca bush cultivation is the 
increase in the price of coca leaf in strategic regions, such 
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as the departments of Meta and Guaviare, where prices 
rose 42 per cent, as well as a perception that there is less 
risk of eradication. In fact, the extent of eradication, nota-
bly aerial spraying, has declined in recent years.
473. One of the largest increases in cocaine seizures in 
the past five years has been observed in Ecuador, where 
the amount of cocaine seized rose by over 242 per cent, 
amounting to 50 metric tons in 2014. The country’s 
authorities arrested 7,772 individuals on drug trafficking 
charges in 2014 and 6,404 individuals in 2013. Cocaine 
and coca paste enter the country from the neighbouring 
countries Colombia and Peru. According to UNODC, 
coca bush cultivation in Ecuador continued to be of lim-
ited relevance in 2014. Coca paste continues to supply 
local consumption while the cocaine is destined for exter-
nal markets. In 2014, authorities mentioned, in descend-
ing order of the total amounts of cocaine destined for 
each country, Spain, Belgium and Guatemala as among 
the countries of destination.
474. Peru continued to make progress in the reduction 
of areas of coca bush cultivation. The estimated area of 
coca bush cultivation decreased for the third consecutive 
year, from 49,800 ha in 2013 to 42,900 ha in 2014, a 
decrease of 13.9 per cent. The production of coca leaf 
dropped 17 per cent from 2013 to 2014. The results are 
in most part due to State-led eradication programmes in 
the context of the national strategy for the fight against 
drugs for the period 2012-2016. Interventions have 
focused on areas that are most notably connected to drug 
trafficking organizations and on intensifying alternative 
development initiatives in those areas. The most affected 
areas are concentrated in the Apurímac, Ene and Mantaro 
river valleys and in the province of La Convención and 
the Lares district of Calca province, which together con-
tain 68 per cent of the country’s coca bush cultivation. 
The shrinking supply has affected the purity levels of the 
coca base and cocaine, which showed a slight decrease in 
prices from 2013 to 2014.
475. In the Bolivarian Republic of Venezuela, authori-
ties reported that cocaine seizures amounted to about 26 
tons in 2014. Seizure totals have been relatively stable 
since 2010, when about 25 tons of cocaine were seized. 
Intended countries of destination for the cocaine seized 
included Australia, Italy and Spain, while Colombia is 
mentioned as country of origin.
476. There is evidence that the area of opium poppy 
cultivation has been increasing and appears to have 
reached a five-year high in Colombia, which had detected 
387 ha of cultivation in 2014. The potential increase 
from  2013 to 2014 in the production of opium and 
manufacture of heroin (13 per cent and 15 per cent, 
respectively), combined with a decrease in their average 
prices (decreases of 37 per cent and 19 per cent, respec-
tively) over the same period may indicate an increase in 
the supply of those drugs.
477. Heroin manufactured in South America is primar-
ily destined for the United States but is also trafficked 
for consumption within the region. The United States 
reported increased trafficking from Mexico and South 
America, and Mexico reported seizures in 2014 of her-
oin produced in Colombia and destined for the United 
States.
(b) Psychotropic substances
478. Various countries in South America have reported 
seizures of amphetamine-type stimulants (ATS) in 2014, 
including amphetamine, methamphetamine and “ecstasy”-
type substances, as well as lysergic acid diethylamide 
(LSD). The substances seem to originate in Europe, with 
South America being a growing consumer market. 
However, some of the psychedelic substances marketed 
in South America as LSD seem in fact to have been new 
psychoactive substances, such as 25B-NBOMe, 25C- 
NBOMe and 25I-NBOMe, that is, substituted phen-
ethylamines which were only scheduled by the Commission 
on Narcotic Drugs in March 2015.
479. According to a study published by UNODC and 
CICAD in 2014 entitled “Amphetamine-type stimulants 
in Latin America”, information on ATS and the use of 
specific substances in the region is still very limited, and 
categories used in drug use surveys are usually too broad 
to differentiate between non-medical use of prescription 
drugs, ATS and new psychoactive substances. While the 
use of those substances is increasingly affecting youth in 
the region, the limited data available prevent the accurate 
estimation of their market size, sources and trafficking 
routes.
480. Seizures of “ecstasy”-type substances increased 
sharply in Brazil in 2014, with 877,853 tablets seized, an 
increase from 183,289 in 2013. In Colombia, seizures 
peaked in 2013, when 117,101 tablets were seized, increas-
ing from 6,664 tablets in 2010, but seizures decreased 
again, to 39,792 tablets, in 2014. Guyana reported, as a 
new development, seizures of small quantities of “ecstasy” 
in the past two years.
481. In 2014, Colombia reported four separate seizures 
of 4-bromo-2,5-dimethoxyphenethylamine (2C-B), 
amounting to 14,068 units in total.
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(c) Precursors
482. Seizures reported by coca-producing countries of 
most of the acids and solvents listed in Table II of the 
1988 Convention have decreased over the past decade, 
partly due to the fact that solvents are increasingly being 
recycled and reused several times and due to changes in 
illicit processing practices. Forensic analysis of seized 
cocaine originating in Colombia in 2013 suggests that 
more illicit cocaine-manufacturing laboratories are using 
significantly reduced amounts of the solvents required for 
processing.
483. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
484. The Colombian Drug Observatory has created an 
early warning system for detecting new psychoactive sub-
stances. The system was triggered for the second time, 
when tablets sold as 2C-B, an internationally controlled 
drug, were found to contain ketamine and small quanti-
ties of other unidentified substances.
485. In 2014, Chile seized NBOMe derivatives of a total 
of 30 milligrams in five different events. The country also 
reported seizures of 2,5-dimethoxy-4-chloroampheta-
mine (DOC).
486. Certain South American countries have placed sev-
eral substances under national control due to their use in 
the illicit manufacturing of cocaine or as cutting agents, 
including caffeine and cement.
5. Abuse and treatment
487. UNODC data confirm that the drugs with the great-
est annual prevalence among the general adult population 
aged 15-64 years in South America continue to be canna-
bis (5.9 per cent) and cocaine (1.2 per cent),  followed by 
amphetamines and prescription stimulants (0.5 per cent) 
and opioids (0.3 per cent). Annual prevalence of cannabis 
and cocaine continued to be higher than the global  average, 
which is calculated by UNODC to be 3.9 per cent for the 
former and 0.4 per cent for the latter.
488. There are gender differences in the prevalence of 
drug abuse in South America. While cannabis is the drug 
most abused by both men and women in terms of annual 
prevalence, cocaine is the second most frequent drug of 
abuse for men, whereas for women cannabis is followed 
closely by the misuse of tranquillizers, with cocaine com-
ing a distant third.
489. Experts in South America perceive an increase in 
cocaine use in the region, which is considered to be 
driven by increased abuse in Brazil. The rise in abuse of 
smokable cocaine has been receiving particular attention 
from national authorities, with the annual prevalence of 
“crack” cocaine being estimated at 0.7 per cent in 2014. 
The country is investing in improving the collection of 
data on drug abuse, and a survey among prisoners is 
planned to take place in 2015.
490. A national study on drug abuse in Bolivian house-
holds in 2013/14, published in March 2015, found that 
among abused illicit substances, cannabis (1.27 per cent), 
cocaine (0.32 per cent) and inhalants (0.30 per cent) had 
the highest rate of annual prevalence. With the exception 
of tranquillizers, the abuse of all other substances appears 
to have decreased between 2007 and 2013. The study 
found that the average age of drug use initiation was 19 
years and that abuse is highest among men and youth. 
Recommendations include the introduction of a selective 
drug prevention policy focusing on young people at uni-
versities and work environments.
491. Increased abuse of synthetic drugs is a concern in 
South American countries such as Colombia, where they 
negatively affect local communities. The drugs are distrib-
uted in small quantities and may have their quality altered 
in mixtures that may be particularly harmful. Another 
trend observed in the country is the decrease in the aver-
age age of the users of such drugs.
492. Small-scale trafficking in Colombia, commonly 
referred to as “microtrafficking”, has become a growing 
problem in several Colombian cities. It has been reported 
that municipal Colombian authorities have been taking 
experimental steps to control such trafficking with the aim 
of reducing social harms, including some types of efforts, 
such as substituting one controlled substance, such as 
cocaine, for another, such as cannabis, which may be incon-
sistent with Colombia’s obligations under the Conventions. 
493. Reports on substances seized at the level of micro-
trafficking reflect the fact that drug abuse is a steadily 
growing problem in Paraguay. The country has reported 
a change with respect to abuse patterns, the substances 
abused and the age of first-time abuse. According to the 
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second national study on persons with problems result-
ing from the consumption of alcohol and other drugs in 
treatment centres and self-help groups, conducted in 
2012, substances of first-time abuse are primarily alcohol 
followed by tobacco, cannabis, smokable forms of cocaine, 
cocaine, solvents, anxiolytics, anti-depressants, ampheta-
mine-type stimulants, opiates and others.
494. Through an integral drug abuse prevention plan, 
the Government of the Bolivarian Republic of Venezuela 
reported reaching over 4.6 million people in 2014 by 
organizing more than 35,000 activities with a focus on 
communities, children and adolescents at risk. The plan 
is based on a strategy of decentralization, the adoption of 
a people-centred approach and the scaling-up of preven-
tion activities that strengthen life skills and promote 
healthy lifestyles, also targeting workplaces, prison set-
tings and indigenous communities.
C. Asia
East and South-East Asia
1. Major developments
495. With an increasing diversification of trafficking 
routes and a significant increase in the amount of sei-
zures, the manufacturing, trafficking and abuse of amphet-
amine-type stimulants show no signs of abating. It has 
been noted that drug trafficking syndicates in other 
regions, attracted by the size of the markets in East and 
South-East Asia, have recently become involved in a 
number of the region’s countries. In addition, regional 
initiatives that facilitate the freer flow of goods and ser-
vices might be exploited by some criminal groups. 
496. The region continues to face the threats posed by 
the proliferation of new psychoactive substances and non-
scheduled precursor chemicals. Exploiting gaps in legis-
lation and creating the illusion of legality, new psychoactive 
substances are marketed as “legal highs”. Although in 
recent years some countries have made greater endeav-
ours to place new psychoactive substances under national 
control, drug trafficking syndicates have responded and 
adapted by producing substances not yet under control, 
thus hindering drug control efforts. The abuse of keta-
mine and its trafficking remain another area of concern 
for countries in the region.
497. The illicit cultivation of opium poppy and the man-
ufacture of heroin continue in the countries of the Golden 
Triangle (Lao People’s Democratic Republic, Myanmar 
and Thailand). The total area of illicit opium poppy cul-
tivation in the region was estimated to be 63,800 hectares 
(ha) in 2014, and production of opium estimated to be 
762 tons. While the amount of illicit cultivation remains 
steady, a declining trend in the abuse of heroin in some 
East and South-East Asian countries has been reported. 
The scope of cocaine-related activities within the region 
remains limited compared with other regions and com-
pared with other drug types.
498. The growing amount of methamphetamine being 
trafficked into East and South-East Asia from other 
regions suggests that new trafficking routes have been 
established connecting previously unrelated markets. In 
recent years, methamphetamine originating in Africa, 
West Asia and, more recently, the Americas, has been 
trafficked into the region. The more timely sharing of 
intelligence and better collaboration among law enforce-
ment agencies across the region are essential for the early 
detection of these new trafficking routes and the imple-
mentation of measures to address them.
2. Regional cooperation
499. Multilateral cooperation among the States mem-
bers of the Association of Southeast Asian Nations 
(ASEAN) continues, as the regional multilateral body for-
mulates its next approach, subsequent to the prior goal 
of making the ASEAN region free of illicit drugs by 2015. 
A ministerial statement adopted at the third ASEAN 
Ministerial Meeting on Drug Matters, held in Indonesia 
in December 2014, underscored the political commit-
ment to further strengthening regional cooperation. In 
September 2014, the ASEAN Narcotics Cooperation 
Centre was launched in Bangkok as a coordinating plat-
form to further the pursuit of that goal of regional coop-
eration. The 12th meeting of the ASEAN Inter- 
Parliamentary Assembly Fact-Finding Committee to 
Combat the Drug Menace, held in Kuala Lumpur in June 
2015, provided an opportunity for the exchange of infor-
mation on the latest national developments. A resolution 
adopted at the meeting emphasized the significance of 
taking a people-centred approach in the delivery of effec-
tive demand and supply reduction programmes. Through 
another platform for multilateral cooperation, the 36th 
ASEAN Senior Officials Meeting on Drug Matters, held 
in Singapore in August 2015, various issues related to 
illicit drugs in the region were discussed. 
500. Faced with the increasing connectivity of drug traf-
ficking organizations across the globe, some regional 
meetings discussed major region-specific challenges in the 
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context of the global evolution of such criminal groups. 
The joint INCB-UNODC international conference on pre-
cursor chemicals and new psychoactive substances held in 
Bangkok in April 2015 highlighted the global challenges 
posed by precursor chemicals and new psychoactive sub-
stances and examined approaches to address those chal-
lenges at both the global and regional levels. Bringing 
together countries of the Asia-Pacific region, the 20th 
Asia-Pacific Operational Drug Enforcement Conference, 
held in Tokyo in February 2015, focused on international 
cooperation in drug law enforcement to counter the threat 
of amphetamine-type stimulants.
501. A ministerial meeting, held in May 2015, of the 
signatories to the 1993 memorandum of understanding 
on drug control of the Greater Mekong subregion reiter-
ated their continued commitment and stated that the 
memorandum had proven to be a constructive mecha-
nism for better regional cooperation in law enforcement 
efforts against drug trafficking in the subregion. The 
evolving drug situation specific to the countries con-
cerned, such as the greater flow of illicit drugs and pre-
cursor chemicals, was highlighted and discussed.
3. National legislation, policy and 
action
502. Confronted with the continued and rapid emer-
gence of new psychoactive substances, countries in the 
region have placed additional substances under temporary 
listing and/or extended the scope of drug control to 
defined groups of substances. For instance, the Republic 
of Korea announced the temporary control of 10 new psy-
choactive substances (6 synthetic cannabinoids, 2  phen-
ethylamines and 2 other miscellaneous substances) for 
three years in December 2014, which brought the number 
of new psychoactive substances currently under temporary 
control to 86. Under that country’s Act on the Control of 
Narcotics, the possession, management, trade, assistance 
in the trade, or the giving or receiving of materials that 
contain a temporary scheduled substance are prohibited. 
In Macao, China, the anti-drug law (Law 17 of 2009) was 
amended in 2014 to control five more substance groups: 
piperazine derivatives, synthetic cannabinoids, derivatives 
of cathinone (excluding bupropion), Salvia divinorum and 
salvinorin A. In China, the Non-Medical Narcotic Drug 
and Psychotropic Substance List Regulation, which listed 
116 non-medical narcotic drugs and psychotropic sub-
stances, entered into force on 1 October 2015. 
503. After the listing of alpha-phenylacetoacetonitrile 
(APAAN) as an internationally controlled precursor in 
October 2014, several countries have placed it under their 
national control. On 14 May 2014, the Government of 
China scheduled APAAN and 2-bromopropiophenone (a 
known intermediate in the synthetic manufacture of 
ephedrine and pseudoephedrine from propiophenone) as 
first-class controlled precursors, requiring import and 
export permits for its international trade. Similarly, the 
Government of Thailand listed APAAN and its optical 
isomers in Schedule 4 (precursor chemicals) of the 
Narcotics Act. In Hong Kong, China, APAAN has also 
been controlled under the Control of Chemicals Ordinance 
(chap. 145). INCB reminds countries that have not yet 
done so to place APAAN under national control without 
delay pursuant to the related Commission on Narcotic 
Drugs decision 57/1 of 19 March 2014.
504. To improve the effectiveness of law enforcement 
and expand the scope of drug control, new legislative and 
administrative changes have been introduced by the 
Government of the Philippines. In July 2015, amend-
ments were made regarding the custody and disposition 
of illegal drugs, in particular the requirement to conduct 
an inventory after seizure operations by law enforcement 
authorities and the need for witnesses. Under the prior 
legislation, law enforcement officers had been required to 
conduct an inventory of the seized illegal drugs and 
chemicals immediately after confiscation in the presence 
of the suspects and representatives of the Department of 
Justice, elected public officials and the media as witnesses. 
Under the amended law, law enforcement officers can 
now conduct the inventory at the nearest office of author-
ities or police station in the case of a warrantless arrest 
as long as the integrity and evidentiary value of the seized 
items are properly preserved. A law penalizing driving 
under the influence of alcohol, dangerous drugs or sim-
ilar substances was also adopted in 2014.
505. In the Philippines, a new national anti-drug pro-
gramme of action for the period 2015-2020 and a time-
line for its implementation have been drafted. The action 
plan outlines strategies in five main areas (demand reduc-
tion, supply reduction, alternative development, civic 
awareness and response, and regional and international 
strategies) and is intended to guide the country’s drug 
control efforts. Similarly, the Thai Government has devel-
oped a national drug control strategic plan for the period 
2015-2019 to offer holistic solutions for drug control 
beyond 2015. The strategic plan contains eight primary 
strategic focus areas and provides the mechanism for its 
implementation and the monitoring and review of that 
implementation. The Government of Myanmar is imple-
menting the last phase of its 20-year drug control plan 
for the period 1999-2019 for achieving an illicit drug-free 
status by 2019. While the eradication of opium poppy 
cultivation was the main priority in the initial phase, 
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other objectives, such as the rehabilitation of drug abus-
ers, the establishment of further special counter- narcotics 
task force units and the participation of local communi-
ties in the implementation of drug control activities, have 
now become the current priorities.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
506. Since the mid-1980s, the illicit cultivation of opium 
poppy in the region has been concentrated in the Golden 
Triangle, which was once the main world supplier of her-
oin. The considerable increases in illicit cultivation in 
Afghanistan, combined with the eradication efforts of the 
countries of the Golden Triangle (Lao People’s Democratic 
Republic, Myanmar and Thailand), have significantly 
reduced the share of illicit opium that is produced in that 
area. However, illicit cultivation of opium poppy in the 
Lao People’s Democratic Republic and Myanmar has 
recently started to increase, after reaching its lowest level 
in recent years, with less than 25,000 ha of illicit cultiva-
tion in 2006. In 2014, the total area of illicit opium poppy 
cultivation reached 63,800 ha, most of it in Myanmar 
(90  per cent) and a small amount in the Lao People’s 
Democratic Republic (10 per cent). The total amount of 
opium produced in the region was estimated to be 
762  tons.
507. Heroin illicitly manufactured in Myanmar has 
been trafficked overland into China through Yunnan 
province. At the same time, precursor chemicals required 
for the illicit manufacture of heroin have been smuggled 
into Myanmar from China. There is a risk that two-way 
trafficking for the manufacture and consumption of her-
oin may grow as drug trafficking syndicates exploit the 
easier movement of people and capital resulting from ini-
tiatives enhancing regional integration within the ASEAN 
community. In the light of such challenges, INCB encour-
ages close cooperation and collaboration among the 
ASEAN member States for the timely exchange of 
intelligence.
508. Heroin seizures in the region rose each year from 
2011 to 2013, reaching 11.8 tons in 2013, with more than 
70 per cent being seizures reported by China. With total 
seizures of 9.5 tons in 2014 (9.4 tons in China, 89 kilo-
grams (kg) in Hong Kong, China, and 3.5 kg in Macao, 
China), China continues to account for most of the sei-
zures in the region. Reductions in seizures have recently 
been reported by other countries such as Cambodia and 
Thailand. The total amount of heroin seized in Cambodia 
and Thailand dropped significantly in 2014 (1.8 kg and 
371 kg, respectively), back to its longer-term average level. 
509. Illicit cannabis cultivation and significant cannabis 
seizures continue to be reported by Indonesia and the 
Philippines. To avoid the eradication efforts of the author-
ities, illicit cannabis cultivation in the Philippines is usu-
ally located in high-altitude and mountainous areas of the 
country that are difficult to access. In 2014, 68 tons of 
cannabis herb were seized in Indonesia, more than three 
times the amount seized in 2012. The amount of canna-
bis seized in transit in Thailand increased from 27 tons 
in 2013 to 33 tons in 2014, following an upward trend 
that began in 2012. In 2014, 164 kg of cannabis herb and 
576 kg of dried cannabis were seized in the Philippines. 
Increases in cannabis herb seizures were moderate for 
Hong Kong, China, and for Singapore.
510. The misuse of cocaine in East and South-East Asia 
remains limited, as evidenced by a relatively low level of 
seizures compared with other regions. The latest data 
point towards a further decline in the amount of cocaine 
seized within the region. In Hong Kong, China, the quan-
tity of cocaine seized dropped by more than half, from 
more than 700 kg in 2012 to less than 300 kg in 2014. 
Similarly, reported seizures in Japan and Macao, China, 
declined by more than 90 per cent, down to 2 kg and 
3 kg respectively in 2014. In Cambodia, cocaine seizures 
fell from around 13 kg in 2013 to less than 8 kg in 2014. 
China (excluding Hong Kong and Macao Special 
Administrative Regions) and the Philippines reported 
cocaine seizures of 113 kg and 70 kg respectively.
(b) Psychotropic substances
511. Growing availability and the prevalence of amphet-
amine-type stimulants in the region persist, as demon-
strated by the continued upsurge in methamphetamine 
seizures and the high level of misuse. East and South-East 
Asia continues to be the region that seizes the largest total 
amounts of methamphetamine, which is available in two 
main forms (methamphetamine tablets and crystalline 
methamphetamine). While the misuse of methampheta-
mine tablets (usually of lower purity) is more concen-
trated in the countries of the Mekong river basin, the 
misuse of crystalline methamphetamine is more wide-
spread geographically. Between 2008 and 2013, seizures 
of crystalline methamphetamine in the region almost 
doubled, and seizures of methamphetamine tablets 
increased eight-fold.
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512. Among the countries of the Mekong river basin, 
Myanmar is considered to be the main country of origin 
for methamphetamine tablets. Information on seizures of 
methamphetamine tablets in China and Thailand suggests 
that more methamphetamine tablets are originating in 
and being trafficked from Myanmar. In Thailand, a size-
able amount of methamphetamine tablets was seized in 
2014 (113 million tablets), while 248 tablets were seized 
in Singapore.
513. The latest national reports by China reveal that 
most of the crystalline methamphetamine available in the 
country is manufactured in the country, with most of the 
illicit manufacturing base located in the southern part of 
the country (Guangdong province). More than 80 per 
cent of the crystalline methamphetamine seized in 2013 
had been manufactured in the cities of Shanwei and 
Jieyang, with the city of Lufeng being the main source of 
supply of the substances required for manufacture. Some 
illicit manufacture of crystalline methamphetamine was 
also found in the western part of the country, in Chengdu 
and its surrounding cities.
514. Across the region, the growing availability of crys-
talline methamphetamine remains a worrying trend. In 
Indonesia, arrests related to crystalline methamphetamine 
have increased significantly since 2012. In the Republic 
of Korea, seizures of crystalline methamphetamine 
increased to about 38 kg in 2013, compared with 21 kg 
the preceding year. In Cambodia, although the amount 
of crystalline methamphetamine seized fell in 2014 
(29 kg), it remained higher than in 2012 (19 kg). In 2013, 
the Lao People’s Democratic Republic reported its first 
crystalline methamphetamine seizure since 2005.
515. The most recent methamphetamine seizure data 
continue to point to a higher volume of trafficking in East 
Asian countries. In 2014, China reported the highest 
amount of methamphetamine seizures in the region: close 
to 28 tons, considerably higher than the amount seized 
in 2013. In Hong Kong, China, 104 kg of methampheta-
mine were found in five express cargo consignments in 
transit from mainland China to Malaysia via Hong Kong, 
China. Most of the methamphetamine seized in Japan 
(570 kg) originated in China, followed by Mexico and 
Thailand. In 2014, totals of 718.5 kg and 12.5 kg of meth-
amphetamine were seized in the Philippines and Singapore 
respectively.
516. Although the majority of methamphetamine con-
tinues to be trafficked within the region, an increasing 
amount of methamphetamine is being trafficked into the 
region from other parts of the world. This seems to sug-
gest that new trafficking routes have been established 
linking previously unconnected methamphetamine mar-
kets of different regions. In recent years, methampheta-
mine originating in Africa has been seized in Cambodia, 
China, Indonesia, Japan, Malaysia, the Philippines, 
Thailand and Viet Nam. While some methamphetamine 
has also been trafficked from West Asia, quantities orig-
inating in Mexico were seized in Japan, the Philippines 
and the Republic of Korea in the period 2013-2014. 
517. In Malaysia, 26 clandestine facilities manufactur-
ing amphetamine-type stimulants were dismantled in 
2013: 18 facilities manufacturing crystalline methamphet-
amine and 8 facilities manufacturing MDMA (“ecstasy”) 
tablets. Also in 2013, two clandestine laboratories manu-
facturing amphetamine-type stimulants were dismantled 
in Indonesia, both manufacturing modest amounts of 
crystalline methamphetamine. In China, 376 clandestine 
laboratories manufacturing methamphetamine were dis-
mantled in 2014, compared with 397 dismantled labora-
tories in 2013.
518. The growing abuse and seizure of MDMA 
(“ecstasy”) has been reported by more East and South-
East Asian countries. A significant amount of MDMA 
(“ecstasy”) (489,311 tablets) was seized in Indonesia in 
2014. In the Philippines, close to 3,600 MDMA (“ecstasy”) 
tablets were seized in 2014—the largest amount seized by 
the country’s authorities since 2002. Similarly, Singapore 
reported total seizures of more than 3,800 tablets 
of  MDMA (“ecstasy”). Reported seizures of MDMA 
(“ecstasy”) in Cambodia went from none in 2013 to 
3.1 kg in 2014.
(c) Precursors
519. A number of countries continued to report the 
trafficking of pharmaceutical preparations containing 
ephedrine and pseudoephedrine, which was spurred by 
the growing illicit demand for amphetamine-type stimu-
lants in the region. Most of the seized quantities reported 
originated in the region, or, to a lesser extent, in the 
neighbouring region of South Asia. Myanmar is one of 
the main destinations for trafficked preparations contain-
ing ephedrine and pseudoephedrine, and precursor chem-
icals seized in Myanmar mainly originated in nearby 
countries, primarily China, India and, to a lesser degree, 
Thailand.
520. To circumvent national legislative controls on pre-
cursor chemicals, more non-scheduled precursor chemi-
cals and/or pre-precursors are being used. For instance, 
following the reinforcement of control of Ephedra plant 
in China, 2-bromopropiophenone is being used to 
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synthesize ephedrine. In 2014, more than half of the crys-
talline methamphetamine in the country was synthesized 
using 2-bromopropiophenone. In response, 2-bromopro-
piophenone was placed under national control in China 
in May 2014. 
521. Faced with these adaptive diversion attempts, 
closer cooperation with industry can provide competent 
national authorities with better intelligence on suspicious 
orders and transactions involving scheduled and non-
scheduled chemicals. For instance, to heighten the aware-
ness of the industry with respect to the potential diversion 
of chemicals, some authorities have provided chemical 
companies in the country with the international special 
surveillance list. Outreach activities for the chemical and 
pharmaceutical industries, through regular meetings, dia-
logue sessions, site visits and seminars, would be useful 
for the more timely detection of changing trends and pat-
terns of diversion attempts.
522. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention. 
(d) Substances not under international 
control
523. From 2008 to 2014, the number of new psychoac-
tive substances identified by countries within the region 
increased significantly, the majority of them belonging to 
the synthetic cannabinoid and synthetic cathinone groups. 
Among countries in the region, the largest number of 
new psychoactive substances were identified by Singapore 
(37 substances), Japan (31 substances) and Indonesia. In 
2013 and 2014, at least 30 new psychoactive substances 
were identified by the Government of Indonesia. These 
include synthetic cannabinoids, synthetic cathinones, 
phenethylamines, piperazines and plant-based new psy-
choactive substances. While some of these substances 
may be imported from countries in the region, some are 
imported from other regions. Of the 1.8 kg of synthetic 
cannabinoids seized in the Republic of Korea in 2013, 
1.4  kg were imported from the United States. The rapid 
emergence of substances not yet under control, the lim-
ited forensic capability to identify such substances in 
some countries and the different listing classification for 
those substances adopted by different countries in the 
region are factors that create considerable challenges in 
mitigating the risks posed by new psychoactive sub-
stances at the regional level. INCB therefore encourages 
all governments to participate in its operational project 
on new psychoactive substances (Project Ion (interna-
tional operations on new psychoactive substances)) and 
make full use of its secure communication platform 
(IONICS) to prevent non-scheduled new psychoactive 
substances from reaching consumer markets.
524. The abuse of ketamine remains a major problem 
for the region, although the amount of seizures has been 
decreasing in some countries. While not under interna-
tional control, ketamine has been brought under national 
control in a number of countries in the region: China, 
Democratic People’s Republic of Korea, Japan, Malaysia, 
Myanmar, Philippines, Republic of Korea, Singapore and 
Thailand. Medical professionals in Brunei Darussalam 
and China (including Macao Special Administrative 
Region) indicated an increase in the abuse of the sub-
stance. In Hong Kong, China, the annual prevalence rate 
of ketamine use remained higher than that of ampheta-
mine-type stimulants. The illicit manufacture of ketamine 
continues to be a problem in China, where the consider-
able increase in ketamine manufacture has led to a 
reported change in the main raw material used. Close to 
12 tons of ketamine were seized in mainland China in 
2014, and more than 80 clandestine laboratories manu-
facturing ketamine were dismantled. A further half ton 
of ketamine was seized in Hong Kong, China. Declining 
quantities of ketamine seizures were reported in Indonesia 
(declining from 117 kg in 2010 to 4.7 kg in 2013) and 
Malaysia.
525. The seizure of the plant-based psychoactive sub-
stances kratom and khat and the eradication of their cul-
tivation continues to be reported. The largest total of 
kratom seizures in the region was reported by Thailand 
in 2014 (54 tons), up from 45.5 tons in 2013. In Malaysia, 
kratom-related seizures and arrests have increased 
recently, with the total amount of kratom seized reaching 
9.1 tons in 2013, up more than 74 per cent from the pre-
vious year. Considerable seizures of kratom were also 
reported in Myanmar (219 kg in 2013). More than 6 tons 
of khat were seized in Hong Kong, China, in 2014. Almost 
2 tons of khat leaves imported from Africa were found 
in the storage facilities of four logistics companies, des-
tined for the United States, Canada and Taiwan Province 
of China. Recent eradication of illicit kratom cultivation 
has been reported by Myanmar.
5. Abuse and treatment
526. The trend of wider misuse of amphetamine-type 
stimulants, in particular methamphetamine, continues to 
be reported by most countries in the region. Increases in 
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the abuse of amphetamine-type stimulants have been 
identified in Brunei Darussalam, Japan, the Lao People’s 
Democratic Republic, the Philippines and the Republic of 
Korea. In the Republic of Korea, crystalline methamphet-
amine remains the primary drug of concern and accounts 
for nearly all drug treatment admissions. In the Lao 
People’s Democratic Republic, the abuse of methamphet-
amine tablets has expanded from urban and land border 
areas to other parts of the country. Even in countries 
where other drugs had been the primary drugs of abuse, 
considerable increases in the abuse of methamphetamine 
have been reported. In Malaysia, amphetamine-type stim-
ulants constituted the most common drug of abuse among 
new drug users in 2013. Significant increases in the abuse 
of methamphetamine and “ecstasy” have been reported 
in China. In Macao, China, authorities reported that 
abuse of methamphetamine was linked to the gambling 
activities in the city. In Myanmar, a more widespread mis-
use of methamphetamine has been reported since 2005, 
as evidenced by a rising number of drug treatment admis-
sions related to the substance. A higher prevalence of the 
misuse of MDMA (“ecstasy”) has also been reported by 
Indonesia and countries in the Mekong region (Cambodia, 
Thailand and Viet Nam).
527. UNODC estimated that in the region there were 
more than 3.3 million opiate users in 2014, with a prev-
alence rate (0.2 per cent) that was lower than the global 
average (0.4 per cent). Heroin remains the main drug of 
concern in China, Malaysia, Myanmar, Singapore and 
Viet Nam. The largest number of opiate abusers in the 
region is found in China, where the number of registered 
opium abusers totalled approximately 1.46 million, almost 
half of the total number of drug addicts within the coun-
try in 2014. According to experts in China and Viet Nam, 
the substitution of heroin by synthetic drugs has become 
common among drug addicts. The same trend is reported 
in Indonesia, where the market for low-purity heroin was 
large and heroin users comprised a significant portion of 
persons admitted to drug treatment centres. A declining 
trend in the abuse of heroin, as reported by experts, has 
been observed over the last five years, although no regu-
lar nationwide surveys of drug-use levels are conducted 
by countries in the region.
528. With a prevalence rate of people who inject drugs 
of 0.2 per cent in East and South-East Asia (compared 
with the global prevalence rate of 0.26 per cent), the 
region continues to have the largest number of people 
who inject drugs. UNODC estimates that there are 
approximately 3.15 million people who inject drugs in the 
region, which is one quarter of the worldwide population 
of people who inject drugs. Around 10.5 per cent of them 
are living with HIV. Data at the national level, however, 
reveal much higher HIV prevalence rates among people 
who inject drugs in certain countries, including the 
Philippines (46.1 per cent), Indonesia (36.4 per cent), 
Cambodia (24.8 per cent) and Thailand (21.9 per cent). 
As evidence regarding the effectiveness of different ser-
vices and treatment programmes (needle and syringe pro-
grammes, opioid substitution therapy, antiretroviral 
therapy and the provision of naloxone) becomes more 
accepted in the countries, it is expected that more tar-
geted service programmes will be implemented in the 
region.
529. The provision of psychological treatment services 
has been expanded in some countries in the region to 
respond to the demand for treatment for amphetamine-
type stimulant use. For instance, the number of persons 
receiving drug abuse treatment services from state and 
private centres in Cambodia totalled more than 3,000 
people in 2014, the majority of them crystalline metham-
phetamine users (82 per cent). Similarly, the Lao People’s 
Democratic Republic plans to expand its community-
based treatment for abusers of amphetamine-type stimu-
lants and include counselling services in hospitals, health 
facilities and educational institutions. Despite a growing 
awareness, the standards of treatment for amphetamine-
type stimulants require further enhancement.
530. Drug abuse among young people continues to be 
a worrying trend in the region. A survey conducted in 
schools in Japan revealed that among all types of illicit 
drug use, solvents and inhalants had the highest life-time 
prevalence rates among young people in 2014 (0.7 per 
cent, compared with 0.2 per cent for cannabis, metham-
phetamine and new psychoactive substances). Male teen-
agers have a higher prevalence rate than female teenagers 
for all types of illicit drug use. Given the various con-
cerns of countries in the region, INCB urges all 
Governments concerned to closely monitor the situation 
and facilitate the implementation of specific and targeted 
interventions.
South Asia
1. Major developments
531. In 2014, Governments in South Asia continued to 
cooperate in responding to the threats posed by illicit 
drugs at the national and regional levels. Those threats 
were trafficking in Afghan heroin; the emergence of new 
psychoactive substances; the rise in manufacturing and 
trafficking in methamphetamine, in both pill and 
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crystalline forms; the diversion of controlled substances 
from licit to illicit channels; and the abuse of pharmaceu-
tical preparations containing narcotic drugs and psycho-
tropic substances.
532. There is a relatively low level of availability of and 
access to opioids for pain relief in all countries in the 
region. The Government of India continued to take sub-
stantial measures to address the situation, including 
through legislative changes that enabled the introduction 
of a simple and uniform regulatory regime in respect of 
opioids for pain relief (Narcotic Drugs and Psychotropic 
Substances (Third Amendment) Rules, 2015).
2. Regional cooperation
533. The countries of the region have continued their 
cooperation in drug abuse prevention and control mat-
ters under the umbrella of the Colombo Plan for 
Cooperative Economic and Social Development in Asia 
and the Pacific. The drug supply and reduction pro-
grammes of the Colombo Plan were strengthened through 
collaboration with other organizations such as the 
Australian Federal Police and were to focus on precursor 
chemical control, border protection, abuse of pharmaceu-
tical preparations and trafficking, and forensic drug 
analysis.
534. The Department of Narcotics of Bangladesh and 
the Narcotics Control Bureau of India held consultations 
at the level of directors general in Dhaka, on 22 and 23 
March 2015. The two national authorities agreed to imple-
ment mechanisms to stop the trafficking in narcotic drugs 
and to control the illicit use of precursor chemicals; to 
exchange intelligence on the cross-border trafficking 
routes; to raise public awareness of illicit drug trafficking; 
to increase efforts to eradicate the illicit cultivation of 
opium poppy and cannabis along their common border; 
and to increase cooperation in capacity-building.
3. National legislation, policy and 
action
535. The Colombo Plan International Centre for 
Certification and Education of Addiction Professionals 
held several training events in the region for national 
trainers on the universal treatment curriculum for sub-
stance use disorders. In May 2015, the universal preven-
tion curriculum was launched as part of the Colombo 
Plan drug demand reduction programme in Bhutan, and 
efforts were under way to introduce the universal treat-
ment curriculum in Bhutan as well. The International 
Centre was working on the translation and adaptation of 
the universal treatment curriculum for Bangladesh. Under 
the Colombo Plan drug advisory programme, the devel-
opment of a new curriculum on child drug addiction was 
initiated, since the incidence and prevalence rates of drug 
addiction among children from infancy to the age of 12 
in the region were increasing.
536. In 2014, the Indian Parliament adopted the 
Narcotic Drugs and Psychotropic Substances (Amend-
ment) Act, 2014. The amending act introduced major 
changes to national policy and legislation, including the 
establishment of a new category of drugs referred to as 
“essential narcotic drugs”, through which the central 
Government could list drugs of medical and scientific use 
and which would include morphine, fentanyl, methadone, 
among other drugs. Narcotic drugs identified as essential 
were made subject to a single set of rules that applied 
throughout the country, whereas before the amendment, 
each state used to have its own regulations. The power to 
amend the rules were vested in the central Government 
to ensure uniformity. Under the amending act, institu-
tions wishing to use essential narcotic drugs would 
require a single licence instead of the several licences pre-
viously needed. The changes were likely to simplify access 
to drugs essential for pain relief and palliative care, 
 making them more readily available to the patients who 
needed them.
537. The amending act included provisions to improve 
treatment and care for people dependent on drugs. It 
allowed for the management of drug dependence, and in 
that context legitimized opioid substitution, maintenance 
and other tertiary services. The amending act also 
repealed the mandatory imposition of the death penalty 
in case of a repeat conviction for trafficking large quan-
tities of drugs. The courts were given the discretion to 
impose, as an alternative, a 30-year custodial sentence for 
repeat offences. INCB takes note of this development and 
again encourages those States which retain and continue 
to impose the death penalty for drug-related offences to 
consider abolishing the death penalty for such offences. 
The amending act further strengthened the forfeiture of 
the property of persons arraigned on charges of drug traf-
ficking. It opened the way for private sector involvement 
in the processing of opium and concentrated opium 
poppy straw.
538. Through notification S.O.376(E) of 5 February 
2015 issued by the Ministry of Finance, the Government 
of India brought mephedrone under the ambit of psycho-
tropic substances by including it in the schedule to the 
Narcotic Drugs and Psychotropic Substances Act, 1985. 
The Government issued another notification listing 
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mephedrone under schedule I of the Narcotic Drugs and 
Psychotropic Substances Rules, 1985, prohibiting its pro-
duction, manufacture, possession, sale, purchase, trans-
portation, warehousing, usage, consumption, import, 
export and transhipment, except for medical and scien-
tific purposes.
539. India continued to develop a system for the online 
registration and submission of returns by manufacturers 
and wholesalers of psychotropic substances. The system 
opened for registration by users in 2015, and the 
Government planned to make it mandatory by the end 
of 2015. Notwithstanding those welcome developments, 
access to internationally controlled substances for medi-
cal purposes in the region remained below the world 
average, in particular for opiate pain medication. The 
Board refers to its 2015 report entitled Availability of 
Internationally Controlled Drugs: Ensuring Adequate 
Access for Medical and Scientific Purposes.
540. In 2014, Bhutan adopted the Narcotic Drugs, 
Psychotropic Substance and Substance Abuse Act, 2015, 
which replaced the Act of 2005 of the same name. The 
previous law had a number of shortcomings, including 
inadequate regulatory and procedural requirements for 
the control and management of controlled drugs and sub-
stances (the description and categorization of drug-
related offences were not clearly outlined); the absence of 
penal provisions for drug-related offences; the lack of a 
basis for determining the magnitude of such offences; and 
the absence of provisions on the need for and validity of 
drug test requirements. The new and comprehensive law 
restored the balance between demand reduction and sup-
ply reduction and addresses shortcomings of the Act of 
2005.
541. To improve port security and prevent the illegal use 
of sea containers in transnational organized criminal activ-
ities including drug and precursor trafficking, Bangladesh 
and Nepal joined the Container Control Programme of 
UNODC and WCO in 2014. The Programme is opera-
tional in the following countries of the region: Bangladesh, 
India, Maldives, Nepal and Sri Lanka.
4. Cultivation, production, 
manufacture and trafficking
542. South Asia continued to be particularly vulnera-
ble to the trafficking of opiates and heroin. In addition, 
widespread trafficking of cannabis, synthetic drugs 
and new psychoactive substances persisted in 2014. The 
diversion of pharmaceutical preparations containing 
 narcotic drugs and psychotropic substances from the 
Indian pharmaceutical industry, as well as their  trafficking, 
including through illegal Internet pharmacies, continued 
over the reporting period.
(a) Narcotic drugs
543. In 2014, in India, the number of arrests for drug-
related offences increased to become the highest in five 
years. The number of prosecutions for drug-related 
offences increased by more than 50 per cent from 2013, 
and the number of convictions by 127 per cent.
544. The data reported by the Narcotics Control Bureau 
of India indicated that most of the seizures made in the 
country in 2014 pertained to three drugs: cannabis (5,510 
cases), heroin (4,467 cases) and cannabis resin 
(2,247 cases).
545. The number of cannabis seizures in India increased 
by 20 per cent, from 4,592 cases reported in 2013 to 5,510 
cases in 2014. Indian authorities seized 108,300 kg of can-
nabis in 2014, up from 91,792 kg in 2013. Seizures peaked 
in 2010 at 173.1 tons. Substantial quantities of cannabis 
were trafficked into India from Nepal. An associated trend 
was the trafficking of cannabis from north-eastern states 
of India to eastern and other states in the country.
546. The number of cannabis resin seizures in 2014 
decreased by 7.5 per cent (2,247 cases, down from the 
2,430 cases reported in 2013). However, in terms of 
weight there was a decrease of approximately 50 per cent 
(decreasing from 4,407 kg seized in 2013 to 2,280 kg 
seized in 2014, the lowest in the past five years). In addi-
tion to domestic production, cannabis resin is trafficked 
into India. A major source is Nepal, with which India 
shares a long, open border that is readily exploited by 
drug traffickers. From India, cannabis resin is also traf-
ficked to destinations in Europe and the Americas by 
means of courier parcels.
547. The number of heroin seizures and the quantity of 
heroin seized in India decreased slightly in 2014 (from 
4,609 seizures reported in 2013 to 4,467 in 2014, and from 
1,450 kg in 2013 to 1,371 kg in 2014). The Indian state of 
Punjab, which shares a border with Pakistan, accounted 
for most of the Afghan heroin seized in India. The larger 
consignments of Afghan heroin are first smuggled into 
India through Pakistan, and then smuggled out in smaller 
quantities to major drug consumer markets in Australia, 
Canada and Europe. Reports from neighbouring countries 
also indicated the seizure of low-quality heroin manufac-
tured in India, but there are no reports of such locally 
manufactured heroin being seized in India itself.
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548. Cocaine trafficking has historically been very lim-
ited in South Asia, but the rise in annual seizures seen in 
India over the past few years suggests an increase in traf-
ficking in cocaine. The quantity of cocaine seized in India 
in 2014 was 15 kg.
549. In India, the quantities of opium seized in 2014 
decreased by 24.3 per cent to 1,766 kg, compared with 
2,333 kg the previous year. The number of seizures of 
opium had been decreasing since 2012 and was at its low-
est since 2010. It was suspected that the opium seized in 
India originated inside the country, both from licitly and 
illicitly cultivated opium poppy. In 2014, 25 kg of mor-
phine were seized, compared with 7 kg in 2013, which 
was still significantly less than in 2012, when 263 kg were 
seized. The Narcotics Control Bureau continued to use sat-
ellite imagery, field surveys and intelligence-gathering to 
track and eradicate illicit poppy cultivation. Eradication 
operations were undertaken by law enforcement authori-
ties. In 2014, approximately 2,470 ha of illicit poppy were 
identified and eradicated. Concerted efforts to eradicate 
illicit opium poppy cultivation yielded encouraging results, 
and the area needing to be cleared had been declining 
since 2011. Another illicit crop targeted by eradication 
efforts was cannabis. In 2014, over 3,198 ha of cannabis 
were eradicated, the highest amount since 2010.
550. The Department of Narcotics Control of Bangladesh 
reported that in 2014, the country had tried 2,689 per-
sons for offences related to drugs. The police of Bangladesh 
reported handling 42,501 cases related to narcotics. The 
long borders that Bangladesh shares with India and 
Myanmar make it vulnerable to drug trafficking. Moreover, 
Bangladesh has a long history of cannabis production and 
consumption, and cannabis is the most common drug of 
abuse in the country. Although it is smuggled into the 
country from India and Nepal, there were also reports of 
illicit cannabis cultivation in remote areas of the country. 
Seizures increased slightly from 35 tons in 2013 to 36.48 
tons in 2014.
551. In June 2015, the Bangladesh Customs Intelligence 
and Investigation Directorate reported a seizure of so-
called “liquid cocaine” at the port of Chittagong. The 
cocaine was found diluted in drums of sunflower oil 
believed to have originated in the Plurinational State of 
Bolivia. The seizure seems to confirm the existence of new 
routes and markets for cocaine, which recently seem to 
be finding its way into countries in South Asia.
552. Seizures of heroin decreased by 32.1 per cent, from 
123.73 kg in 2013 to 84 kg in 2014, the lowest amount 
since 2009. The heroin abused in Bangladesh was mostly 
crude and impure, with the estimated purity of heroin 
sold on the street not exceeding 5 per cent. According to 
experts, most of the heroin seized in Bangladesh was 
either manufactured in India, or originated in Afghanistan 
and smuggled through India. At the same time, heroin of 
high purity from the Golden Triangle (Lao People’s 
Democratic Republic, Myanmar and Thailand) some-
times entered the country from the south-east. There were 
some reports of seizures in China of heroin trafficked 
through sea ports in Bangladesh. Dhaka airport contin-
ued to be a transit point for heroin being trafficked to 
China, Europe and the Middle East.
553. In 2013, 11.62 kg of opium were seized in 
Bangladesh, but no seizures were reported in 2014.
554. Trafficking of codeine-based cough syrups, such as 
phensedyl, from India to Bangladesh continued to be 
reported. Although Bangladesh banned codeine-based 
cough syrups, its medical use is allowed in India. In 2014, 
748,730 bottles of codeine-based preparations were seized 
in Bangladesh, a decrease from the 987,661 bottles seized 
in 2013. Seizures of phensedyl had been declining con-
sistently since 2012, and the seizures recorded in 2014 
were the smallest since 2009. Synthetic opiates such as 
buprenorphine and pethidine (chemical name meperi-
dine) in injectable form continued to be trafficked into 
Bangladesh. Seizures of buprenorphine decreased to 
99,509 ampoules in 2013.
555. In 2014, Bhutan witnessed the highest number of 
drug cases ever registered by the authorities (644 cases). 
The great majority (90 per cent) were related to the pos-
session of controlled substances. Cannabis, which in addi-
tion to being cultivated also grew in the wild, was the 
most common drug of abuse. Cannabis, along with small 
quantities of low-quality heroin, was also being smuggled 
into the country from India.
556. In 2014, in Nepal, both the illicit cultivation and 
the wild growth of cannabis were reported in the districts 
bordering India and in the interior. Although the 
Government carries out cannabis eradication campaigns 
every year, illicit cultivation continued in the reporting 
period. The porous border with India facilitates the 
 trafficking of cannabis. While the seizures of cannabis 
rose sharply over the period from 2011 to 2013, with a 
15-year record of 47,086 kg of cannabis being seized in 
2012, they decreased to 6,910 kg in 2014.
557. A similar trend was reported for cannabis resin 
trafficked along land routes from Nepal to India and 
China, and by air to destinations such as Canada, Japan, 
the Russian Federation, the United States and Europe. In 
2014, 2,053 kg of cannabis resin were seized in Nepal, 
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compared with 1,931 kg in 2013 and a record of 5,169 kg 
in 2012.
558. In 2014, in Nepal, the downward trend in heroin 
seizures continued: 3.8 kg of heroin were seized, against 
12.42 kg in 2013 and 15.7 kg in 2012. Heroin from South-
West and South-East Asia was smuggled into Nepal 
across the border with India and through Kathmandu 
international airport. Traffickers were also reported to use 
Nepal as a transit country through which they smuggled 
heroin to destinations such as Australia, China and the 
Netherlands. There were also seizures of low-quality her-
oin smuggled in small quantities from India, mainly 
intended for domestic consumption.
559. There is also evidence of illicit opium cultivation 
in Nepal. There have been no extensive surveys to deter-
mine its extent, but cultivation in small patches was 
reported in remote hilly areas that are difficult for enforce-
ment agencies to access. No illicit heroin manufacturing 
facility has as yet been detected in Nepal. According to 
the Narcotics Control Bureau of Nepal, illicit opium is 
also being smuggled into India.
560. The first case of cocaine trafficking in Nepal was 
recorded in 2012. Since then there has been an increase. 
Instances of cocaine trafficking into the country by car-
riers from Namibia, Pakistan and Thailand via Brazil were 
identified in 2014. Reports indicated that Nepal was also 
being used as a transit point for cocaine smuggling. In 
2014, 5.5 kg of cocaine were reported seized in the coun-
try. In April 2015, 11 kg of cocaine were seized at 
Kathmandu international airport, the largest cocaine sei-
zure so far in Nepal.
561. In 2014, authorities in Nepal arrested 2,918 indi-
viduals for drug trafficking offences, against 2,673 in 
2013. The Narcotics Control Bureau reported that an 
increasing number of Nepalese nationals were involved 
in drug trafficking. Previously, drug trafficking used to be 
dominated by foreign nationals.
562. Trafficking of heroin into Sri Lanka has been stead-
ily increasing. The main trafficking routes were by sea, 
from southern India (for Indian heroin) and from 
Pakistan (for Afghan heroin). Heroin is smuggled into 
the island in sea containers and fishing boats. In 2014, 
313 kg of heroin were seized, a decrease of about 11 per 
cent compared with the previous year.
563. Other than along the established sea routes, traf-
ficking of drugs into Sri Lanka by air, largely through 
Colombo international airport, has been a regular occur-
rence. In recent years, the majority of the heroin seized 
at the airport has been found on couriers arriving from 
Pakistan. They use various methods, including ingestion 
and concealment in body cavities and various kinds of 
equipment and luggage.
564. Cannabis and heroin are the major illicit drugs of 
abuse in Sri Lanka. Cannabis is illicitly cultivated in the 
country. The estimated land area under cannabis cultiva-
tion was nearly 500 ha in 2014. Cannabis abuse has 
become a significant problem. No cannabis resin produc-
tion had been reported. In 2014, 19,644 kg of cannabis 
from India were seized. In 2014, cannabis seizures 
decreased by 76 per cent compared with 2013.
(b) Psychotropic substances
565. South Asia is increasingly being used for the illicit 
manufacture of amphetamine-type stimulants (ATS). ATS 
are also increasingly being abused. ATS in powder form 
is increasingly being smuggled from and illicitly manu-
factured in India, which is emerging as the main source 
in the region. Tablets containing ATS trafficked in India 
are also being smuggled into the country from Myanmar. 
In 2014, 196 kg of ATS were seized, more than twice the 
amount of 2013 (85 kg) and almost five times that of 2012 
(41 kg). The number of ATS seizures and the quantities 
seized have been rising steadily. In 2014, 42 ATS seizures 
were reported, the highest number in five years. In 2014, 
the Narcotics Control Bureau of India reported the dis-
mantling of five illicit manufacturing facilities, from 
which about 155 kg of amphetamines and 162 kg of 
ephedrine and pseudoephedrine were seized.
566. Seizures of methaqualone in India registered a 
sharp decrease, from 3,205 kg in 2013 to 54 kg in 2014, 
the lowest in five years. Methaqualone is often trafficked 
by means of courier parcels to Australia, Canada, Ethiopia, 
South Africa, the United Kingdom and countries in 
South-East Asia.
567. India and China are perceived as major sources of 
various new psychoactive substances. One of those is 
mephedrone,38 whose increasing abuse has been reported 
globally in recent years. India was one of the source coun-
tries for mephedrone trafficked to various overseas des-
tinations. After establishing its control over mephedrone 
and regulating it as a controlled psychotropic substance, 
India effected various seizures (1,106 kg from January to 
June 2015).
 38 The substance was brought under the control of the 1971 Conven-
tion by the Commission on Narcotic Drugs in March 2015.
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568. In 2014, 109 grams of LSD were seized in India, 
which was the highest quantity in the past five years.
569. In Bangladesh, “yaba” (methamphetamine) contin-
ues to be smuggled from Myanmar across the south- 
eastern border. The quantities seized by Bangladesh law 
enforcement agencies have been rapidly increasing dur-
ing the past five years. In 2014, 6.76 million “yaba” tab-
lets were seized, compared with 2.8 million in 2013, a 
growth of 141 per cent. The quantity seized in 2014 was 
the highest since 2009. Sharp increases in seizures have 
been recorded since 2011. The proximity of Bangladesh 
to Myanmar and the surge in domestic demand made the 
country a big market for “yaba”. “Yaba” is mainly smug-
gled from Myanmar by fishing boat. It is bartered for 
other drugs of abuse, such as buprenorphine and tran-
quillizers, that are then smuggled in the opposite direc-
tion, from Bangladesh to Myanmar.
570. Diazepam and buprenorphine ampoules were 
reported to be smuggled into Nepal from India. In 2014, 
44,495 ampoules of diazepam and 37,000 ampoules of 
buprenorphine were seized in Nepal, slightly more than 
the 43,227 ampoules of diazepam and 30,887 ampoules 
of buprenorphine seized in 2013.
(c) Precursors
571. The diversion of ephedrine and pseudoephedrine 
from legal manufacture in India to illicit channels remains 
a major challenge for law enforcement agencies. Indian 
drug law enforcement agencies continued to report sei-
zures of pharmaceutical preparations containing ephed-
rine and pseudoephedrine trafficked from India to 
Myanmar for the extraction of the precursors. Instances 
of ephedrine and pseudoephedrine trafficking to South-
East Asia were also reported in 2014. The quantity of 
ephedrine and pseudoephedrine seized in India declined 
sharply, from 6,655 kg in 2013 to 1,662 kg in 2014.
572. Bangladesh has a growing chemical and pharma-
ceutical industry, and has recently emerged as a source 
and transit location for methamphetamine precursors 
such as ephedrine and pseudoephedrine. The drug-related 
challenges facing the authorities in Bangladesh in 2015 
continued to be the diversion of precursor-based phar-
maceutical preparations from the legitimate market, and 
the smuggling of shipments out of the country.
573. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the 2015 report of the Board on the implementation 
of article 12 of the 1988 Convention.
(d) Substances not under international 
control
574. India continues to be a source country for keta-
mine trafficked to South-East Asia. Since February 2011, 
ketamine has been a controlled substance under the 
Narcotic Drugs and Psychotropic Substances Act, 1985. 
In 2014, Indian law enforcement agencies seized 32 kg of 
ketamine, a significant decrease from the 1,353 kg seized 
in 2013. Seizures indicate that ketamine trafficking may 
now be declining as a result of the authorities’ stringency 
that followed the recent amendments to the Act.
5. Abuse and treatment
575. Most countries in South Asia do not regularly 
carry out national drug surveys; information on abuse 
and prevalence therefore needs to come from other 
sources. Cannabis is the most common drug of abuse in 
the region. According to the World Drug Report 2015, 
the annual prevalence rate for cannabis abuse in South 
Asia is estimated to be about 3.5 per cent of the popu-
lation, or 33 million persons. According to UNODC, the 
annual prevalence of abuse of opioids remained stable at 
0.3 per cent of the population and continued to be lower 
than the estimated world annual prevalence rate of 
0.7  per  cent.
576. The estimated prevalence of drug abuse by injec-
tion in South Asia in 2013 among the population aged 
15 to 64 (the most recent information available from 
countries in the region) remained stable at 0.03 per cent, 
which was very low compared with the global average of 
0.26 per cent. As mentioned above, the lack of reliable 
data on drug abuse in the region may be the reason why 
the reported prevalence is so low.
577. The abuse of “yaba” (methamphetamine) and 
codeine-based preparations continues to be widespread 
in Bangladesh, and is still increasing. Among street chil-
dren, the abuse of glue and solvents by sniffing is com-
mon. Buprenorphine, mainly smuggled into the country 
from India, is one of the most popular drugs of abuse 
among those who inject drugs. Pethidine used to be the 
main drug of abuse among those who inject drugs in 
Bangladesh, but because of the emergence of buprenor-
phine over the past three decades and the high price of 
pethidine, the abuse of pethidine has decreased.
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578. In 2014, Bangladesh stepped up its campaign 
against drug abuse and drug trafficking. The campaign 
included the distribution of posters, leaflets, stickers and 
booklets. Furthermore, speeches and discussion meetings 
were held in schools, and short films were produced with 
WHO. In 2014, a total of 10,364 patients were treated in 
private treatment centres, up from 8,108 patients in 2013. 
Women continued to make up a very small proportion 
of those receiving drug abuse treatment in Bangladesh, 
with only 25 female patients receiving treatment in 2014.
579. The Government of India accorded a high priority 
to the issue of drug abuse. The Prime Minister used many 
platforms to spread the message to parents that they 
should spend more time with their children. There was 
an emphasis on skill development, which was also encour-
aged among drug users. 
580. In January 2015, the Government of India approved 
and launched a revised scheme of assistance for the pre-
vention of alcoholism and substance (drug) abuse and for 
social defence services, which included the provision of 
financial assistance and grants for buildings and a toll-
free national helpline for those with alcohol and drug 
abuse problems. The scheme was to provide a complete 
range of services such as awareness-raising and the iden-
tification, counselling, treatment and rehabilitation of 
addicts by voluntary and other organizations. Through 
preventive education programmes and whole-person 
recovery treatment of drug-dependent persons, its main 
pillars, the scheme was to reduce the demand for and 
consumption of alcohol and other dependence-producing 
substances.
581. Bangladesh, India and Nepal have implemented 
comprehensive packages for HIV prevention among drug 
users, including needle and syringe programmes and opi-
oid substitution therapy.
582. Under its national AIDS control programme for 
2013-2014, India established 45 new opioid substitution 
therapy centres for injecting drug users, thereby doubling 
the availability of such services in one year. The depart-
ment of AIDS control of the Ministry of Health and 
Family Welfare is supporting the provision of opioid sub-
stitution therapy services through more than 150 dedi-
cated centres across 30 states and union territories in 
India. After the successful completion of a pilot project 
in 2013, India decided to scale up the methadone main-
tenance treatment programme and its adoption by health 
clinics through the Ministry of Health. 
583. In 2015, UNODC published the findings of the 
first study held among women in north-eastern India who 
use drugs. The study identified their drug use patterns, 
the adverse impact of their drug use, and the impedi-
ments that limited their access to services. The study 
included the recommendation to expand the nature and 
scope of services provided to women in the future.
584. Cannabis and heroin continued to be the two 
drugs most commonly abused in Sri Lanka. Opium, 
 opiates and opioids such as morphine, methadone and 
tramadol, were also reported to be misused in Sri Lanka. 
However, they were not being manufactured in the 
 country. In 2014, a total of 1,646 people received drug 
abuse treatment, of whom 1,414 were treated for opioid 
addiction and 915 for cannabis addiction.
585. Sri Lanka does not manufacture any synthetic 
drugs or precursor chemicals, but the use of ATS, includ-
ing methamphetamine and MDMA (“ecstasy”), and of 
other synthetic drugs, such as LSD and ketamine, is 
reportedly on the rise.
586. In Nepal, the common pharmaceutical prepara-
tions containing controlled substances that were being 
trafficked and abused were codeine-based cough syrups, 
buprenorphine, diazepam, nitrazepam and morphine.
587. In the Maldives, the problem of drug abuse was 
growing, especially among young people, who constituted 
about one third of the total population. The authorities 
reported that almost half of those who abused drugs 
(46 per cent) were aged between 16 and 24 years. While 
the variety of drugs available in Maldives is increasing, 
heroin and liquid cannabis (hash oil) are the most com-
monly used drugs. Maldives has implemented opioid sub-
stitution therapy.
West Asia
1. Major developments
588. The continuing instability and climate of insecurity 
that prevail in some parts of the Middle East, in particu-
lar Iraq, the Syrian Arab Republic and Yemen, continue 
to undermine law enforcement efforts and pose a chal-
lenge to drug control efforts among countries in the 
region. Poor border controls and the intensified move-
ment of the population across countries is certainly 
favourable to illicit drug trafficking destined for markets 
in the region and can lead to a greater number of indi-
viduals abusing drugs.
ChaPTER III. aNalysIs Of ThE wORld sITuaTION  79
589. The significant and rapid deterioration of the 
humanitarian situation in some countries of the region 
continues to pose a grave risk to peace and security, with 
various implications, following the displacement of mil-
lions of inhabitants. The difficult and traumatic situation 
of refugees escaping conflict zones, in particular in Iraq 
and the Syrian Arab Republic, makes them particularly 
vulnerable to and at high risk of exposure to drug traf-
ficking and addiction. Lack of governmental control and 
a general atmosphere of lawlessness in many areas make 
it virtually impossible to monitor drug control activities.
590. The armed conflict and refugee crisis situations 
have given rise to increased demands for emergency sup-
plies, including internationally controlled substances for 
medical purposes. However, as supply is wholly depend-
ent on emergency aid, delivery in certain areas has been 
inadequate or severely limited. In that context, INCB 
wishes to draw attention to the special topic published in 
its annual report for 2014 on availability of narcotic drugs 
and psychotropic substances in emergency situations39 
and remind all States that, under international humani-
tarian law, parties to armed conflicts have an obligation 
not to impede the provision of medical care to civilian 
populations located in territories under their effective 
control. This includes access to necessary narcotic drugs 
and psychotropic substances. 
591. Against the backdrop of a long-standing lack of 
official sources of reliable information on illicit drug pro-
duction, trafficking and abuse among countries in the 
region, there have been several media and anecdotal 
reports regarding the widespread abuse of counterfeit 
Captagon tablets (containing amphetamine) among all 
parties engaged in armed violence in the Syrian Arab 
Republic.
592. The drug control situation in the region remains 
complex. The most recent estimates reported in the 
 executive summary of the Afghanistan opium survey 2015 
suggest that the situation concerning illicit opium poppy 
cultivation in Afghanistan, a significant factor for drug 
control efforts in the region, may be improving. 
Nevertheless, drug trafficking and illicit manufacture of 
heroin continue to be matters of concern for Governments 
in transit and destination countries. The completion in 
December 2014 of the International Security Assistance 
Force mission in Afghanistan may further affect the secu-
rity situation in the country, which, in turn, could have 
implications for the drug control situation.
 39 E/INCB/2014/1, paras. 228-238.
593. Significantly, for the first time in six years, the 
Afghanistan Opium Survey 2015, for which the executive 
summary is available, notes that there has been a decrease 
in the estimated total area under illicit opium poppy cul-
tivation in Afghanistan, which in 2015 totalled 183,000 
hectares (ha). That represents a decrease compared with 
2014, when cultivation reached record levels, at 224,000 ha. 
However, the area of cultivation in 2015 remains the 
fourth highest amount reported since the beginning of 
estimations in 1994. The extent of the decrease (19 per 
cent) may have been augmented by a recent change in 
the estimation methodology: the reliability of data is said 
to have improved significantly from 2014 to 2015. 
However, the results of different years must be compared 
with caution. The estimated potential opium production 
in the country decreased from 6,400 tons in 2014 to 3,300 
tons in 2015. Similarly, average opium yield decreased to 
18.3 kilograms per hectare, compared with 28.7 kilograms 
per hectare in 2014. At the same time, the total verified 
Governor-led eradication of opium poppy increased to 
3,760 ha eradicated in 2015 in comparison with 2,693 ha 
in 2014. 
594. Central Asian countries reported a decrease in sei-
zures in 2014 of opiates originating in Afghanistan. 
Nevertheless, for criminal groups engaged in drug traf-
ficking, the subregion remains attractive as a channel for 
smuggling opiates from Afghanistan to markets in the 
Russian Federation and Europe. Further, the abolition of 
customs controls at the borders between the countries in 
the Eurasian Economic Union, comprising Armenia, 
Belarus, Kazakhstan, Kyrgyzstan and the Russian 
Federation, may pose an additional challenge for the drug 
law enforcement authorities.
595. Similar to previous years, almost all illicit drugs 
are available in the Middle East subregion, which drug 
trafficking networks mainly use as a transit area for the 
smuggling of cocaine, heroin and amphetamine-type 
stimulants (ATS). Various seizure reports suggest that a 
trend of increasing traffic in cocaine emerged in the 
Middle East in 2014. According to various reports, 
cocaine seizures increased, in particular in Jordan, Saudi 
Arabia and the United Arab Emirates.
2. Regional cooperation
596. The London Conference on Afghanistan, held on 
4 December 2014, brought together representatives of 
more than 50 States, multilateral organizations, non- 
governmental organizations and representatives of Afghan 
civil society to discuss development, governance and 
80  INCB REPORT 2015
stability in Afghanistan, including issues related to drug 
control. The Conference provided a platform for the 
Government of Afghanistan to set out its vision for 
reform and for the international community to demon-
strate its support and solidarity for Afghanistan.
597. The summit of the Collective Security Treaty 
Organization (CSTO), held in Moscow on 23 December 
2014 and attended by the Presidents of Armenia, Belarus, 
Kazakhstan, Kyrgyzstan, the Russian Federation and 
Tajikistan, adopted the CSTO anti-drug strategy for the 
period 2015-2020. 
598. At a meeting in Dushanbe in May 2015, the heads 
of the drug law enforcement agencies of CSTO member 
countries discussed the situation in Afghanistan and 
decided to continue their cooperation in tackling the 
manufacture and distribution of new psychoactive sub-
stances and to prepare a plan of action for the period 
2016-2017.
599. At its summit held in Ufa, Russian Federation, in 
July 2015, the Shanghai Cooperation Organization’s 
Council of Heads of State decided to accept the acces-
sion of India and Pakistan to the Organization. The 
Organization’s main goals are the provision and mainte-
nance of peace, security and stability among its mem-
bers, including drug control. At the summit, the 
Organization adopted a development strategy outlining 
priority areas until 2025, including issues related to 
regional stability and drug control, and plans to address 
drug challenges were incorporated into the declaration 
of the Council of Heads of State issued at the summit. 
The Organization’s member States expressed concern at 
the scale of narcotic drug manufacture in Afghanistan, 
which posed a threat to development and security in the 
region. 
600. The Central Asian Regional Information and 
Coordination Centre, a standing intergovernmental body 
for combating trafficking in narcotic drugs, psychotropic 
substances and their precursors, continues to serve as a 
regional platform for exchanging information and expe-
riences on countering drug trafficking and promoting law 
enforcement cooperation.
601. Several regional and subregional organizations 
such as the Cooperation Council for the Arab States of 
the Gulf and its Criminal Information Centre to Combat 
Drugs and the League of Arab States, including its Council 
of Arab Ministers of the Interior and the Council of Arab 
Ministers for Health, continue to actively promote coop-
eration and harmonization of efforts among Arab coun-
tries, including in the area of drug control.
602. In June 2015, the Board participated in the 11th 
international conference on drug control, organized by 
the Dubai Police. The event, attended by representatives 
of Ministries of the Interior and counter-narcotics agen-
cies from countries of the Middle East and North Africa 
and of the Gulf Cooperation Council, focused on access 
to controlled substances for licit purposes while prevent-
ing diversion and abuse, and conducted a workshop to 
guide national delegations in identifying recommenda-
tions for incorporation into national strategies.
603. The international anti-drug forum organized by 
the Qatari Ministry of Interior in Doha in May 2015 rec-
ommended measures to tackle emerging drug trafficking 
trends in the region through the establishment of an early 
warning observatory and the inclusion of legal provisions 
to criminalize the promotion of illicit drug use through 
the Internet.
3. National legislation, policy and 
action
604. In order to counter the rapidly developing illicit 
market for synthetic drugs and the emergence of new psy-
choactive substances, the abuse of which is becoming a 
matter of concern in West Asia, some countries in the 
region have amended their national legislation and have 
begun to place some new psychoactive substances under 
national control. The Government of Armenia amended 
its national legislation in May 2015, placing 114 new psy-
choactive substances on the list of nationally controlled 
substances.
605. In March 2014, the Government of Georgia 
adopted a package of legislative amendments, pursuant to 
which illicit trafficking in pharmaceutical preparations 
containing codeine, ephedrine, norephedrine or pseudo-
ephedrine is now subject to criminal prosecution.
606. In Kazakhstan, the new penal code and the code 
of criminal procedure, which entered into force in January 
2015, stipulate criminal liability for offences related to 
trafficking in analogues of narcotic drugs and psycho-
tropic substances. In addition, the law on narcotic drugs, 
psychotropic substances and their analogues and precur-
sors, the main drug control legislation of Kazakhstan, was 
also strengthened and supplemented with provisions on 
analogue scheduling in July 2014.
607. In 2014, the Government of Kyrgyzstan approved 
a counter-narcotics strategy and implementation plan 
which defined measures and activities in the field of drug 
control for the period 2014-2019. The strategy seeks to 
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promote healthy lifestyles among the country’s young 
people through different types of activities, including 
awareness-raising campaigns. The strategy also aims to 
strengthen the law enforcement agencies of Kyrgyzstan 
and enhance drug demand reduction and prevention 
efforts, including the implementation of tertiary preven-
tion measures such as needle exchange, counselling, the 
provision of health care, and educational activities, as well 
as treatment and rehabilitation programmes.
608. In order to prevent the abuse of substances not 
under international control, Turkey placed 246 new psy-
choactive substances under national control in 2014. In 
addition, article 19 of the national law on the control of 
drugs was supplemented with provisions on generic 
scheduling in January 2015.
609. The Government of Israel has taken legislative 
measures to curb the growing market for new psychoac-
tive substances and their popularity among the youth in 
particular. In 2014, new synthetic cannabinoids and their 
derivatives were listed as narcotic drugs in the national 
legislation.
610. In June 2015, the United Arab Emirates health 
authorities recommended the inclusion of three plant 
materials, namely kava (Piper methysticum), kratom 
(Mitragyna speciosa) and Salvia divinorum in Table 4 of 
that country’s Federal Law No. 14 of 1995 (article 2) on 
the countermeasures against narcotic drugs and psycho-
tropic substances.
611. In the United Arab Emirates, efforts are also being 
made to standardize procedures for prescriptions involv-
ing controlled substances, restricted pharmaceuticals and 
psychoactive drugs, including innovative measures such 
as the establishment of an electronic system for the issu-
ance of prescriptions and the dispensing of medicines 
containing controlled narcotic drugs and psychotropic 
substances. 
612. In February 2015, Turkmenistan strengthened its 
main drug control law on narcotic drugs, psychotropic 
substances and precursors through an amendment 
 establishing that amnesty may not be granted to 
 individuals who have been convicted of crimes related to 
trafficking in narcotic drugs, psychotropic substances or 
precursors.
613. In Jordan, the Security Directorate and the Ministry 
of Labour entered into agreements to secure employment 
for inmates, including those incarcerated for drug-related 
sentences, upon completion of their sentence period or 
treatment period. Furthermore, some reforms within the 
Jordanian social security institution will broaden the 
social security system to include rehabilitation centres.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
614. Cannabis production, trafficking and abuse con-
tinue to be widespread in West Asia. Cannabis plants, 
seeds and oil are frequently seized in the region and 
remain the most widely abused substances. Afghanistan 
continues to be considered one of the largest illicit pro-
ducers of cannabis resin worldwide. While the trend of 
illicit cannabis cultivation and production is believed to 
be stable in that country, on the basis of the results of 
annual surveys conducted by the United Nations Office 
on Drugs and Crime between 2009 and 2011, systematic 
data collection efforts have not been undertaken since. 
Further, there are continued reports of illicit cultivation 
of cannabis in the Bekaa valley of Lebanon, where erad-
ication efforts have been sustained.
615. According to the data available to the Board, can-
nabis seizures increased in West Asia in 2014, with the 
exception of Israel, where quantities of both cannabis 
herb and cannabis resin seizures decreased from 2013 to 
2014 (from 38 kilograms (kg) to 7 kg of cannabis herb 
and from 320 kg to 6 kg of cannabis resin). The coun-
tries reporting the largest seizures of cannabis in 2014 
were, in descending order of seizure amount, Saudi 
Arabia, Jordan and Lebanon. According to the data pro-
vided to the Board by the authorities of Saudi Arabia, sei-
zures of cannabis herb in the country have nearly doubled: 
from 23 tons in 2011 to nearly 38 tons in 2014.
616. Large shipments of cannabis destined for Libya are 
regularly stopped in Lebanon, where almost 3 tons of can-
nabis herb were seized in 2014, a considerable increase 
compared with the 164 kg seized in 2013. Furthermore, 
in early 2015, Lebanese police had already seized a total 
of 2 tons of cannabis on the way to Libya. Similarly, nearly 
7 tons of cannabis, of which about 20 per cent was can-
nabis resin, were smuggled across land borders into 
Jordan, where they were seized in 2014.
617. The executive summary of the Afghanistan Opium 
Survey 2015 estimated the total area under illicit opium 
poppy cultivation in that country to be 183,000 ha in 
2015. Even taking into account the impact of methodo-
logical changes introduced between 2014 and 2015, this 
figure represents a marked decrease from the previous 
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year, when cultivation had reached record levels at 
224,000 ha. While 2015 marked the first decrease since 
2009, cultivation levels remained high in absolute terms. 
The estimated area of illicit opium poppy cultivation in 
2015 was nevertheless the fourth highest since estima-
tions began in 1994, surpassed only by the estimated 
amounts for 2007, 2013 and 2014. A corresponding 
decrease in Afghanistan’s estimated potential production 
of opium was recorded: 3,300 tons (48 per cent less than 
in 2014). The low production estimates are believed to be 
a result of the reduction in total area under cultivation, 
combined with a significantly reduced average opium 
yield per hectare. The reduced average yield was report-
edly owing to a lack of water in certain regions, which 
may have affected plant density. In 2015, the average 
opium yield was 18.3 kilograms per hectare, compared 
with 28.7 kilograms per hectare in 2014 (a 36 per cent 
decrease).
618. In 2015, 97 per cent of the total illicit opium 
poppy cultivation in Afghanistan took place in the east-
ern, southern and western regions of the country, which 
include the country’s most insecure provinces. The same 
three regions experienced the greatest relative decrease 
in opium poppy cultivation levels in 2015 (decreases of 
40 per cent, 20 per cent and 10 per cent respectively, 
compared with 2014), while steep increases were observed 
in the central and northern regions (increases of 38 per 
cent and 154 per cent, respectively). Poppy cultivation 
levels in the north-eastern region of the country remained 
stable. The extent to which these comparative figures 
might be attributable to the recent change in estimation 
methodology must, however, be borne in mind. At the 
province level, Helmand continued to account for more 
than 47 per cent of all illicit opium cultivation in 
Afghanistan. 
619. The Government of Afghanistan continued its 
efforts to eradicate illicit opium poppy cultivation in the 
country, increasing total eradication of opium poppy to 
3,760 ha in 2015. However, the total eradicated area 
remains very limited in absolute terms compared with the 
total estimated area under illicit opium poppy cultivation 
in Afghanistan (1-2 per cent). 
620. The route from Afghanistan through the Islamic 
Republic of Iran is one of the shortest trafficking routes 
from West Asia into Europe, with significant amounts of 
Afghan opiates seized there every year, primarily opium 
and heroin. Accordingly, the Islamic Republic of Iran has 
remained the country in the world with the largest quan-
tity of opium seized: 393 tons in 2014. In total, the coun-
try’s authorities seized 511 tons of illicit drugs in 2014, 
compared with 555 tons in 2013.
621. Heroin smuggling routes through the southern 
Caucasus are marked by constant changes. According to 
data provided to the Board, seizures of heroin in Georgia 
increased from 117 kg in 2013 to more than 591 kg in 
2014, and seizures of heroin in Azerbaijan totalled nearly 
296 kg in 2014, compared with 101 kg in 2013. Significant 
increases in heroin seizures were also reported in Armenia, 
where over 850 kg were seized in 2014, in contrast to the 
low levels of seizures made in the country in the previous 
years (less than 5 grams were seized in 2012 and in 2013).
622. Drug seizures in Central Asia have followed a 
decreasing trend. In particular, the amount of heroin 
seized in the subregion decreased by 24.6 per cent, from 
1.6 tons in 2013 to 1.2 tons in 2014. The amount of  heroin 
seized in Kazakhstan decreased by 48 per cent (from 
754  kg to 392 kg) and by 12.4 per cent in Uzbekistan 
(from 121.6 kg to 106.5 kg). Only Kyrgyzstan and 
Tajikistan reported a moderate increase in seizures of 
 heroin, from 247 kg to 285 kg and from 483 kg to 507 kg, 
respectively. In Turkmenistan, seizures of heroin decreased 
from 12.6 kg in 2013 to 1.8 kg in 2014.
623. Countries in the region continued their coopera-
tion in countering illicit drug trafficking within the frame-
work of CSTO. In particular, the counter-narcotics 
operation “Channel Patrol”, conducted on 18-22 May 
2015, resulted in the seizure of more than 12 tons of nar-
cotics, including over 7 tons of opium, approximately 3 
tons of hashish, more than 1 ton of heroin and 126 kg of 
cannabis herb. The operation involved cooperation among 
the law enforcement agencies of Armenia, Belarus, 
Kazakhstan, Kyrgyzstan, the Russian Federation and 
Tajikistan, with the involvement of the agencies of 
Afghanistan, China and Iran (Islamic Republic of) and 
INTERPOL as observers.
624. Similarly, the information available to the Board 
shows that heroin seizures decreased among countries in 
the Middle East in 2014. Heroin seizures, which increased 
significantly in several countries of the region in 2013, 
decreased in 2014, particularly in, in decreasing order of 
seizure amounts, Jordan, Lebanon, Saudi Arabia and 
Israel. In July 2015, a joint security operation of Pakistan 
and the United Arab Emirates resulted in the dismantling 
of a major heroin ring, the arrest of 40 drug traffickers 
and the seizure of 150 kg of heroin.
625. Data available to the Board indicate that annual 
opium seizures in the Middle East subregion in 2014 were 
also small, ranging from 34 grams in Jordan to about 4 kg 
in Saudi Arabia.
626. The extent of cocaine trafficking in West Asia 
continued to increase in 2014, with some countries in 
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the region reporting a marked increase in drug seizures. 
For example, Saudi Arabia reported an increase in sei-
zures of cocaine, rising from 4.6 kg in 2013 to 533.5 kg 
in 2014, and Jordan reported an increase from 12 kg in 
2013 to 319 kg in 2014.
627. As in previous years, the territory of the United 
Arab Emirates served as a transit area for traffickers 
smuggling drugs from South America to Africa and Asia. 
In June 2015, cocaine traffickers who had transited Dubai, 
United Arab Emirates, were arrested in Nigeria, South 
Africa and Turkey.
628. Further, increasing quantities of South American 
cocaine, in particular cocaine originating in Mexico and 
destined for Israel and Lebanon, are being seized while 
the drug is in transit through Jordan and Saudi Arabia; 
most of the cocaine is trafficked by sea, using containers, 
and seizures take place at seaports; 320 kg were seized by 
the Lebanese authorities during the first eight months of 
2014, and 319 kg were intercepted by the Jordanian 
authorities in 2014, compared with 12 kg in 2013.
(b) Psychotropic substances
629. According to seizure data, pharmaceutical prepa-
rations containing psychotropic substances are trafficked 
in most countries in West Asia. In particular, abuse of 
sedatives and anxiolytics (for example, diazepam and 
nitrazepam) in the form of tablets is widespread, which 
may indicate weaknesses in national systems for the con-
trol of the networks for licit distribution of prescription 
medicines containing controlled substances. INCB calls 
upon the countries concerned to increase their vigilance 
with respect to diversion, trafficking and abuse of such 
preparations and to reinforce controls on domestic dis­
tribution channels for pharmaceutical preparations con­
taining controlled substances.
630. Seizures of psychotropic substances in Central 
Asian countries remain relatively low. In 2014, authori-
ties of Kazakhstan reported the seizure of 13,983 vials 
and 3,496 tablets of psychotropic substances. The law 
enforcement authorities of Tajikistan in the same year 
reported the seizure of 2,590 MDMA tablets, 2,025 phe-
nobarbital tablets and 10 tablets of diazepam. The total 
amount of pharmaceutical preparations seized in 
Kyrgyzstan amounted to 3,604 grams in 2014.
631. Trafficking and abuse of ATS have been reported 
by a growing number of countries in West Asia, particu-
larly abuse of amphetamine, methamphetamine and 
MDMA, with a marked increase in abuse of “ecstasy”-
type substances noted in Lebanon in 2014. For 2014, 
there were reports of significant seizures of MDMA 
(“ecstasy”) in Israel and amphetamine in Saudi Arabia.
632. The quantity of reported seizures of ATS in the 
Islamic Republic of Iran decreased considerably. The 
amount of seized ATS was 2,644 kg in 2014, a decrease 
of 28 per cent compared with the previous year. The num-
ber of clandestine drug laboratories dismantled in the 
Islamic Republic of Iran in 2014 (340 laboratories) was a 
decrease of 24 per cent from 2013 (445 laboratories).
633. Seizures of counterfeit Captagon tablets (believed 
to contain amphetamine) continue to be reported by most 
countries in the Middle East. In particular, Lebanon, 
Saudi Arabia and the Syrian Arab Republic reported that 
seizures of amphetamine illicitly manufactured under the 
brand name “Captagon” in 2014 were higher than in pre-
vious years. Most of the Captagon tablets are smuggled 
across the non-official border crossings between Jordan 
and the Syrian Arab Republic, transiting Jordan, with 
Saudi Arabia as the main final destination. In October 
2015, 2 tons of Captagon destined for Saudi Arabia were 
reportedly seized at the international airport in Beirut.
634. Trafficking and abuse of amphetamine among 
countries in the Middle East continued to be reported. 
Saudi Arabia is among the countries that registered a sig-
nificant increase in the amount of amphetamine tablets 
seized, as the country seized more than 100 million tab-
lets in 2014, compared with 57 million in 2013. 
Furthermore, almost 32 million amphetamine tablets 
were seized in Jordan in 2014.
635. In March 2014, a special joint operation between 
the drug enforcement administrations of Saudi Arabia 
and Bahrain resulted in the dismantling of a trafficking 
ring and the seizure of 22 million amphetamine tablets.
636. In 2014, Jordanian authorities seized more than 
43  million tablets made using procyclidine, an antipar-
kinsonian agent, obtained from Kemadrin tablets; the 
seized tablets had originated in India and been smuggled 
by air. Kemadrin is apparently mixed with other sub-
stances to produce hallucinogenic effects. It appears that 
Jordan is used as a transit country as more than 98 per 
cent of the drug was destined for Iraq.
(c) Precursors
637. Seizures of acetic anhydride, the key precursor 
chemical used in the illicit manufacture of heroin, 
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declined in Afghanistan in 2014. The change of traffick-
ing routes and modi operandi used by traffickers were 
among the possible reasons for the decrease in seizures. 
Further, the black market price of acetic anhydride in 
Afghanistan, which is an indicator of the chemical’s avail-
ability on the market, increased slightly in 2014, likely 
due to an increase in demand caused by the high levels 
of opium production in the country. INCB urges all rel-
evant stakeholders of Member States in the region to 
increase the exchange of drug-related intelligence among 
their national competent law enforcement authorities, 
including through the relevant regional intelligence cen-
tres such as the Central Asian Regional Information and 
Coordination Centre, the Joint Planning Cell of 
Afghanistan, Iran (Islamic Republic of) and Pakistan and 
the Gulf Cooperation Council’s Criminal Information 
Centre to Combat Drugs.
638. The territories of Central Asian countries contin-
ued to be exploited by trafficking organizations involved 
in the diversion of and trafficking in precursor chemicals. 
The total amount of precursors seized in Kazakhstan 
reached 729 tons in 2014. The law enforcement authori-
ties of Kyrgyzstan reported seizures of precursor chemi-
cals totalling 6,197 tons.
639. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention.
(d) Substances not under international 
control
640. Abuse of substances not under international con-
trol, such as ketamine and khat, have continued to be 
reported by some countries in the region. The abuse of 
tramadol, a synthetic opioid not under international con-
trol, continued to be reported by some countries in the 
region. New drug abuse patterns for Salvia divinorum and 
synthetic cannabinoids were also reported in Lebanon.
641. Seizures of substances not under international con-
trol continued to be reported in Turkey in 2014. A total 
of 773 kg of synthetic cannabinoids were seized in the 
country. Georgia reported a 90 per cent decrease in con-
sumption of new psychoactive substances, known locally 
as “bios” and “spices”, in the period June-December 2014 
following the adoption of the new law on new psychoac-
tive substances in May 2014.
5. Abuse and treatment
642. According to latest available data, for 2012, the 
number of drug users in Afghanistan was estimated to be 
between approximately 1.3 million and 1.6 million, and 
2.65 per cent of the total population were abusing opi-
ates. In contrast to many other countries, drug abuse in 
Afghanistan appears to be highest among older segments 
of society (9 per cent among those aged 45 years and 
older). The overall annual prevalence of drug use in 
Afghanistan is estimated to be 6.6 per cent, while in 
urban areas drug use prevalence is estimated to be about 
5.3 per cent. Although the number of treatment centres 
in Afghanistan increased from 43 in 2009 to 102 in 2012 
and to 108 in 2013, drug treatment capacity in Afghanistan 
still covers less than 8 per cent of opium and heroin users.
643. The number of drug users in the Islamic Republic 
of Iran was estimated to be about 1,325,000 in 2014, 
which is 2.26 per cent of the adult population of the coun-
try. The Government also estimated that some 750,000 
persons had received treatment for drug-related prob-
lems. There are currently more than 4,500 private and 
around 600 public treatment and rehabilitation centres in 
the country.
644. According to official statistics, in 2014 there were 
a total of 65,216 persons registered as drug users in 
Kazakhstan, Kyrgyzstan, Tajikistan and Uzbekistan, com-
pared with a total of 73,345 persons in 2013. The num-
ber of officially registered drug-dependent persons in 
Kazakhstan in 2014 stood at 34,221 persons, which is a 
significant decrease compared with 40,224 persons in 
2013. In Kyrgyzstan, 9,024 persons were officially regis-
tered as drug-dependent in 2014, which is 8.8 per cent 
less than in 2013. The number of people suffering from 
drug addiction remained stable in Tajikistan in 2014. 
According to official statistics, there were 7,279 registered 
drug-dependant individuals in the country, of which 
80.8 per cent were abusing heroin. A total of 14,692 drug-
dependent persons were officially registered in Uzbekistan 
in 2014, a decrease of 9.2 per cent from the previous year.
645. Despite the lack of reliable estimates concerning 
the age range and the number of drug abusers, drug abuse 
in the Middle East is a growing problem. In Lebanon, for 
example, it is estimated that about 2,500 people need 
treatment for drug abuse. Among the 3,016 patients 
admitted in treatment centres in Lebanon in 2014, 89 per 
cent abused cannabis, 51 per cent abused heroin and 
42  per cent reported abusing cocaine. Other substances 
of abuse of those patients included ATS, benzodiazepines, 
hallucinogens, GHB, ketamine, Salvia divinorum and 
tramadol.
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646. In view of the lack of comprehensive and reliable 
data on the extent of drug abuse in the region, INCB urges 
the Governments concerned to assess the situation in their 
country by setting up drug monitoring systems and con-
ducting population-based surveys on the extent of drug 
abuse, in order to develop and implement the appropriate 
prevention, treatment and rehabilitation programmes.
647. Access to drug dependence treatment is hampered 
by the limited number of specialized medical facilities in 
the region, in addition to the stigma associated with drug 
dependence. Nevertheless, the Board notes that a num-
ber of countries in the region established or are in the 
process of establishing treatment facilities and services to 
address the negative health and social consequences of 
drug abuse. INCB is hopeful that this will improve the 
availability of drug abuse treatment and rehabilitation 
services.
648. In May 2014, under the auspices of the Palestinian 
Ministry of Health, an opioid substitution therapy clinic 
was opened in Ramallah, in which methadone is provided 
under medical supervision. Prior to the opening of the 
centre, health professionals conducted a study visit to opi-
oid substitution therapy in Jerusalem and training in col-
laboration with the Nazareth methadone centre. By 
mid-June 2015, there were 52 patients benefiting from the 
centre.
649. The Board also notes that the opioid substitution 
therapy programme launched in Lebanon in 2011 is now 
fully operational and serves 1,375 patients, double the 
number registered by mid-2013. Nearly 95 per cent of the 
patients are male and more than half are between the ages 
of 26 and 35. Comprehensive care is provided, including 
medical treatment, psychiatric evaluation, psychological 
and social assistance.
D. Europe
1. Major developments
650. Europe continues to be an important market for 
drugs produced locally and drugs smuggled from other 
regions, in particular Latin America, West Asia and North 
Africa. The synthetic drugs manufactured in Western and 
Central Europe supply illicit markets both in that sub-
region and in other parts of the world. In recent years, 
Eastern Europe has emerged as a transit and destination 
area for cocaine, although the amounts of cocaine seized 
in the subregion remain relatively small.
651. In Western and Central Europe, cannabis is the 
most commonly seized drug, accounting for about 80 per 
cent of all seizures. Cocaine ranks second overall, account-
ing for more than double the number of reported seizures 
of amphetamines or heroin. The number of seizures of 
MDMA (“ecstasy”), was relatively low in Western and 
Central Europe. 
652. By March 2015, more than 450 new psychoactive 
substances were being monitored by the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). During 2014 alone, 101 new psychoactive 
substances were reported for the first time via the European 
Union early warning system. The increase in the  trafficking 
and abuse of those substances continued to pose a public 
health challenge in many European countries.
653. Both the purity and the potency of all the drugs 
of abuse commonly found in Western and Central Europe 
have increased. The reasons for that increase are complex, 
and may include advances in technology and market 
competition. In some countries that produce high-
potency cannabis, the share of that substance on the 
domestic market has increased in recent years. New data 
indicate that the potency of cannabis resin smuggled in 
the region has also increased. Recently, EMCDDA and 
Europol alerted the European Union community to health 
risks associated with the consumption of high-purity 
“ecstasy” and tablets containing para-methoxymetham-
phetamine (PMMA) but sold to users as “ecstasy”. In 
some countries, high-quality synthetic cannabinoids and 
cathinones offered in the illicit market compete with low-
quality and relatively more expensive most commonly 
abused drugs.
654. The Internet and social media have become impor-
tant tools in marketing drugs. According to EMCDDA 
more than 600 websites selling new psychoactive sub-
stances, sometimes in amounts in the kilograms, were 
identified in the European Union in 2013 and 2014. 
Assessment of the size of the online drug market is not 
easy and there is a need for further awareness-raising 
regarding the growing potential role of the Internet and 
use of cryptocurrencies, such as bitcoin, in drug supply 
and marketing with respect to both established drugs and 
new psychoactive substances. There is also a need for a 
review of existing regulatory models to perform in a 
global and virtual context.
2. Regional cooperation
655. The countries of South-Eastern Europe continued 
to intensify their regional law enforcement cooperation 
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in the area of organized crime and drug control. All 
 countries of the region are active participants in the 
UNODC regional programme for South-Eastern Europe 
(2012-2015). 
656. In September 2014, in Sarajevo, the Southeast 
European Law Enforcement Center held a workshop on 
tackling drug trafficking, at which experts from the 
Center’s member States and the United States discussed 
forfeiture investigations and money-laundering related to 
drug trafficking. In March 2015, a meeting on facilitation 
of common and coordinated measures in the western 
Balkan region, at which the participants agreed on annual 
plans for common and coordinated operations in 2015, 
was held in Belgrade within the framework of the Border 
Security Programme of the Geneva Centre for the 
Democratic Control of Armed Forces.
657. In 2014, the Russian Federation continued sup-
porting the provision of law enforcement training in 
counter-narcotics at its national institutions to the 
Counter-Narcotics Police of Afghanistan as part of the 
UNODC regional programme for Afghanistan and neigh-
bouring countries. That joint cooperation will be extended 
into 2016 and expanded to include assistance to the five 
countries of Central Asia. Moreover, the Russian 
Federation informed the Board about a number of initi-
atives to strengthen joint efforts to tackle the world drug 
problem, including the international conference of the 
Russian-African Anti-Drug Dialogue, held in Banjul on 
23 July 2015, and the regional anti-drug operation, 
“Operation Channel”, for the period 2014-2015.
658. Large-scale international counter-narcotics opera-
tions were carried out in 2014 by the member States of 
CSTO and Afghanistan, in cooperation with the Federal 
Drug Control Service of the Russian Federation. As a 
result of those operations, 16.5 tons of narcotic drugs 
were seized.
659. The European Union continued intensive cooper-
ation among its member States and with third countries 
and other regions. The Horizontal Working Party on 
Drugs, a working group of the Council of the European 
Union, held talks with third countries, namely Brazil, the 
Russian Federation, the United States and the States of 
the Western Balkans and Central Asia.
660. In July 2015, the European Union and the 
Government of Afghanistan signed a cooperation agree-
ment on partnership and development, the first official 
contractual framework governing cooperation between 
the European Union and Afghanistan. The agreement 
builds on the European Union strategy for Afghanistan 
for the period 2014-2016 and enshrines the Union’s com-
mitment to a partnership with Afghanistan in order to 
fulfil the Government’s vision of “realizing self-reliance”.
661. “Shaping our common future: working for pros-
perous, cohesive and sustainable societies for our citizens” 
was the theme of the second European Union-Community 
of Latin American and Caribbean States (CELAC) sum-
mit, held in Brussels on 10 and 11 June 2015, which 
adopted a declaration on a “Partnership for the next gen-
eration”, the Brussels declaration entitled “Shaping our 
common future” and an updated European Union-
CELAC action plan.
662. The Cooperation Group to Combat Drug Abuse 
and Illicit Trafficking in Drugs (Pompidou Group) of the 
Council of Europe, at its sixteenth Ministerial Conference, 
adopted its working programme for the period 2015-
2018, entitled “Drug policy and human rights: new trends 
in a globalised context”. The work programme establishes 
the following thematic priorities: bringing human rights 
to the forefront of drug policy; analysing policy coher-
ence, costs, impact and potentially adverse effects of drug 
policy measures; addressing changing patterns and con-
text of drug use, production and supply; and identifying 
opportunities and challenges for drug policies arising 
from the Internet. Furthermore, the States members of 
the Pompidou Group continued to foster the exchange of 
information on drugs and addictions with and within 
countries of the Mediterranean basin through the 
Mediterranean Network (MedNET).40 The activities of 
MedNET network include the establishment of country 
profiles for Algeria, Egypt, Jordan, Lebanon, Morocco and 
Tunisia with a view to sharing information on the drug 
control situation in those countries, including informa-
tion on the drug trafficking situation and drug preven-
tion and treatment programmes.
3. National legislation, policy and 
action
663. During the reporting period, the European coun-
tries continued to adopt measures to counteract the 
spread of new psychoactive substances. Germany, 
Lithuania, Romania and Slovenia added 32, 31, 30 and 9 
new psychoactive substances, respectively, to their lists of 
nationally controlled substances. 
664. In 2014, Belarus addressed the growing threat of 
new psychoactive substances to public health by adding 
 40 MedNET countries include Algeria, Cyprus, Egypt, France, 
Greece, Italy, Jordan, Lebanon, Malta, Morocco, Portugal and Tunisia.
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nine new substances to its National List of Narcotic 
Drugs, Psychotropic Substances, their Precursors and 
Analogues Subject to State Control. Sweden placed 11 
substances under control as narcotic drugs and an addi-
tional 21 substances as “goods dangerous to health”. In 
the same year, 36 substances were added to the list of 
substances subject to control in the Russian Federation, 
including 27 new psychoactive substances. In addition, 
Belgium adopted a law providing for the listing of con-
trolled substances according to definitions for generic 
groups. In December 2014, Finland brought into force 
new legislation introducing a definition of “new psycho-
active substance” and listing 294 substances as psychoac-
tive substances banned from the consumer market. The 
new legislation prohibits the production and supply of 
those substances, although it does not establish criminal 
liability for their possession or use. 
665. The Board recommends that countries continue to 
monitor trends and collect data on the use, abuse, illicit 
domestic and international distribution and manufacture 
of new psychoactive substances and share those data with 
the Board.
666. In March 2014, an action plan to prevent and sup-
press criminal activity relating to the cultivation of plants 
containing narcotic substances was approved by the State 
Police of Albania. The action plan provides for measures 
aimed at discouraging illicit cultivation of such plants 
and increasing awareness—among youth, State adminis-
tration entities and locally elected officials—of illicit 
 cultivation and State Police operations to eradicate such 
cultivation.
667. In Belarus, a system of measures to stabilize the drug 
situation and a comprehensive action plan to counter drug 
trafficking, prevent drug abuse and facilitate the social 
rehabilitation of drug abusers were approved in 2014. 
668. The National Committee for the Coordination and 
Planning of Drug Responses of Greece drafted a new 
national strategy on drugs (for the period 2014-2020) and 
a new action plan (for 2014-2016).
669. In 2014, Italy launched a national action plan to 
address the threat posed by the illicit sale and distribu-
tion of new psychoactive substances via the Internet.
670. In Malta, the Drug Dependence (Treatment not 
Imprisonment) Act came into force in April 2015. 
Pursuant to the Act, drug possession for personal use is 
not a criminal offence and any person found in posses-
sion is tried before a Commissioner for Justice and sub-
ject to a fine. If the person reoffends within a two-year 
period, he or she is called before the Drug Offenders 
Rehabilitation Board, which determines whether the 
offender is drug-dependent and issues any necessary 
orders accordingly. Failure to comply with such orders is 
punishable by a fine or three months’ imprisonment.
671. In September 2014, the Republic of Moldova 
adopted a national action plan to combat drug  trafficking 
for the period 2014-2016. The plan provides for a wide 
range of measures aimed at reducing drug abuse, 
 especially among youth, addressing the economic, 
health  and social impact of drug abuse, strengthening 
 prescription regulations and combating illicit cultivation 
and trafficking.
672. Several legislative acts were adopted in Romania 
with the aim of strengthening the drug control regime. 
Legislation on preventing and countering drug abuse and 
trafficking, together with provisions on the legal regime 
governing plants and preparations containing narcotic 
drugs and psychotropic substances, were amended with 
a view to the further protection of public health, espe-
cially the health of young people. The Government 
amended administrative regulations to optimize the 
licensing regime and improve the access of drug- 
dependent persons to medical and social programmes. In 
2014, an interministerial office was established to coordi-
nate drug policy and oversee the activities of the Ministry 
of Health and the Ministry of the Interior.
673. In December 2014, the Government of the Russian 
Federation approved legislative amendments setting out 
legal conditions facilitating the assistance provided by 
non-commercial organizations involved in drug demand 
reduction activities and establishing priority access to 
controlled substances for patients in need of pain relief. 
Furthermore, in response to increased trafficking of new 
psychoactive substances into the country, in January 
2015, the Government adopted a law introducing crimi-
nal liability for offences involving new psychoactive sub-
stances and authorizing the drug control authorities to 
impose a temporary ban on any potentially dangerous 
psychoactive substances.
674. In December 2014, Serbia adopted a national drug 
strategy (for 2014-2021) and an action plan for its imple-
mentation (2014-2017). 
675. The National Assembly of Slovenia adopted a new 
resolution on the National Programme on Drugs for 
2014-2020. The goals of the Programme include reduc-
ing the number of new drug users among youth and the 
number of drug-related offences and reducing the num-
ber of deaths caused by overdose.
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676. In June 2015, the European Commission approved 
implementing Regulation (EU) 2015/1013 laying down 
rules for the monitoring of trade in drug precursors 
between the Union and third countries. The Regulation, 
which applies to all member States of the European 
Union, also establishes uniform procedural rules for the 
licensing and registration of operators and users and their 
listing in the European database on drug precursors.
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
677. There are two main cannabis products found on 
the European illicit drug market: cannabis herb and can-
nabis resin. Cannabis is both illicitly cultivated in coun-
tries of the region and also trafficked, in sizeable amounts, 
within the region and from other regions. There is an 
increasing tendency for criminal groups operating in the 
region to run numerous small-scale cannabis plant culti-
vation sites, usually indoors, rather than fewer but large-
scale outdoor plantations, in order to mitigate the risk of 
detection. Most cannabis resin destined for Europe is 
smuggled from Morocco.
678. According to the European Drug Report 2015, in 
2013, the European Union countries reported 431,000 
individual seizures of cannabis herb and 240,000 seizures 
of cannabis resin.
679. The total amount of cannabis resin seized in the 
European Union in 2013 (460 tons) was much higher 
than that of cannabis herb (130 tons). Spain, a major 
point of entry for cannabis produced in Morocco, 
reported more than two thirds of the total quantity of 
cannabis resin seized in Europe that year. Afghanistan, 
Lebanon, Morocco and Pakistan were among the coun-
tries of origin or departure of shipments of cannabis resin 
seized in Western Europe in 2014. Analysis of trafficking 
trends in those European countries that regularly report 
seizures of cannabis shows a large increase from 2006 to 
2013 in the potency (level of THC) of both herbal can-
nabis and cannabis resin. Among the causes of that 
increasing potency may be the introduction of intensive 
production techniques in Europe and, more recently, the 
introduction of high-potency plants in Morocco.
680. South-Eastern Europe continued to see an expan-
sion in the trafficking of cannabis produced in Albania 
in 2014. The State Police of Albania continued its efforts 
to contain cannabis cultivation following its successful 
operations carried out in the southern region and other 
parts of the country. The Albanian authorities have inten-
sified cooperation with their Italian counterparts in map-
ping illicit cultivation areas through aerial surveys. The 
quantity of cannabis seized in Albania in 2014 (101.7 
tons) exceeded the total quantity seized during the pre-
vious nine years (96 tons). 
681. Seizures of cannabis plants in a country may indi-
cate the production of the drug in its territory. According 
to EMCDDA, seizures of cannabis plants have signifi-
cantly increased in Western and Central Europe since 
2002. In 2013, Italy and Belgium each identified 1,100 
illicit outdoor cannabis plant cultivation sites and eradi-
cated 885,000 and 394,000 plants respectively. In the same 
year, the eradication of cannabis plants cultivated indoors 
was reported by Germany (94,000 plants), the Czech 
Republic (66,000 plants), Ireland (29,000 plants), Latvia 
(14,000 plants) and Italy (10,300 plants). In 2014, eradi-
cation of cannabis plants were reported by the United 
Kingdom (461,300 plants), Germany (131,800 plants), 
Greece (52,300 plants) and Finland (21,800 plants). 
According to the Finnish drug control authorities, small-
scale domestic cultivation has recently become more 
common in Finland. Cannabis growers usually grow up 
to 20-30 cannabis plants in their homes for personal use.
682. With the increasing involvement of organized 
criminal groups in the production and trafficking of can-
nabis, the drug plays a major role in drug-related crime 
in Western and Central Europe, where it accounts for 
80 per cent of drug seizures and cannabis use or posses-
sion for personal use accounts for more than 60 per cent 
of all reported drug-related offences. However, there are 
considerable differences between European countries 
with respect to practice in sentencing for offences relat-
ing to cannabis supply; for example, the penalties for a 
first-time offence of supplying 1 kilogram of cannabis in 
Europe may range from less than 1 year to 10 years in 
prison.
683. Since 2010, several Western and Central European 
countries have reported declining trends with respect to 
heroin, inter alia, in the number of seizures and the 
amounts of the drug seized, the number of offences relat-
ing to supply, heroin prices and scale of abuse. According 
to the latest EMCDDA report on opioid trafficking routes 
from Asia to Europe, published in 2015, there has been 
an overall increase in the purity of heroin in the region 
in recent years. 
684. According to EMCDDA, there is also evidence of 
an increased range of opioids appearing on the European 
market. Since 2005, 14 new synthetic opioids have been 
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reported via the European Union early warning system. 
In 2014, seizures of diverted or counterfeit pharmaceuti-
cal products containing opioids, such as methadone, 
buprenorphine, fentanyl and tramadol, were reported by 
competent national authorities of several European coun-
tries, including Austria, Finland, Greece and Sweden.
685. According to the World Drug Report 2015 heroin 
seizures have recently increased slightly in Eastern and 
South-Eastern Europe.41 In particular, in 2013, heroin sei-
zures in South-Eastern Europe increased slightly in com-
parison to 2012, although they remained below the levels 
observed in the subregion between 2007 and 2009. The 
amounts of heroin seized in Eastern Europe increased 
slightly in 2013, but remained stable from the long-term 
perspective.
686. The three main routes used by trafficking rings to 
smuggle heroin to Europe are: (a) the traditional Balkan 
route, a major heroin trafficking route into the European 
Union that links Afghanistan and the Islamic Republic of 
Iran and passes through Turkey and the Balkans; (b) the 
southern route, which has been used in recent years to 
smuggle heroin to Europe directly from ports in the 
Islamic Republic of Iran and Pakistan, or via the Arabian 
Peninsula or Africa; and (c) the northern route, which, 
according to EMCDDA, is used for heroin trafficking by 
land from the northern borders of Afghanistan to supply 
illicit drug markets in Belarus, the Russian Federation, 
Ukraine and countries in Central Asia.
687. The discovery of heroin processing laboratories in 
Europe, in particular two laboratories processing mor-
phine into heroin, dismantled in Spain in late 2013 and 
early 2014, may indicate possible shifts in heroin supply 
channels. Greece reported that it had destroyed facilities 
involved in cutting and packaging heroin from Afghanistan 
or Pakistan that had been intended for illicit drug mar-
kets in other European Union countries.
688. In December 2014, an extensive network engaged 
in trafficking heroin into the European Union was dis-
mantled by a joint investigation team, facilitated by 
Eurojust and supported by Europol. Some 400 suspects 
were arrested and 100 kg of heroin were seized together 
with cocaine, cannabis and cash. The network, operating 
from Austria, Germany and the former Yugoslav Republic 
of Macedonia, brought heroin into the European Union 
along the Balkan route and distributed it in several 
European countries.
 41 Reported according to the regional groupings of the World Drug 
Report, annex II.
689. According to figures released in 2015, cocaine and 
“crack” cocaine accounted for 10 per cent of the total num-
ber of seizures in Western and Central Europe. Overall, 
the purity of cocaine seized in the European Union has 
increased in recent years, while its price has remained rel-
atively stable. In most parts of Eastern and South-Eastern 
Europe the availability of cocaine remained limited.
690. Africa continued to be used as a trans-shipment 
area for the smuggling of cocaine across the Atlantic 
Ocean into Europe. An example of involvement of the 
African region in cocaine trafficking is the seizure, in 
April 2015, of 3 tons of cocaine on a vessel registered in 
Tanzania. The vessel was intercepted by the authorities of 
the United Kingdom 100 miles east of the coast of 
Scotland. The interdiction was conducted in cooperation 
with the French customs service and other international 
partners, and represents one of the largest cocaine sei-
zures in the history of the United Kingdom.
691. Of the European countries, Spain has seized the 
most cocaine in recent years. In 2013, Spain, Belgium, 
the Netherlands, France and Italy together accounted for 
more than 80 per cent of the 62.6 tons seized in the 
European Union. In 2014, seizures of cocaine in quanti-
ties exceeding 100 kg were reported by Spain, France, the 
United Kingdom, Germany, Greece, Lithuania and 
Sweden (listed in descending order).
692. Organized criminal groups from South-Eastern 
Europe, closely connected with cocaine producers in 
South America, have been actively involved in trafficking 
cocaine to Western and Central European ports. Recent 
seizures of cocaine, albeit in small quantities, in ports on 
the eastern Mediterranean, Baltic and Black seas have 
provided new evidence of the diversification of cocaine 
trafficking routes into Europe.
693. In 2013, a total of 478 kg of cocaine was seized in 
Eastern Europe and more than 100 kg in South-Eastern 
Europe. Seizure data show that cocaine traffickers continue 
to target many parts of those subregions, cocaine seizures 
being reported by almost all of the countries concerned in 
2013. Eastern Europe is emerging both as a transit area 
and as a destination for cocaine, of which there has been 
an increased number of seizures (although only in small 
quantities) in recent years, which points toward the 
 emergence of a cocaine market in the subregion.
(b) Psychotropic substances
694. Europe is a major illicit manufacturer of amphet-
amine-type stimulants; most of the amphetamine and 
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methamphetamine manufactured in Europe is destined 
for national illicit markets, although some is destined for 
other regions, particularly East and South-East Asia. 
Amphetamine manufacture in Europe mainly takes place 
in Belgium, the Netherlands, Poland and the Baltic States 
and, to a lesser extent, in Germany; illicit methampheta-
mine manufacture is concentrated in the Baltic States and 
Central Europe. Europe is also known as a transit hub 
for methamphetamine trafficked from Africa and the 
Islamic Republic of Iran to East and South-East Asia.
695. In 2013, a total of 6.7 tons of amphetamine was 
seized in the European Union, exceeding the figure for the 
period 2010-2012. Germany, the Netherlands and the 
United Kingdom accounted for more than half of that 
amount. Both the number of methamphetamine seizures 
and the amount of methamphetamine seized in the 
European Union increased in 2013 compared with the 
previous year. In 2013, seizures of methamphetamine 
reported in the European Union amounted to 0.5 tons. In 
2014, the following Western and Central European coun-
tries reported seizures of amphetamine exceeding 100 kg: 
Germany (1,336 kg), the United Kingdom (1,225  kg), 
Poland (783 kg), Spain (562 kg), the Czech Republic 
(442  kg), Sweden (412 kg), Finland (298 kg), Denmark 
(292 kg) and France (268 kg). Romania reported that the 
quantity of amphetamine-type stimulants seized in 2014 
was almost 11 times greater than that seized in 2013.
696. In 2014, Austria reported the detection of three 
amphetamine and nine methamphetamine laboratories, 
while German authorities dismantled 11 amphetamine 
laboratories and three laboratories that had been manu-
facturing methamphetamine from pseudoephedrine 
extracted from nasal decongestants. In the Czech 
Republic, the number of dismantled methamphetamine 
laboratories slightly increased to 272 in 2014, compared 
with 262 laboratories dismantled in 2013. An ampheta-
mine-refining laboratory was also discovered in Sweden. 
Bulgaria continued to seize methamphetamine, 
which,  according to the Bulgarian authorities, had been 
 dispatched from the Netherlands and Turkey. It also 
 dismantled 12 clandestine laboratories producing meth-
amphetamine in 2014.
697. There was a significant increase in the smuggling 
of amphetamine and methamphetamine into the Russian 
Federation in 2014, while the smuggling of “ecstasy”-type 
substances into that country has substantially decreased. 
The Russian Federation reported that amphetamine-type 
stimulants seized by its authorities had been illicitly man-
ufactured in European Union countries, the Islamic 
Republic of Iran and China and were destined for illicit 
markets in the Russian Federation, Belarus and Kazakhstan.
698. Ukraine observed an increase in illicit home-based 
production of amphetamine-type stimulants. At the same 
time, Ukraine reported that the amphetamine seized by 
its authorities had been sourced mainly from Poland and 
Belarus and had been intended for the illicit market in 
Ukraine.
699. In Europe, illicit manufacture of “ecstasy” has for 
a number of years been associated mainly with two coun-
tries, Belgium and the Netherlands. European experts 
recently expressed concerns that high-purity “ecstasy” 
powder and tablets appearing on the European market 
had started replacing tablets that were previously being 
sold on the market as “ecstasy” but often contained only 
little or none of that substance and had consequently 
fallen out of favour with consumers on account of their 
poor quality and high adulteration.
700. Seizures of “ecstasy”-type substances in South-
Eastern Europe, while low in number compared to sei-
zures of other substances, increased in 2014 compared 
with the previous year, reaching their highest number 
since 2006.
701. Bulgaria reported that seizures of “ecstasy”-type 
substances, originating in the Netherlands and Bulgaria 
itself, increased in 2014. The trafficking of “ecstasy” via 
Bulgaria has been affected by the growing illicit markets 
in the Middle East. According to Bulgarian authorities, a 
proportion of the “ecstasy” smuggled through the coun-
try was exchanged for heroin in barter deals. In 2014, the 
country also observed an increasing trend in “ecstasy” 
trafficking via surface predominantly from the Netherlands 
via Bulgaria and Turkey along the Balkan route. In 2014, 
there were 37 seizures of “ecstasy”-type substances, a total 
of 148 kg (16,845 pills) being seized. 
702. Similarly, Moldova reported a large increase in sei-
zures of “ecstasy”-type substances in 2014, those sub-
stances having been dispatched mainly from France, 
transiting Romania before entering Moldova.
703. In 2014, seizures of “ecstasy” tablets exceeding 
100,000 units were also reported by France, Germany, 
Spain, the United Kingdom, Ireland, Finland and Greece 
(listed in descending order).
(c) Precursors
704. For several years, large-scale trafficking in APAAN, 
a pre-precursor of amphetamine and methamphetamine, 
has been of concern to drug control authorities world-
wide. In March 2014, the Commission on Narcotic Drugs 
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decided to include APAAN and its optical isomers in 
Table I of the 1988 Convention, that decision taking effect 
on 6 October 2014. In the European Union, following 
control measures implemented in member States from 
January 2014, both the number of seizures and the 
amounts of APAAN seized have decreased gradually from 
34 seizures (a total of 28.7 tons) in 2012 to 9 seizures (8.1 
tons) in 2014. In the first half of 2015, five incidents 
involving a total of 1,250 kg of the substance were 
reported.
705. In December 2013, the European Union adopted 
new control measures aimed at preventing the large-scale 
diversion of acetic anhydride from the European Union 
market. Since then, the number of attempts to divert sup-
plies from trade among European Union-based trading 
companies have decreased considerably, although they 
have not ceased altogether, as was evidenced by a seizure 
of 2.2 tons of the substance in Austria in April 2015. New 
control measures have also led traffickers to revert to 
other forms of crime to secure supplies. For example, in 
2015, the Netherlands reported that 18,000 litres of ace-
tic anhydride had been stolen during transportation 
between two companies in that country.
706. In 2014 and 2015, Belgium, Germany, the 
Netherlands and Spain reported seizures of large amounts 
of diverse “designer” precursors, derivatives of interna-
tionally controlled precursors included in Table I of the 
1988 Convention. Those seizures corroborate continued 
concerns that traffickers are attempting to trade in 
 purpose-made precursor derivatives with a view to cir-
cumventing existing precursor control mechanisms and 
using those substances in the illicit manufacture of 
amphetamine-type stimulants.42
707. In 2014, Bulgarian authorities prevented a number 
of attempts to smuggle pseudoephedrine (approximately 
500 kg in total) in the form of pharmaceutical prepara-
tions. The preparations were legally produced in Turkey 
but then trafficked via Bulgaria for use in the illicit syn-
thesis of methamphetamine in the Czech Republic and 
Poland.
708. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention.
 42 For more information, see E/INCB/2015/4.
(d) Substances not under international 
control
709. Seizure data provided by Governments and infor-
mation gathered through the European Union early warn-
ing system indicate the increased diversification and 
availability and continued proliferation of new psychoac-
tive substances in Western and Central Europe. As at 
March 2015, more than 450 new psychoactive substances 
were being monitored by EMCDDA, 101 new substances 
being reported via the European Union early warning sys-
tem for the first time during 2014. Most of those sub-
stances were synthetic cathinones (31 substances)—often 
sold as replacements for “ecstasy”, amphetamine and 
cocaine—and synthetic cannabinoids (30 substances), 
which are sold as replacements for cannabis.
710. Seizures of new psychoactive substances increased 
seven-fold across Europe between 2008 and 2013. In 
2013, some 47,000 seizures of new psychoactive sub-
stances—a total of more than 3.1 tons—were reported by 
the 28 European Union member States, Norway and 
Turkey, including 21,500 seizures of synthetic cannabi-
noids (almost 1.6 tons) and 10,700 seizures of synthetic 
cathinones (more than 1.1 tons). Seizures of synthetic 
cannabinoids have risen sharply since 2011.
711. In 2014, the Romanian authorities reported sei-
zures of 5 kg of tryptamines and 75 kg of khat (Catha 
edulis). Nineteen incidents involving seizures of dried 
khat amounting to 664 kg were also reported by Bulgarian 
customs authorities in 2014. The khat seized in Bulgaria 
originated in Kenya and Uganda.
712. Many of the new psychoactive substances that were 
destined for European markets were reported to have 
been manufactured, in bulk, by chemical companies 
established in China and India and shipped to Europe by 
air freight, where they were processed, packaged and then 
sold to consumers. In 2013, EMCDDA identified more 
than 600 websites selling new psychoactive substances to 
consumers in the European Union.
5. Abuse and treatment
713. Drug abuse is one of the major causes of mortal-
ity among European youth, both directly through over-
dose and indirectly through drug-related diseases, 
accidents, violence and suicide. Every year in the European 
Union, more than 6,000 drug users die as a result of over-
dose, most of those cases involving opioids. According to 
a recent EMCDDA paper entitled “Mortality among drug 
users in Europe: new and old challenges for public health”, 
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published in 2015, the risk of death among problem drug 
users is at least 10 times higher than that among their 
peers in the general population.
714. Almost a quarter of the adult population in the 
European Union, or over 80 million adults, have tried 
illicit drugs at least once in their lives. The most com-
monly used drug in the European Union (according to 
past-year prevalence among adults between 15 and 64 
years of age) is cannabis (19.3 million), followed by 
cocaine (3.4 million), “ecstasy” (2.1 million) and amphet-
amines (1.6 million). Denmark, France and the United 
Kingdom are among the European Union countries with 
the highest lifetime prevalence of drug abuse among the 
general population.
715. According to an EMCDDA report entitled “Drug 
use and its consequences in the Western Balkans 2006-
14”, the lifetime prevalence of illicit drug use among the 
general population in the Western Balkan region appears 
to be lower than the European average. There are no 
marked differences between the Western Balkan countries 
with respect to lifetime prevalence of drug abuse among 
school students aged 15-16 years, all estimates of lifetime 
illicit drug use falling between 4 per cent and 8 per cent, 
which is 2.5 times lower than the European average. The 
drug most commonly used is cannabis, between 2 per 
cent and 8 per cent of those surveyed reporting lifetime 
cannabis use—a range considerably lower than the 17 per 
cent European average.
716. The relatively high annual prevalence of cannabis 
abuse (5.7 per cent) among the general population in 
Western and Central Europe has stabilized or in some 
cases decreased, in particular in countries where canna-
bis consumption is long-established. It is not clear, how-
ever, whether that decrease could be linked to the 
emerging use of synthetic cannabinoids or other new psy-
choactive substances.
717. The overall number of first-time treatment admis-
sions for cannabis abuse in the European Union increased 
from 45,000 to 61,000 between 2006 and 2013. The 
increase in demand for cannabis abuse treatment, how-
ever, has to be understood in the context of service pro-
vision and referral practice. For example, in some 
countries, direct referrals from the criminal justice system 
account for a high proportion of treatment admissions.
718. The abuse of heroin and synthetic opioids remains 
relatively low in the European Union. The average annual 
prevalence of opioid use, mainly of heroin, among the 
general population between 15 and 64 years of age was 
estimated at about 0.4 per cent. Nonetheless, opioids 
continue to be the drugs associated with the greatest pro-
portion of morbidity, mortality and treatment costs relat-
ing to drug abuse in the region.
719. In 2013, opioids were the primary drug of abuse 
for 41 per cent of all those receiving drug abuse treat-
ment in Western and Central Europe. While the number 
of new first-time treatment admissions for heroin abuse 
has more than halved from a peak of 59,000 in 2007 to 
23,000 in 2013, the consumption of opioids other than 
heroin raises concerns. Eleven countries in Western and 
Central Europe reported that more than 10 per cent of 
all opioid users who received drug abuse treatment in 
2013 were treated for problems primarily related to opi-
oids other than heroin.
720. The high prevalence of opioid abuse in Eastern 
Europe overall is mainly due to high levels of such abuse 
in the Russian Federation and Ukraine: an estimated 2.4 
million persons, representing a prevalence rate of 2.3 per 
cent. According to the World Drug Report 2015, the pro-
portion of persons in treatment for opioid abuse in Eastern 
Europe continues to be high, which reflects the extent of 
problem opioid abuse, particularly problem abuse of her-
oin, in the subregion. Ukraine reported that more than 
25,000 persons received drug treatment for opioid abuse 
in 2014. Also of concern is the reported suspension of opi-
oid substitution treatment in the Autonomous Republic of 
Crimea and the city of Sevastopol43 since March 2014, 
which reportedly has had serious consequences on the 
patients who were receiving such treatment.
721. Worldwide, the highest prevalence rates of persons 
who inject drugs continue to be found in Eastern and 
South-Eastern Europe. Approximately 40 per cent of the 
estimated global number of persons who abuse drugs by 
injection and are living with HIV reside in Eastern and 
South-Eastern Europe. For example, Ukraine reported a 
prevalence rate of HIV infection of 6.7 per cent among 
injecting drug users. According to WHO, the Russian 
Federation and Ukraine have rates of mortality due to 
HIV/AIDS of over 40 per 100,000 population. According 
to the European Centre for Disease Prevention and 
Control, 18 countries benefited from the 45 million dol-
lars in aid that was provided by the European Commission 
to support national responses to HIV in the European 
Union and in European Neighbourhood Policy countries 
and the Russian Federation; of which the largest amount 
was allocated for Ukraine and the Russian Federation. 
There have also been epidemics of hepatitis C among per-
sons who inject drugs in the Western Balkans, where the 
 43 In accordance with General Assembly resolution 68/262 on the 
territorial integrity of Ukraine.
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prevalence of that virus ranges from 12 per cent to more 
than 77 per cent.
722. Overall, the cocaine market in the European Union 
remained stable in 2013. The annual prevalence of cocaine 
abuse among the general population aged 15-64 remained 
high, at around 1 per cent, in Western and Central 
Europe. In some countries with high levels of abuse, such 
as Denmark, Italy and Spain, the prevalence of cocaine 
abuse has decreased since 2008. The demand for treat-
ment for cocaine abuse in the region indicates an overall 
declining trend.
723. In many countries of Western and Central Europe, 
the abuse of amphetamines remained stable. EMCDDA 
estimates that 1.3 million (1.0 per cent) of young adults 
between 15 and 34 years of age have used amphetamine or 
methamphetamine in the past year. Methamphetamine 
abuse was predominant in the Czech Republic and, more 
recently, Slovakia, although there are also indications of 
increasing abuse of the substance in other countries. 
Between 2007 and 2013, the Czech authorities observed an 
increasing prevalence of high-risk methamphetamine 
abuse, including by injection. In 2014, an increase in 
amphetamine abuse was reported by Germany while stable 
or decreasing trends in amphetamine abuse were reported 
by Cyprus, Finland, Portugal and the United Kingdom.
724. It is estimated that some 1.8 million Western and 
Central European young adults between 15 and 34 years 
of age have used “ecstasy” in the past year. In 2014, a slight 
increase in “ecstasy” abuse was reported by Finland and 
Germany, while stable or decreasing trends were reported 
by Lithuania, Portugal and the United Kingdom. The 
demand for treatment for “ecstasy” abuse is not very high 
in Western and Eastern Europe, accounting for less than 
1 per cent of reported first-time treatment entrants in 2013.
725. For a number of years the prevalence rates of hal-
lucinogenic mushroom and LSD abuse in Europe have 
been low and stable; according to the latest national sur-
veys, the past-year prevalence of abuse of both substances 
was estimated to be less than 1 per cent among young 
adults between 15 and 34 years of age.
726. Overall, estimating the prevalence of abuse of new 
psychoactive substances remains a challenge. A Flash 
Eurobarometer survey conducted in 2014, entitled “Young 
people and drugs”, showed that 8 per cent of 13,000 
respondents between the ages of 15 and 24 in the European 
Union member States had used a new psychoactive sub-
stance at least once in their lives, compared to 5 per cent 
in 2011, 3 per cent having used the substance in the past 
year. The highest levels of past-year prevalence of use were 
recorded in Ireland (9 per cent), Spain (8 per cent), France 
(8 per cent) and Slovenia (7 per cent).
727. Belarus reported that, in 2014, the number of indi-
viduals abusing cannabinoids increased by 9 per cent, 
mainly as a result of the increase in the number of per-
sons using synthetic cannabinoids compared to the pre-
vious year. The main trend of 2014 was a significant 
increase in the number of persons abusing new psycho-
active substances, mostly synthetic cannabinoids, and 
other psychoactive substances.
728. The number of persons who abuse drugs by injec-
tion residing in Eastern and South-Eastern Europe is esti-
mated to be 2.91 million, which is 24 per cent of the global 
total number of persons who abuse drugs by injection. 
729. The World Drug Report 2015 suggests that in 
Eastern and South-Eastern Europe, 1.27 per cent of the 
general population aged 15-64 years is estimated to use 
drugs by injection, a rate nearly five times the global aver-
age. The estimate for Eastern Europe is heavily influenced 
by the high prevalence of drug abuse by injection in the 
Russian Federation (2.29 per cent of the population aged 
15-64 years). This high level of drug abuse continued to 
constitute a challenge to public health in the Russian 
Federation, despite a trend towards a stabilization of the 
situation. According to the State Anti-Drug Committee 
of the Russian Federation, in recent years the number of 
individuals abusing narcotic drugs and psychotropic sub-
stances has reached about 6 per cent of the country’s pop-
ulation, or 8 million to 8.5 million people.
730. According to the EMCDDA report “Perspectives 
on drugs: injection of synthetic cathinones”, the abuse of 
synthetic cathinones by injection has emerged among 
high-risk drug abusers in Austria, Belgium, the Czech 
Republic, France, Germany, Ireland, Poland, Romania, 
Spain and the United Kingdom, but is considered to be 
a relatively low-level and localized phenomenon.
E. Oceania
1. Major developments
731. The region of Oceania is vulnerable to the traffick-
ing, manufacture and abuse of a wide range of drugs, with 
countries reporting significant seizures of many sub-
stances, including cocaine, heroin, MDMA (“ecstasy”), 
and precursor chemicals. Cannabis continues to be the 
most trafficked and abused drug in the region, mainly 
due to domestic cultivation.
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732. In its reporting period from July 2013 to June 2014, 
Australia recorded 93,000 drug seizures weighing more 
than 27 tons in total, the highest numbers on national 
record. Police and customs seizures of amphetamine-type 
stimulants in the country were also the highest on record. 
In 2014, New Zealand saw marked increases in seizures 
of certain substances, including cocaine. Countries in the 
region continue to focus on taking action to improve 
regional border security and the sharing of information 
on the flows and transhipments of drugs.
733. Although cannabis is the most widely abused drug, 
amphetamine-type stimulants, particularly methamphet-
amine, pose a serious threat to the countries of Oceania. 
The region has also seen strong increases in the abuse of 
new psychoactive substances. The role of regional joint 
operations has been critical to the success of large meth-
amphetamine seizures.
2. Regional cooperation
734. The Oceania Customs Organization held its seven-
teenth annual conference in Koror, Palau, in June 2015, at 
which it addressed the region’s border security challenges. 
The keynote address was delivered by the President of 
Palau, who spoke about the importance of coordinating 
efforts to secure national borders. Coordination was neces-
sary, given the Pacific Ocean’s usefulness as a route for drug 
trafficking. The members adopted a three-year plan for the 
period 2015-2017, which sets out the strategic direction of 
the Organization and helps members’ administrations to 
align their activities with the best international customs 
standards and practices, in order to foster greater economic 
prosperity and increased border security.
735. In June 2015, the annual meeting of the Regional 
Security Committee of the Pacific Islands Forum was held 
in Suva. The Forum is a political group of States that 
works to promote regional cooperation and integration 
in the Pacific region. Also in June 2015, the Forum’s 
Working Group on Counter-Terrorism and Transnational 
Crime held a meeting for members to discuss trends in 
and patterns of transnational crime, including illicit drug 
trafficking in the region.
736. In December 2014, in Auckland, New Zealand, the 
UNODC Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) programme and the Pacific Islands Forum 
secretariat jointly hosted a forensic capacity-building train-
ing session that brought together law enforcement officials 
from the Cook Islands, Fiji, Niue, Palau, Papua New Guinea, 
the Marshall Islands, Samoa, Solomon Islands, Tonga and 
Vanuatu. The workshop included interactive and practical 
sessions at which participants learned about methods for 
identifying drugs and precursors.
737. A major regional achievement has been the com-
pletion and opening of a narcotics laboratory on the 
premises of the Scientific Research Organization of Samoa 
in late July 2013, and the subsequent training sessions, in 
2014 and 2015 for Samoan scientists in New Zealand. The 
training sessions, which focused on examining cannabis 
and using equipment for testing drugs, was led by the 
Institute of Environmental Science and Research and the 
University of the South Pacific. This regional project 
makes the investigation and prosecution of narcotics-
related offences more efficient and has continued in 2015 
with the aim of developing testing methods for other 
drugs such as methamphetamine.
738. The 2014 Pacific Islands Chiefs of Police Conference 
was held in Auckland, New Zealand. National police ser-
vices of the Pacific island countries gathered to agree on 
a new strategic plan and to discuss regional issues, includ-
ing illicit drugs and organized crime. In August 2015, the 
organization’s forty-fourth annual conference was held in 
Alofi and hosted by the Niue Police Department.
3. National legislation, policy and 
action
739. On 5 March 2015, Australia adopted the Crimes 
Legislation Amendment (Psychoactive Substances and 
Other Measures) Act No. 12. The Amendment lays down 
measures to help the Government respond to new and 
emerging psychoactive substances by banning the impor-
tation of all substances, not banned or otherwise regulated, 
that have a psychoactive effect. The Amendment helps to 
ensure that new psychoactive substances cannot be 
imported until the Government has assessed their poten-
tial harmful effects and determined the appropriate con-
trols to be applied. To prosecute an offence under the law, 
it will not be necessary to prove that a defendant knew or 
was reckless as to the particular identity of a substance or 
whether the substance had a particular psychoactive effect.
740. New Zealand has released its national drug policy 
for the period 2015-2020, which sets out the Government’s 
approach to alcohol and drug issues. The aim of the pol-
icy is to minimize harm and promote and protect health 
and well-being. Harm minimization will be a central fea-
ture of drug classification measures, and the regulation of 
controlled drugs for legitimate purposes will be reviewed. 
In the period 2017/18, New Zealand will commence a 
review of the policy and operation of the Psychoactive 
Substance Act 2013. An ongoing feature of the Government’s 
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actions will be to conduct the national cannabis and crime 
operation as well as to work with authorities in source and 
transit countries to break supply chains into New Zealand 
for precursor chemicals and drugs.
741. In 2014, New Zealand announced that its drug 
enforcement relationship with China will be strengthened 
further to help identify members of organized criminal 
groups in China and to reduce the supply of precursors 
and methamphetamine from China trafficked into New 
Zealand. The move follows the signing of a memorandum 
of arrangement on precursor controls between China and 
New Zealand in April 2013.
742. New Zealand has also taken action to improve 
regional border security through cooperation with the 
authorities of Fiji. In 2015, New Zealand established a 
training programme for the Fiji Revenue and Customs 
Authority and the Fiji Police Force to focus on border 
security by introducing drug detector dogs in Fiji. In 
2015, the Fiji Revenue and Customs Authority announced 
that it aimed to further strengthen its partnership with 
both Australia and New Zealand in order to carry out 
joint operations and share more information about the 
flow of drugs in the region.
743. In 2013, the Government of New Zealand intro-
duced the Psychoactive Substances Act to control the 
importation, manufacture and sale of new psychoactive 
substances in the country—with interim approvals for 47 
products by 150 licensed retailers. In 2014, an amend-
ment Act came into effect that banned the use of animal 
testing in clinical trials, effectively bringing the industry 
and product development to a standstill. Retail regula-
tions due to come into force in November 2015 would 
allow for the licensing of the sale, both wholesale and 
retail, of psychoactive substances, and the licensing of 
retail premises. As of 1 June 2015, approximately 37 local 
authorities had adopted local approved product policies, 
which provided directions about where psychoactive 
products may be sold in a particular area. 
4. Cultivation, production, 
manufacture and trafficking
(a) Narcotic drugs
744. Cannabis is the most trafficked and widely abused 
drug throughout Oceania. The Australian Crime Commission 
has reported that, despite illicit domestic cultivation, the 
quantity of cannabis seized at the border in the 2013/14 
reporting period was the highest in the past decade. In 2014, 
the number of cannabis seizures in New Zealand remained 
about the same as in 2013, with approximately 4,800 
instances of cannabis herb being seized. However, at the 
fifty-eighth session of the Commission on Narcotic Drugs, 
held in March 2015, New Zealand authorities stated that the 
previous 18 months had seen a resurgence in the visibility 
of cannabis. Data from the region also indicate that the 
potency of the available cannabis may be increasing.
745. Oceania in general, and Fiji, Papua New Guinea, 
Samoa, Tonga and Vanuatu in particular, continue to be 
used as illicit transit areas for various narcotic drugs. In 
December 2014, for example, the Fiji Police Force reported 
a significant heroin seizure worth around $15 million. The 
Force believed that the consignment was intended for 
onward trafficking to Australia or New Zealand.
746. Although the market for cocaine and heroin in 
Oceania remains limited, there are signs that trafficking 
in some countries may be increasing. Moreover, Oceania 
is considered a hub for the transhipment of cocaine. In 
2014, New Zealand saw increases in both the quantity and 
the frequency of seizures of cocaine and heroin. 
Approximately 80 per cent of cocaine that was seized 
entered New Zealand by air, with about 59 per cent of 
that amount entering from Brazil. Therefore, in 2014, the 
cocaine market appeared to be expanding in New Zealand, 
with seizures more than doubling over 2013. The abuse of 
cocaine in New Zealand also has the potential to increase, 
at least partly because of the high market prices and profit 
margins, which can be an incentive for traffickers.
747. In Australia, one of the key findings in the 2013/14 
reporting period was that the cocaine seized at the coun-
try’s border had primarily come from Peru. Previously, 
the primary source country had been Colombia. 
Furthermore, for the first time an incident of heroin 
seized at the Australian border was identified as having 
originated in South America. Australia reported 3,121 
domestic seizures of cocaine in the period 2013/14, a 
record number, although the total weight of the seizures 
had decreased by 70 per cent. While the number of sei-
zures at the border had increased every year since 
2009/10, in 2013/14 both the weight and number of bor-
der seizures of cocaine decreased.
(b) Psychotropic substances
748. In response to the increasing threats and regional 
interconnections in the methamphetamine market, as well 
as extensive domestic manufacture in some  countries of 
the region, New Zealand continues to implement its multi-
agency initiative entitled “Tackling methamphetamine: an 
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action plan”, which has helped to improve resource tar-
geting and thereby to gather more accurate data on meth-
amphetamine abuse and trafficking. The increase in 
smuggling of small amounts of methamphetamine in 
2014 may have occurred in response to increased law 
enforcement pressure on the diversion of precursors and 
on clandestine laboratories.
749. The Fiji Revenue and Customs Authority has 
emphasized the role of joint regional operations in large 
methamphetamine seizures. For example, in July 2015, a 
sea container sent from South America to Fiji contained 
80 kg of methamphetamine and was intercepted in a joint 
operation of Australia, New Zealand and Fiji. 
750. The Australian Crime Commission has also deter-
mined that, of all drug types, methamphetamine poses 
the greatest threat to the Australian public because of its 
increasing purity and the involvement of organized crim-
inal groups. In its 2013/14 report, the Australian Customs 
and Border Protection Service asserted that seizures of 
amphetamine-type stimulants had increased by nearly 
19 per cent from the previous year. Most of the amphet-
amine-type stimulants were detected in cargo and in 
postal consignments. In the 2014/15 reporting period, the 
Service maintained its focus on detecting and seizing 
amphetamine-type stimulants in postal consignments, 
while the country’s law enforcement authorities expressed 
concern about the potential for transnational organized 
criminal groups to exploit the market for synthetic drugs.
751. In 2014, law enforcement authorities in Australia 
reported “ecstasy” seizures of several tons each. The 
Australian Crime Commission indicated that a seizure of 
almost two tons made in November 2014 was indicative 
of the resurgence of the “ecstasy” market in both the 
country and the region. The Ecstasy and Related Drugs 
Reporting System reported that in 2014 the availability of 
“ecstasy” pills, powder, and capsules appeared to have 
increased significantly from 2013. In 2013, amphetamine-
type stimulants, particularly methamphetamine, were the 
most detected drug at the Australian border.
(c) Precursors
752. Strong demand for methamphetamine in the region 
and the involvement of organized crime in its manufacture 
have had the result that the majority of precursors seized 
have been pseudoephedrine and ephedrine. The Australian 
Crime Commission has reported that China and India are 
the primary source countries of several precursor chemi-
cals but that precursors are also diverted from licit domes-
tic trade. In the period 2013/14, the number of clandestine 
laboratories detected nationally decreased to 744 compared 
with 757 in the period 2012/13, and although that was the 
third highest number on record, it is not indicative of abuse 
rates or availability. Methamphetamine was nevertheless 
the main drug produced in laboratories detected. Australia 
also saw a 10-ton seizure of benzaldehyde, a precursor used 
to produce methamphetamine. There were 1,035 detections 
of amphetamine-type stimulants precursors in the period 
2013/14, a slight decrease from the detections in the pre-
vious reporting period.
753. New Zealand has reported that although it still sees 
a large amount of pseudoephedrine, it appears that ephed-
rine is now the precursor preferred by traffickers. 
Ephedrine continues to be the main precursor seized at 
the border. Seizures of those substances were on the 
decline for a couple of years, but the amounts seized in 
2013 were significantly higher, attributable to intercep-
tions of ContacNT and ephedrine by the Organised and 
Financial Crime Agency of New Zealand and customs 
officers during Operation Ghost in 2013. However, New 
Zealand saw more finished methamphetamine trafficked 
in 2014, possibly in response to increased law enforce-
ment pressure on precursor imports and on domestic 
clandestine laboratories.
754. Although increasing methamphetamine abuse is of 
concern throughout the Pacific island States and territo-
ries, there is insufficient data region-wide on trafficking, 
transhipment and seizures of precursors and substances 
listed in Tables I and II of the 1988 Convention. 
Information on diversion of chemicals is limited despite 
the actions of transnational organized criminal groups in 
the region of Oceania. Moreover, only 1 of 16 countries 
in the region submitted form D (annual information on 
substances frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances) for 2014 to 
the Board by the annual reporting deadline of 30 June, 
thus affecting the Board’s ability to analyse regional pre-
cursor trends and patterns.
755. A comprehensive review of the situation with 
respect to the control of precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances in the region can be found 
in the report of the Board for 2015 on the implementa-
tion of article 12 of the 1988 Convention.
(d) Substances not under international 
control
756. New Zealand has reported that it continues to see 
new psychoactive substances, including a large number of 
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synthetic cannabinoids and other substances. Detected 
blotter paper increasingly contains new substances and not 
the more commonly abused substances such as lysergic 
acid diethylamide, making them significantly cheaper for 
consumers. At the fifty-eighth session of the Commission 
on Narcotic Drugs, New Zealand reiterated that the pres-
ence of new synthetic psychoactive substances necessitated 
changes to national legislation in 2013 and 2014 in order 
to address the widespread availability and constantly 
changing composition of those substances. Drug analogues 
and new psychoactive substances also continue to increase 
in availability and popularity in Australia. The number of 
seizures of these substances in Australia in the period 
2013/14 increased by more than 64 per cent from the pre-
vious period, comprising synthetic cannabinoids, synthetic 
cathinones and different NBOMe compounds. 
5. Abuse and treatment
757. Data on the extent and patterns of abuse of most 
drugs, as well as treatment figures and therapeutic 
options, remain limited throughout most of Oceania. 
Governments are encouraged to increase data collection 
on the prevalence of abuse and availability of treatment 
options as part of the region’s approach to drug abuse as 
a serious public health issue.
758. As the Board has previously noted, the high prev-
alence of abuse of cannabis remains stable throughout the 
region; however, data on its abuse are generally limited 
to Australia and New Zealand. In the latter country, data 
from the 2012/13 survey indicated that 11 per cent of 
adults aged 15 years and over had reported using canna-
bis in the previous 12 months, while 34 per cent of peo-
ple abusing cannabis had reported consumption of the 
drug at least weekly in the previous 12 months. In New 
Zealand, the 2012/13 survey indicated that past-year 
abuse of amphetamines, including methamphetamine, 
among adults aged 16-64 years was 0.9 per cent, which 
was roughly the same as prevalence found by the 2011/12 
survey. However, rates of amphetamine abuse appeared 
to have declined since 2003, when the past-year preva-
lence rate was 2.7 per cent. 
759. The National Drug and Alcohol Research Centre 
of Australia has released reports showing that deaths 
involving methamphetamine have been steadily increas-
ing since 2010 and that abuse of methamphetamine 
among injecting drug users has increased by 52 per cent 
over the past 10 years. With respect to opioid drugs, the 
Australian Institute of Health and Welfare has indicated 
that heroin is the most common opioid drug of abuse 
leading to treatment, with the number of people receiv-
ing treatment for opioid dependence almost doubling 
between 1998 and 2014. Survey data published by the 
Institute in 2014 show that about 3.3 per cent of 
Australians aged 14 years or older had used painkillers/
analgesics for non-medical reasons in the previous 12 
months, and 1.2 per cent had used heroin at least once 
in their lifetime.
760. The Australian Crime Commission has stated that 
the order of prevalence of drug abuse in the country is 
cannabis, MDMA and then methamphetamine—with the 
prevalence of abuse for all illicit substances remaining sta-
ble during the period 2010-2013. The 2013 National Drug 
Strategy Household Survey in Australia showed that 7 per 
cent of the Australian population aged 14 years or older 
reported abusing amphetamine or methamphetamine at 
least once in their lifetime. Recent analyses of waste water 
compared with household survey data, however, have 
indicated that in regions of Australia methamphetamine 
was potentially abused to a much greater extent than sug-
gested by household surveys alone. Treatment data in 
Australia generally show that people aged 20-29 years 
have the highest rates of acute and chronic harm related 
to amphetamine and methamphetamine abuse. The pro-
portion of recent methamphetamine abusers that abused 
crystal methamphetamine increased from 22 per cent in 
2010 to 50 per cent in 2013, along with the tripling, since 
2010, in the level of purity of methamphetamine detected 
in some Australian jurisdictions.
761. In New Zealand, it was reported that in 2014 more 
than 41,000 people received drug abuse treatment for 
substances other than alcohol or tobacco, and that more 
than 37 per cent of those people were entering treatment 
for the first time. It is estimated that about 20,000 peo-
ple inject drugs in New Zealand, and that 10 per cent of 
those injecting drug abusers had shared needles at the 
time they last injected. New Zealand has also indicated 
that as many as 57 per cent of injecting drug users are 
infected with hepatitis C and 20 per cent with hepatitis 
B due to drug abuse at some time in their past.
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Chapter IV.
Recommendations to Governments, 
the United Nations and other relevant 
international and national organizations
762. The following paragraphs contain the most signi-
ficant observations contained in the present report and a 
number of related recommendations. The Board invites 
Governments and international organizations to provide 
it with any feedback and information they consider rele-
vant regarding their achievements and difficulties in 
implementing these recommendations and the recom-
mendations of previous years in fulfilling their obligations 
under the international drug control treaties.
Health and welfare as the main 
objectives of the international drug 
control treaties
Special session of the General 
Assembly on the world drug problem
763. States parties have made important strides towards 
implementing more cohesive and coherent drug control 
strategies as envisioned in the Conventions. However, the 
evolving nature of the complex social problem of drug 
abuse, drug trafficking and illicit drug cultivation and pro-
duction requires that Governments be cognizant of the 
challenges and opportunities facing them. The special ses-
sion of the General Assembly on the world drug problem 
to be held in 2016 is a timely opportunity to review drug 
control policies and practices grounded in evidence and 
science and based upon the principle of shared responsi-
bility and a comprehensive, integrated and balanced 
approach. The international drug control system should 
promote the application of scientific knowledge, respect for 
human rights and the principle of proportionality in deal-
ing with the set of problems related to drugs. Legalization 
of the use of internationally controlled narcotic drugs and 
psychotropic substances for non-medical purposes is not 
an adequate response to the existing challenges.
Recommendation 1: INCB recommends that States ap proach 
the review to be undertaken through the special session 
of the General Assembly with the goal of reinforcing best 
practices, while modifying measures that have not worked 
and expanding the options used to cope with new drugs, 
social developments, the use of the Internet for illicit 
 purposes and money-laundering. 
764. Strong communities with rich economic potential 
are more capable of withstanding the corrupting influ-
ence of illicit crop cultivation or drug dealing. Poverty 
reduction measures within a framework for sustainable 
development that give farmers an economically viable, 
legal alternative to growing illicit crops are of fundamen-
tal importance for the success of the efforts to reduce 
illicit cultivation. 
Recommendation 2: States should promote alternative live-
lihood programmes in order to support communities and 
provide farmers engaged in illicit drug crop cultivation 
with licit and sustainable income-generating activities that 
can reduce and eliminate their dependency on income 
from that illicit crop cultivation. Such programmes 
include, inter alia, services related to health, education, 
infrastructure, community development and security.
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Demand reduction
765. States are reminded of their obligation to imple-
ment effective drug abuse prevention, treatment and 
rehabilitation programmes.
Recommendation 3: Prevention of substance abuse in 
society at large, particularly among the youth, should 
remain the prime objective of government action. Such 
action is not limited to drug-specific policies: anything 
that strengthens social cohesion and individuals’ capacity 
for self-determination and resilience can reduce the prev-
alence of drug abuse. Reducing the adverse health and 
social consequences of drug abuse is an essential element 
of a comprehensive demand reduction strategy. States 
should provide effective and humane assistance to people 
affected by drug abuse, including both medically appro-
priate and evidence-based treatment. States should ensure 
that sanctions for drug-related criminal offences are 
 proportionate and, where such offences are committed by 
drug users, consider alternatives to conviction and 
 punishment as provided for in the treaties, such as treat-
ment, education, after-care, rehabilitation and social 
reintegration.
Availability
766. The international drug control system, as established 
by the conventions and built upon in the relevant political 
declarations, provides a comprehensive framework for 
ensuring the proper provision of narcotic drugs and psy-
chotropic substances to reduce pain and suffering while 
preventing their diversion into illicit use. However, about 
75 per cent of the world population still has limited or no 
access to proper pain relief treatment. The supplement to 
the present report, Availability of Internationally Controlled 
Drugs: Ensuring Adequate Access for Medical and Scientific 
Purposes, demonstrates that the availability of internation-
ally controlled drugs can be—and has been—improved 
within the framework of the international conventions.
Recommendation 4: Striking a balance between overpre-
scribing and underprescribing requires continuous study 
and an ongoing review of policies. Drug abuse should 
and will remain a concern for society as a whole, includ-
ing those in the medical profession and public health offi-
cials. Adequate access to narcotic drugs and psychotropic 
substances for medical purposes can be improved through 
corrective action by States that should address the regu-
latory, attitudinal, knowledge-related, economic and pro-
curement-related aspects identified as the causes of 
inadequate availability. The Board urges Member States 
to implement the recommendations made in the above-
mentioned supplementary report on the availability of 
internationally controlled drugs.
International Import and Export 
Authorization System 
767. As part of its endeavours to ensure effective and effi-
cient implementation of the import and export authoriza-
tion system for licit international trade in narcotic drugs 
and psychotropic substances, the Board developed the 
International Import and Export Authorization System 
(I2ES). I2ES is an electronic platform that allows 
Governments to electronically generate import and export 
authorizations for narcotic drugs and psychotropic sub-
stances, to exchange those authorizations in real time and 
to instantly verify the legitimacy of individual transactions 
while ensuring full compliance with the requirements of 
the conventions. The system significantly reduces the risk 
of drug consignments being diverted into illicit channels.
Recommendation 5: The Board urges all competent 
national authorities that have not yet done so to register 
and start using I2ES as soon as possible, as only through 
its widespread application will Governments be able to 
avail themselves of all the advantages that the tool can 
provide. The Board reiterates the call made to Member 
States by the Commission on Narcotic Drugs, in its res-
olution 58/10, to provide the fullest possible financial sup-
port to enable the secretariat of the Board to continue 
administering and monitoring the System.
Psychotropic substances
768. The status of control in some countries for many 
psychotropic substances included in Schedules II, III and 
IV of the 1971 Convention remains unknown. 
Recommendation 6: The Board reiterates its call for 
Governments to review their laws and regulations to ver-
ify that they are fully in line with all the relevant provi-
sions of the 1971 Convention and relevant resolutions of 
the Economic and Social Council. The Board reminds the 
Governments concerned of the treaty requirement of 
issuing import/export authorizations for Schedule II sub-
stances, and calls on them to submit the missing infor-
mation regarding their national control over Schedules 
III and IV substances, in particular in view of the recent 
scheduling of six new substances and the change in the 
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scope of control of GHB, which was transferred from 
Schedule IV to Schedule II of the Convention in 2013.44
769. The widespread prescription of benzodiazepines 
and unwarranted treatment, particularly among older 
people, with sedative-hypnotics and anxiolytics carries 
the risk of overuse of pharmaceutical preparations con-
taining those substances and the resulting adverse and 
toxic reactions. 
Recommendation 7: The Board calls on all Governments 
to remain vigilant to the consequences of misuse and over-
use of benzodiazepines, particularly among older patients. 
Governments are urged to closely monitor the consump-
tion levels of benzodiazepines and ensure that they are 
prescribed in accordance with sound medical practices 
and in line with the rational use of psychoactive drugs.
Precursors
770. Since the entry into force of the 1988 Convention, 
States have succeeded in substantively reducing the diver-
sion of scheduled substances from international trade into 
illicit drug manufacture. To further support the monitor-
ing of the licit trade in precursor chemicals and to pre-
vent their diversion into illicit channels, INCB has 
developed electronic tools such as Pre-Export Notification 
Online (PEN Online) and the Precursors Incident 
Communication System (PICS). 
Recommendation 8: All Governments are urged to make 
use of PEN Online and PICS to improve monitoring of 
the international trade in precursors and to exchange 
intelligence on related illicit activities in real time. 
771. Insufficient attention has been given to national 
controls and the monitoring of domestic movements and 
the end use of precursor chemicals. Further challenges 
today are the emergence of non-scheduled substitute 
chemicals, including “designer precursors”, and the 
increase in the sophistication, diversification and scale of 
illicit synthetic drug manufacturing operations. States 
have a shared responsibility to adopt a forward-looking 
strategy that addresses the limitations of the existing sys-
tem, mainly in relation to non-scheduled chemicals. 
Recommendation 9: In view of new developments, 
Governments should take the following set of actions: 
 (a) Use the opportunity provided by the special ses-
sion of the General Assembly on the world drug 
 44 Commission on Narcotic Drugs decision 56/1.
problem to reconfirm the importance of precursor con-
trol as a preventive component in a balanced drug con-
trol strategy; 
 (b) Make industry a critical partner in the preven-
tion of chemical diversion and formalize the commitment 
to such partnerships;
 (c) Review the effectiveness of national regulatory 
control systems and work to close any gaps in those 
domestic systems; 
 (d) Ensure that law enforcement authorities inves-
tigate seizures, stopped shipments and attempted diver-
sions in order to identify the sources of diversion and the 
criminal organizations behind those activities, and share 
their findings globally to prevent future diversions using 
similar modi operandi.
New psychoactive substances 
772. INCB notes the cooperation between WHO and 
UNODC to establish criteria for prioritizing new psycho-
active substances that should be the subject of scrutiny 
for possible review and consideration for possible inter-
national control. In addition to scheduling at the inter-
national level, countries continue to bring new psychoactive 
substances under national control. New psychoactive sub-
stances have also been the subject of an increasing num-
ber of meetings and conferences worldwide; however, 
effective strategies are still forthcoming. The challenges 
posed by those substances and the diversification of the 
abuse market continue to grow, with a rising number of 
reports about new psychoactive substances as the cause 
of hospital emergency admissions and deaths. 
Recommendation 10: INCB encourages all Governments 
to build on relevant resolutions of the Economic and 
Social Council and the Commission on Narcotic Drugs, 
regional experiences and the experiences of individual 
Member States, and use the upcoming special session of 
the General Assembly to explore and devise regulatory, 
practical and realistic measures to protect individuals and 
the public at large from the harmful effects of new psy-
choactive substances. INCB also urges all Governments 
to make full use of the global focal point network Project 
Ion and the related incident communication platform 
(IONICS), which support operational cooperation among 
Governments with a view to preventing new psychoac-
tive substances from reaching markets of drug abuse. 
INCB also reiterates the importance of primary preven-
tion in addressing the challenge posed by new psychoac-
tive substances.
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Promoting the consistent application of 
the international drug control treaties
773. Africa continues to be one of the world’s major 
drug trafficking hubs. While West Africa has tradition-
ally been used to traffic drugs, such as cocaine, to Europe, 
the subregion has also been identified as a source of 
amphetamine-type stimulants. Furthermore, East Africa’s 
prominence as a transit region for Afghan heroin has 
increased. Recent developments on the continent have 
also included a rise in domestic drug abuse in some coun-
tries, particularly among youth.
Recommendation 11: The Board requests Governments to 
enhance regional cooperation and the sharing of infor-
mation in an effort to target established and emerging 
trafficking routes, bolster security throughout the region 
and combat the rise of drug abuse.
774. The rates of intravenous drug abuse in Eastern 
Europe have not abated and now stand at almost five 
times the global average. According to UNAIDS, one 
third of global population infected with AIDS who con-
tracted the virus due to injecting drug use reside in that 
subregion. 
Recommendation 12: The Board recommends the imple-
mentation by Governments in the region of prevention 
mechanisms to dissuade individuals from engaging in 
intravenous drug abuse. Treatment facilities for sufferers 
of drug-related diseases should also be provided, in addi-
tion to comprehensive rehabilitation programmes 
designed to facilitate the cessation of drug abuse, recov-
ery and the social reintegration of drug abusers into 
society.
775. The Board notes the measures taken by Afghanistan 
concerning regional and international cooperation in an 
attempt to address the drug-related threats facing the 
country. The Government has also committed to imple-
menting initiatives such as alternative livelihood pro-
grammes. Although, according to the latest UNODC 
opium poppy survey, the area of illicit cultivation in 2015 
was the lowest since 2001, the Board expresses its con-
tinuing concern about illicit opium poppy cultivation, 
drug production and drug trafficking in the country, 
including the situation with respect to the illicit cultiva-
tion of cannabis in the country. 
Recommendation 13: INCB calls on the Government of 
Afghanistan to continue its efforts to tackle illicit drug 
crop cultivation and the illicit production and manufac-
ture of drugs and for the interdiction of drug trafficking 
and increased prevention, treatment, rehabilitation, social 
reintegration and recovery from drug abuse. INCB rec-
ommends that international partners continue to provide 
assistance to Afghanistan in this regard. 
776. A worrying trend has emerged in North America 
regarding the number of people who have developed opi-
oid dependencies, often following prescribed courses of 
treatment with opioid analgesics. Such dependency has 
resulted in both the abuse of prescription opioids and 
other narcotic drugs such as heroin. The result has been 
a high loss of life in the region due to overdoses. 
Recommendation 14: The Board urges Governments to 
ensure the training of prescribers and dispensers of nar-
cotic drugs in best practices for the prescribing and dis-
pensing of, in particular, opioid-based analgesics. 
777. The South American continent accounts for almost 
all the world’s illicit cultivation of coca bush. Both Bolivia 
(Plurinational State of ) and Peru registered decreases in 
the size of the total area under illicit coca bush cultiva-
tion in 2014. In contrast, Colombia had a 44 per cent 
year-on-year area increase in coca bush cultivation in 
2014.
Recommendation 15: The Board urges the Governments 
of the Andean region to increase their sharing of infor-
mation and best practices to tackle and reduce illicit drug 
crop cultivation. Colombian authorities should look at 
ways to reverse the trend in the country, and both Bolivia 
(Plurinational State of) and Peru should ensure the con-
tinuation of the decreasing trend of area under illicit coca 
bush cultivation.
778. The 1961 Convention establishes that the parties 
to the Convention shall take such legislative and admin-
istrative measures as may be necessary to give effect to 
and carry out the provisions of the Convention and to 
limit exclusively to medical and scientific purposes the 
production, manufacture, export, import, distribution 
of, trade in, use and possession of controlled narcotic 
drugs. Likewise, the 1971 Convention requires States 
parties to adopt such legislative and administrative 
measures as may be necessary to give effect to the pro-
visions of the Convention within their respective terri-
tories and to cooperate with other States and international 
organizations in the execution of the aims of the 
Convention.
Recommendation 16: The Board stresses the importance 
of the universal adherence to the international drug con-
trol treaties and urges all Governments to carefully 
review the implementation of their respective obligations 
under the international drug control treaties and to 
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ensure that domestic legislation does not contravene the 
provisions of the international conventions to which they 
are parties. The Board will continue to monitor 
developments and looks forward to continuing its dia-
logue with all authorities on matters related to the imple-
mentation of the drug control conventions.
(Signed)
Werner Sipp
President
(Signed)
Bernard Leroy
Rapporteur
(Signed)
Andrés Finguerut
Secretary
Vienna, 13 November 2015
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Annex I.
Regional and subregional groupings used in the 
report of the International Narcotics Control 
Board for 2015
The regional and subregional groupings used in the report of the International Narcotics Control Board for 2015, 
together with the States in each of those groupings, are listed below.
Africa
Algeria Libya
Angola Madagascar
Benin Malawi
Botswana Mali
Burkina Faso Mauritania
Burundi Mauritius
Cameroon Morocco
Cabo Verde Mozambique
Central African Republic Namibia
Chad Niger
Comoros Nigeria
Congo Rwanda
Côte d’Ivoire Sao Tome and Principe
Democratic Republic of the Congo Senegal
Djibouti Seychelles
Egypt Sierra Leone
Equatorial Guinea Somalia
Eritrea South Africa
Ethiopia South Sudan
Gabon Sudan
Gambia Swaziland
Ghana Togo
Guinea Tunisia
Guinea-Bissau Uganda
Kenya United Republic of Tanzania
Lesotho Zambia
Liberia Zimbabwe
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Central America and the Caribbean
Antigua and Barbuda Guatemala
Bahamas Haiti
Barbados Honduras
Belize Jamaica
Costa Rica Nicaragua
Cuba Panama
Dominica Saint Kitts and Nevis
Dominican Republic Saint Lucia
El Salvador Saint Vincent and the Grenadines
Grenada Trinidad and Tobago
North America
Canada United States of America
Mexico
South America
Argentina Guyana
Bolivia (Plurinational State of) Paraguay
Brazil Peru
Chile Suriname
Colombia Uruguay
Ecuador Venezuela (Bolivarian Republic of)
East and South-East Asia
Brunei Darussalam Mongolia
Cambodia Myanmar
China Philippines
Democratic People’s Republic of Korea Republic of Korea
Indonesia Singapore
Japan Thailand
Lao People’s Democratic Republic Timor-Leste
Malaysia Viet Nam
South Asia
Bangladesh Maldives
Bhutan Nepal
India Sri Lanka
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West Asia
Afghanistan Oman
Armenia Pakistan
Azerbaijan Qatar
Bahrain Saudi Arabia
Georgia State of Palestine
Iran (Islamic Republic of) Syrian Arab Republic
Iraq Tajikistan
Israel Turkey
Jordan Turkmenistan
Kazakhstan United Arab Emirates
Kuwait Uzbekistan
Kyrgyzstan Yemen
Lebanon
Europe
Eastern Europe
Belarus Russian Federation
Republic of Moldova Ukraine
South-Eastern Europe
Albania Montenegro
Bosnia and Herzegovina Romania
Bulgaria Serbia
Croatia The former Yugoslav Republic of  Macedonia
Western and Central Europe
Andorra Liechtenstein
Austria Lithuania
Belgium Luxembourg
Cyprus Malta
Czech Republic Monaco
Denmark Netherlands
Estonia Norway
Finland Poland
France Portugal
Germany San Marino
Greece Slovakia
Holy See Slovenia
Hungary Spain
Iceland Sweden
Ireland Switzerland
Italy United Kingdom of Great Britain and  Northern Ireland
Latvia
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Oceania
Australia Niue
Cook Islands Palau
Fiji Papua New Guinea
Kiribati Samoa
Marshall Islands Solomon Islands
Micronesia (Federated States of) Tonga
Nauru Tuvalu
New Zealand Vanuatu
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Annex II.
Current membership of the International 
Narcotics Control Board
Wei Hao 
Born in 1957. National of China. Professor of Psychiatry 
and Deputy Director of the Mental Health Institute, 
Central South University, Changsha, China. Director of 
the World Health Organization (WHO) Collaborating 
Centre for Psychosocial Factors, Substance Abuse and 
Health, Western Pacific Region. Currently serving as 
Chair, Education Committee of the Asian-Pacific Society 
for Alcohol and Addiction Research, and as President, the 
China Association of Drug Abuse Prevention and 
Treatment and Chinese Association of Addiction Medicine.
Bachelor of Medicine, Anhui Medical University; Master’s 
and Doctorate degrees of Psychiatry, Hunan University of 
Chinese Medicine.
Previously held positions as Scientist, Substance Abuse 
Department, WHO, Geneva (1999-2000); Medical Officer, 
Department of Mental Health and Substance Abuse, 
WHO, Western Pacific Region, and President, the Chinese 
Psychiatrist Association (2008-2011). Membership in the 
Scientific Advisory Committee on Tobacco Product 
Regulation, WHO (2000-2004). Currently holding mem-
bership on the Expert Advisory Panel on Drug Dependence 
and Alcohol Problems, WHO (2006-present); and the 
national focal point for China for the implementation of 
the regional plan of action for the reduction of alcohol-
related harm in the Western Pacific, WHO (2009- present); 
and member of the Working Group on the Classification 
of Substance Abuse for the eleventh revision of the 
International Classification of Diseases (ICD-11), WHO 
(2011-present).
Recipient of research support from various bodies at the 
national level (Ministry of Health, Ministry of Science 
and Technology, National Natural Science Foundation) 
and at the international level (WHO and the National 
Institute on Drug Abuse and the National Institute on 
Alcohol Abuse and Alcoholism of the United States). 
Coordinator of series of WHO/China workshops on 
addictive behaviour. Member of the Expert Committee of 
the national project on mental health service in commu-
nities in China. Consultant for the development, imple-
mentation and evaluation of China’s mental health law, 
and for the development of the anti-drug law and regu-
lations in China.
Published over 400 academic articles and 50 books on 
alcohol and drug dependence. Selected recent publica-
tions in peer-reviewed journals include the following: 
“Longitudinal surveys of prevalence rates and use pat-
terns of illicit drugs at selected high-prevalence areas in 
China from 1993 to 2000”, Addiction (2004); “Drug pol-
icy in China: progress and challenges”, Lancet (2014); 
“Transition of China’s drug policy: problems in practice” 
Addiction (2015); “Improving drug addiction treatment 
in China”, Addiction (2007); “Stigmatization of people 
with drug dependence in China: a community-based 
study in Hunan province”, Drug Alcohol Dependence 
(2013); and “Drinking and drinking patterns and health 
status in the general population of five areas of China”, 
Alcohol & Alcoholism (2004).
Member of the International Narcotics Control Board 
(since 2015).a Member of the Committee on Finance and 
Administration (2015). Member of the Standing 
Committee on Estimates (2015).
 a Elected by the Economic and Social Council on 17 November 2014.
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David T. Johnson
Born in 1954. National of the United States. Vice-
President, Sterling Global Operations; retired diplomat. 
Bachelor’s degree in economics from Emory University; 
graduate of the National Defence College of Canada.
United States Foreign Service officer (1977-2011). 
Assistant Secretary for the Bureau of International 
Narcotics and Law Enforcement Affairs, United States 
Department of State (2007-2011). Deputy Chief of 
Mission (2005-2007) and Chargé d’affaires, a.d. (2003-
2005), United States Embassy, London. Afghan 
Coordinator for the United States (2002-2003). United 
States Ambassador to the Organization for Security and 
Cooperation in Europe (1998-2001). Deputy Press 
Secretary at the White House and Spokesman for the 
National Security Council (1995-1997). Deputy Spokesman 
at the State Department (1995) and Director of the State 
Department Press Office (1993-1995). United States 
Consul General, Vancouver (1990-1993). Assistant 
National Trust Examiner, Office of the Comptroller of the 
Currency, United States Treasury (1976-1977).
Member of the International Narcotics Control Board 
(since 2012). Member of the Committee on Finance and 
Administration (since 2012). Chair of the Committee on 
Finance and Administration (2014).
Bernard Leroy 
Born in 1948. National of France. Honorary Deputy 
Prosecutor General and Director of the International 
Institute of Research against Counterfeit Medicines.
Degrees in Law from the University of Caen, Institute of 
European Studies of Saarbrucken, Germany, and 
University Paris X. Graduate of the French National 
School for the Judiciary (1979).
Previously held positions of Deputy General Prosecutor, 
Versailles Court of Appeal, 2010-2013. Senior Legal 
Advisor, United Nations Office on Drugs and Crime 
(UNODC) (1990-2010). Advisor in charge of interna-
tional, legislative and legal affairs in the French National 
Drug Coordination (1988-1990). Investigating judge spe-
cializing in drug cases, Evry High Court (1979-1988). 
Head of the Legal Assistance Programme, UNODC, and 
Coordinator of the decentralized team of legal experts, 
Bogota, Tashkent and Bangkok (1990-2010). Leader of 
the legal assistance team assisting the Government of 
Afghanistan in the drafting process of the new drug con-
trol law, 2004. Co-author of the preparatory study for the 
law introducing community service sentencing as an 
alternative to imprisonment in France (1981). Co-founder 
of “Essonne Accueil”, a non-governmental organization 
providing treatment services for drug addicts (1982). 
Member of the French delegation for the final negotia-
tions of the United Nations Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances, 
1988. Chair of the study group on cocaine trafficking in 
Europe, Council of Europe (1989). Author of the report 
resulting in the first European political coordinating com-
mittee to combat drugs (1989). Chair of the World Bank 
and UNODC joint team (the Stolen Asset Recovery 
(StAR) Initiative) which organized the freezing and sub-
sequent recovery in Switzerland of the assets stolen by 
the former dictator Jean-Claude Duvalier in Haiti (2008).
Organizer of the lifelong learning programme on com-
bating drug trafficking and addiction for members of the 
French judiciary, French National School for the Judiciary 
(1984-1994). Lecturer for medical graduates in psychia-
try in the field of forensic expertise and responsibility, 
Faculty of Medicine, Paris-Sud University (1983-1990). 
Lecturer in the field of social work, University of Paris 
13 (1984-1988). Lecturer for second year Master’s courses 
in Security and Public International Law, Jean Moulin 
Lyon 3 University (2005-2013).
Member of the Executive Board of the international sec-
tion of the National Association of Drug Court 
Professionals (2006). External member of the Management 
Board of the French Monitoring Centre for Drugs and 
Drug Addiction (2013). Member of the committee of the 
Reynaud report (2013).
Selected publications include “Le travail au profit de la 
communauté, substitut aux courtes peines d’empri-
sonnement”, Revue de science criminelle et de droit com-
paré, No. 1 (Sirey, 1983); Drogues et drogués, École 
nationale de la magistrature, studies and research (1983); 
Étude comparative des législations et des pratiques judici-
aires européennes face à la drogue (Commission of the 
European Communities, 1991); Ecstasy, Inserm Collective 
Expertise series (Editions Inserm, 1997); The International 
Drug Control System, in cooperation with Cherif Bassiouni 
and J. F. Thony, in International Criminal Law: Sources, 
Subjects and Contents (Martinus Nijhoff Publishers, 2007); 
Routledge Handbook of Transnational Criminal Law, Neil 
Boister and Robert Curie, eds. (Routledge, 2014).
Member of the International Narcotics Control Board 
(since 2015).b Rapporteur (2015). 
 b Elected by the Economic and Social Council on 23 April 2014.
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Richard P. Mattick 
Born in 1955. National of Australia. Professor of Drug 
and Alcohol Studies at the National Drug and Alcohol 
Research Centre, Faculty of Medicine, University of New 
South Wales; Professor of Brain Sciences, University of 
New South Wales; Principal Research Fellow, Australian 
Government National Health and Medical Research 
Council (2013-2017), and Registered Clinical Psychologist.
Bachelor of Science (Psychology), Honours, Class 1, 
University of New South Wales, 1982; Master of 
Psychology (Clinical), University of New South Wales, 
1989; Doctor of Philosophy, University of New South 
Wales, 1988; and Certificate in Neuroanatomy, Anatomy, 
University of New South Wales, 1992.
Director of Research, Australian National Drug and 
Alcohol Research Centre (1995-2001), and Executive 
Director, Australian National Drug and Alcohol Research 
Centre, Faculty of Medicine, University of New South 
Wales (2001-2009). Member, Australian National Expert 
Advisory Committee on Illicit Drugs (2002-2004), 
Australian national expert advisory group on sustained 
release naltrexone (2002-2004), Monitoring Committee of 
the Medically Supervised Injecting Centre for the New 
South Wales Government Cabinet Office (2003-2004), 
Australian Ministerial Council on Drug Strategy Working 
Party on Performance and Image Enhancing Drugs (2003-
2005), Australian Government Department of Health and 
Ageing Expert Advisory Committee on Cannabis and 
Health (2005-2006), New South Wales Expert Advisory 
Group on Drugs and Alcohol for the New South Wales 
Minister of Health (2004-2013), Australian National 
Council on Drugs advising the Prime Minister (2004-
2010), WHO/UNODC Technical Guidelines Development 
Group on Pharmacotherapy of Opioid Dependence 
(2004-2008), Australian Research Alliance for Children 
and Youth (2005-2015).
Served on the editorial and executive boards of the Drug 
and Alcohol Review (1994-2005), and as Deputy Editor 
(1995-2000) and Executive Editor (2000-2005). Assistant 
Editor of the international peer-reviewed journal 
Addiction (1995-2005). Editor, Cochrane Review Group 
on Drugs and Alcohol (1998-2003). Authored over 280 
books, chapters in edited volumes on substance abuse, 
addiction and treatment, and peer-reviewed academic 
journal articles on those subjects. Recent articles include 
“Buprenorphine maintenance versus placebo or metha-
done maintenance for opioid dependence”, “Young adult 
sequelae of adolescent cannabis use” and “The Pain and 
Opioids IN Treatment study: characteristics of a cohort 
using opioids to manage chronic non-cancer pain”. 
Recipient of academic and research support from the 
Australian Government Department of Health; the New 
South Wales Government Department of Health; the 
Australian National Drug Law Enforcement Research 
Fund; the Alcohol Education and Rehabilitation 
Foundation; UNODC; the National Institute on Drug 
Abuse of the United States; the Australian Research 
Council; and the Australian Government National Health 
and Medical Research Council.
Member of the International Narcotics Control Board 
(since 2015).c Member of the Standing Committee on 
Estimates (2015).
Alejandro Mohar Betancourt 
Born in 1956. National of Mexico. Director General of 
the National Cancer Research Institute of Mexico (2003-
2013) and member of the National System of Researchers 
of Mexico, the National Academy of Medicine, the 
Mexican Academy of Sciences and the American Society 
of Clinical Oncology.
Doctor of Medicine, National Autonomous University of 
Mexico (UNAM) (1980); Postgraduate studies in anatom-
ical pathology, National Institute of Nutrition (1985), 
Master of Sciences (1986) and Doctor of Sciences in 
Epidemiology (1990), Harvard School of Public Health. 
Recipient of academic and research support from the 
National Council on Science and Technology (CONACYT) 
and the Mexican Foundation of Health. Head of the 
Department of Epidemiology (1988-1989), Deputy 
Director of Clinical Research (1993-1999) and Director 
of Research (1999-2003), National Cancer Research 
Institute of Mexico. Lecturer and Research Associate, 
Harvard School of Public Health (1988-1990). Lecturer 
and Director of master’s and doctoral dissertations at the 
Faculty of Medicine, UNAM (since 1991). Coordinator of 
the Unit for Biomedical Research on Cancer, Biomedical 
Research Institute, UNAM (1998). Author of more than 
110 scientific and popular works, 70 of which appear in 
indexed journals, including “Intratypic changes of the E1 
gene and the long control region affect ori function of 
human papillomavirus type 18 variants”, “Screening breast 
cancer: a commitment to Mexico (preliminary report)”, 
“Impact of diabetes and hyperglycemia on survival in 
advanced breast cancer patients”, “Ovarian cancer: the 
new challenge in gynaecologic oncology?” and “Validation 
of the Mexican-Spanish version of the EORTC 
 c Elected by the Economic and Social Council on 8 April 2015.
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QLQ-C15-PAL questionnaire for the evaluation of health-
related quality of life in patients on palliative care”. 
Awarded various recognitions including the following: 
Miguel Otero Award for clinical research, General Health 
Council (2012); third place for best pharmacoeconomics 
work, Mexican College for Pharmacoeconomics and 
International Society for Pharmacoeconomics and 
Outcomes Research, Mexico chapter (2010); member of 
the Group of the 300 Most Influential Leaders of Mexico; 
recognition for participation in the meeting of the Global 
Health Strategic Operations Advisory Group of the 
American Cancer Society (2009); member of the Board of 
Governors of the National Autonomous University of 
Mexico (2008); Distinction of Edward Larocque Tinker 
Visiting Professor, Stanford University (2000); member of 
the External Advisory Group for the Mexico Report on 
Social Determinants of Health (2010); member of the jury 
for the Aaron Sáenz Annual Prize for Paediatric Research, 
Federico Gómez Children’s Hospital of Mexico and the 
“General y Lic. Aarón Sáenz Garza, A.C.” Association 
(2010); member of the Global Health Strategic Operations 
Advisory Group of the American Cancer Society (2010); 
Certificate of Achievement for dedication and commitment 
to establishing a national cancer plan for Mexico, American 
Cancer Society (2006); member of the Scientific Committee 
of the Mexican Association of Pathologists (1993-1995).
Member of the International Narcotics Control Board 
(since 2013). Member of the Standing Committee on 
Estimates (since 2014). Vice-Chair of the Standing 
Committee on Estimates (2015).
Jagjit Pavadia 
Born in 1954. National of India. Graduate in English 
Honours (1974), Dhaka University, LL.B from Delhi 
University (1988), Master’s Diploma in Public 
Administration, Indian Institute of Public Administration 
(1996). Completed dissertation “Forfeiture of Property 
under the Narcotics Drugs and Psychotropic Substances 
Act, 1985” towards completion of Master’s Diploma. 
Held several senior positions in Indian Revenue Service 
for 35 years in the Government of India, including 
Narcotics Commissioner of India, Central Bureau of 
Narcotics (2006-2012); Commissioner, Legal Affairs 
(2001-2005); Chief Vigilance Officer, Power Finance 
Corporation (1996-2001); Customs Training Adviser 
Maldives, deputed by the Commonwealth Secretariat 
(1994-1995); Deputy Director, Narcotics Control Bureau 
(1990-1994); and retired as Chief Commissioner, Customs, 
Central Excise and Service Tax, Nagpur, in 2014.
Recipient of Presidential Appreciation Certificate for 
Specially Distinguished Record of Service on the occa-
sion of Republic Day (2005), published in the Gazette of 
India Extraordinary.
Member of the Indian delegation to the Commission on 
Narcotics Drugs, Vienna (2007-2012); introduced resolu-
tions 51/15 (2008) and 53/12 (2010), adopted by the 
Commission on Narcotic Drugs, and organized a side 
event on the margins of the Commission’s session (2011), 
presenting issues involved in the illegal movement of 
poppy seeds to producing, importing and exporting 
countries. As representative of the competent national 
authority, attended Project Prism and Project Cohesion 
task force meetings (2006-2012), and coordinated and 
organized the Project Prism and Project Cohesion meet-
ing in New Delhi (2008). Participated in the Meeting of 
the Heads of National Drug Law Enforcement Agencies 
(HONLEA), Asia and the Pacific, held in Bangkok (2006), 
and organized the Meeting of HONLEA, Asia and the 
Pacific, held in Agra, India (2011). Member of the INCB 
advisory expert group on the scheduling of substances 
(2006), and member of the advisory group finalizing the 
INCB Guidelines for a Voluntary Code of Practice for the 
Chemical Industry (2008). Rapporteur of the forty-first 
session of the Subcommission on Illicit Drug Traffic and 
Related Matters in the Near and Middle East, held in 
Amman (2006); Chairperson of the forty-second session 
of the Subcommission, held in Accra, India (2007); organ-
ized the meeting of the Paris Pact Initiative Expert 
Working Group on Precursors, held in New Delhi (2011), 
and participated in the International Drug Enforcement 
Conferences hosted by the United States Drug Enforcement 
Agency, held in Istanbul (2008) and Cancún, Mexico 
(2011).
Member of the International Narcotics Control Board 
(since 2015).d Second Vice-President and Chair of the 
Standing Committee on Estimates (2015).
Ahmed Kamal Eldin Samak
Born in 1950. National of Egypt. Graduated with a Law 
and Police Licence in 1971. Worked in the field of anti-
narcotics for more than 35 years, until becoming the 
Minister Assistant of Police and Head of the Anti-
Narcotics General Administration of Egypt, which is con-
sidered the first organization of anti-narcotics in the world 
and was founded in 1929. Independent adviser in the field 
of anti-narcotics and crime. First-rank badge of honour 
on the occasion of the police festival (1992). Contributed 
 d Elected by the Economic and Social Council on 23 April 2014.
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to several missions, such as to Jordan, for anti-narcotics 
training (1988); India, for the signing of an agreement 
between India and Egypt to strengthen anti-narcotics and 
security cooperation to combat crime and terrorism 
(1995); France, for cooperation between Egypt and the 
International Criminal Police Organization (INTERPOL) 
relating to drugs and money-laundering (1996); 
Palestine,e to participate in a regional anti-narcotics work-
shop (1999); Saudi Arabia, to participate in a training pro-
gramme related to drug cases (2001); United Arab 
Emirates, to represent the Ministry of the Interior at the 
thirty-sixth session of the committee concerned with ille-
gal trade in drugs (2001); Libyan Arab Jamahiriya,f to 
participate in the celebration of the International Day 
against Drug Abuse and Illicit Trafficking (2002); Kenya, 
to participate in the twelfth and seventeenth conferences 
of African national anti-narcotics department leaders 
(2002 and 2007); Mauritius, for the second ministerial 
anti-narcotics meeting (2004); Lebanon, to participate in 
the conference “Drugs are a social epidemic”, organized 
by Lebanese organizations for human rights (2004); 
Tunisia, to participate in the seventeenth to twenty-first 
Arab conferences of anti-narcotics department leaders 
(2003-2007); United States (2004); Austria, to represent 
the Ministry at the forty-fifth, forty-sixth and forty-eighth 
to fiftieth sessions of the Commission on Narcotic Drugs 
(2002-2007); Saudi Arabia, as a member of a scientific 
organization to prepare an article about arrest and inves-
tigation procedures (2007); United Arab Emirates, for the 
Regional Seminar for Strategic and Cooperative Planning 
in the Field of Anti-Narcotics (2007). Member of the 
National General Trust Fund for Anti-Narcotics and 
Addiction; and the Committee of National Strategy 
Planning on Anti-Narcotics.
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012, 2014 and 2015). 
Werner Sipp
Born in 1943. National of Germany. Lawyer (Universities 
of Heidelberg, Germany, and Lausanne, Switzerland, 
University Institute of European Studies, Turin, Italy).
Assistant lecturer in Public Law, University of Regensburg 
(1971-1977). Senior administrative posts in several 
 e Pursuant to General Assembly resolution 67/19 of 29 November 
2012, Palestine has been accorded the status of a non-member observer 
State. The name “State of Palestine” is now used in all United Nations 
documents.
 f Since 16 September 2011, “Libya” has replaced “Libyan Arab Jama-
hiriya” as the short name used in the United Nations.
federal ministries (1977-2008). Head of the Division for 
Narcotic Law and International Narcotic Drugs Affairs in 
the Federal Ministry of Health (2001-2008); Permanent 
Correspondent of Germany in the Pompidou Group of 
the Council of Europe (2001-2008); Legal Correspondent 
of Germany in the European Legal Database on Drugs, 
Lisbon (2002-2008); Chairman of the Horizontal Working 
Party on Drugs of the Council of the European Union 
(2007); Coordinator of the German delegation to the 
Commission on Narcotic Drugs (2001-2009). 
Expert Consultant to the German Federal Ministry of 
Health and Drug Commissioner of the Federal 
Government in international drug matters (2008-2009); 
Expert Consultant on drug issues to the Deutsche 
Gesellschaft für Internationale Zusammenarbeit (2008-
2011); Expert on several European Union drug projects 
such as “Implementing the national strategy to fight drug 
abuse in Serbia” and the Central Asia Drug Action 
Programme.
Member of the International Narcotics Control Board 
(since 2012). Member of the Standing Committee on 
Estimates (2012-2014). Rapporteur (2013). First Vice-
President of the Board (2014). President of the Board 
(2015).
Viroj Sumyai
Born in 1953. National of Thailand. Retired Assistant 
Secretary-General of the Food and Drug Administration, 
Ministry of Public Health of Thailand, and clinical phar-
macologist specializing in drug epidemiology. Professor, 
Mahidol University (since 2001).
Bachelor of Science degree in chemistry (1976), Chiang 
Mai University. Bachelor’s degree in pharmacy (1979), 
Manila Central University. Master’s degree in clinical 
pharmacology (1983), Chulalongkorn University. Appren-
ticeship in narcotic drugs epidemiology at St. George’s 
University of London (1989). Doctor of Philosophy, 
Health Policy and Administration (2009), National 
Institute of Administration. Member of the Pharmaceutical 
Association of Thailand. Member of the Pharmacological 
and Therapeutic Society of Thailand. Member of the Thai 
Society of Toxicology. Author of nine books in the field 
of drug prevention and control, including Drugging 
Drinks: Handbook for Predatory Drugs Prevention and 
Déjà vu: A Complete Handbook for Clandestine Chemistry, 
Pharmacology and Epidemiology of LSD. Columnist, Food 
and Drug Administration Journal. Recipient, Prime 
Minister’s Award for Drug Education and Prevention 
(2005). 
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Member of the International Narcotics Control Board 
(since 2010). Member (since 2010) and Chair (2012 and 
2014) of the Standing Committee on Estimates. Chair of 
the Committee on Finance and Administration (2011 and 
2013). Second Vice-President of the Board (2012 and 2014). 
Sri Suryawati
Born in 1955. National of Indonesia. Professor and Head, 
Division of Medicine Policy and Management, Faculty 
of  Medicine, Gadjah Mada University, Yogyakarta. 
Educational background includes pharmacy (1979), spe-
cialist in pharmacology (1985); doctoral degree in clini-
cal pharmacokinetics (1994), certificate in medicine 
policy (1997). Lecturer in pharmacology/clinical pharma-
cology (since 1980); supervisor for more than 150 mas-
ter’s and doctoral theses in the areas of medicine policy, 
essential medicines, clinical pharmacology, pharmacoeco-
nomics and pharmaceutical management.
Member of the WHO Expert Advisory Panel for Medicine 
Policy and Management (since 1999). Member of the 
Executive Board of the International Network for the 
Rational Use of Drugs (INRUD). Member of the WHO 
Expert Committee on the Selection and Use of Essential 
Medicines (2002, 2003, 2005 and 2007). Member of the 
WHO Expert Committee on Drug Dependence (2002 
and 2006). Member of the United Nations Millennium 
Project Task Force on HIV/AIDS, Malaria and Tuberculosis 
and Access to Essential Medicines (Task Force 5) (2001-
2005). Consultant in essential medicine programmes and 
promoting rational use of medicines in Bangladesh (2006-
2007), Cambodia (2001-2008), China (2006-2008), Fiji 
(2009), the Lao People’s Democratic Republic (2001-
2003), Mongolia (2006-2008) and the Philippines (2006-
2007). Consultant in medicine policy and drug evaluation 
in Cambodia (2003, 2005 and 2007), China (2003), 
Indonesia (2005-2006) and Viet Nam (2003). Facilitator 
in various international training courses in medicine pol-
icy and promoting the rational use of medicines, includ-
ing WHO and INRUD courses on promoting the rational 
use of medicines (1994-2007), training courses on hospi-
tal drugs and therapeutics committees (2001-2007) and 
international courses on medicine policy (2002-2003).
Member of the International Narcotics Control Board 
(2007-2012 and since 2013). Member (2008-2011 and 
since 2013), Vice-Chair (2009) and Chair (2010 and 
2013) of the Standing Committee on Estimates. Second 
Vice-President of the Board (2010 and 2013). Rapporteur 
(2011 and 2014). First Vice-President of the Board 
(2015).
Francisco E. Thoumi
Born in 1943. National of Colombia and the United 
States. Bachelor of Arts and Doctor of Philosophy in 
Economics. Senior member of the Colombian Academy 
of Economic Sciences and Corresponding Member of the 
Royal Academy of Moral and Political Sciences (Spain).
Professor at the University of Texas, Rosario University 
(Bogotá) and California State University, Chico. Worked 
for 15 years in the research departments of the World 
Bank and the Inter-American Development Bank. Founder 
and Director, Research and Monitoring Center on Drugs 
and Crime, Rosario University (August 2004-December 
2007); Research Coordinator, Global Programme against 
Money-Laundering, Proceeds of Crime and the Financing 
of Terrorism; Coordinator for the World Drug Report, 
UNODC (August 1999-September 2000); Researcher, 
Comparative Study of Illegal Drugs in Six Countries, 
United Nations Research Institute for Social Development, 
Geneva (June 1991-December 1992); Fellow, Woodrow 
Wilson International Center for Scholars (August 1996-
July  1997); Research Coordinator, Research Programme 
on the Economic Impact of Illegal Drugs in the Andean 
Countries, United Nations Development Programme, 
Bogota (November 1993-January 1996).
Author of two books and co-author of one book on ille-
gal drugs in Colombia and the Andean region. Editor of 
three volumes and author of over 60 academic journal 
articles and book chapters on those subjects.
Member of the Friedrich Ebert Foundation Observatory 
of Organized Crime in Latin America and the Caribbean 
(since 2008) and the World Economic Forum’s Global 
Agenda Council on Organized Crime (2012-2014). 
Member of the International Narcotics Control Board 
(since 2012). Rapporteur (2012). Member of the Standing 
Committee on Estimates (2013). Member of the Committee 
on Finance and Administration (2014 and 2015).
Jallal Toufiq 
Born in 1963. National of Morocco. Head of the National 
Centre for Drug Abuse Prevention and Research; Director 
of the Moroccan National Observatory on Drugs and 
Addictions; Director of the Ar-razi University Psychiatric 
Hospital and Professor of Psychiatry at the Rabat Faculty 
of Medicine.
Medical Doctor, Rabat Faculty of Medicine (1989); 
Diploma of Specialization in Psychiatry (1994); and 
aNNEXEs  115
lecturer at the Rabat Faculty of Medicine (since 1995). 
Undertook specialized training in Paris at the Sainte-
Anne Psychiatric Hospital and Marmottan Centre (1990-
1991); and at Johns Hopkins University as a National 
Institute on Drug Abuse research fellow and Clinical 
Observer (1994-1995). Conducted research at the 
University of Pittsburgh (1995); and gained Clinical Drug 
Research certificates at the Vienna School of Clinical 
Research (2001 and 2002).
Currently holding positions in Morocco as Head of the 
Harm Reduction Programme, National Centre for 
Drug Abuse Prevention and Research; teaching and 
residency training coordinator, Ar-razi Hospital; 
Director of the National Diploma Programme on 
Treatment and Prevention of Drug Abuse, Rabat 
Faculty of Medicine; Director of the National Diploma 
Programme on Child Psychiatry, Rabat Faculty of 
Medicine and Member of the Ministry of Health 
Commission on Drug Abuse.
At the international level, Representative of the 
Mediterranean Network (MedNET) for Morocco 
(MedNET/Pompidou Group/Council of Europe); former 
permanent correspondent of the Pompidou Group for 
Morocco (Council of Europe) on drug abuse prevention 
and research and former member of the Reference Group 
to the United Nations on HIV and Injecting Drug Use. 
Founding member and steering committee member, 
Middle East and North Africa Harm Reduction 
Association (MENAHRA); Director of Knowledge Hub 
Ar-razi for North Africa, MENAHRA; Member, Mentor 
International Scientific Advisory Network (drug abuse 
prevention in youth); former focal point/expert on pre-
vention, United Nations Office on Drug Control and 
Crime Prevention (local network for North Africa); 
founding member, MedNET (advisory group on AIDS 
and drug abuse policies) of the Council of Europe, and 
member of the Reference Group to the United Nations 
on HIV and Injecting Drug Use.
Held consultancy roles with the WHO Regional Office 
for the Eastern Mediterranean, UNODC and other inter-
national institutions, research fellowships and the 
National Institute on Drug Abuse of the United States. 
Published widely in the field of psychiatry, alcohol and 
drug abuse. 
Member of the International Narcotics Control Board 
(since 2015).g Member of the Standing Committee on 
Estimates (2015).
 g Elected by the Economic and Social Council on 23 April 2014.
Raymond Yans
Born in 1948. National of Belgium. Graduate in Germanic 
philology and in philosophy (1972). 
Belgian Foreign Service: Attaché, Jakarta (1978-1981); 
Deputy-Mayor of Liège (1982-1989); Consul, Tokyo 
(1989-1994); Consul, Chargé d’affaires, Luxembourg 
(1999-2003); Head of the Drug Unit, Ministry of Foreign 
Affairs (1995-1999 and 2003-2007); Chairman of the 
Dublin Group (2002-2006); Chairman of the European 
Union Drug Policy Cooperation Working Group during 
the Belgian Presidency of the European Union; charged 
with the national coordination of the ratification and 
implementation process of the Convention on Psychotropic 
Substances of 1971 and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (1995-1998); liaison between the 
Ministry of Foreign Affairs and the National Police for 
drug liaison officers in Belgian embassies (2003-2005); 
participation in the launching by the European Union 
Joint Action on New Synthetic Drugs of an early warn-
ing system to alert Governments to the appearance of 
new synthetic drugs (1999); active in the creation of the 
Cooperation Mechanism on Drugs between the European 
Union, Latin America and the Caribbean (1997-1999). 
Author of numerous articles and speeches, including: 
“The future of the Dublin Group” (2004) and “Is there 
anything such as a European Union Common Drug 
Policy” (2005). Member of the Belgian delegation to the 
Commission on Narcotic Drugs (1995-2007); all the pre-
paratory sessions (on amphetamine-type stimulants, pre-
cursors, judicial cooperation, money-laundering, drug 
demand reduction and alternative development) for the 
twentieth special session of the General Assembly; 
European Union Seminar on Best Practices in Drug 
Enforcement by Law Enforcement Authorities, Helsinki 
(1999); Joint European Union/Southern African 
Development Community Conferences on Drug Control 
Cooperation, Mmabatho, South Africa (1995) and 
Gabarone (1998); UNODC/Paris Pact round tables, 
Brussels (2003), Tehran and Istanbul (2005); meetings of 
the High-level Dialogue on Drugs between the Andean 
Community and the European Union, Lima (2005) and 
Vienna (2006).
Member of the International Narcotics Control Board 
(since 2007). Member of the Standing Committee on 
Estimates (2007-2010). Member (2007-2009) and Chair 
(2015) of the Committee on Finance and Administration. 
Rapporteur (2010). First Vice-President of the Board 
(2011). President of the Board (2012 and 2013).
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About the International Narcotics Control Board
The International Narcotics Control Board (INCB) is an 
independent and quasi-judicial control organ, established 
by treaty, for monitoring the implementation of the inter-
national drug control treaties. It had predecessors under 
the former drug control treaties as far back as the time 
of the League of Nations.
Composition
INCB consists of 13 members who are elected by the 
Economic and Social Council and who serve in their per-
sonal capacity, not as government representatives. Three 
members with medical, pharmacological or pharmaceu-
tical experience are elected from a list of persons nomi-
nated by the World Health Organization (WHO) and 10 
members are elected from a list of persons nominated by 
Governments. Members of the Board are persons who, 
by their competence, impartiality and disinterestedness, 
command general confidence. The Council, in consulta-
tion with INCB, makes all arrangements necessary to 
ensure the full technical independence of the Board in 
carrying out its functions. INCB has a secretariat that 
assists it in the exercise of its treaty-related functions. The 
INCB secretariat is an administrative entity of the United 
Nations Office on Drugs and Crime, but it reports solely 
to the Board on matters of substance. INCB closely col-
laborates with the Office in the framework of arrange-
ments approved by the Council in its resolution 1991/48. 
INCB also cooperates with other international bodies 
concerned with drug control, including not only the 
Council and its Commission on Narcotic Drugs, but also 
the relevant specialized agencies of the United Nations, 
particularly WHO. It also cooperates with bodies outside 
the United Nations system, especially the International 
Criminal Police Organization (INTERPOL) and the 
World Customs Organization.
Functions
The functions of INCB are laid down in the following 
treaties: the Single Convention on Narcotic Drugs of 1961 
as amended by the 1972 Protocol; the Convention on 
Psychotropic Substances of 1971; and the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Broadly speaking, INCB 
deals with the following:
  (a) As regards the licit manufacture of, trade in 
and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs 
are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels 
does not occur. INCB also monitors Governments’ con-
trol over chemicals used in the illicit manufacture of 
drugs and assists them in preventing the diversion of 
those chemicals into the illicit traffic;
  (b) As regards the illicit manufacture of, traffick-
ing in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contrib-
utes to correcting such situations. INCB is also responsi-
ble for assessing chemicals used in the illicit manufacture 
of drugs, in order to determine whether they should be 
placed under international control.
In the discharge of its responsibilities, INCB:
  (a) Administers a system of estimates for narcotic 
drugs and a voluntary assessment system for psychotropic 
substances and monitors licit activities involving drugs 
through a statistical returns system, with a view to assist-
ing Governments in achieving, inter alia, a balance 
between supply and demand;
  (b) Monitors and promotes measures taken by 
Governments to prevent the diversion of substances fre-
quently used in the illicit manufacture of narcotic drugs 
and psychotropic substances and assesses such substances 
to determine whether there is a need for changes in the 
scope of control of Tables I and II of the 1988 Convention;
  (c) Analyses information provided by Governments, 
United Nations bodies, specialized agencies or other com-
petent international organizations, with a view to ensur-
ing that the provisions of the international drug control 
treaties are adequately carried out by Governments, and 
recommends remedial measures;
 (d) Maintains a permanent dialogue with Gov-
ernments to assist them in complying with their obliga-
tions under the international drug control treaties and, 
to that end, recommends, where appropriate, technical or 
financial assistance to be provided.
INCB is called upon to ask for explanations in the event 
of apparent violations of the treaties, to propose appro-
priate remedial measures to Governments that are not 
fully applying the provisions of the treaties or are encoun-
tering difficulties in applying them and, where necessary, 
to assist Governments in overcoming such difficulties. If, 
however, INCB notes that the measures necessary to 
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remedy a serious situation have not been taken, it may 
call the matter to the attention of the parties concerned, 
the Commission on Narcotic Drugs and the Economic 
and Social Council. As a last resort, the treaties empower 
INCB to recommend to parties that they stop importing 
drugs from a defaulting country, exporting drugs to it or 
both. In all cases, INCB acts in close cooperation with 
Governments.
INCB assists national administrations in meeting their 
obligations under the conventions. To that end, it pro-
poses and participates in regional training seminars and 
programmes for drug control administrators.
Reports
The international drug control treaties require INCB to 
prepare an annual report on its work. The annual report 
contains an analysis of the drug control situation world-
wide so that Governments are kept aware of existing and 
potential situations that may endanger the objectives of 
the international drug control treaties. INCB draws the 
attention of Governments to gaps and weaknesses in 
national control and in treaty compliance; it also makes 
suggestions and recommendations for improvements at 
both the national and international levels. The annual 
report is based on information provided by Governments 
to INCB, United Nations entities and other organizations. 
It also uses information provided through other 
 international organizations, such as INTERPOL and the 
World  Customs Organization, as well as regional 
organizations.
The annual report of INCB is supplemented by detailed 
technical reports. They contain data on the licit move-
ment of narcotic drugs and psychotropic substances 
required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are 
required for the proper functioning of the system of con-
trol over the licit movement of narcotic drugs and psy-
chotropic substances, including preventing their diversion 
to illicit channels. Moreover, under the provisions of arti-
cle 12 of the 1988 Convention, INCB reports annually to 
the Commission on Narcotic Drugs on the implementa-
tion of that article. That report, which gives an account 
of the results of the monitoring of precursors and of the 
chemicals frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances, is also pub-
lished as a supplement to the annual report.
Since 1992, the first chapter of the annual report has been 
devoted to a specific drug control issue on which INCB 
presents its conclusions and recommendations in order 
to contribute to policy-related discussions and decisions 
in national, regional and international drug control. The 
following topics were covered in past annual reports:
1992:  Legalization of the non-medical use of drugs
1993:  The importance of demand reduction
1994:  Evaluation of the effectiveness of the interna-
tional drug control treaties
1995:  Giving more priority to combating 
money-laundering
1996:  Drug abuse and the criminal justice system
1997:  Preventing drug abuse in an environment of 
illicit drug promotion
1998:  International control of drugs: past, present 
and future
1999:  Freedom from pain and suffering
2000:  Overconsumption of internationally controlled 
drugs
2001: Globalization and new technologies: challenges 
to drug law enforcement in the twenty-first century
2002:  Illicit drugs and economic development
2003:  Drugs, crime and violence: the microlevel 
impact
2004:  Integration of supply and demand reduction 
strategies: moving beyond a balanced approach
2005: Alternative development and legitimate 
livelihoods
2006: Internationally controlled drugs and the 
unregulated market
2007: The principle of proportionality and drug-
related offences
2008: The international drug control conventions: 
history, achievements and challenges
2009: Primary prevention of drug abuse
2010: Drugs and corruption
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2011: Social cohesion, social disorganization and 
illegal drugs
2012: Shared responsibility in international drug 
control 
2013: Economic consequences of drug abuse
2014: Implementation of a comprehensive, integrated 
and balanced approach to addressing the world drug 
problem
Chapter I of the report of the International Narcotics 
Control Board for 2015 is entitled “The health and wel-
fare of mankind: challenges and opportunities for the 
international control of drugs”.
Chapter II presents an analysis of the operation of the 
international drug control system based primarily on 
information that Governments are required to submit 
directly to INCB in accordance with the international 
drug control treaties. Its focus is on the worldwide con-
trol of all licit activities related to narcotic drugs and psy-
chotropic substances, as well as chemicals used in the 
illicit manufacture of such drugs.
Chapter III presents some of the major developments in 
drug abuse and trafficking and measures by Governments 
to implement the international drug control treaties by 
addressing those problems.
Chapter IV presents the main recommendations addressed 
by INCB to Governments, UNODC, WHO and other rel-
evant international and regional organizations.
 United Nations system and drug control organs and their secretariat
General Assembly
Economic and Social 
Council
INCB Commission onNarcotic Drugs
UNODCa/INCB secretariatb
Key:
Direct connection (administrative or constitutional)
Reporting, cooperating and advising relationship 
a United Nations Office on Drugs and Crime.
b The INCB secretariat reports on substantive matters to INCB only.
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implementation of United Nations international drug control conventions. It was established in 
1968 in accordance with the Single Convention on Narcotic Drugs, 1961. It had predecessors 
under the former drug control treaties as far back as the time of the League of Nations.
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body, INCB tries to identify and predict dangerous trends and suggests necessary measures to 
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